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ABSTRACT
Within 14 years of the seminal experiments of J. D. Roberts leading to the first
proposal of the structure of benzyne, synthetic organic chemists recognized the potential
to exploit this highly reactive intermediate (and its substituted variants) in the synthesis
of natural products.  More specifically, it was recognized that arynes offered the strategic
advantage of rapidly functionalizing an aromatic ring by forming multiple carbon–carbon
or carbon–heteroatom bonds in a single operation, often in a regioselective manner.
Herein are reported three separate efforts aimed at constructing natural products by
aryne-based methodologies.  In each of the studies described in the following chapters,
the implementation of new aryne technologies developed in our group to natural product
synthesis has resulted in concise, convergent, and general strategies to our targets.
The first project discussed in this work is the enantioselective total synthesis of (–)-
curvularin by an acyl-alkylation reaction of a protected resorcinylic silyl aryl triflate
aryne precursor with a !-ketolactone.  Application of this strategic disconnection resulted
in a six-step convergent synthesis of the polyketide natural product, the shortest to date.
These efforts also resulted in the syntheses of curvulin and diplodialide C.
In our efforts toward the total synthesis of two naturally occurring HIV integrase
inhibitors, integrastatins A and B, we attempted to utilize a sequence involving an acyl-
alkylation followed by an ortho-Fries-type rearrangement to access the tetracyclic core of
the natural products.  However, this proved to be a significant challenge and led to the
development of an alternative route to the tetracyclic integrastatin core by a Wacker
cyclization of a diol onto a pendant olefin.
Finally, ongoing progress toward the synthesis of the bis-tetrahydroisoquinoline
natural product jorumycin is detailed.  In a departure from the efforts toward curvularin
and the integrastatins, jorumycin has been targeted through the application of a
combination of aryne annulation and acyl-alkylation/condensation methodologies aimed
at the synthesis of a functionalized bis-isoquinoline intermediate.  Reduction of this key
bis-isoquinoline to a bis-tetrahydroisoquinoline and subsequent lactamization provided
the pentacyclic core of jorumycin and related natural products in only two steps from
simple isoquinoline building blocks.
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Chapter 1
A Comprehensive History of Arynes in Natural Product Total Synthesis
1.1 INTRODUCTION
Within 14 years of the seminal experiments of J. D. Roberts leading to the first
proposal of the structure of benzyne (1),1 synthetic organic chemists recognized the
potential to exploit this highly reactive intermediate (and its substituted variants) in the
total synthesis of natural products.  More specifically, it was recognized that arynes
offered the strategic advantage of rapidly functionalizing an aromatic ring by forming
multiple carbon–carbon or carbon–heteroatom bonds in a single operation, often in a
regioselective manner.  Initially, the scope of synthetic applications was somewhat
limited by the harsh conditions required to produce the aryne species.2  Many of these
methods required strong bases, such as n-BuLi, or high temperatures (Scheme 1.1).
However, with the development of milder methods for the generation of arynes came
increased interest in employing them in the synthesis of more complex polycyclic
systems.  Most recently, the use of o-silyl aryl triflates as aryne precursors has allowed
generation of the reactive intermediate under almost neutral conditions.3
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Scheme 1.1.  Methods for the generation of benzyne (1).
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(1)
To date, over 75 individual natural products have been prepared using arynes to
generate key synthetic intermediates.  Herein are recounted the reports of total syntheses
that utilize arynes in ways that build complexity or introduce motifs essential to the
completion of their targets.  The methods by which the authors featured in this review
accomplish this task reflect the versatility of arynes as reactive intermediates for
synthesis (Scheme 1.2).4,2g  For the purposes of organization, the syntheses are divided
into subgroups on the basis of the type of aryne transformation: 1) nucleophilic additions
or multicomponent reactions, 2) !-bond insertion reactions, 3) [4 + 2] and [2 + 2]
cycloaddition strategies, and 4) metal-catalyzed aryne reactions.  It should be noted that
only completed natural product syntheses have been detailed in this review; formal total
syntheses and efforts toward natural products have not been included.
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Scheme 1.2.  Representative reactions of benzyne (1).5
O
OMe
OMe
OMeMeO
O
BrMg
[2+2]
cycloadditions
[4+2]
cycloadditions
nucleophilic
additions
!-bond insertion
reactions
metal-catalyzed
reactions
multicomponent
reactions
Benzyne
Pd(PPh3)4CO2Me
O
O
CO2Me
t-BuNC
R R
Nt-Bu
R
R
1.2 NUCLEOPHILIC ADDITION AND MULTICOMPONENT REACTION
STRATEGIES
Strategies for the total synthesis of natural products that rely on nucleophilic
additions to arynes (including multicomponent approaches) predominate in the literature
over other approaches.  The examples presented in this section have been divided into
two groups: nucleophilic additions that form only a single new carbon–carbon or
carbon–heteroatom bond to the intermediate aryne, and multicomponent reactions, in
which three or more components are united in such a way that two new bonds to the
aryne are formed in a single operation.  Syntheses that employ nucleophilic addition
strategies represent some of the oldest known applications of arynes to total synthesis,
while multicomponent approaches to natural products have only emerged within the past
decade.
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1.2.1  Nucleophilic Additions to Arynes
The first instance in which arynes were applied to the total synthesis of natural
products was reported by Kametani and co-workers at Tohoku University in 1967.6
Kametani’s synthesis of cryptaustoline (6) and cryptowoline (7) marked the beginning of
a long-term research program to utilize aryne intermediates in alkaloid synthesis that
would span more than 10 years.  In the synthesis of cryptaustoline (6) and cryptowoline
(7), substituted tetrahydroisoquinolines 2  and 3 were treated with sodamide in liquid
ammonia to generate tetracycles 4 and 5, respectively, by nucleophilic addition of the
secondary amine to a pendant aryne (Scheme 1.3).  From this point, tetracycle 4 was
converted to cryptaustoline (6) over three steps, while tetracycle 5 afforded cryptowoline
(7).
Scheme 1.3.  Kametani’s 1967 synthesis of cryptaustoline (6) and cryptowoline (7).
NH
MeO
BnO
X
RO
RO
NaNH2
NH3 (l), THF
–40 °C
N
MeO
BnO
OR
OR
3 steps
N
MeO
HO
OR
OR
I
X = Br, R = Me, 2
X = Cl, R = –CH2–, 3
R = Me, 4 (24% yield)
R = –CH2–, 5 (77% yield)
R = Me, Cryptaustoline (6)
R = –CH2–, Cryptowoline (7)
Building on this synthetic strategy, Kametani next reported the syntheses of
domesticine (1 0 ) and amurine (1 1 ) (Scheme 1.4).7,8  N -Methylat ion of
tetrahydroisoquinoline intermediates such as 2 and 3 and removal of the benzyl protective
group led to alternative reactivity in the key aryne cyclization, allowing access to a
different class of alkaloids.  Upon treatment of phenol 8 with sodamide in liquid
ammonia, the authors isolated low yields of both domesticine (10) and amurine (11),
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resulting from attack of the phenoxide ortho (path a, blue bond) and para (path b, red
bond) positions, respectively, on the aryne (9).  Notably, the formation of amurine results
in a dearomatization upon aryne cyclization.
Scheme 1.4.  Kametani’s 1971 synthesis of domesticine (10) and amurine (11).
NMe
MeO
HO
Br
O
O
NMe
MeO
O
O
O
b
a
NMe
MeO
HO
O
O
NMe
MeO
O
O
O
8 9
Domesticine (10)
Amurine (11)
(6.3% yield)
(1.9% yield)
NaNH2
NH3 (l)
–40 °C
path a
path b
Na
Similarly, aryne cyclization of phenol 12 under these same conditions resulted in
the formation of a mixture of compounds, including thaliporphine (14) (Scheme 1.5).9
Following extraction of thaliporphine (14) and two additional side products (16 and 17),
concentration of the aqueous washes and treatment with potassium iodide also afforded
cryptaustoline (6).
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Scheme 1.5.  Kametami’s 1972 synthesis of thaliporphine (14) and cryptaustoline (6).
NMe
MeO
O
13
NaNH2
NH3 (l)
–40 °C
NMe
MeO
HO
12
Br
MeO
OMe
MeO
OMe
NMe
MeO
HO
Thaliporphine (14)
MeO
OMe
N
MeO
HO
OMe
OMe
Br
15
KI, H2O
N
MeO
HO
OMe
OMe
I
Cryptaustoline (6)
(0.8% yield)
NMe
MeO
HO
16
H
MeO
OMe
NMe
MeO
HO
17
MeO
MeO
NH2
side products
(3.3% yield, 2 steps)
Na
In their final report on this work, Kametani and co-workers extended their
synthetic efforts one step further to prepare three different natural products from a single
aryne precursor in one pot (Scheme 1.6).10  Depending on the substitution, treatment of
either tetrahydroisoquinoline 18 or 8  with sodamide in liquid ammonia yielded
cryptaustoline (6) (following treatment with potassium iodide), thaliporphine (14), and O-
methylflavinantine (19), or cryptowoline (7) (following treatment with potassium iodide),
domesticine (10), and amurine (11), respectively.
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Scheme 1.6.  Kametani’s 1973 one-pot synthesis of cryptaustoline (6), thaliporphine (14), and O-
methylflavinantine (19); and cryptowoline (7), domesticine (10), and amurine (11).
NMe
MeO
ONaNH2
NH3 (l)
–40 °C
NMe
MeO
HO
RO RO
OR
Br
RO
NMe
MeO
HO
RO
OR
NMe
MeO
O
N
MeO
HO
OR
OR
I
RO
OR
R = Me, Thaliporphine (14)
(0.7% yield)
R = –CH2–, Domesticine (10)
(1% yield)
R = Me, O-methylflavinantine (19)
(0.1% yield)
R = –CH2–, Amurine (11)
(0.3% yield)
R = Me, Cryptaustoline (6)
(0.7% yield)
R = –CH2–, Cryptowoline (7)
R = Me, 13
R = –CH2–, 9
R = Me, 18
R = –CH2–, 8
(following treatment with KI)
Na
It should be noted that subsequent to Kametani’s publication of the syntheses
featured in Scheme 1.6, Kessar and Gandhi reported an identical approach to domesticine
(10), cryptaustoline (6), cryptowoline (7), amurine (11), N-methylcaaverine (21), and
thalicmidine with similarly low yields.11  Generally speaking, the consistently low yields
reported in early aryne-based total syntheses stem from competing reactivity pathways
and reflect the infant state of such synthetic methods.  Interestingly, the structure given
by Kessar for thalicmidine is identical to Kametani’s thaliporphine (14).  Furthermore,
the only natural product prepared by Kessar that was not targeted by Kametani was N-
methylcaaverine (2 1 ), which was isolated upon aryne cyclization of
tetrahydroisoquinoline 20 in 18% yield (Scheme 1.7).
Furthermore, Castedo and co-workers extended this aryne cyclization method to
include the synthesis of more oxidized relatives of natural products like thaliporphine
(14 ) and domesticine (10).  In the synthesis of tetradehydroglaucine (23), aryne
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cyclization of N-methyl isoquinolinium iodide 22 directly afforded the natural product
upon treatment with sodium dimsylate (Scheme 1.8).12
Scheme 1.7.  Kessar’s 1975 synthesis of N-methylcaaverine (21).
KNH2
NH3 (l), –40 °C
(18% yield)
NMe
MeO
HO
Br
NMe
MeO
HO
N-Methylcaaverine (21)20
Scheme 1.8.  Castedo’s 1987 synthesis of tetradehydroglaucine (23).
NaH2CS(O)CH3
DMSO, 40 °C
(56% yield)
NMe
MeO
MeO
Br
NMe
MeO
MeO
Tetradehydroglaucine (23)22
IMeO
MeO MeO
OMe
Kametani and co-workers next turned their attention to a slightly different
isoquinoline-derived alkaloid framework in their synthesis of oxynitidine (28) and
nitidine iodide (27) (Scheme 1.9).13  In this case, advanced intermediate 26 was prepared
by arylation of "-tetralone 25 with the aryne generated in situ from aryl bromide 24.
Arylated "-tetralone 26 was converted to nitidine iodide (27) over six additional steps.
Subsequent oxidation of nitidine iodide (27) provided oxynitidine (28).
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Scheme 1.9.  Kametani’s 1973 synthesis of nitidine iodide (27) and oxynitidine (28).
Oxynitidine (28)
26 Nitidine Iodide (27)
O
O
O
MeO
MeO
Br NaNH2
THF
(13% yield)
O
O
O
MeO
MeO
6 steps
O
O
N
MeO
MeO I
K3[Fe(CN)6]
KOH, H2O
O
O
N
MeO
MeO
O
24 25
The final alkaloid synthesis in which Kametani and co-workers employed arynes
deviates somewhat from the examples detailed above.14  In the synthesis of xylopinine
(33), a protoberberine alkaloid, treatment of C(1)-methylene isoquinoline derivative 29
with sodamide in liquid ammonia resulted in enamine cyclization onto the pendant aryne,
furnishing tetracycle 32 upon deprotonation (Scheme 1.10).  Finally, reduction of both
the lactam and enamine by a two-step sequence afforded xylopinine (33).
Scheme 1.10.  Kametani’s 1977 synthesis of xylopinine (33).
Xylopinine (33)32
31
N O
MeO
MeO
Br
OMe
MeO
NaNH2
NH3 (l), –40 °C
(15% yield)
N O
MeO
MeO
OMe
OMe
N O
MeO
MeO
OMe
OMe
N
MeO
MeO
OMe
OMe
N
MeO
MeO
OMe
OMe
O 1. POCl3, reflux
2. NaBH4, MeOH
    0 °C
(80% yield, 2 steps)
29 30
1
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Outside the realm of alkaloid synthesis, Kametani also explored how arynes could
expedite the synthesis of steroid structures.  In one example, treatment of nitrile 34 with
sodamide in liquid ammonia resulted in formation of benzocyclobutene 36 via
intermediate aryne 35 (Scheme 1.11).15  Benzocyclobutenes, such as 36, have proven to
be valuable intermediates for the in situ generation of o-quinone dimethides (37).
Intramolecular Diels–Alder reactions of such o-quinone dimethides with tethered
dienophiles have provided an efficient entry into tetralene synthesis.  Kametani has used
this method in several instances to accomplish the formal synthesis of naturally occurring
steroids.
Scheme 1.11.  Kametani’s synthesis of benzocyclobutenes via intramolecular nitrile arylation.
CN
Br
R
NaNH2
NH3 (l), –33 °C CN
R R
CN
!
R
CN
R
R
R
CN
R
R
34 35 36 37 38
In the synthesis of estradiol (42), Kametani elaborated benzocyclobutene 39 to
enantioenriched cyclopentane 40, the precursor for the key Diels–Alder cycloaddition
(Scheme 1.12).16  Upon heating, benzocyclobutene 40 underwent a 4# electrocyclic ring
opening and subsequent Diels–Alder reaction to afford tetracycle 41, which was
converted to estradiol (42) over two steps.
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Scheme 1.12.  Kametani’s 1978 synthesis of estradiol (42).
MeO
CN
39
MeO
40
H
Ot-Bu
!
1,2-dichlorobenzene
(84% yield) MeO
H
Ot-Bu
HH
HO
H
OH
HH
41 Estradiol (42)
During this same time period, Semmelhack and co-workers reported a concise and
convergent approach to the cephalotaxus alkaloids (49 and 50) based on a late-stage
aryne cyclization strategy.17  Beginning with 2-ethoxy-1-pyrroline (43), heterospirocycle
44 was generated in three steps, while nosylate 46 was prepared over a two-step sequence
beginning with carboxylic acid 45 (Scheme 1.13).  Following coupling of nosylate 46
with pyrrolidine 44 , treatment of tertiary amine 47  with excess potassium
triphenylmethide produced cephalotaxinone (49) directly by enolate addition to the
pendant aryne (e.g., intermediate 48).  Diastereoselective reduction of cephalotaxinone
(49) with DIBAL then produced cephalotaxine (50).  In total, Semmelhack and co-
workers was able to achieve the synthesis of cephalotaxinone (49) and cephalotaxine (50)
in only five and six steps, respectively, from 2-ethoxy-1-pyrroline (43).
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Scheme 1.13.  Semmelhack’s 1972 synthesis of cephalotaxinone (49) and cephalotaxine (50).
N
OEt
HN
O OMe
O
O Cl
O
O Cl
ONs
CO2H
i-Pr2NEt
MeCN, 55 °C
(65–87% yield)
O
O Cl
N
O OMe
KCPh3
DME, 50 °C
(13–16% yield)
O
O
N
O OMe
O
O
N
O
OMe
H
O
O
N
HO
OMe
H
DIBAL
THF, 0 °C
(74% yield)
43 44
45 46
47
48 Cephalotaxinone (49) Cephalotaxine (50)
3 steps
2 steps
Concurrent with Kametani’s efforts toward the synthesis of isoquinoline-
containing alkaloids (vide supra), Kessar and co-workers targeted other members of this
class of compounds through different aryne-centered strategies.  In the synthesis of
chelerythrine chloride (55), Kessar forged a key carbon–carbon bond by treatment of aryl
bromide 51 with potassium amide in liquid ammonia (Scheme 1.14).18  The tetracyclic
product of this aryne cyclization (54) was then methylated to afford the natural product
(55).  This same strategy was employed again by Kessar in the subsequent syntheses of
decarine (56)19 and nitidine iodide (27).20
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Scheme 1.14.  Kessar’s synthesis of chelerythrine chloride (55) (1974), decarine (56) (1984), and
nitidine iodide (27) (1988).
Decarine (56)
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NH3 (l) NH
O
O
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MnO2
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(80% yield,
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N
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Me2SO4
then HCl N
O
O
OMe
MeO Cl
N
O
O
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HO
N
O
O
MeO
51 52 53
54 Chelerythrine Chloride (55) Nitidine Iodide (27)
MeO
I
Just months after Kessar’s synthesis of chelerythrine chloride (55), Stermitz and
co-workers employed an identical strategy in their synthesis of the alkaloid fagaronine
chloride (59) (Scheme 1.15).21  Aryne cyclization of aryl bromide 57 produced tetracycle
58, which was converted to fagaronine chloride (59) over three steps.
Scheme 1.15.  Stermitz’s 1974 synthesis of fagaronine chloride (59).
NH
MeO
Br
NaNH2
NH3 (l);
air oxidation
(24% yield)57
MeO
OMe
Oi-Pr
N
MeO
58
MeO
OMe
Oi-Pr
3 steps
N
MeO
Fagaronine Chloride (59)
MeO
OMe
OH
Cl
Whereas the previously described synthetic efforts all focused on the formation of
new carbon–carbon and carbon–nitrogen bonds, Castedo’s synthesis of oxocularine (68)
and oxocompostelline (69) sought to forge carbon–oxygen bonds between an
intermediate aryne and a pendant phenolate.22  In the key aryne cyclization, treatment of
isoquinoline 60 or 61 with sodium dimsylate led to the isolation of two new products
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each (64 and 66 , or 65  and 67, respectively) resulting from competing addition of
nitrogen or oxygen to the aryne (path a or b) (Scheme 1.16).  Though isolated as the
minor products of aryne cyclization, cyclic ethers 65 and 64 were readily oxidized either
in air or through the use of Fremy’s salt to afford oxocularine (68) and oxocompostelline
(69).
Scheme 1.16.  Castedo’s 1983 synthesis of oxocularine (68) and oxocompostelline (69).
N
MeO
HO
Br OR
OR
N
MeO
+Na–O
OR
OR
N
MeO
O
RO OR
NaH2CS(O)CH3
DMSO, 40 °C
air
–OR–
Fremy's salt
N
MeO
O
RO OR
O
R = Me, 60
R = –CH2–, 61
R = Me, 62
R = –CH2–, 63
R = Me, 64 (25% yield)
R = –CH2–, 65 (20% yield)
R = Me, 
Oxocularine (68)
R = –CH2–, 
Oxocompostelline (69)
N
MeO
HO
R = Me, 66 (50% yield)
R = –CH2–, 67 (65% yield)
OR
OR
a
b
To this point, all natural product syntheses employing a nucleophilic addition
strategy relied on simple monocyclic arynes as the electrophilic reaction parter.  In 1998,
Iwao and co-workers turned to a 4,5-indolyne intermediate in their synthesis of
makaluvamines A (77), D (78), I (79), and K (76) (Scheme 1.17).23  Beginning with
tryptamine intermediates 7 0  and 7 1 , and differing only in the indole nitrogen
functionality, treatment with lithum isopropylcyclohexylamide (LICA) resulted in
cyclization of the pendant amine onto the transient 4,5-indolyne (80), affording tricycles
72 and 73, respectively, in very good yields.  From here two paths diverge: for R = Me,
oxidation of tricycle 72 with oxygen and salcomine yielded the iminoquinone (74).
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Alternatively, for R = TBS (73), desilylation of the indole nitrogen was followed by
oxidation to iminoquinone 75.  Makaluvamines A (77) and I (79) were completed by
treatment of iminoquinones 74 and 75, respectively, with ammonium chloride in
methanol.  Alternatively, iminoquinones 74 and 75 were converted to makaluvamines K
(76) and D (78), respectively, upon addition of with tyramine hydrochloride.
Scheme 1.17.  Iwao’s 1998 synthesis of makaluvamines A (77), D (78), I (79), and K (76).
Makaluvamine K (76)
Makaluvamine A (77)
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    THF
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MeOH
(40% yield,
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HN
O
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R = TBS, 73 (75% yield)
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75
Makaluvamine D (78)
Makaluvamine I (79)
N
RMeO
NH2
80
Beginning in the late 1990s, Couture and co-workers embarked on a research
program aimed at the synthesis of the aristolactam alkaloids by a general route involving
a tandem aryne cyclization/olefination and radical cyclization.  Their initial report
focused on the synthesis of cepharanone A (91) and B (90)24 and was soon followed by
the synthesis of three more members of this alkaloid class, velutinam (103), taliscanine
(101), and enterocarpam II (102).25  In the synthesis of cepharanone A (91) and B (90),
Chapter 1 – A Comprehensive History of Arynes in Natural Product Total Synthesis 16
amides 81 and 82 were treated with excess KHMDS to effect simultaneous aryne
generation and formation of phosphonate anion 83 (Scheme 1.18).24  Following the initial
cyclization of the pendant carbanion onto the aryne, isomerization of the resulting aryl
anion (84) to the "-amino carbanion (85) preceded addition of o-iodobenzaldehyde and
subsequent olefinination.  The products of this tandem sequence, isoindolinones 86 and
87 (as a mixture of E  and Z  isomers), underwent smooth radical cyclization upon
treatment with Bu3SnH and AIBN to yield tetracycles 88 and 89, respectively.  Finally,
cleavage of the N-protective groups furnished cepharanone A (91) and B (90).
Scheme 1.18.  Couture’s 1997 synthesis of cepharanone A (91) and B (90).
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Ph Ph
KHMDS
THF
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O
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O
Ph Ph
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NPMB
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O Ph
PhK
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P
O Ph
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K
O
H
I
THF, –30 °C
R
R
NPMB
O
I
Bu3SnH
AIBN
PhH, reflux
R
R
NPMB
O
TFA, anisole
DCE, reflux
(87–91% yield)
R
R
NH
O
R = Me, 81
R = –CH2OCH2–, 82
R = Me, 86 (74% yield)
R = –CH2OCH2–, 87 (71% yield)
83 84 85
R = Me, 88 (52% yield)
R = –CH2OCH2–, 89 (46% yield)
R = Me, Cepharanone B (90)
R = –CH2OCH2–, Cepharanone A (91)
This strategy was subsequently applied by the same group to the syntheses of
additional aristolactam natural products 101–103.25  Amides 92 and 93 were converted to
the respective isoindolinones (95–97) by the tandem aryne cyclization/olefination and
radical cyclization sequence (Scheme 1.19).  Finally, cleavage of the protective groups
yielded velutinam (103), taliscanine (101), and enterocarpam II (102).
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Scheme 1.19.  Couture’s 1998 synthesis of velutinam (103), taliscanine (101), and enterocarpam II
(102).
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A final natural product synthesis reported by Couture utilizing the aryne
cyclization/olefination/radical cyclization sequence was that of eupolauramine (111)
(Scheme 1.20).26  This work is distinguished by the intermediacy of a 2,3-pyridyne (105)
in place of the standard aryne employed above; the synthesis of eupolauramine (111) is
one of only three syntheses to date to feature a pyridyne intermediate.  Pyridyne
cyclization of amide 104 produced azaisoindolinone 106 in good yield upon cleavage of
the phosphoryl group.  By performing the olefination in a stepwise fashion on
azaisoindolinone 106, excellent selectivity for the desired E isomer was achieved.
Radical cyclization of iodide 107 yielded tetracycle 108, which was advanced to
eupolauramine (111) over three steps.
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Scheme 1.20.  Couture’s 2001 synthesis of eupolauramine (111).
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In a departure from the examples shown in Schemes 1.18–1.20, Couture targeted
the isooxindoloisoquinoline natural product neuvamine (114) by a simpler aryne
nucleophilic addition.27  Elimination of fluoroarene 112 with KHMDS and simultaneous
deprotonation of the pendant isooxindole resulted in formation of the pentacyclic natural
product neuvamine (114) (Scheme 1.21).
Scheme 1.21.  Couture’s 2004 synthesis of neuvamine (114).
N
O
OMe
MeO
F
O
O
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THF, –78 °C
(71% yield)
N
O
OMe
MeO
O
O
N
O
OMe
MeO
O O
112 113 Neuvamine (114)
A unique approach to a pair of Amaryllidaceae alkaloids, trisphaeridine (122) and
N-methylcrinasiadine (121), was reported in 2007 by Sanz and co-workers.28  Their
strategy relies upon the generation of an aryne through dehydrofluorination with
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concomitant lithium-halogen exchange of a pendant aryl bromide (Scheme 1.22).  In the
event, treatment of either N-methyl aniline 115 or N-allyl aniline 116 with t-BuLi
generated the intermediate aryne tethered to the aryl lithium species (117 and 118), which
underwent cyclization to yield tetracycles 119 and 120, respectively.  Notably, with strict
temperature control, aryne formation occurs selectively on the fluoroarene, while lithium-
halogen exchange is exclusive to the aryl bromide.  Furthermore, Sanz and Barluenga
have shown that this approach can be generalized to give access to a wide range of
polycyclic aromatic structures.29  N-allyl tetracycle 120 was advanced to trisphaeridine
(122) by deallylation and oxidation, while the N-methyl variant (119) was converted to
N-methylcrinasiadine (121) by air oxidation.
Scheme 1.22.  Sanz’s 2007 synthesis of trisphaeridine (122) and N-methylcrinasiadine (121).
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In addition to Iwao’s synthesis of the makaluvamines (vide supra), Garg and co-
workers recently employed a 4,5-indolyne intermediate en route to the macrocyclic
lactam natural product, indolactam V (129) (Scheme 1.23).30,31  In this case, the
intermolecular nucleophilic addition of peptide 124 to 6-bromo-4,5-indolyne (125),
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generated in situ from silyl aryl triflate 123, proceeds regioselectively to provide the 4-
amino-6-bromo indole product (126) exclusively.  Remarkably, the presence of the 6-
bromo substituent reverses the native selectivity (i.e., addition to the 5-position) for
nucleophilic additions to 4,5-indolyne.31a,b  At this point, reduction of the bromide and
elimination of the primary alcohol produced enamide 127, which underwent conjugate
addition with diastereoselective protonation upon treatment with ZrCl4 to generate
macrocycle 128.  Finally, epimerization of the newly formed C(9) stereocenter and
reduction of the ester afforded indolactam V (129).
Scheme 1.23.  Garg’s 2011 synthesis of indolactam V (129).
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The most recent example of nucleophilic addition to arynes in total synthesis was
reported by Stoltz and co-workers in their synthesis of the tetracyclic meroterpenoid (+)-
liphagal (137) (Scheme 1.24).32  More specifically, an aryne cyclization was used to close
the final ring of the natural product.  Toward this end, secondary alcohol 131, which was
constructed over ten steps from enantioenriched enone 130, was successfully converted to
dihydrobenzofuran 133 through the intermediacy of aryne 132.  Notably, a number of
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alternative methods to form this key carbon–oxygen bond, including palladium-catalyzed
etherifications, failed to yield the desired product.  Furthermore, reduction of the
trisubstituted olefin of dihydrobenzofuran 133 to generate the trans-fused [6,7] ring
system of tetracycle 134 could only be accomplished following the aryne cyclization.
From this point, the synthesis of (+)-liphagal (137) was completed by oxidation of the
dihydrobenzofuran (134), formylation, and demethylation.
Scheme 1.24.  Stoltz’s 2011 synthesis of (+)-liphagal (137).
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1.2.2  Multicomponent Reactions of Arynes
In general, arynes are well suited to function as a relay species for
multicomponent reactions. For over 70 years,33 research groups have sought to develop
three- and four-component methods for the rapid preparation of 1,2-disubstituted
arenes.34,5b  Despite the efficiency of such methodologies, only three approaches to
natural products in the literature to date have employed multicomponent aryne strategies.
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The first was Barrett’s synthesis of ent-clavilactone B (145) by a three-component
coupling involving an aryne, an organomagnesium reagent, and an aldehyde (Scheme
1.25).35  More specifically, treatment of fluoroarene 138 with n-BuLi resulted in the
formation of an aryne to which methallylmagnesium chloride 139 was added.  Next, the
newly formed intermediate arylmagnesium species (140) underwent addition to the third
component, aldehyde 141 , yielding benzylic alcohol 142  as a 2:1 mixture of
diastereomers.  The separable diastereomers 142a and 142b were individually converted
to lactone 143 over two and three steps, respectively.  Finally, ring-closing metathesis
using a Grubbs second generation catalyst (146) and oxidation afforded ent-clavilactone
B (145).
Scheme 1.25.  Barrett’s 2006 synthesis of ent-clavilactone B (145).
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More recently, in their synthesis of dehydroaltenuene B (154), Barrett and co-
workers made excellent use of a four-component aryne coupling reaction to build the
tricyclic core of the natural product (Scheme 1.26).36  Beginning with elimination of
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fluoroarene 148 to generate aryne 150, sequential addition of cyclohexenylmagnesium
chloride 149, carbon dioxide, and iodine generated iodolactone 153.  The authors propose
that the reaction proceeds through addition of organomagnesium reagent 149 to aryne
150, followed by carboxylation of the resulting arylmagnesium species (151), and finally
diastereoselective iodolactonization.  The multicomponent adduct (153) was then
converted to dehydroaltenuene B (154) over a series of six additional steps.
Scheme 1.26.  Barrett’s 2008 synthesis of dehydroaltenuene B (154).
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The most recent use of an aryne multicomponent coupling strategy was reported
by Tokuyama and co-workers in their synthesis of dictyodendrins A–E (161–165).37  In
this case, an initial intramolecular nucleophilic addition of a nitrogen anion into a pendant
aryne (155 $ 156) was linked to a palladium-catalyzed Kumada–Tamao coupling to
append p-iodoanisole.  The product of this three-component coupling (158) was then
advanced over a three-step sequence to indole 160, which was subsequently converted to
dictyodendrin A (161) over eight steps.  This same strategy was also applied to the
synthesis of dictyodendrins B (162), C (163), D (164), and E (165).
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Scheme 1.27.  Tokuyama’s 2010 synthesis of dictyodendrins A–E (161–165).
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1.3 BOND INSERTION REACTION STRATEGIES
Carbon–carbon bond insertion reactions are some of the most recent
methodologies to emerge from the aryne literature.  Remarkably, their use was first
reported in the context of total synthesis, while generalized methods were not disclosed
until 2005.5a,38,39  Since these initial reports, a number of additional carbon–carbon bond
insertion methods have been disclosed.40,34d  All of these general methods have been
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enabled by the development of silyl aryl triflate precursors,3 which allow mild generation
of arynes in the presence of a wide range of functional groups.
The earliest example of a total synthesis employing a !-bond insertion reaction of
an aryne in the synthesis of a natural product was completed by Danheiser and co-
workers.  Their total synthesis of salvilenone (178) employed a ring-expansive
carbon–carbon bond insertion reaction between an aryne and a ketone enolate (Scheme
1.28).41  More specifically, ring expansion of 2-methylcyclopentanone (166) with
benzyne (1), generated in situ from bromobenzene (167) under basic conditions,
produced benzannulated cycloheptanone 171 in addition to "-arylation product 172 in a
7:3 ratio (Scheme 1.28a).  Importantly, this ratio could be improved to 85:15 by
employing the silyl enol ether 2-methylcyclopentanone (166), ultimately providing
benzannulated cycloheptanone 171 in 42% isolated yield (Scheme 1.28b).  Regioselective
bromination of the arene ring followed by "-diazotization provided "-diazoketone 173
(Scheme 1.29).  In the key transformation, irradiation of "-diazoketone 173 in the
presence of alkyne 174 resulted in a cascade reaction consisting of Wolff rearrangement,
[2 + 2] ketene cycloaddition, 4# electrocyclic ring opening, and 6# electrocyclic ring
closing to furnish tricycle 175.  From this point, completion of salvilenone (178) was
readily accomplished by annulation of the final ring, desilylation, and oxidation.  In full,
salvilenone (1 7 8 ) was prepared in 7 steps and 9% overall yield from 2-
methylcyclopentanone (166) and bromobenzene (167).
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Scheme 1.28.  Danheiser’s ring–expansive carbon–carbon bond insertion of benzyne (1) into 2-
methylcyclopentanone (166).
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Scheme 1.29.  Danheiser’s 1994 synthesis of salvilenone (178).
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Soon after Danheiser’s ring-expansive C–C bond insertion studies, the
Danishefsky group employed a !-bond insertion of dimethyl malonate (181) with a
functionalized aryne en route to the enediyne antibiotic dynemicin A (179).42  Much like
the enediynes calicheamicin43 and esperamicin44, dynemicin A (179) has demonstrated
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potent antitumor activity (Scheme 1.30).45  Danishefsky and co-workers focused their
approach to the natural product on a late-stage convergent assembly of the hexacyclic
ring system, one half of which contained the sensitive enediyne functionality.  The
second fragment was readily accessed in three steps beginning with the carboxy-
alkylation of the aryne derived from bromoarene 180 with the lithium salt of dimethyl
malonate (181) to yield diester 182.  Although the reaction of a malonate with an aryne
had been reported prior to this synthesis, the yields were significantly lower and the
desired carboxy-alkylation products were accompanied by extensive side product
formation.46  Saponification of the diester was followed by treatment with
(trimethylsilyl)ethynyl ether to furnish cyclic anhydride 184, which comprises the D and
E rings of the natural product.
Scheme 1.30.  Dynemicin A (179) and the synthesis of cyclic anhydride 184 by carboxy-alkylation
of arynes (1995).
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With a suitable DE-ring fragment in hand, cyclic anhydride 184 was joined to
enediyne-containing ABC-ring fragment 188 (Scheme 1.31).  Deprotonation of cyclic
anhydride 184  and addition to quinone imine 188  resulted in a formal [4 + 2]
cycloaddition and loss of CO2 to yield a putative anthrone (189), which was immediately
oxidized to the anthracendiol (190).  Further oxidation to the corresponding
anthraquinone (191) followed by global deprotection yielded dynemicin A (179) in 15%
yield over the final four steps.
Scheme 1.31.  Completion of Danishefsky’s synthesis of dynemicin A (179) (1995).
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As in the Danishefsky synthesis of dynemicin A, Kita and co-workers employed a
carboxy-alkylation with dimethyl malonate (181) en route to fredericamycin A (208).47
However, in this case, an unsymmetrical aryne derived from trimethoxy bromoarene 192
was employed (Scheme 1.32).  As a result, the carboxy-alkylation proceeded with little
regioselectively to give a mixture of two separable isomeric products (193 and 194) in a
2:3 ratio.  Following separation, diesters 193 and 194 were each converted to their
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respective "-methoxy cyclic anhydrides, 197 and 198, which represent the A and B rings
of the natural product.
Scheme 1.32.  Synthesis of cyclic anhydrides 197 and 198 by a carboxy-alkylation route (1999).
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At the time of this work, the absolute configuration of fredericamycin A (208)
was unknown.  Strategically, the authors devised a way to convert each isomeric cyclic
anhydride (197 and 198) into each enantiomer of the natural product by coupling them to
an enantioenriched CDEF-ring fragment (204).  Mechanistically, upon treatment of 197
or 198 with base, a reactive pyrone structure was generated (200) capable of reacting
with dienophile 199 by a formal [4 + 2] cycloaddition (Scheme 1.33).  Subsequent CO2
extrusion and syn elimination then produced the fully aromatized products.  In the event,
cycloadducts 205 and 206 were isolated in 97% and 94% ee, respectively (Scheme 1.34).
Methylation of the free phenols yielded the enantiomeric ethers ((R)-207 and (S)-207).
Finally, over a series of five steps, each of these intermediates ((R)-207 and (S)-207) was
converted to a each enantiomer of the natural product (208 and ent-208).  Ultimately,
Kita and co-workers determined that the compound bearing the S absolute configuration
at the single stereocenter was the naturally occurring fredericamycin.
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Scheme 1.33.  Mechanism for coupling of the AB-ring fragment and CDEF-ring fragment.
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Scheme 1.34.  Kita’s 1999 stereodivergent approach to fredericamycin (208).
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Despite the previous two examples of aryne acyl-alkylation with malonate-
derived nucleophiles, a thorough examination of this specific reactivity was not
undertaken until 2005 when Stoltz and co-workers reported the reaction of arynes derived
from silyl aryl triflates3 (e.g., 209) with %-ketoesters (e.g., 210) (Scheme 1.35).38  Of
particular interest is the ring-expansive variant of this transformation, employing cyclic
%-ketoesters.  To date, the Stoltz group has employed this method in the enantioselective
syntheses of two natural products: the isopavine alkaloid amurensinine (216) and the
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benzannulated macrolatone curvularin (221).  In each of these examples, the acyl-
alkylation reaction is used to construct key C–C bonds between a functionalized aryne
and a %-ketoester to convergently assemble the natural products.
Scheme 1.35.  Stoltz’s acyl-alkylation of arynes with %-ketoesters.
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In the enantioselective total synthesis of (+)-amurensinine (216), the tetracyclic
core of the alkaloid (214) was targeted by an acyl-alkylation of a sesamol-derived aryne
(generated in situ from silyl aryl trflate 212) with benzannulated %-ketoester 213 (Scheme
1.36).48  In this case, the aryne formation and the subsequent acyl-alkylation are triggered
by a mild fluoride source, instead of the strong bases used in prior examples.  The
resulting tetracycle (214) contained all but one of carbons present in the natural product.
To render the synthesis enantioselective, Stoltz and co-workers employed a palladium-
catalyzed oxidative kinetic resolution of activated alcohols.49  Following
diastereoselective reduction and selective protection of the primary alcohol, oxidative
kinetic resolution of secondary benzylic alcohol (±)-215 provided enantioenriched
alcohol (–)-215 in 47% yield and >99% ee, corresponding to a selectivity factor of >47.
From this point, the final ring of amurensinine was installed, completing the natural
product in seven additional steps.  Overall, the enantioselective synthesis of (+)-
amurensinine was completed in 12 steps from silyl aryl triflate 212 and %-ketoester 213.
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Scheme 1.36.  Stoltz’s 2006 synthesis of (+)-amurensinine (216).
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In a second application of a ring-expansive aryne acyl-alkylation, the Stoltz lab
reported the enantioselective synthesis of (–)-curvularin (221), a benzannulated
macrolactone natural product.50  The 12-membered lactone of the natural product was
targeted by the reaction of an unsymmetrical aryne (219) (generated in situ from silyl aryl
triflate 217) with 10-membered %-ketolactone 218 (Scheme 1.37).  Prior to this work, %-
ketolactones had not been employed as substrates in the acyl-alkylation reaction.
Application of the acyl-alkylation transformation in this way results in regioselective
formation of the benzannulated lactone, without any formation of the undesired isomeric
product derived from initial nucleophilic addition to C(2).  Finally, debenzylation
revealed the resorcinol core, completing (–)-curvularin (221) in six steps from known
compounds.
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Scheme 1.37.  Stoltz’s 2010 enantioselective synthesis of (–)-curvularin (221).
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Concurrent with their report on (–)-curvularin, Stoltz and co-workers reported two
additional syntheses of natural products utilizing the same protected resorcinylic silyl aryl
triflate (217).51  Acyl-alkylation of silyl aryl triflate 217 with ethyl acetoacetate (222)
under modified conditions followed by debenzylation produced curvulin (224), an acyclic
relative of curvularin often isolated from the same natural sources (Scheme 1.38).
Alternatively, acyl-alkylation of precursor 217 with &-methoxy-%-ketoester 225, followed
by base-mediated cyclization and aerobic oxidation yielded hydroxynaphthoquinone 227
(Scheme 1.39)  Debenzylation of this intermediate (227) provided Cercospora isolate
228.
Scheme 1.38. Stoltz’s 2010 synthesis of curvulin (224).
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Scheme 1.39.  Stoltz’s 2010 synthesis of Cercospora isolate 228.
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The acyl-alkylation/condensation/air oxidation method for the formation of
hydroxynaphthoquinones was further developed into a one-pot procedure by Stoltz and
co-workers.52  This streamlined method was demonstrated by the one step synthesis of
lawsone (230) from unsubstituted silyl aryl triflate 209 and methyl acetoacetate (229) by
treatment of the acyl-alkylation product with sodium methoxide in situ (Scheme 1.40).
Scheme 1.40.  Stoltz’s 2009 synthesis of lawsone (230).
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Shortly after publication of Stoltz’s syntheses of (–)-curvularin and related natural
products, Yoshida and co-workers employed a similar strategy toward cytosporone B
(237) and phomopsin C (234) (Scheme 1.41).53  Acyl-alkylation of ethyl 3-oxodecanoate
(231) with unsymetrical dimethoxy aryne precursor 232 regioselectively yielded arene
233 as a single isomer in modest yield.  Subsequent selective mono-demethylation then
afforded phomopsin C (234).  Alternatively, acyl-alkylation of silyl aryl triflate 235 with
ethyl 3-oxodecanoate (231) provided arene 236, which was converted into cytosporone B
(237) upon cleavage of the methoxymethyl ether groups.
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Scheme 1.41.  Yoshida’s 2010 syntheses of phomopsin C (234) and cytosporone B (237).
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1.4  [4 + 2] AND [2 + 2] ARYNE CYCLOADDITION STRATEGIES
1.4.1  [4 + 2] Aryne Cycloaddition Strategies
The prevalence of [4 + 2] aryne cycloadditions as a strategy for natural product
total synthesis is second in the literature only to the use of nucleophilic additions.
However, despite the large volume of such approaches, there remain significant
limitations to the application of aryne [4 + 2] cycloadditions.  Notably, the majority of
examples described herein, with a few exceptions, require constrained dienes, most
commonly furans.  The use of acyclic dienes in natural product synthesis is still a
considerable challenge and represents an under-explored area of aryne methodology.
Mechanistically, although some of the [4 + 2] cycloadditions may proceed by a
concerted mechanism, it is more likely that the majority of examples discussed herein
occur by stepwise processes.  Generally speaking, substitution on both the aryne and the
diene components can heavily influence the reaction pathway to favor one mechanism
over the other.
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The first example of the application of an aryne [4 + 2] cycloaddition (formal,
stepwise, or concerted) in the synthesis of a natural product comes from Townsend and
co-workers’ preparation of averufin (245) in 1981 (Scheme 1.42).54  Averufin (245) was
targeted by a formal aryne [4 + 2] cycloaddition reaction that would build the central
quinone ring from a benzannulated lactone (239) and an aryl bromide (238).  In the key
transformation, treatment of aryl bromide 238 and lactone 239 with LiTMP resulted in
enolization of the lactone (239) and concomitant formation of aryne 241.  Regioselective
addition of enolate 240 to aryne 241 was followed by addition of the resulting aryl anion
to the lactone to generate a hemiacetal (242).  Elimination of the alkoxide from the
tetrahedral intermediate furnished pentacycle 243, which then underwent addition of
acetic acid and exposure to air, resulting in oxidation to the quninone (244).  Finally,
removal of the methoxy methyl ether protecting groups yielded averufin (245).
Scheme 1.42.  Townsend’s 1981 synthesis of averufin (245).
238
OMOM
O
O
Br
MOMO
MOMO
O
O
239
LiTMP
then air
AcOH
MOMO
MOMO
O
O–Li+
240
OMOM
O
O
241
MOMO
MOMO
243
O
O
OMOMO
OH
MOMO
MOMO
244
O
O
OMOMO
O
50% AcOH
H2SO4, 85 °C
(28% yield)
HO
HO
Averufin (245)
O
O
OHO
O
MOMO
MOMO
242
O
O
OMOM
O
O–Li+
Chapter 1 – A Comprehensive History of Arynes in Natural Product Total Synthesis 37
Following Townsend’s work on averufin (245), Biehl and co-workers employed
this same strategy to the synthesis of four different anthraquinone natural products,
morindaparvin A (251), rubiadin 1-methyl ether (254), rubiadin (255), and damnacathol
(256).  In the first example, morindaparvin A (251) was accessed by reaction of 3-
cyanophthalide 247 with aryl bromide 246 in the presence of LDA (Scheme 1.43).55
Notably, the use of a 3-cyanophthalide (247) in place of a lactone removed the need for
subsequent air oxidation as in the case of averufin.  Instead, cycloaddition and
fragmentation generated cyanohydrin 250, which furnished the anthraquinone directly
upon ejection of cyanide.
Scheme 1.43.  Biehl’s 1989 synthesis of morindaparvin A (251).
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The second of Biehl’s reports applied this same method to the synthesis of
rubiadin (266), rubiadin 1-methyl ether (254), and damnacathol (256) (Scheme 1.44).56
Replacing dioxolane 246 with trisubstituted bromoarene 252 led to anthraquinone 253,
the point of divergence from which the three products were targeted.  Mono-
demethylation with HBr in acetic acid produced rubiadin 1-methyl ether (254), while bis-
demethylation with excess BBr3 furnished rubiadin (255).  Alternatively, benzylic
oxidation of anthraquinone 253 followed by mono-demethylation yielded damnacathol
(256).
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Scheme 1.44.  Biehl’s 1995 synthesis of rubiadin (255), rubiadin 1-methyl ether (254), and
damnacathol (256).
O
O
NC
Br LDA
THF
–78 ! –40 °C
(65% yield)
252 247
OMe
Me
MeO
253
OMe
Me
MeO
O
O
BBr3
CH2Cl2
(61% yield)
Rubiadin (255)
OH
Me
HO
O
O
Rubiadin 1-methyl ether (254)
OMe
Me
HO
O
O
Damnacathol (256)
OMe
HO
O
O
OH
48% HBr
AcOH
(90% yield)
1. CAN
    AcOH
2. 48% HBr
    AcOH
(39% yield,
   2 steps)
In the same year as Townsend’s seminal report of an aryne [4 + 2] cycloaddition
employed in total synthesis, Best and Wege published the total synthesis of mansonone E
(264).57  Additional syntheses of mansonones I (265) and F (266) and biflorin (267) were
reported the following year from a common intermediate.58  In this work, Best and Wege
report the first intramolecular Diels–Alder reaction of an aryne by tethering an anthranilic
acid-derived aryne precursor2d,e to a furan.  Preparation of cycloaddition precursor 258
was accomplished in five steps beginning with phenol 257 (Scheme 1.45).  Upon
treatment of anthranilic acid 258 with i-C5H11ONO in acidic ethanol, an intermediate
diazonium hydrochloride (259) was generated that then underwent spontaneous thermal
decomposition to the aryne (260).  Cycloaddition between the aryne and the pendant
furan then produced pentacyclic cycloadduct 261 in 86% yield.  Subsequent
deoxygenation and acetal cleavage yielded tricycle 263, which was readily converted to
mansonones E (264), I (265), and F (266) and biflorin (267).
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Scheme 1.45.  Best and Wege’s 1981 synthesis of mansonone precursor 263.
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Given the potential risk of explosion associated with use of anthranilic acid-
derived aryne precursors,59 Best and Wege noted that the key intramolecular Diels–Alder
cycloaddition can also be performed by elimination of the corresponding o-dibromide
compound (268) with n-BuLi, producing cycloadduct 270 in 90% yield (Scheme 1.46).
Scheme 1.46.  Alternative aryne generation in the intramolecular aryne Diels–Alder toward
mansonone E (264).
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Beginning in the mid-1980s, Castedo and co-workers embarked on a program
spanning more than 10 years in which they investigated the synthesis of various
isoquinoline-derived alkaloids by intermolecular aryne Diels–Alder cycloadditions.  One
of the various general strategies they developed relied upon the [4 + 2] cycloaddition of
substituted arynes (both symmetrical and unsymmetrical) with 1-methylene-substituted
isoquinoline derivatives such as 271 to generate aporphinoid alkaloids (Scheme 1.47).60
Mechanistically, this annulation can be envisioned to proceed in a stepwise fashion
beginning with an enamine addition of isoquinoline derivative 271 to an aryne (1) to
generate an intermediate aryl anion (273).  The aryl anion (273) can then undergo a
dearomatizing conjugate addition to the pendant iminium ion to produce tetracycle 274,
which then undergoes a formal loss of hydrogen to give rise to aromatized tetracycle 275.
By varying the substitution on both the 1-methylene isoquinoline derivative (271) and the
aryne (1), a variety of alkaloids were prepared, including PO-3 (299), norcepharadione B
(279), cepharadione B (281), duguenaine (292), pontevedrine (282), O-methylatheroline
(294), and lysicamine (293).61
Scheme 1.47.  Castedo general approach to the aporphinoid alkaloids.
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In the syntheses of norcepharadione B (279), cepharadione B (281), and
pontevedrine (282), reaction of 6,7-dimethoxy-1-methylene isoquinoline-3,4-dione (276)
with either benzenediazonium-2-carboxylate (277) or its dimethoxy relative (278) yielded
norcepharadione B (279) and des-methyl pontevedrine (280), respectively (Scheme
1.48).61a  N-methylation of each of these compounds (279 and 280) furnished the natural
products cepharadione B (281) and pontevedrine (282).
Scheme 1.48.  Castedo’s 1991 syntheses of norcepharadione B (279), cepharadione B (281), and
pontevedrine (282).
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A variation on this theme produced duguenaine (292), lysicamine (293), and O-
methylatheroline (294) by employing differentially substituted 1-methylene-3,4-dihydro
isoquinoline cycloaddition partners (283 and 284) (Scheme 1.49).61a  The cycloadducts of
these aryne [4 + 2] reactions (285–287) were each treated with NaBH4 to remove the
labile trifluoroacetaamides.  Condensation of pentacycle 291 with formaldehyde
furnished duguenaine (292) in 84% yield.  Alternatively, oxidation of tetracycles 289 and
290 with Fremy’s salt provided the isoquinoline alkaloids lysicamine (293) and O-
methylatheroline (294) in 70% and 65% yields, respectively.
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Scheme 1.49.  Castedo’s 1991 syntheses of duguenaine (292), lysicamine (293), and O-
methylatheroline (294).
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Finally, the synthesis of the alkaloid PO-3 (299) highlights the excellent
selectivity displayed by this particular [4 + 2] cycloaddition when applied to
unsymmetrical arynes, such as that derived from 3-methoxy benzenediazonium-2-
carboxylate (295) (Scheme 1.50).61  Following the cycloaddition, removal of the N-
trifluoroacetyl protective group, oxidation with Fremy’s salt, methylation, and
thermolysis provided PO-3 (299).
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Scheme 1.50.  Castedo’s 1985 synthesis of PO-3 (299).
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As part of their ongoing program aimed at the development of new aryne [4 + 2]
cycloadditions for alkaloid total synthesis, Castedo and co-workers targeted another class
of isoquinoline-derived natural products—the protoberberines—by the cycloaddition of
isoquinolinepyrrolinediones (e.g., 300) with arynes (e.g., 1) (Scheme 1.51).62
Mechanistically, this reaction sequence begins with enamide addition to the aryne,
generating intermediate aryl anion 301.  Instead of the conjugate addition observed in the
synthesis of the aporphinoids (vide supra), transannular addition of the aryl anion to the
amide carbonyl produces bicyclic intermediate 302, which undergoes subsequent CO
extrusion and tautomerization to furnish tetracycle 304.
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Scheme 1.51.  Castedo’s tandem [4 + 2] cycloaddition/CO extrusion approach to the
protoberberine alkaloids.
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This transformation was applied to the total synthesis of the protoberberine
alkaloid corydaline (308) beginning with cycloaddition of pyrrolinedione 306 and
dimethoxy benzenediazonium carboxylate (305) to regioselectively provide tetracycle
307 in modest yield (Scheme 1.52).62  Amide reduction followed by treatment of the
resulting enamine with NaBH4 furnished corydaline (308).
Scheme 1.52.  Castedo’s 1986 synthesis of corydaline (308).
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Analogous  to  corydaline, 8-oxypseudopalmatine (3 1 1 ) and
decarbomethoxydihydrogambirtannine (314) were prepared by the tandem [4 + 2]
cycloaddition/CO extrusion sequence.63  Combination of bromopyrrolinedione 309 with
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4,5-dimethoxy benzenediazonium-2-carboxylate 309 under standard thermolysis
conditions produced tetracycle 310 in a modest 24% yield (Scheme 1.53).  The presence
of a bromine substituent on the pyrrolinedione prevents further arylation at C(13)
following the initial cycloaddition and CO extrustion.  Hydrogenolysis of the bromide
provided 8-oxypseudopalmatine (311).
Scheme 1.53.  Castedo’s 1988 synthesis of 8-oxypseudopalmatine (311).
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In the synthesis of decarbomethoxydihydrogambirtannine (314), the reaction of %-
carboline-derived chloropyrrolinedione 312 and benzenediazonium-2-carboxylate (277)
generated pentacyclic intermediate 313 in good yield (Scheme 1.54).63b  Upon
hydrogenolysis of the chloride and reduction of the amide,
decarbomethoxydihydrogambirtannine (314) was obtained.
Scheme 1.54.  Castedo’s 1992 synthesis of decarbomethoxydihydrogambirtannine (314).
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Similarly, oxoavicine (320) and oxonitidine (319) could be accessed by [4 + 2]
cycloaddition and CO extrusion with pyrrolinedione 316 and aryne precursors 315 and
278, respectively (Scheme 1.55).64  The resulting cycloadducts (317 and 318) were
converted to oxonitidine (319) and oxoavicine (320), respectively, upon oxidation.
Scheme 1.55.  Castedo’s 1989 synthesis of oxoavicine (320) and oxonitidine (319).
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In 1989, Castedo and co-workers reported syntheses of the aristolactam and
phenanthrene alkaloids featuring novel aryne [4 + 2] cycloaddition strategies.65  In these
examples, the cycloaddition occurs between a tethered aryne-diene pair in an
intramolecular aryne Diels–Alder reaction.  In the synthesis of naturally occurring
aristolactam 327, a suitable substrate (324) for cycloaddition was prepared by coupling of
acid chloride 321 with amine 322, followed by oxidation and elimination (Scheme
1.56).65a  Upon treatment of amide 324 with LDA at decreased temperatures, elimination
of the bromide produced the aryne (325), which underwent a [4 + 2] cycloaddition with
the pendant styrene functionality.  Aerobic aromatization of the newly formed 6-
membered ring furnished the natural product, aristolactam 327.
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Scheme 1.56.  Castedo’s 1989 synthesis of aristolactam 327.
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Following the synthesis of aristolactam 327, Castedo attempted to extend this
strategy to the analogous synthesis of the aporphine ring system.65b  However, attempts to
accomplish the intramolecular aryne Diels–Alder on urethane 328 with LDA at decreased
temperature did not produce the expected tetracycle (333) (Scheme 1.57).  Instead,
phenanthrene 331 was isolated as the major product in 60% yield.  Presumably this
product arises from a pathway beginning with the desired intramolecular [4 + 2]
cycloaddition following aryne generation; however, the initial adduct (330) then
undergoes fragmentation during aromatization to form phenanthrene 331.  Despite this
surprising result, phenanthrene 331  was converted to the natural product
atherosperminine (332) in three steps.66  Notably, the [4 + 2] cycloadditions employed in
this example and in the synthesis of aristolactam 327 feature an acyclic diene, an
uncommon occurrence in aryne Diels–Alder methodology.
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Scheme 1.57.  Castedo’s 1995 synthesis of atherosperminine (332).
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The group of Watanabe and co-workers investigated the synthesis of acronycine
(338) by a formal [4 + 2] cycloaddition between anthranilate 334 and the unsymmetrical
aryne (337) derived from aryl bromide 335 (Scheme 1.58).67  Sequential bond formation
consisting of vinylogous lithium amide (336) addition to the aryne (337) and aryl anion
addition into the pendant ester resulted in direct formation of acronycine (338) in 41%
yield.
Scheme 1.58.  Watanabe’s 1984 synthesis of acronycine (338).
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In the mid-1980s, the groups of both Moody68 and Gribble69 separately reported
very similar approaches to the alkaloid ellipticine (344) using a 3,4-pyridyne
intermediate.  These reports, separated by only two months, represent the first use of
pyridyne in total synthesis.
Moody’s three-step synthesis of ellipticine (344) begins with conversion of indole
(339) to pyrone 340 (Scheme 1.59).68  Upon thermal decomposition of triazine 341,
nonselective [4 + 2] cycloaddition of pyrone 340 with 3,4-pyridyne (342) yielded a 1:1
separable mixture of ellipticine (344) and isoellipticine (345), following extrusion of
CO2.
Scheme 1.59.  Moody’s 1984 synthesis of ellipticine (344).
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By comparison, Gribble and co-workers relied upon a [4 + 2] cycloaddition
between furan 346 and 3,4-pyridyne (342) in their synthesis of ellipticine (344) (Scheme
1.60).69  The oxabicyclic product (348/349) was formed as a mixture of inseparable
isomers, which were readily converted to ellipticine (344) and isoellipticine (345) upon
reaction with sodium borohydride.
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Scheme 1.60.  Gribble’s 1984 synthesis of ellipticine (344).
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Soon after the extensive work of Castedo and co-workers involving the synthesis
of isoquinoline-derived alkaloids, the Rigby group reported a convergent route to the
naturally occurring isoquinoline N-nornitidine (357) employing a [4 + 2] cycloaddition
between an aryne and a vinyl isocyanate (Scheme 1.61).70  To this end, vinyl isocyanate
351 was prepared by a Curtius rearrangement of acid 350.  Upon decomposition of the N-
aminobenzotriazole (352) to the corresponding aryne (353) with stoichiometric
Pb(OAc)4, a [4 + 2] cycloaddition between the aryne (353) and the vinyl isocyanate (351)
produced pentacyclic isoquinolone 355 following tautomerization of the initial
cycloadduct (354).  Once again, this serves as a rare example of the use of an acyclic
diene in an aryne [4 + 2] cycloaddition.  Subsequent exposure of the isoquinolone (355)
to refluxing POCl3 directly generated the fully aromatized chloroisoquinoline (356) in
45% yield for the three-step sequence beginning with acid 350.  Finally, hydrogenolysis
of the chloride under standard conditions afforded N-nornitidine (357).
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Scheme 1.61.  Rigby’s 1991 synthesis of N-nornitidine (357).
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Departing from alkaloid synthesis, Watanabe and co-workers have targeted a
variety of naphthol and naphthoquinone natural products by [4 + 2] cycloadditions of
arynes with acylic dienolate-type dienes (Scheme 1.62).71  In the synthesis of plumbagin
(370) and plumbagin methyl ether (368), treatment of either aryl bromide 358 or 359 with
N,N-diethylsenecioamide (360) in the presence of LICA resulted in the regioselective
intermolecular [4 + 2] cycloaddition between aryne 361 or 362 and dienolate 363 to
furnish naphthols 366 (itself an unnamed natural isolate of Diospyros melanoxylon
ROXB) and 367, respectively.  These compounds were readily oxidized to their
corresponding naphthoquinones with oxygen and salcomine, affording plumbagin methyl
ether (368) and quinone 369.  The latter was converted to plumbagin (370) upon acidic
hydrolysis of the methoxy methyl ether protective group.  Additional naphthol and
naphthoquinone natural products prepared by these methods are shown in Scheme 1.62.
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Scheme 1.62.  Watanabe’s 1986 synthesis of plumbagin methyl ether (368), plumbagin (370), and
other naphthol and naphthoquinone natural products.
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Additional naphthol and naphthoquinone natural 
products:
In 1992, Suzuki and co-workers reported the synthesis of gilvocarcin M (382), a
member of the C-glycoside antibiotics that bear a common aromatic core with pendant
rare sugars.72  This work, including Suzuki’s later synthesis of gilvocarcin V (386),
includes the first example of an intermolecular furan-aryne Diels–Alder reaction applied
in total synthesis.  More specifically, the [4 + 2] cycloaddition between the aryne
generated from ortho-iodotriflate 374 and 2-methoxyfuran (375) produced naphthol 378
as the principle product in 88% yield following aromatization (Scheme 1.63).
Importantly, the selective formation of naphthol 378 in favor of the alternative isomeric
cycloadduct (isolated in 7% yield) demonstrates the predominance of electronic factors
over steric interactions in determining the regiochemical outcome of addition to
unsymmetrical arynes.  In this case, the more nucleophilic C(5) position of the furan
undergoes addition to the position meta to the inductively withdrawing benzyloxy group
on the intermediate aryne (376).  Under the basic reaction conditions, deprotonation of
the initial cycloadduct (377) led to ring-opening aromatization, yielding naphthol 378.
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Scheme 1.63.  Suzuki’s 1992 synthesis of naphthol 378 en route to the gilvocarcin antibiotics.
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Naphthol 378 served as a key intermediate in the synthesis of both gilvocarcin M
and V, which differ only in the identity of the C(8) substituent.  Acylation of the hydroxyl
group of naphthol 378 with either acid chloride 379 or carboxylic acid 383 produced aryl
esters 380 and 384, respectively (Scheme 1.64).  Treatment of iodide 380 or triflate 384
with a palladium source resulted in ring-closing C–H functionalization to afford
tetracycles 381 and 385, respectively.  Global deprotection of tetracycle 381 furnished
gilvocarcin M (382), while tetracycle 385 required five additional steps for installation of
the C(8) vinyl group and completion of gilvocarcin V (386).  Furthermore, the synthesis
of these two natural products determined the absolute configuration of the gilvocarcins to
be the opposite of that originally proposed at the time of isolation.73  The enantiomer
prepared by Suzuki (shown in Schemes 1.63 and 1.64) was proven to be the non-natural
enantiomer of the gilvocarcins.
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Scheme 1.64.  Completion of gilvocarcin M (382) and V (386) by Suzuki and co-workers (1992).
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Soon after their synthesis of the gilvocarcins, Suzuki and co-workers reported the
total synthesis of antibiotic C104 (393), a member of the angucycline class of
antibiotics.74  The tetracyclic aromatic core of the natural product was prepared by a
regioselective intermolecular aryne Diels–Alder cycloaddition with a functionalized furan
serving as the diene.  In fact, the authors were able to carry out a one-pot procedure
consisting of in situ generation of silyloxyfuran 388 from butenolide 387, followed by the
[4 + 2] cycloaddition with the aryne derived from iodoaryl triflate 389 (Scheme 1.65).
The cycloadduct initially formed by this sequence (390) undergoes ring-opening
aromatization under the reaction conditions to yield tetracycle 391.  However, this
intermediate was found to be unstable and was thus treated with CAN upon workup to
give the quinone (392) as the final product of this sequence.  Importantly, the aryne
cycloaddition proceeded with a high degree of regioselectivity to provide quinone (392)
in greater than a 14:1 ratio over the minor isomeric quinone.  Over 11 subsequent
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synthetic operations, quinone 392 was advanced to antibiotic C104 (393), thereby
establishing the absolute configuration of the natural product.
Scheme 1.65.  Suzuki’s 1995 synthesis of antibiotic C104 (393).
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Among the examples in the literature of aryne [4 + 2] cycloadditions in natural
product synthesis that have employed acyclic dienes are Hoye’s syntheses of
michellamines A–C (413–415),75 korupensamine C (409), and ancistrobrevine B (411)76.
In each of these syntheses, the Diels–Alder reaction between the dienolate of N,N-
diethylsenecioamide (360) and the aryne generated in situ from 2,4-dibromo phenol
derivatives 394 and 395 resulted in the selective formation of naphthols 400 and 401,
respectively (Scheme 1.66).  Close examination of the aryne precursors (394 and 395)
reveals that, upon removal of the proton between both bromides, two potential arynes
could result from base-promoted dehydrohalogenation: 405 and 406.  Although a number
of side products are observed in this reaction in addition to the desired product, they all
arise from reaction with the para-bromo aryne (406).  Furthermore, the cycloaddition
itself proceeds with good selectivity for naphthols 400 and 401 over isomeric naphthol
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407 (5:1 ratio of 400:407).  The desired naphthol products (400 and 401) were
subsequently converted to their respective boroxines (402 and 403) through methylation
of the free phenol and borylation.
Scheme 1.66.  Synthesis of naphthyl boroxines (402 and 403) by aryne Diels–Alder cycloadditions
(1994).
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Upon synthesis of the required boroxines (402 and 403), palladium-catalyzed
biaryl coupling with either iodotetrahydroisoquinolines 408 or 410 yielded a pair of
naphthyl tetrahydroisoquinolines, which were separately advanced to korupensamine C
(409) and ancistrobrevine B (411), respectively, upon cleavage of the benzyl groups and
separation by HPLC (Scheme 1.67).  Completion of the michellamines (413–415) (as an
inseparable mixture) was achieved in a similar manner through coupling of boronic acid
403 with iodotetrahydroisoquinolines 408 followed by removal of the methoxymethyl
ether to yield naphthyl tetrahydroisoquinoline 412 as a 4:3 mixture of diastereomers.
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Oxidative dimerization, reduction/global deprotection, and HPLC separation provided
michellamines A, B, and C in a ratio of 1:2:1.
Scheme 1.67.  Hoye’s syntheses of korupensamine C (409), ancistrobrevine B (411), and
michellamines A–C (413–415) (1994 and 1996).
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More recently, Martin and co-workers have employed aryne-furan Diels–Alder
reactions en route to the glycosidic antibiotic vineomycinone B2 methyl ester (423).77  In
this unique approach, the authors rely upon a tandem tethered [4 + 2] cycloaddition
Chapter 1 – A Comprehensive History of Arynes in Natural Product Total Synthesis 58
strategy to append both aromatic rings of the tricyclic core to a central diaryne.  To this
end, a tandem cycloaddition precursor (419) was constructed by sequential Mitsunobu
reactions beginning with phenol 417 and furanyl fragments 416 and 418 (Scheme 1.68).
Treatment of tetrabromoarene 417 with n-BuLi triggered a cascade sequence consisting
of two separate intramolecular aryne-furan [4 + 2] cycloadditions to yield cycloadduct
419 as an inconsequential mixture of diastereomers in excellent yield.  Cleavage of the
silyl tethers and oxidation of the system was accomplished by treatment of
biscycloadduct 420 with base followed by acid, affording anthrarufin 421 upon air
oxidation.  Critically, use of the silyl tethers dictated the regioselectivity of the
cycloadditions to provide only the desired anthrarufin isomer (421).  Finally, the
synthesis of vineomycinone B2 methyl ester (423) was completed by a three-step
sequence involving protecting group removal and alteration of the side chain oxidation
state.
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Scheme 1.68.  Martin’s 2006 synthesis of vineomycinone B2 methyl ester (423) by tandem tethered
aryne cycloadditions.
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Departing from aryne Diels–Alder reactions with furans, Lautens and co-workers
utilized a [4 + 2] cycloaddition between an aryne derived from dibromoarene 424 and N-
Boc-pyrrole (425) to access azabicycle 426 en route to the alkaloid (+)-homochelidonine
(431) (Scheme 1.69).78  In this case, the tetracyclic product (426) does not undergo
immediate ring opening.  Instead, following exchange of the carbamate, treatment of
azabicycle 427 with a chiral palladium catalyst and arylboronic acid 428 resulted in an
asymmetric migratory insertion of the meso azabicycle (427) into an aryl palladium(II)
species, forming intermediate 429.  Following this insertion event, %-elimination of the
bridging heteroatom afforded homoallylic carbamate 430 in 90% ee.79  Finally,
homoallylic carbamate 430 was converted into (+)-homochelidonine (431) over five
synthetic steps.
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Scheme 1.69.  Lautens’ 2007 synthesis of (+)-homochelidonine (431).
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In 2008, Stoltz and co-workers reported a unique annulation of N-acyl enamines
and arynes to generate isoquinolines.80  The reaction is believed to proceed through a
formal [4 + 2] addition reaction between the N-acyl enamine (432) and the aryne (433,
derived from silyl aryl triflate 209) followed by dehydrative aromatization under the
reaction conditions (Scheme 1.70).  By this method, any position on the isoquinoline
heterocyclic scaffold can be readily functionalized, rendering it ideal for use in natural
product total synthesis.  To date, the Stoltz group has reported two different syntheses
employing this novel aryne annulation.
Scheme 1.70.  Stoltz’s aryne annulation with N-acyl enamines to produce isoquinolines.
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In the synthesis of the papaverine, a clinically used non-narcotic antispasmotic
agent, annulation of the aryne generated in situ from silyl aryl triflate 438 with N-acyl
enamine 437 (available in one step from homoveratric acid and serine methyl ester)
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produced tetrasubstituted isoquinoline 439 in good yield (Scheme 1.71).80  Saponification
and thermal decarboxylation furnished the natural product (440) in three steps.
Scheme 1.71.  Stoltz’s 2008 synthesis of papaverine (440).
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A greater extension of this work can be seen in Stoltz’s synthesis of the
tetrahydroisoquinoline antitumor antibiotic (–)-quinocarcin (447) (Scheme 1.72).81  The
success of the approach hinged on the sequential regioselective aryne annulation and
diastereoselective reduction of the isoquinoline to generate the tetrahydroisoquinoline
found in the natural product.  Annulation of the aryne derived from 3-methoxy silyl aryl
triflate 441 with enantioenriched N-acyl enamine 442 (available in 4 steps from known
compounds) yielded isoquinoline 443 as a single isomer.  Subsequent two-step reduction
of the isoquinoline proceeded with 3:1 diastereoselectivity for the initial reduction and
complete diastereoselectivity for the secondary reduction of the resulting enamine,
affording tetrahydroisoquinoline 445a  as the major diastereomer in 55% yield.
Following thermal lactamization to yield tetracycle 446, (–)-quinocarcin (447) was
completed by a three-step sequence involving debenzylation/reductive methylation,
saponification, and reductive closure of the oxazolidine ring.  Overall, this 11-step
enantioselective synthesis of (–)-quinocarcin (447) is the shortest to date.
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Scheme 1.72.  Stoltz’s 2008 enantioselective synthesis of (–)-quinocarcin (447).
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The most recent example of the application of an aryne [4 + 2] cycloaddition to
natural product synthesis is Buszek’s syntheses of cis-trikentrin A (454) and herbindole A
(455).82  This work significantly differs from the various syntheses described above in
that the aryne counterpart is a 6,7-indolyne.  More specifically, elimination of 6,7-
dibromoindoles 448 and 449 with n-BuLi generated the corresponding 6,7-indolynes
(450 and 451), which, upon treatment with cyclopentadiene, underwent a [4 + 2]
cycloaddition to afford tetracycles 452 and 453, respectively (Scheme 1.73).  These
intermediates were then advanced to cis-trikentrin A (454) and herbindole A (455),
respectively, over four steps.
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Scheme 1.73.  Buszek’s 2009 syntheses of cis-trikentrin A (454) and herbindole A (455).
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1.4.2  [2 + 2] Aryne Cycloaddition Strategies
Aryne [2 + 2] cycloadditions are some of the most poorly developed and
underutilized methods, largely due to significant side product formation.  To date, there
has been only one reported total synthesis employing an aryne [2 + 2] cycloaddition.  In
1982, Stevens and co-workers disclosed the synthesis the quinone methide diterpene,
taxodione (464), by a convergent route including a [2 + 2] cycloaddition between an
aryne and a ketene acetal (Scheme 1.74).83  In the event, treatment of aryl bromide 456
with sodamide in THF in the presence of 1,1-dimethoxyethylene (457) resulted in
regioselective formation of benzocyclobutene 459, which was immediately hydrolyzed to
benzocyclobutenone 460.  Addition of the organolithium reagent derived from vinyl
chloride 461 to the benzocyclobutenone (460) and regioselective, yet contrasteric, ring
fragmentation of the resulting benzocyclobutenol (462) yielded enone 463, which was
readily advanced to taxodione (464).
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Scheme 1.74.  Stevens’ 1982 synthesis of taxodione (464).
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1.5  METAL CATALYZED ARYNE REACTION STRATEGIES
Among all of the known reactions involving arynes, metal-catalyzed processes are
still considered to be underdeveloped.  In fact, metal-catalyzed reactions of arynes have
only been employed in total synthesis on one occasion by Mori and co-workers en route
to a series of aryl-naphthalene lignans.84  In this elegant approach, the naphthyl portions
of taiwanins C (469) and E (468) and dehydrodesoxypodophyllotoxin (472) were targeted
by a palladium-catalyzed [2 + 2 + 2] cocyclization of an aryne and diyne.  Cocyclization
of sesamol-derived diyne 465 with the aryne generated in situ from silyl aryl triflate 212
resulted in formation of arylnaphthalene 467, which was subsequently converted to
taiwanin E (468) in six additional steps and taiwanin C (469) over five steps (Scheme
1.75).  Alternatively, use of diyne 470 (derived from 3-(trimethoxyphenyl)propiolic acid)
in the palladium-catalyzed [2 + 2 + 2] cocyclization afforded trimethoxyarylnaphthalene
471, which was advanced to dehydrodesoxypodophyllotoxin (472) over eight synthetic
transformations.
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Scheme 1.75.  Mori’s 2004 synthesis of taiwanin C (4 6 9 ), taiwanin E (468), and
dehydrodesoxypodophyllotoxin (472).
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1.6  CONCLUDING REMARKS
When J. D. Roberts first assigned the structure of benzyne in 1953, few could
have recognized the significant synthetic potential of this highly reactive intermediate.
However, to the benefit of the synthetic organic chemistry community, the manifold
types of reactivity possessed by arynes have been explored and exploited largely through
efforts aimed at the synthesis of natural products.  Since the first aryne-based total
synthesis in 1967, there has been a progression from early strategies that
monofunctionalize aryne intermediates to approaches that utilize the full potential of the
uniquely reactive triple bond to generate 1,2-disubstituted arenes.  While there has been
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significant progress in expanding the utility of arynes in organic synthesis, there is still
work that remains in increasing the yields of theses processes and minimizing
background reactions.  Fortunately, the recent resurgence in aryne research promises to
improve what is already known while adding to the known compendium of aryne
transformations.
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Chapter 2
The Total Synthesis of (–)-Curvularin
2.1 INTRODUCTION
2.1.1 Benzannulated Natural Products
Benzannulated macrolactones are an ever-growing class of natural products with
potential therapeutic and agrochemical applications.  As part of our ongoing research
directed toward the development of new reactions of arynes, we have targeted these
natural products in a general sense by using an acyl-alkylation reaction between an aryne
and a !-ketolactone.  As a demonstration of this strategic disconnection, we chose as our
initial target (–)-curvularin, a polyketide natural product isolated from several species of
the mold Curvularia that has recently been shown to be an inhibitor of human-inducible
nitric oxide synthase expression.  The development of a general and convergent synthesis
of curvularin would provide access to valuable benzannulated macrolactone natural
products and various synthetic analogs for biological evaluation.
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2.1.2 Isolation and Structural Determination of (–)-Curvularin and Related
Natural Products
The benzannulated macrolactone natural product (–)-curvularin (221) was first
isolated in 1956 by Musgrave and co-workers from a mold of the species Curvularia
(Figure 2.1).1  Over the next several years, the structure was determined by a combination
of degradation and reactivity studies without the aid of NMR experiments.2  Curvularin
was isolated along with a related natural product, (–)-",!-dehydrocurvularin (473);
despite its similarity to curvularin, the structure of " ,!-dehydrocurvularin was not
elucidated until 1967.3  Following the first isolation reports, curvularin (and related
natural products) has since been isolated from a number of other fungal species, such as
Penicillium,4 Cochiobolus, and Alternaria.
Figure 2.1. (S)-(–)-Curvularin (221) and (S)-",!-dehydrocurvularin (473).
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Since the initial discovery of curvularin (221) and its ",!-dehydro relative (473),
several other members of the curvularin family have been isolated from a range of natural
sources (Figure 2.2).  Among the earliest curvularin relatives isolated were curvulin (224)
and curvulinic acid (474) from Curvularia siddiqui and Curvularia ellisii.5  These
compounds are unique in this family of natural products for lacking the characteristic
benzannulated macrolactone.  In addition to these isolates, several relatives of curvularin
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 79
containing the signature 12-membered lactone have been found in nature, including
various !-hydroxycurvularins (482–485), #- and $-hydroxy-",!-unsaturated curvularins
(478–481), and 12-oxocurvularin (476 and 477).6  Notably, these structural relatives have
been isolated in enantiopure forms with both R and S absolute configurations at the C(15)
stereocenter.  This difference in absolute configuration appears to be due to
stereochemical variability in polyketide biosynthesis in different fungal sources.  The
final noteworthy member of the curvularin family, citreofuran (486), contains a bridging
furan ring within the macrolactone moiety.7
Figure 2.2. Curvularin (221) and related natural products.
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In addition to the curvularins, there are a large number of biogenetically-related
septa-, octa-, and nonaketide natural products that possess benzannulated macrocycles
resulting from alternative biosynthetic cyclizations of linear precursors.  These
polyketides include lasiodiplodin (487),8 radicicol (488),9 zearalenone (489),10 the
xestodecalactones (490 and 491),11 and sporostatin (492),12 to name a few (Figure 2.3).
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Figure 2.3. Polyketide benzannulated macrocyclic natural products.
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2.1.3 Biosynthetic Studies of (–)-Curvularin
Curvularin and related natural products are biosynthesized by a polyketide
pathway in nature.  Vederas and co-workers have studied some aspects of the
biosynthesis of ",!-dehydrocurvularin in Alternaria cinerariae with 13C and 2H labeling
studies.13  They first determined that ",!-dehydrocurvularin arises from the condensation
of eight acetate units in the expected head-to-tail arrangement typical of polyketide
biogenesis (Figure 2.4).  From here, the oxidation states and identities of several
intermediates bound to polyketide synthase (PKS) enzymes were identified; these
intermediates include diketides 493 and 494 and tetraketide 495.  Importantly, tetraketide
496 was not incorporated by the PKS enzymes into the natural products, indicating that
",!-dehydrocurvularin (473) might be the initial product of the PKS biosynthetic
pathway.
Figure 2.4. Acetate assembly in ",!-dehydrocurvularin (473) and potential starting material for PKS
enzymes.
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This result seems to suggest that curvularin (221) is produced via " ,!-
dehydrocurvularin (473) in nature by a post-PKS transformation.  In attempts to verify
this potential pathway, Vederas investigated the potential for oxidation of curvularin
(221) to ",!-dehydrocurvularin (473) by cytochrome P450 enzymes.  However, a series of
experiments showed that P450 enzymes are not involved in the oxidation of curvularin
(221) (or other reduced structures) to ",!-dehydrocurvularin (473).
During the course of these investigations, Vederas also isolated quantities of 11-
hydroxycurvularin (482 and 484) as a 2.6:1 mixture of diastereomers at C(11) displaying
identical labeling patterns to the " ,!-dehydrocurvularin isolated with it.  Further
experiments, however, demonstrated that the co-occurrence of 11-hydroxycurvularin
(482 and 484) with ",!-dehydrocurvularin (473) is not due to any fungal transformation
but instead is a result of conjugate addition of water catalyzed by some component in the
media.
These studies have led Vederas and co-workers to postulate the biosynthetic
pathway leading to ",!-dehydrocurvularin (473), curvularin (2 2 1 ) and 11-
hydroxycurvularin (482 and 484) shown in Scheme 2.1.  Importantly, this pathway
supports the hypothesis that tetraketide 501 possesses the final oxidation state installed by
the PKS enzyme.  Incorporation of the last four acetate units by the PKS enzyme does not
require any reduction, suggesting that ",!-dehydrocurvularin (473) is the initial product
of the polyketide pathway.  Curvularin (221) and 11-hydroxycurvularin (482 and 484) are
the products of subsequent post-PKS transformations.
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Scheme 2.1. Proposed biosynthesis of curvularin (221).
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2.1.4 Biological Activity of (–)-Curvularin
Some of the earliest biological studies on curvularin and ",!-dehydrocurvularin
demonstrated its cytotoxic activity toward sea urchin embryogenesis by acting as a
spindle poison during cell division.14  Curvularin was able to effectively inhibit cell
division at concentrations of 2.5 µg/mL by disordering microtubule centers in
centrosomes and inducing barrel-shaped spindles.  ",!-Dehydrocurvularin was somewhat
more active, inhibiting cell division at a concentration of 1.2 µg/mL.  Itoh and co-workers
noted that the efficacy of curvularin (221) is strikingly similar to a compound called T-1
(503) (Figure 2.5), which also possesses a 2,4-dihydroxybenzene core.15  Although T-1 is
about 100 times more active than curvularin, Itoh postulates that the 2,4-
dihydroxybenzene moiety is required for induction of barrel-shaped spindles.
Figure 2.5. Common structural motifs in curvularin (221) and T-1 (503).
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In addition to its effect on cell division, curvularin and related compounds are
well known for their phytotoxicity.  In fact, many of the known fungal sources of
curvularin are plant pathogens.  Studies by Robeson and co-workers determined LD50
values of 21 and 15 µg/mL for curvularin and ",!-dehydrocurvularin, respectively, in
assays with cucumber protoplasts.16
The de Souza group has evaluated the antimycobacterial activity of curvularin and
",!-dehydrocurvularin against Mycobacterium tuberculosis H37Rv, a multiple drug-
resistant bacteria responsible for tuberculosis.17  The minimal inhibitory concentration
(MIC) values for curvularin and ",!-dehydrocurvularin were 642 and 40 µmol/L,
respectively.  Furthermore, IC50 values were also determined to be 300 and 30 µmol/L for
curvularin and ",!-dehydrocurvularin, respectively.  In this study, which examined a
range of natural isolates against M. tuberculosis, phenolic compounds displayed the
greatest activity.  Despite the significant antimycobacterial activity displayed by both
these fungal isolates, the selectivity indices (SI) were only 0.47 and 0.75 for curvularin
and ",!-dehydrocurvularin, respectively.  It is generally accepted that SI values above 10
are good indications of the therapeutic safety and effectiveness of a potential drug
candidate against tuberculosis.
In addition to M. tuberculosis H37Rv, curvularin and ",!-dehydrocurvularin have
each been tested against a variety of fungal, bacterial, and tumor cell lines.  Xie and
coworkers found that curvularin and ",!-dehydrocurvularin were both weakly bioactive
against the fungi Saccharomyces cerevisiae Hansen (MIC values of 750 and 375 µg/mL,
respectively) and  Sclerotinia sclerotiorum (MIC values of >3000 µg/mL, each).18
Furthermore, ",!-dehydrocurvularin showed significant activity against the bacterial
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strain Staphylococcus aureus (MIC value of 375 µg/mL), while curvularin was inactive
against this strain.
This same study by Xie also examined the activity of curvularin and " ,!-
dehydrocurvularin against four cancer cell lines and determined IC50 values for each.  The
results are shown in Table 2.1, with Taxol activity shown for comparison.
Table 2.1. IC50 values of curvularin and ",!-dehydrocurvularin against cancer cell lines.
A549 HeLa Ehrlich MCF-7
Curvularin
!,"-Dehydrocurvularin
Taxol
142.6 92.5 47.8 113.6
15.3 10.3 20.4 19.8
4.5 7.4 8.6 3.2
IC50 values in µg/mL
Most recently, curvularin was found to be an inhibitor of human-inducible nitric
oxide synthase (iNOS) expression in the human epithelial alveolar cell line A549/8.19
Aberrant iNOS expression, leading to excessive nitric oxide (NO) production, has been
implicated in several human diseases, such as rheumatoid arthritis, multiple sclerosis,
asthma, colitis, psoriasis, neurodegenerative diseases, as well as transplant rejection,
tumor development, and septic shock.  One approach to block iNOS-dependent NO
production is the suppression of iNOS induction by targeting the interferon-# Janus
kinase and signal transducer and activator of transcription (IFN-#-JAK-STAT) pathway
with small molecules.  Kleinert and co-workers have found that curvularin inhibits
cytokine-induced activity of the human iNOS promoter, cytokine-induced iNOS mRNA
expression, and cytokine-induced NO production in a concentration-dependent manner.
From these studies, it appears that curvularin prevents tyrosine (Tyr701) phosphorylation
of STAT1, thereby disrupting the IFN-#-JAK-STAT pathway to iNOS induction.
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2.2 PREVIOUS SYNTHETIC EFFORTS TOWARD (–)-CURVULARIN
2.2.1 Introduction
There have been numerous synthetic efforts toward curvularin since its first
isolation in 1956.  Of these efforts, four have resulted in completed total syntheses of the
natural product prior to our synthesis.  Several other groups have completed syntheses of
the benzannulated framework of curvularin as well as protected variants of the natural
product.
While several approaches have been examined to forge the 12-membered
benzannulated macrolactone, three strategies predominate.  The most obvious
disconnection for the 12-membered ring is along the C–O bond of the lactone to give a
",%-hydroxyacid intermediate (504) (Scheme 2.2).  However, despite the simplicity of
this approach, all but one attempt in the literature to form this bond have failed (vide
infra).  Alternatively, the macrolactone of curvularin can be disconnected by an
intramolecular Friedel–Crafts acylation of a symmetric resorcinol derivative (505).  This
is by far the most commonly reported method for generating the 12-membered ring.  The
final, and most recently applied, strategy for macrocyclization relies on a ring-closing
metathesis (RCM) of an appropriately substituted ",%-diene (506).
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Scheme 2.2. Common approaches toward curvularin (221).
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Although each of these disconnections provides access to the natural product,
their common linear strategic approach imposes numerous limitations to synthetic
efficiency.  In general, to access the cyclization precursors (e.g., 504–506), the required
functionality must be built off a single aromatic ring.  To prepare intermediates such as
504 and 506, this means that each half of the 12-membered macrocycle is separately
appended to the resorcinylic fragment.
2.2.2 Studies Toward the Total Synthesis of Curvularin
Some of the earliest synthetic studies toward curvularin were performed by Baker,
Bycroft, and Roberts in an attempt to confirm the postulated structure of the natural
product.20  In their first report, several attempts were made to form the 12-membered ring
by a macrolactonization event from hydroxyacid 509 (Scheme 2.3).  Baker and co-
workers note that all attempts to lactonize the hydroxyacid (509) using trifluoroacetic
anhydride or DCC under a variety of conditions failed to yield any quantites of
macrolactone 510.  Abandoning this approach, they turned their attention to an alternative
disconnection involving an intramolecular Friedel–Crafts acylation of protected
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resorcinol derivative 512 via benzyl ester 511.  In the event, treatment of carboxylic acid
512 with a mixture of trifluoroacetic acid and trifluoroacetic anhydride at room
temperature provided di-O-methylcurvularin (510), albeit in only 14% isolated yield.
With this compound in hand, a sample of curvularin (221) isolated from Curvularia was
doubly methylated; the product of this reaction (510) matched the product of the
Friedel–Crafts acylation (510), thus confirming the structure of curvularin (221).
Importantly, Baker and co-workers never attempted to demethylate the two phenolic
ethers of 510 to produce curvularin (221).
Scheme 2.3. Baker’s’ approach to di-O-methylcurvularin (510).
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Following the structural proof of curvularin, Tsuji and co-workers sought to build
the framework of curvularin in a more rapid fashion.21  Their strategy focused on a
carbonylative Pd-catalyzed coupling of a benzyl chloride (514) and a secondary alcohol
(516) (Scheme 2.4).  Secondary alcohol 516 was prepared in 4 steps from acetate 515,
while 3,5-dimethoxybenzyl chloride (514) was prepared in 4 steps from resorcinylic acid
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513.  Treatment of benzyl chloride 514 and secondary alcohol 516 with catalytic
PdCl2(PPh3)2 under an atmosphere of carbon monoxide generated ester 511 in 70%
isolated yield.  At this point, Tsuji and co-workers claim that the conversion of ester 511
to curvularin (221) is a known process, citing the early work of Baker and co-workers
(vide supra).  However, this appears to be an erroneous claim of a formal total synthesis
of curvularin (221); ester 511 has only been converted to di-O-methylcurvularin (510) in
previous literature reports.  As previously stated, to date there are no reports of the
conversion of di-O-methylcurvularin (510) to curvularin (221) by demethylation.
Scheme 2.4. Tsuji’s synthesis of di-O-methylcurvularin (510).
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Despite great effort to close the macrocycle of curvularin by macrolactonization
reactions, only one report has demonstrated the viability of this approach.  Wasserman
and co-workers found that macrolactonization could be effected by masking the
carboxylic acid functionality as a diphenyl oxazole.22  Oxazole 518, bearing a pendant
secondary alcohol, was prepared in 4 steps from the known compounds "-hydroxy
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ketone 517 and carboxylic acid 507 (Scheme 2.5).  Upon reaction with singlet oxygen,
the oxazole functionality (518) was converted to a reactive triimide (519), which was
trapped by the pendant alcohol upon acidic activation to yield macrolactone 510.  This
single example of macrolactonization directed toward curvularin resulted in the synthesis
of di-O-methylcurvularin (510).
Scheme 2.5. Wasserman’s macrolactonization approach to di-O-methylcurvularin (510).
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Subsequent to Wasserman’s publication, Subba Rao and co-workers reported the
same oxazole-based macrolactonization to produce di-O-methylcurvularin (510).23  Like
Tsuji, however, Subba Rao erroneously asserts that synthesis of di-O-methylcurvularin
(510) constitutes a formal total synthesis of curvularin (221), citing the 1967 publication
by Baker, Bycroft, and Roberts (vide supra).
Synthetic studies of compounds related to curvularin, both natural and non-
natural, followed these early efforts toward the natural product’s benzannulated ring
system.  The majority of these published reports use the ubiquitous intramolecular
Friedel–Crafts acylation strategy to close the 12-membered lactone ring.
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Ayyangar and co-workers targeted the framework of 12-oxocurvularin (476) and
citreofuran (486) in their synthesis of di-O-methyl-12-oxocurvularin (522).24  Following
preparation of furan 520, oxidative ring opening of the furan to ketoacid 521 and
intramolecular Friedel–Crafts acylation provided di-O-methyl-12-oxocurvularin (522) in
16% yield (Scheme 2.6).
Scheme 2.6. Ayyangar’s synthesis of di-O-methyl-12-oxocurvularin (522).
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Similarly, Pan and co-workers completed the first total syntheses of the natural
products 11"- (525) and 11!-methoxycurvularin (526).25  Intramolecular Friedel–Crafts
acylation of !-methoxyacid 523 resulted in a 42% isolated yield of macrocycle 524, a
significantly higher yield than that reported for substrates lacking the methoxy group
(Scheme 2.7).  Furthermore, this report is the only one in which the methyl ethers were
successfully cleaved, revealing the resorcinol core and furnishing the natural product.
Although the synthetic sequence shown only includes 11"-methoxycurvularin (525), the
same sequence was executed for the 11!-diastereomer (526).  Subsequent to Pan’s report,
Yadav and co-workers utilized the same final two transformations to generate these
natural products in nearly identical yields.26
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Scheme 2.7. Pan’s synthesis of 11"- (525) and 11!-methoxycurvularin (526).
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The final synthetic study of the curvularin framework was reported by Kuwahara
and co-workers and employed a ring-closing metathesis (RCM) to close the 12-
membered macrolactone.27  Kuwahara notes that this highy optimized RCM, which
required microwave irradiation with 35 mol% catalyst 146, only generated the desired
product (528) as the E-isomer and without any undesired olefin migration (Scheme 2.8).
Furthermore, cleavage of the two methyl ethers proved to be unsuccessful with a variety
of Lewis acids.
Scheme 2.8. Kuwahara’s RCM approach to curvularin (221).
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2.2.3 Previous Total Syntheses of Curvularin
The first total synthesis of curvularin was reported in 1977 by Gerlach.28  Building
upon difficulties reported by previous groups (vide supra), Gerlach protected the
resorcinol of curvularin at an early stage with removable benzyl groups and relied on an
intramolecular Friedel–Crafts acylation of 2-(trimethylsilyl)ethyl ester 533 to forge the
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12-membered macrolactone (Scheme 2.9).  Following the racemic synthesis of curvularin
by this route, Gerlach rendered the route enantioselective by beginning his synthesis with
(–)-(S)-#-valerolactone (530).  It is unclear exactly how the chiral (S)-#-valerolactone was
prepared and subsequently advanced to chiral ester 531, since the synthetic sequence is
not explicitly shown.  However, it appears from the references in this report that chiral
lactone 530 was prepared from (R)-glutamic acid (529) over a series of four steps.  From
this point, likely reduction of lactone 530 to the lactol, olefination, hydrogenation, and
esterification with 2-trimethylsilylethanol could have produced the hydroxyester (531)
used in the racemic synthesis of curvularin.  Secondary alcohol 531 was next acylated
with acyl chloride 532 to yield diester 533, which, upon exposure to a fluoride source,
provided acid 534.  In the final two steps of the synthesis, intramolecular Friedel–Crafts
acylation and hydrogenolysis of the benzyl ethers furnished the natural product, (–)-
curvularin (221), in eight linear steps from (S)-#-valerolactone (530).
Scheme 2.9. Gerlach’s total synthesis of (–)-curvularin (221).
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The second synthesis of curvularin was published in 1997 by Bracher and Schulte
and employs an enantiodivergent route to access both enantiomers of curvularin from a
single enantiomer of secondary alcohol (S)-536 (available in 2 synthetic steps from (S)-
propylene oxide) (Scheme 2.10).29  Beginning with carboxylic acid 535, Mitsunobu
reaction with secondary alcohol (S)-536 provided ester (R)-537 with complete inversion
of stereochemistry.  Alternatively, conversion of the acid (535) to the acid chloride (532)
and esterification with secondary alcohol (S)-536 yielded ester (S)-537.  Intermediates
(S)-537 a n d  (R)-537 were then each advanced through a sequence involving
saponification of the methyl ester, intramolecular Friedel–Crafts acylation, and
debenzylation to furnish (S)- and (R)-curvularin, respectively, in six linear steps from (S)-
propylene oxide.
Scheme 2.10. Bracher’s total synthesis of (–)- and (+)-curvularin (221).
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More recently, alternative strategies to close the macrolactone of curvularin have
been investigated.  In particular, ring-closing metathesis has proven to be a viable method
to construct the 12-membered ring in significantly higher yields than the ubiquitous
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intramolecular Friedel–Crafts acylation reaction.  In 2008, Kunz first published a RCM
approach to curvularin and several analogs for biological studies.30  Preparation of a
RCM substrate began with coupling of acid 535 and chiral secondary alcohol 538 to
generate ester 539 (Scheme 2.11).  Intermolecular Friedel–Crafts acylation of ester 539
with adipic acid derivative 540 (available in two steps from adipic acid) led to allyl ester
541, which was subsequently deallylated by palladium catalysis to yield the acid (542).
Kochi decarboxylation of carboxylic acid 542 then provided diene 543 in a modest 39%
yield for RCM studies.  Upon treatment with the Grubbs 2nd generation catalyst in toluene
at 80 °C, diene 543 underwent smooth ring closing to produce macrloactone 544 in 84%
yield and as a 7.4:1 mixture of E:Z olefin isomers.  Finally, reduction of the olefin and
debenzylation were accomplished simultaneously under palladium reduction conditions
to yield (–)-curvularin (221) in seven linear steps from adipic acid.
Scheme 2.11. Kunz’s total synthesis of (–)-curvularin (221).
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The final reported total synthesis of curvularin, by Mohapatra and co-workers,
also utilizes a RCM to close the 12-membered ring.31  However, RCM along the
C(11)–C(12) bond was targeted instead of the C(12)–C(13) bond, as in the synthesis by
Kunz.  The result is a synthesis that is longer than Kunz’s and includes significant
protecting group manipulation.  Beginning with benzyl alcohol 545, oxidation and Wittig
olefination provided styrene 546 (Scheme 2.12).  This intermediate (546) was converted
to the primary PMB-protected alcohol (547) by hydroboration, oxidation, and alkylation
with PMBCl.  Arene 547 was formylated with DMF and subsequently allylated to
generate benzyl alcohol 548.  Protection of the secondary alcohol as a silyl ether followed
by cleavage of the PMB ether and two-step oxidation furnished carboxylic acid 549.
Acid 549 was next coupled to chiral secondary alcohol 550, yielding diene 551 as a 1:1
mixture of diastereomers.  Ring-closing metathesis of diene 551 with Grubbs 2nd
generation catalyst (146) resulted in macrolactone 552 as an unspecified mixture of E and
Z isomers in a combined 83% yield.  In the final steps of the synthesis, the secondary
alcohol was desilylated and oxidized, and the olefin and benzyl ethers were reduced to
provide (–)-curvularin (221) in 15 linear steps from benzyl alcohol 545.
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Scheme 2.12. Mohapatra’s total synthesis of (–)-curvularin (221).
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2.3 A CONVERGENT APPROACH TO (–)-CURVULARIN
2.3.1 Retrosynthetic Analysis
The common feature of the three approaches (i.e., macrolactonization,
intramolecular Friedel–Crafts acylation, and ring-closing metathesis) employed toward
the synthesis of the curvularin framework is that they all require a stepwise formation of
the C(2)–C(3) and C(8)–C(9) bonds that connect the resorcinylic core to the
macrolactone (Scheme 2.13).  In designing our strategy toward the curvularin scaffold,
we aimed to eliminate this linearity in the synthesis by convergently bringing together
two separate fragments: an aromatic fragment and a macrolactone fragment (i.e., 555).  In
doing so, we sought to form both the C(2)–C(3) and the C(8)–C(9) bonds in a single
transformation.
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Scheme 2.13. Comparison of previous linear approaches to curvularin (221) to a convergent
assembly strategy.
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One powerful strategy for achieving a convergent assembly of curvularin is to
employ aryne intermediates in order to form the C(8)–C(9) and C(2)–C(3) concomitantly.
Throughout their history, arynes have demonstrated versatile reactivity, participating in
cycloaddition, polar, multicomponent, and even transition metal-catalyzed reactions
(Scheme 2.14).32,33  Beyond their diverse modes of reactivity, arynes have the ability to
form two new carbon–carbon or carbon–heteroatom bonds to the aromatic ring in a single
step, allowing for a rapid and convergent synthesis of highly functionalized arenes.  One
facet of aryne reactivity that is critical to their application in synthesis is the
regioselectivity with which unsymmetrically substituted arynes undergo addition.34
When they bear polarizing substitution, exquisite levels of regioselectivity are often
achievable, permitting the preparation of highly functionalized unsymmetrically
substituted arene products.35  Because of these properties as reactive intermediates, arynes
provide an excellent alternative to well-known classical methods of aromatic
functionalization that have significant limitations.
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Scheme 2.14. Representative reactions of benzyne (1).
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For these reasons, we targeted curvularin using an acyl-alkylation reaction of an
appropriately substituted aryne (556) with a !-ketolactone (218) (Scheme 2.15).  This
powerful transformation, developed by our group in 2005, represents a formal insertion
into the C(")–C(!) bond of the !-ketolactone (218), forms two new C–C bonds in a
single synthetic step (C(2)–C(3) and C(8)–C(9)), and expands the !-ketolactone (218) by
two carbons.  This strategic disconnection is the cornerstone of our rapid and convergent
synthesis of (–)-curvularin.  To this point, however, the acyl-alkylation reaction of an
aryne with a lactone substrate had never been examined.  As such, we sought to answer
two key questions before embarking on our synthetic effort: 1) whether !-ketolactone
218 would be a competent acyl-alkylation substrate and 2) whether an unsymmetrical
aryne such as 556 could react in a regioselective manner to give only the acyl-alkylation
product that corresponds to the structure of curvularin.
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Scheme 2.15. Retrosynthetic analysis of (–)-curvularin (221).
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2.3.2 The Direct Acyl-Alkylation of Arynes: Discovery and Substrate Scope †,36,37
Traditionally, the Stoltz lab has sought to develop new and innovative methods to
synthesize all-carbon quaternary stereocenters.38  As part of these efforts, we envisioned
that electrophilic arynes could serve as substrates for the formation of benzylic all-carbon
quaternary centers.  Specifically, we postulated that arynes, generated from o-silyl aryl
triflate precursors39 (209) by the action of fluoride ion, could undergo addition by a !-
ketoester substrate (557) to produce "-quaternary-!-ketoesters, such as 558 (Scheme
2.16).  To our surprise, though, "-arylation product 558 was the minor product of the
process; the major product was acyl-alkylated arene 559.  The acyl-alkylation product
(559) is the result of benzyne insertion into the ",! C–C bond of the !-ketoester and
presumably occurs by a formal [2 + 2] cycloaddition/fragmentation cascade (i.e., 560 &
561 & 562 & 563).  This result represents the first mild and direct aryne insertion into a
carbon–carbon bond.40,41
                                                 
† The work described in this section was performed by former Stoltz group graduate students Prof. Uttam
K. Tambar and Dr. David C. Ebner.  The initial discovery of the acyl-alkylation of arynes, reaction
optimization, and substrate scope investigations were carried out by Prof. Uttam K. Tambar.
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Scheme 2.16. The direct acyl-alkylation of arynes.
TMS
OTf
OEt
O O
+
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80 °C, 1.5 h
O
CO2EtOEt
O O
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+
OEt
O O
+
Cs+ O
CO2Et
Cs+ O
OEtO
Cs+
H+ H+
558, 42% yield 559, 53% yield209 557
1 561 562560
Following brief optimization studies to minimize the formation of "-arylation
side products, the substrate scope of this process was investigated.  In general, we found
that !-ketoesters possessing "-substitution furnish higher levels of "-arylation side
product than !-ketoesters lacking substitution at this position.  Examination of a range of
"-unsubstituted-!-ketoesters resulted in a wide range of acyl-alkylation products bearing
aliphatic (572–574), aryl (577), benzyl (575), and heteroatomic substitution (576) (Table
2.2).  Additionally, the ester moiety may be varied while maintaining good yields (578
and 579).  Furthermore, the reaction of methyl acetoacetate (229) with o-silyl aryl triflate
209 can be performed on scales greater than five grams and has been the subject of an
Organic Syntheses procedure.36b
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Table 2.2. Acyl-alkylation of arynes substrate scope: substituted !-ketoesters.
CsF (2.5 equiv)
MeCN (0.2 M)
80 °C, 45–60 min
TMS
OTf
209
R1 OR2
O O
563
+
O
R1
O OR2
564
entry
1
yield!-ketoestera product
OMe
O O
OMe
O O
O
CO2Me
O
CO2Me
OMe
O O
i-Pr
O
CO2Me
OEt
O O
Ph
O
CO2Et
Ph
OMe
O O
BnO
O
CO2Me
OBn
Ph OMe
O O Ph
O
CO2Me
O
O O
O
O
O
90%
2 78%
3 84%
4b 85%
5 53%
6 99%
7 72%
O
H
H H
R
H
O O
O
H
H H
R
H
O
O
8 75%
R = R =
229 572
565 573
566 574
567 575
569
568 576
577
570 578
571 579
a Reaction performed with 1.25 equiv ortho-silyl aryl triflate 209 relative to !-ketoester 563.
b Reaction performed with 2 equiv ortho-silyl aryl triflate 209 relative to !-ketoester 567.
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We next turned our attention to examination of substitution on the silyl aryl
triflate reaction partners.  These early studies showed that substituted silyl aryl triflates
bearing monosubstitution at the ortho (441) and meta (583) positions as well as
disubstitution (212) produced the corresponding acyl-alkylated arenes (584–587) in good
yields (Table 2.3).  Of particular note is the complete regioselectivity observed for the
reaction of an ortho-methoxy aryne to furnish acyl-alkylation product 584 as a single
isomer.  This indicates a likely stepwise mechanism leading to the key
alkoxybenzocyclobutene intermediate (562) featured in Scheme 2.16.  In the case of less
polarizing substituents on the aryne precursor, such as methyl silyl aryl triflate 583, little
to no selectivity for a given acyl-alkylation isomer was observed (585 and 586).
Table 2.3. Acyl-alkylation of arynes substrate scope: substituted silyl aryl triflates.
82%
(1 : 1)
CsF (2.5 equiv)
MeCN (0.2 M)
80 °C
TMS
OTf
581
OMe
O O
229
+
O
O OMe
582
entry
1
yieldortho-silyl aryl triflatea product
O
CO2Me
O
CO2Me
O
CO2Me
95%
2b
3 75%
R3
R2
R1
R3
R2
R1
MeO
O
O
MeO
TMS
OTf
TMS
OTf
Me
TMS
OTf
O
O
O
CO2MeMe
Me
+
441 584
583 585 586
212 587
a Reaction performed with 2 equiv ortho-silyl aryl triflate 581 relative to !-ketoester 229.
b Reaction performed with 1.25 equiv ortho-silyl aryl triflate 583 relative to !-ketoester 229.
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An interesting variation on the acyl-alkylation was uncovered when linear !-
ketoesters were replaced with cyclic !-ketoesters.  Although these !-ketoester substrates
contain substitution at the "-position (590–593, 213), they underwent facile acyl-
alkylation to yield benzannulated acyl-alkylation products that were ring-expanded by
two carbon atoms.  The medium-sized rings furnished by this process continue to be
difficult structures to synthesize despite their prevalence in natural products and drug
substances.42  However, application of our optimized acyl-alkylation conditions to a
series of cyclic !-ketoesters (590–593, 213) led to formation of a range of bi- and
tricyclic benzannulated carbocycles (594–598) in good yields (Table 2.4).  Importantly,
the reaction conditions are not limited to those employing CsF in acetonitrile, and often
yields can be increased by altering the fluoride source, solvent, and temperature of these
transformation.  For example, the product in entry 1 of Table 2.4 can be obtained in 93%
yield upon use of KF/18-crown-6 in THF at room temperature (Scheme 2.17)
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Table 2.4. Ring-expansive acyl-alkylation reactions.
CsF (2.5 equiv)
MeCN (0.2 M)
80 °C
TMS
OTf
209
R1 OR3
O O
588
+
589
entry
1
yieldb!-ketoestera product
50%
2 61%
3 65%
R2 R
2
R1
OR3O
O
O
OEt
O
O
OMe
O
O
O
EtO
MeO
MeO
O
O OEt
O
OMeO
OEtO
O
OMe
OMe
4 45%
O
OMe
O
O
O
OMe
O O
OMe
O
O OMe
5 69%
590 594
591 595
213 596
592 597
593 598
a Reaction performed with 1.25 equiv ortho-silyl aryl triflate 209 relative to !-ketoester 588.
b The "-arylated !-ketoester was isolated as the major side product in these reactions.
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Scheme 2.17.  Optimized ring-expansive acyl-alkylation of silyl aryl triflate 209 and cylic !-ketoester
590.
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OTf
209
O
OEt
O
O
O OEt
590 594
KF, 18-crown-6
THF, 23 °C
(93% yield)
2.3.3 Regioselective Acyl-Alkylation of Highly Substituted Arynes†,35
It has been well established that substituted arynes undergo nucleophilic attack
with levels of regioselectivity dependent on the identity of substituents and their locations
relative to the reactive aryne triple bond.34  In our own investigations, we have observed
fully regioselective acyl-alkylation (i.e., 584) with the aryne (599) generated in situ from
a 3-methoxy-substituted silyl aryl triflate (441) (Scheme 2.18).  Beyond this example, we
have observed similar regioselectivity in aryne heteroannulation reactions of N-acyl
dehydroamino esters with the same silyl aryl triflate precursor (441) to yield methoxy-
substituted isoquinoline 600.43  Each of these products (584 and 600) stems presumably
from initial attack at C(1) of the aryne (599), which suggests that the ortho-methoxy
substituent electronically polarizes the triple bond and sterically shields the adjacent atom
to favor this reactivity.  More recently, we have been able to exploit this selectivity in
aryne acyl-alkylation/condensation sequences to produce either substituted
hydroxynaphthoquinones (602) or hydroxyisoquinolines (601).44  These observations led
us to investigate whether more highly functionalized silyl aryl triflates would also exhibit
the predicted regioselectivity seen for silyl aryl triflate 441.
                                                 
† The work described in this section was completed in collaboration with Christopher D. Gilmore, a current
graduate student in the Stotltz research group, and Pradeep Bugga, a former undergraduate researcher in the
Stoltz group.
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Scheme 2.18. Regioselective reactions of 3-methoxybenzyne (599).
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Specifically, we chose to examine whether unsymmetrically substituted
polyalkoxy silyl aryl triflates would react regioselectively.  Similar to the 3-methoxy
aryne (599), 4-methoxy aryne 603 also reacts in a regioselective manner,45,41n although
more modestly than aryne 599 (Scheme 2.19).  On the basis of these data, we chose to
examine two silyl aryl triflates (232 and 217) bearing alkoxy groups at both C(3) and
C(5), in which it is possible for the two alkoxy substituents to favor opposing sites of
nucleophilic attack upon the aryne triple bond (606 and 219).  Investigation of the
reactivity of precursors 232 and 217 would establish whether the influence exerted by the
C(3) substituent can override that of the C(5) alkoxy group.  Two additional silyl aryl
triflates (604 and 605) we have targeted feature methoxy groups at C(3) and C(4) of the
arynes (607 and 608), offering the potential for enhanced selectivity due to cooperative
electronic polarization of the triple bond.  Furthermore, precursors 604  and 605
incorporate additional substitution at C(5); to the best of our knowledge, arynes 607 and
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608 are the first examples of trisubstituted arynes derived from silyl aryl triflate
precursors.46
Scheme 2.19. Targeted polyalkoxy arynes.
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On the basis of the observation that aryne adducts derived from the 3-methoxy
silyl aryl triflate (599) have been employed in the context of total synthesis (Figure 2.6,
447),47 we believe that these more highly substituted nonsymmetrical precursors (607,
608, and 612) will provide valuable entry points into more complex natural products
(e.g., 221, 609, 610, and 611) were they also to react in a regioselective manner.  In
general, the use of aryne-based methods enables the convergent construction of
functionalized arenes, thereby circumventing the difficulties associated with traditional
late-stage elaboration of embedded aromatic rings.
As a demonstration of the advantages of this strategy, we report the synthesis and
regioselective reactions of four novel silyl aryl triflates (217, 232, 604, and 605) and the
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application of one of these precursors (2 1 7 ) to the synthesis of a simple
hydroxynaphthoquinone natural product.  In fact, these particular aromatic substitution
motifs were targeted for their prevalence in classes of natural products that possess both
diverse structures and significant biological activity (447, 221, 609, 610, and 611).
Figure 2.6. Representative natural products containing highly oxygenated arenes.
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The first aryne precursor we targeted was a protected resorcinylic silyl aryl triflate
(232) (Scheme 2.20).  Preparation of dimethoxy silyl aryl triflate 232 began with
bromination of commercially available 3,5-dimethoxyphenol (613) at low temperature to
form o-bromophenol 614.  This compound was then converted to the silyl aryl triflate
(232) by a known one-pot procedure involving silylation of the phenol, lithium-halogen
exchange, silyl group migration, and triflation.48
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Scheme 2.20. Preparation of silyl aryl triflate 232.
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Although dimethoxy silyl aryl triflate 232 contains functionality present in several
natural products, removal of the methyl groups would be required to access a large
number of these targets.49  To avoid the potentially harsh Lewis acidic conditions
commonly used to cleave the methyl groups (e.g., BCl3),50 we designed a dibenzyl variant
of precursor 217 (Scheme 2.21).  Beginning with phloroglucinol (615), a sequence
including monosilylation, dibenzylation, and desilylation generated phenol 616, which
was subsequently brominated to produce bromophenol 617.  Bromophenol 617 was then
converted to silyl aryl triflate 217 as before.
Scheme 2.21. Preparation of silyl aryl triflate 217.
(90% yield)
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Following our preparation of silyl aryl triflates 232 and 217, we progressed to
more highly substituted variants.  Specifically, we targeted a trioxygenated aryne derived
from silyl aryl triflate 604 (Scheme 2.22).  Beginning with brominated methyl gallate
derivative 618,51 reduction with DIBAL followed by Dess–Martin oxidation provided
aldehyde 619 in excellent yield.  Baeyer–Villiger oxidation with m-CPBA and basic
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methanolysis of the resulting formate ester produced bromophenol 620, which was
readily converted into silyl aryl triflate 604.
Scheme 2.22. Preparation of silyl aryl triflate 604.
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We next turned our attention to the preparation of silyl aryl triflate 605 because of
the prevalence of its substitution motif in several bioactive natural products.  We began
with a regioselective bromination of vanillin (621) to provide exclusively the 5-bromo
product, which was methylated to produce bromo dimethoxy benzaldehyde 622 (Scheme
2.23).52  Next, Stille coupling of the bromoarene (622) with tetramethyltin enabled the
introduction of the 5-methyl substituent to generate arene 623.53  Further elaboration of
this intermediate via one-pot Baeyer–Villiger oxidation and cleavage of the resultant
formate ester yielded intermediate phenol 624.  All attempts to install a bromide
selectively at C(2) of phenol 624 failed, instead resulting in exclusive bromination at
C(6).  In order to selectively functionalize phenol 624, we turned to a recently disclosed
3-step procedure for the general synthesis of o-silyl aryl triflates by Garg, et al.54
Analysis of this approach indicated that conversion of the phenol to a carbamate might
facilitate silylation at C(2) over C(6).  Application of this sequence to our intermediate
(624) allowed the direct ortho-silylation of carbamate 625 to produce the 2-silyl
carbamate (626) exclusively.  Subsequent cleavage of the carbamate and triflation of the
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resulting phenoxide furnished the desired aryne precursor (605) in 5 steps from known
aldehyde 623.
Scheme 2.23. Preparation of silyl aryl triflate 605 by directed ortho-lithiation of phenol derivative
625.
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Following preparation of silyl aryl triflates 217, 232, 604, and 605, we examined
their reactivities in acyl-alkylation reactions with various !-ketoesters (222, 225, and
229) (Scheme 2.24).55  To our delight, in each of these reactions only a single insertion
product was observed.  For silyl aryl triflates 232 and 217, the closer o-alkoxy substituent
completely overrides any influence of the distal alkoxy group.  In the case of acyl-
alkylation of precursors 604 and 605, slightly modified conditions varying solvent and
fluoride sources were required to generate the desired products.  The presence of
methoxy groups at both the ortho and meta positions of the arynes derived from 604 and
605 potentially influences the regioselectivity of their reactions in a cooperative manner.
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Scheme 2.24. Acyl-alkylation reactions of polyalkoxy silyl aryl triflates 232, 217, 604, and 605.
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Furthermore, we were able to verify the regioselective formation of arene 226 in
the acyl-alkylation of silyl aryl triflate 217 with !-ketoester 225 by its conversion to a
naturally occurring hydroxynaphthoquinone (228),56 previously isolated from a species of
the fungus Cercosporta (Scheme 2.25).  Cyclization and oxidation of ketoester 226 under
basic conditions yielded quinone 227 .  Subsequent debenzylation produced
hydroxynaphthoquinone 228, thus confirming the structure of arene 226.44,57
Scheme 2.25. Conversion of ketoester 226 to Cercospora isolate 228.
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In addition to acyl-alkylaton, exposure of silyl aryl triflate 605  to tetra-n-
butylammonium difluorotriphenylsilicate (TBAT) in the presence of N-acyl enamine 630
produced a single isomer of the product isoquinoline (631) in good yield (Scheme 2.26).43
Indeed, 631 corresponds to the isoquinoline produced from initial C(!) nucleophilic
addition of enamide 630 at C(1) of the aryne derived from precursor 605.
Scheme 2.26. Regioselective aryne heteroannulation of enamide 630 with silyl aryl triflate 605 to
yield isoquinoline 631.
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The regioselectivity displayed in these reactions underscores the importance of
methods that facilitate the direct and predictable introduction of highly substituted arene
components.  Our ability to employ these arynes in the syntheses of complex polycyclic
natural products hinges on the regioselectivity observed for silyl aryl triflates 232, 217,
604, and 605 in a variety of aryne annulation reactions.  In conjunction with their ability
to form multiple C–C and C–N bonds in a single transformation, these arynes have
enabled convergent approaches to several natural product classes, including the
curvularins, the integrastatins, and bis-tetrahydroisoquinoline alkaloids such as
jorumycin.
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2.3.4 The Enantioselective Total Synthesis of (+)-Amurensinine†,58,59,37
The first natural product completed by employing our acyl-alkylation approach
was (+)-amurensinine (216) (Scheme 2.27).  Amurensinine is a member of the isopavine
family of alkaloids, which are exemplified by a characteristic tetracyclic
tetrahydroisoquinoline core structure consisting of a doubly benzannulated
azabicyclo[3.2.2]nonane.60  Upon close examination of the products in Table 2.4 (vide
supra), we recognized that tricyclic acyl-alkylation product 596 bears a close resemblance
to the carbocyclic framework (214) of the alkaloid (+)-amurensinine (216).  In fact, !-
ketoester 213 already contained all the required aromatic functionality for the eastern half
of amurensinine; replacement of the parent silyl aryl triflate (209) with a substituted
aryne precursor (212) would provide access to the natural product.
Scheme 2.27. Retrosynthetic analysis of amurensinine (216).
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In the forward sense, !-ketoester was prepared beginning with homologation of
homoveratric acid (632) to acyclic !-ketoester 633 (Scheme 2.28).  Treatment of !-
ketoester 633  with p-ABSA resulted in formation of "-diazo-!-ketoester, which
underwent completely regioselective rhodium-catalyzed C–H bond insertion to produce
the desired cyclic !-ketoester (213).
                                                 
† The work described in this section was accomplished jointly by Prof. Uttam K. Tambar and Dr. David C.
Ebner, two former graduate students in the Stoltz research group.
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In the key bond-forming transformation, treatment of !-ketoester 213 with
sesamol-derived aryne precursor 212 in the presence of CsF yielded ketoester 214, a
compound that contains the entire carbocyclic framework of amurensinine.  Application
of the acyl-alkylation reaction to this system resulted in the formation of two new C–C
bonds to convergently unite the two halves of the natural product.
Scheme 2.28. The total synthesis of (+)-amurensinine (216).
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With tetracycle 214 in hand, we turned our attention to rendering the synthesis
enantioselective.  Following ketone reduction, diastereoselective ester reduction, and
selective silylation of the primary alcohol, benzyl alcohol (±)-215 was subjected to
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 116
palladium-catalyzed oxidative kinetic resolution conditions to produce (–)-215 in 47%
yield and >99% ee, corresponding to an s-factor of >47.61  From here, all that remained
was closure of the tetrahydroisoquinoline ring.  The nitrogen was installed by Mitsunobu
inversion of the benzyl alcohol with DPPA to generate benzyl azide (–)-635, which was
subsequently desilylated and oxidized to the corresponding acid (636).  Reduction of the
azide resulted in spontaneous lactamization, and exhaustive reduction of the lactam
followed by reductive methylation yielded the natural product, (+)-amurensinine ((+)-
216).
2.4 THE ENANTIOSELECTIVE TOTAL SYNTHESIS OF (–)-CURVULARIN
Importantly, the total synthesis of amurensinine demonstrated the viability of the
ring-expansive acyl-alkylation in the synthesis of complex polycyclic natural product
architectures.  The ability to convergently assemble these carbocyclic frameworks from
simple and easily accessible starting materials is a significant advantage of such an aryne-
based strategy over more traditional approaches.  As such, we sought to further test the
limits of this transformation through its application to additional polycyclic natural
products.  More specifically, we targeted natural products containing unsymmetrically
substituted arene moieties, beginning with (–)-curvularin.
2.4.1 Retrosynthetic Analysis Revisited
Returning to our retrosynthetic analysis of (–)curvularin (221), we initially
disconnected the benzannulated macrolactone framework of the natural product along the
C(2)–C(3) and C(8)–C(9) bonds by an acyl-alkylation reaction of resorcinylic aryne 556
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and chiral !-ketolactone 218 (Scheme 2.29).  To reiterate, lactones had not been
investigated as substrates for the acyl-alkylation reaction to this point and their viability
in this transformation was not initially clear.  Turning to the aryne precursor, since the
free phenolic groups on aryne 556 would likely interfere with the desired reactivity, we
opted to protect these groups as benzyl ethers, leading back to silyl aryl triflate 217.
Previous studies had already shown that silyl aryl triflate 217 undergoes regioselective
acyl-alkylation and that the benzyl ethers could be readily cleaved under standard
hydrogenolysis conditions (vide supra).35
Scheme 2.29. Retrosynthetic analysis of (–)-curvularin (221).
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With aryne precursor 217 already in hand, we initially focused our attention on
chiral !-ketolactone 218.  Importantly, !-ketolactones such as 218 represent a substrate
class that had not previously been investigated in aryne acyl-alkylation reactions and
would be amenable to the preparation of other members of this class of natural products.
Furthermore, by applying this retrosynthetic disconnection to curvularin, we recognized
that the !-ketolactone fragment (218) mapped onto the carbon framework of the
diplodialide natural products (638–641),62 revealing an unusual synthetic (i.e.,
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nonbiomimetic) link between the two natural product families (Figure 2.7).  Thus, the
development of a general synthesis of benzannulated macrolactone natural products, such
as curvularin, via ring-expansive aryne insertion chemistry from the diminutive
macrolactone would provide access to these valuable natural products and numerous
synthetic analogs for biological evaluation.
Figure 2.7. !-Ketolactone 218 and the diplodialide polyketide natural products (638–641).
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2.4.2 Previous Syntheses of !-Ketolactone 218 and the Diplodialide Natural
Products
The synthesis of medium-sized rings is an under-appreciated challenge in organic
synthesis.  Two main factors account for this difficulty: enthalpic and entropic barriers.63
Generally speaking, the development of transannular interactions in the transition states
for medium-sized ring formations leads to significant enthalpic costs in both the
transition state and the product.  Furthermore, there is a substantial entropic cost in the
transition state for cyclizations to form 8-, 9-, 10-, and 11-membered rings.  For these
reasons, effective methods for the synthesis of medium-sized rings are scarce and often
require inconvenient experimental conditions, such as high dilution, to encourage
cyclization.  As it will become clear, simple modifications to cyclization substrates can
often lead to dramatic and unpredictable differences in reactivity.  This problem is well
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exemplified by synthetic efforts toward !-ketolactone 218 and the diplodialide natural
products (638–641).
!-Ketolactone 218 has been previously prepared in the literature by a number of
different methods, including macrolactonization, ring-closing metathesis, ring expansion,
ring contraction, and aldol reactions.  In devising a route to !-ketolactone 218, known
total syntheses of the diplodalide natural products were also considered as potential
strategies due to the similarity between these structures.  In fact, !-ketolactone 218 has
been previously utilized as an intermediate in the total syntheses of several diplodialides
(vide infra).
The most prevalent strategy employed in the synthesis of the diplodialide natural
products is macrolactonization from an appropriate hydroxyacid surrogate.  In all these
efforts, and indeed in all known efforts toward these structures, high dilution techniques
must be used to minimize formation of dimeric and oligomeric esters.  The groups of
Wada64 and Gerlach65 each relied on macrolactonization of thioesters (642 and 644,
respectively) according to the method of Mukaiyama to form the decanolide (Scheme
2.30).  While Gerlach performs the macrolactonization with the E-olefin present (644),
Wada opted instead to proceed through !-ketolactone 218 en route to diplodialide A
(638).  Alternatively, Boeckman66 accessed diplodialide A (638) by macrolactonization of
vinyl dioxolenone 646; thermolysis of dioxolenone 646 produces an intermediate reactive
ketene (647) that is subsequently trapped by the pendant alcohol to yield diplodialide A
(638) directly in 68% yield.
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Scheme 2.30. Macrolactonization approaches to the diplodialide natural products.
O
O
O
Diplodialide A (638)
HO
O
SN
642
Prepared in 7 steps
xylene
reflux
(38% yield)
S
S
O
S
S
O
643
2 steps
Wada's Approach
O
O
O
Diplodialide A (638)
HO
O
S
644
Prepared in 6 steps
1. AgNO3
    H2O
2. PPh3
3. AgClO4
(62% yield)
O
O
645
2 steps
Gerlach's Approach
NBS
acetone
H2O
(82% yield)
O
O
218
O
TBDPSO
N S
2
TBDPSO
•11 linear steps•
•11 linear steps•
O
O
O
(+)-Diplodialide A (638)
O HOO
646
Prepared in 5 steps
PhMe
reflux
(68% yield)
Boeckman's Approach
•6 linear steps•
O
HO
O
647
O
The groups of Singh67 and Laxmi Reddy68 targeted the diplodialides through ring-
closing metathesis reactions to form the 10-membered ring (Scheme 2.31).  Singh
prepared diene 648 as a RCM substrate with the aim of forming the C(7)–C(8) bond.
Treatment of diene 648 with Grubbs 2nd generation catalyst (146) in refluxing benzene
resulted in formation of decanolide 649 in 88% yield as a 2:1 mixture of cis and trans
olefin isomers.  Conversion of the isomeric mixture of 649 to !-ketolactone 218
completed the formal total synthesis of diplodialide A (638).  Laxmi Reddy, on the other
hand, chose to close the 10-membered ring along the C(4)–C(5) bond by RCM of allylic
alcohol 650 with superstoichiometric Grubbs 1st generation catalyst (652), generating
lactone 651 in 64% yield as a 10:1 mixture of trans and cis olefins.  Separation of the
major trans isomer, diplodialide B (639), constituted a formal synthesis of diplodialide A
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(638); alternatively, the diplodialide B (639) was then successfully converted to
diplodialide C (640) by olefin hydrogenation.
Scheme 2.31. RCM approaches to the diplodialides natural products.
O
648
Prepared in 5 steps
Grubbs 2
(10 mol%)
PhH
reflux
(88% yield)
O
O
O
O
O
O
649
2 steps
Singh's Approach
O
O
218
O
•8 linear steps•
O
2:1 cis:trans
N N
Cl2Ru
Ph
PCy3
Grubbs 2 (146)
O
650
Prepared in 8 steps
Grubbs 1
(125 mol%)
CH2Cl2
reflux
(64% yield)
O
O
651
2 steps
Laxmi Reddy's Approach
O
O
218
O
•11 linear steps•
O
10:1 trans:cis
PCy3
Cl2Ru
Ph
PCy3
Grubbs 1 (652)
HO HO
separation
O
O
Diplodialde B
HO
H2, Pd/C
EtOAc
(93% yield)
MnO2
CH2Cl2
(71% yield)
O
O
Diplodialde C (640)
HO
O
O
Diplodialde A (638)
O
•9 linear steps•
•10 linear steps••10 linear steps• 639
7
8
4
5
The final three approaches employed either Reformatsky cyclization, ring
expansion, or ring contraction methods to construct the challenging 10-membered ring.
Tsuji and co-workers69 prepared "-bromo ester 653, which, upon treatment with zinc,
generated !-hydroxyester 651 (Scheme 2.32).  Oxidation with MnO2 then furnished
diplodialide A (638).
Wakamatsu70 investigated the preparation of the macrolactone from a decalin
substrate by ring expansion.  Treatment of diol 654 with lead tetraacetate resulted in
ketoester 655.  This was further elaborated to !-ketolactone 218 over an additional 6
steps, completing the formal total synthesis of diplodialide A (638) as a result.
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Finally, Ireland relied on a sulfide-based ring contraction strategy to form the
C(2)–C(3) bond of diplodialide A (638).71  Thioamide 656 was successfully converted to
macrolatone 657 in 25% yield upon treatment with chloroacetyl chloride followed by
triethylphosphite.  Elimination of the acetate then provided diplodialide A (638) in eight
synthetic steps.
Scheme 2.32. Tsuji’s, Wakamatsu’s, and Ireland’s approaches to diplodialide A (638).
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2.4.3 !-Ketolactone Synthesis: Macrolactonization Studies
In evaluating each of these strategies, we sought to prepare targeted !-ketolactone
218 in a concise and enantioselective fashion.  Among the shortest of the routes presented
above is Boeckman’s thermal macrolactonzation of dioxolenone substrates (e.g., 646) in
only six steps.66  Our initial attempts to prepare ! -ketoester 218  targeted this
retrosynthetic disconnection (Scheme 2.33).  While Boeckman prepared dioxolenone 646
by sequential olefination reactions, we proposed a more straightforward cross-metathesis-
based route to this macrolactonization substrate, beginning with vinyl dioxolenone 658
and chiral secondary alcohol 659.
Scheme 2.33. Retrosynthetic analysis of !-ketolactone 218 by macrolactonization.
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Vinyl dioxolenone (658) has been previously prepared in the literature and was
readily accessed in 3 steps beginning with Claisen condensation of t-butyl acetate (660)
and ethyl 3-chloropropionate (661) to yield !-ketoester 662 (Scheme 2.34).72  Treatment
of !-ketoester 662 with acetic anhydride, acetone, and sulfuric acid generated chloro
dioxolenone 663, which was converted to vinyl dioxolenone 658 by elimination with
triethylamine.
Initial cross-metathesis investigations were carried out with a model system
alcohol substrate (665) lacking the stereogenic methyl group.  The model system cross-
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metathesis partner, silylated alcohol 665, was prepared from commercially available 5-
hexen-1-ol (664) by simple protection with TBSCl.
Scheme 2.34. a) Synthesis of vinyl dioxolenone 658.  b) Synthesis of protected alcohol 665.
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With vinyl dioxolenone 658 and protected alcohol 665 in hand, we turned our
attention to the cross-metathesis reaction to generate disubstituted olefin 667 (Scheme
2.35).73  Early efforts utilized the Grubbs 2nd generation ruthenium metathesis catalyst74
(146) in 5 mol% in refluxing dichloromethane with equimolar amounts of the two
metathesis partners (658 and 665).  We were encouraged to isolate 28% yield of the
desired product, but observed modest levels of dimerization of protected alcohol 665 as a
side product (669).  Furthermore, attempts to use dimer 669 in the metathesis process
yielded no desired product (667), indicating that dimerization was not reversible under
the reaction conditions.  To circumvent these issues, the molar equivalents of
dioxolenone 658 were increased optimally to three, keeping all other reaction parameters
the same.  To our delight, we were able to isolate cross-metathesis product 667 in 81%
yield.  Additionally, only trace quantities of dimer 669 were isolated and the majority of
unreacted dioxolenone 658 could be recovered and resubmitted to the reaction conditions.
Seeking to improve upon this route, attempts were made to perform the cross-
metathesis on unprotected 5-hexen-1-ol (664) in order to eliminate two steps from the
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overall synthesis.  A thorough screen of several Grubbs metathesis catalysts ultimately
provided alcohol 666 in 26% yield using Grubbs–Hoveyda 2nd generation catalyst75 (668)
in 5 mol% in refluxing dichloromethane with equimolar amounts of vinyl dioxolenone
658 and 5-hexen-1-ol (664).  The poor yield of this transformation led us to return to
protected alcohol 665 as the cross-metathesis partner for vinyl dioxolenone 658.
Scheme 2.35. Optimization of cross-metathesis with vinyl dioxolenone 658.
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Following cross-metathesis of vinyl dioxolenone 658 and protected alcohol 665,
desilylation was attempted with tetra-n-butylammonium fluoride (TBAF) in THF
(Scheme 2.36).  To our surprise, however, we were unable to isolate primary alcohol 666;
the alkoxide formed under the desilylation conditions appears to have added in a
conjugate fashion to the vinyl dioxolenone (670), presumably resulting in formation of a
tetrahydropyran ring (671).  This unwanted reactivity was avoided by buffering the
TBAF with equimolar amounts of acetic acid, resulting in isolation of the primary alcohol
(666) in 93% yield.
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Scheme 2.36. Desilylation of dioxolenone 667 with a) TBAF and b) acetic acid-buffered TBAF.
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With alcohol 666  in hand, we shifted our focus to effecting the thermal
macrolactonization to produce des-methyl diplodialide A.  However, under the conditions
given by Boeckman for this transformation,66 we were disappointed to find that none of
the macrolactone was formed, despite the use of high dilution techniques (1.0 mM
concentration) and slow addition of alcohol 666 over several hours (Scheme 2.37).  In
fact, the sole identifiable compound from these reactions was cyclic dimer 672 (observed
only by mass spectrometry).  Unable to optimize this process, we opted to pursue !-
ketolactone 218 by other means.
Scheme 2.37. Attempted thermal macrolactonization of dioxolenone 666.
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Interestingly, following our work toward !-ketolactone 218 by the thermal
macrolactonization route, Willis and co-workers published a revision to the decanolide
structure reported by Boeckman.76  During attempts to reproduce the synthesis of
diplodialide A (638), Willis noted that their isolated product possessed a similar optical
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rotation, ["]D +124 (c 1.0, CHCl3), to that of Boeckman’s product, ["]D +128 (c 1.09,
CHCl3), while the optical rotation of the natural product (638) had been previously
reported as ["]D +142 (c 1.02, CHCl3) (Scheme 2.38).  Furthermore, the NMR spectra of
Willis’ material and the natural product displayed small but significant differences in the
chemical shifts of several signals.  Finally, observation of the mass of dimer 673 and
correlation of 1H NMR data with that of Ley and co-workers77 for dimer 673 led Willis to
conclude that Boeckman had incorrectly assigned dimer 673 as diplodialide A (638).
Scheme 2.38. Structural misassignment in Boeckman’s reported synthesis of diplodialide A (638).
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2.4.4 !-Ketolactone Synthesis: Dieckmann Cyclization Studies
Following the macrolactonization studies toward !-ketolactone 218, we chose to
investigate an alternate disconnection of the 10-membered ring by various Dieckmann
cyclizations (Scheme 2.39).78  We initially targeted cyclization along the C(2)–C(3) bond
from linear substrates such as 674, which could be accessed in turn from acetate 676 by
cross-metathesis with various acrylates (675).
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Scheme 2.39. Retrosynthetic analysis of !-ketolactone 218 by Dieckmann cyclization.
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For some of these studies, we opted to work with starting materials bearing the
C(9) methyl group instead of model alcohol 5-hexen-1-ol (664).  Preparation of 6-hepten-
2-ol (678) in a racemic sense was straightforward beginning with commercially available
5-bromo-1-pentene (677) (Scheme 2.40).  Formation of the Grignard reagent, followed
by quenching with freshly distilled acetaldehyde yielded the secondary alcohol (678) in
70% yield.79
Scheme 2.40. Racemic synthesis of secondary alcohol 678.
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Secondary alcohol 678  was next advanced to diester 680  beginning with
acetylation of the alcohol to yield acetate 676 (Scheme 2.41).  Cross-metathesis with
methyl acrylate (679) proceeded in excellent yield, producing diester 680 exclusively as
the Z-isomer.
Scheme 2.41. Synthesis of diester 680 for Dieckmann cyclization studies.
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Initial examination of Dieckmann condensation reactions focused on unsaturated
diester 680 as a substrates.  Several bases were screened for this transformation, though
none but LDA provided anything other than starting material (Scheme 2.42).  Use of
LDA in THF at –78 °C provided small quantities of a compound lacking the olefinic
protons observed by 1H NMR in the starting material indicating that enoate 680 may act
as a conjugate electrophile under the reaction conditions.  In response to this unwanted
reactivity at the !-position and in order to impart additional flexibility on the system,
enoate 680 was hydrogenated to give diester 681.  Unfortunately, exposure of this fully
saturated substrate (681) to a variety of bases never yielded any tractable products.
Scheme 2.42. Unsuccessful attempts at Dieckmann cyclization of diesters 680 and 681.
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A final modification to these diester substrates that was examined was the
replacement of the acetate group with a mixed malonate.  By lowering the pKa value of
the desired site of enolization (i.e., as in mixed malonate 682), selectivity for 10-
membered ring formation would be significantly higher than for diester 681, which
possesses multiple acidic sites with similar pKa values (Scheme 2.43).80  A model system
of mixed malonate 682 was prepared beginning with acetylation of 5-hexen-1-ol (664)
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with methyl malonyl chloride (683).  Cross-metathesis of the resulting mixed malonate
(684) with methyl acrylate (679), followed by hydrogenation of the olefin yielded
Dieckmann cyclization substrate 685.  To our disappointment, though, upon treatment
with a number of different bases, including NaH, LDA, and Et3N, mixed malonate 685
failed to produce any 10-membered ring products.  In many cases, decomposition of
mixed malonate 686 quickly occurred under the reaction conditions.
Scheme 2.43. Preparation of mixed malonate 682 and attempted Dieckmann cyclizations.
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2.4.5 !-Ketolactone Synthesis: Ring-Closing Metathesis Studies and the Synthesis
of (±)-Diplodialide C
With the failure of the Dieckmann cyclization strategy to generate any 10-
membered ring products, we moved on to the final retrosynthetic disconnection of !-
ketolactone 218.  Our initial plan involved formation of the C(4)–C(5) bond by a ring-
closing metathesis from vinyl !-ketoester 688 (Scheme 2.44).  Fortuitously, vinyl !-
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ketoester 688 could be prepared from two previously prepared compounds: vinyl
dioxolenone 658 and secondary alcohol 659.
Scheme 2.44. Retrosynthetic analysis of !-ketolatone 218 by ring-closing metathesis.
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In essence, this synthetic plan reverses the order of operations from that of the
macrolactonization attempts (vide supra).  Instead of joining dioxolenone 658 and
secondary alcohol 659 by cross-metathesis followed by macrolactonization, this new
strategy would join the two fragments by thermal esterification and close the macrocycle
with a ring-closing metathesis reaction.
Initial studies into this approach were performed with the model system alcohol,
5-hexen-1-ol (664).  Simple heating of vinyl dioxolenone 658 with 5-hexen-1-ol (664)
resulted in formation of vinyl !-ketoester 689 in excellent yield (Scheme 2.45).81
However, neither Grubbs 2nd generation catalyst (1 4 6 ) nor the more active
Grubbs–Hoveyda 2nd generation catalyst (668) were able to effect the ring-closing of
vinyl !-ketoester 689.  In the ring-closing metathesis reactions using Grubbs 2nd
generation catalyst (146), catalyst deactivation appeared to be significant at early stages
of the reaction.  One potential reason for catalyst deactivation could be the formation of a
stable six-membered chelate with the substrate (e.g., 691). On the other hand, attempted
ring-closing metathesis with the Grubbs–Hoveyda catalyst (668) led to significant
starting material decomposition and oligomerization.
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Scheme 2.45. Synthesis and attempted ring-closing metathesis of vinyl !-ketoester 689.
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Given the decomposition of catalyst 146 in the presence of vinyl !-ketoester 689,
we considered modifications that could be made to the ring-closing metathesis substrate
(689) to circumvent these difficulties.  The 1H NMR of vinyl !-ketoester 689 shows a
significant quantity (~50%) of enol tautomer present in the sample, which has the
potential to negatively impact cyclization.  Two strategies were explored to avoid
problems associated with the enol tautomer: 1) installation of a temporary blocking group
at the "-position, and 2) masking of the enol as the corresponding silyl enol ether.  For a
temporary blocking group to prevent enolization, a diazo functionality was selected; upon
treatment of vinyl !-ketoester with MsN3 and Et3N, "-diazo-!-ketoester 693 was formed
in 75% yield (Scheme 2.46).  Alternatively, vinyl !-ketoester 689 was converted to a
single (unassigned) isomer of TBS enol ether 695 by reaction with TBSCl and Et3N in
81% yield.  When "-diazo-!-ketoester 693 and silyl enol ether 695 were each subjected
to ring-closing metathesis conditions, however, no cyclic products were formed.  In fact,
"-diazo-!-ketoester 693 returned only starting material, while silyl enol ether 695 yielded
small quantities of vinyl !-ketoester 689 in addition to recovered starting material (695).
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Scheme 2.46. Synthesis of vinyl !-ketoester derivatives 693 and 695 and ring-closing metathesis
attempts.
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Although use of "-diazo-!-ketoester 693 and silyl enol ether 695 as ring-closing
metathesis substrates prevents reactivity issues arising from the presence of enol tautomer
692, it also likely introduces significant conformational restrictions that could prohibit
such substrates from cyclizing.  It is well-known that the level of unsaturation can
significantly impact the success of ring-closing for medium-sized rings.  With this in
mind, the enone of vinyl !-ketoester 689 was reduced in a 1,2-fashion under Luche’s
conditions to yield allylic alcohol 697, which was immediately protected as a silyl ether
(698) (Scheme 2.47).  To our delight, upon treatment of silyl ether 698 with Grubbs 2nd
generation catalyst (146) in toluene at 80 °C, lactone 699 was generated in 54% isolated
yield as a single olefin isomer.  Critical to the success of this ring-closing metathesis was
the continuous slow addition of solutions of both silyl ether 698 and Grubbs 2nd
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generation catalyst (146) throughout the course of the 20-hour reaction.  At this point, we
were unable to assign the olefin geometry in lactone 699.  In order to determine the olefin
geometry of lactone 699, it was converted to enone 701 by desilylation and Dess–Martin
oxidation.  By 1H NMR, the olefin geometry of enone 701 was then assigned as cis (J =
12.2 Hz).
Scheme 2.47. Synthesis of lactone 701 and assignment of the olefin geometry.
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With this key initial result in hand, we turned our attention toward ring-closing
metathesis of substrates bearing the C(9) methyl group of !-ketolactone 218.  While !-
ketolactone 218 could be constructed in a way analogous to that of lactone 701, a
significantly shorter route was devised to access ring-closing metathesis substrate 703.
Beginning with acetate 676, which was previously employed in the Dieckmann
cyclization studies, diene 703 was constructed in two steps by an aldol reaction with
acrolein followed by protection as the silyl ether (Scheme 2.48).  This sequence
generated diene 703 as a 1:1 mixture of diastereomers; this mixture would eventually be
inconsequential since the silyl ether will be converted to the C(3) ketone in !-ketolactone
218.
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Scheme 2.48. Successful ring-closing metathesis of silyl ether 703 and synthesis of (±)-diplodialide C
(640).
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Upon treatment of the diastereomeric mixture of diene 703 with Grubbs 2nd
generation catalyst (146), we were intrigued to find that lactone 704 was isolated in 44%
yield as a single diastereomer having the cis olefin geometry exclusively.  To the best of
our knowledge, only two other examples of a resolution of diastereomers by ring-closing
metathesis using an achiral catalyst are known.82
Due to the configurational flexibility of 10-membered lactone 704, the relative
stereochemistry of the C(3) silyl ether and C(9) methyl group were unable to be assigned.
However, desilylation and hydrogenation of lactone 704 produced a compound whose
data matched that of diplodialide C (640), which features the C(3) alcohol and C(9)
methyl groups oriented in an anti relative configuration.  Thus, lactone 704 was assigned
the same anti relative configuration of the C(3) silyl ether and C(9) methyl group, in
addition to the previously assigned cis olefin.  Furthermore, we found that diplodialide C
(640) was easily oxidized to the key !-ketolactone (218) required for the synthesis of
curvularin.
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It should be noted that Laxmi Reddy and co-workers reported successful ring-
closing metathesis of allylic alcohol 650 with Grubbs 1st generation catalyst (652) in 64%
yield (Scheme 2.49).68  However, this transformation required the use of a
superstoichiometric amount of catalyst 652 (125 mol%).  Attempts to directly form !-
hydroxylactone 705 from allylic alcohol 702 with several metathesis catalysts failed to
produce macrocycle 705 in more than 10% isolated yield.
Scheme 2.49. Laxmi Reddy’s RCM of allylic alcohol 650 compared with our efforts.
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While the resolution of the 1:1 mixture of diastereomeric silyl ethers (703) by
ring-closing metathesis is notable, more than half of the material was simultaneously lost
through unproductive metathesis pathways (Scheme 2.50)  All attempts to overcome this
resolution by altering solvent, concentration, and temperature detrimentally affected the
process.  We believe that the bulky mesityl groups flanking the N-heterocyclic carbene
ligand on the catalyst 146 hinders the ring-closing process due to unfavorable interactions
with one or both of the stereocenters present in silyl ether cis-703.
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Scheme 2.50. Resolution of silyl ethers cis-703 and trans-703 by Grubbs 2nd generation metathesis
catalyst 146.
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Fortuitously, concurrent with these studies, a new metathesis catalyst bearing less
sterically encumbered ortho-tolyl groups on the N-heterocyclic carbene ligand was
reported by Grubbs and co-workers.83  This Grubbs 3rd generation catalyst (706)
displayed remarkable activity for the formation of more sterically congested olefins that
had remained inaccessible using previous generations of catalysts (Figure 2.8).  In
addition to the phosphine-ligated catalyst (706), a variant containing the isopropoxy
benzylidene ligand, referred to as the Grubbs–Hoveyda 3rd generation catalyst (707), was
also excellent for these transformations.  Notably, the Grubbs–Hoveyda 3rd generation
catalyst possesses significantly better thermal stability than the phosphine-ligated Grubbs
3rd generation catalyst.
Figure 2.8. The Grubbs 3rd generation catalysts.
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Because of the higher temperatures required for ring-closing metathesis of silyl
ether 703, we examined the Grubbs–Hoveyda 3rd generation catalyst (707) for this
transformation.  To our delight, in the first reaction with this catalyst, ring closing of the
1:1 diastereomeric mixture of silyl ether 703 proceeded to form lactone 704 as a mixture
of diastereomers and olefin isomers in 67% isolated yield (Scheme 2.51).  Increasing the
temperature of the reaction from 60 °C to 80 °C further increased the yield to 77%.
Importantly, no material was lost in this ring-closing metathesis due to resolution of the
diastereomeric mixture of silyl ether 703.  Furthermore, the diastereomeric mixture of
lactone 704 was readily converted to !-ketolactone 218 by sequential desilylation,
hydrogenation, and Dess–Martin oxidation.
Scheme 2.51. Ring-closing metathesis of silyl ether 703 with Grubbs–Hoveyda 3rd generation
catalyst.
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We were interested in determining the composition of the diastereomeric mixture
of lactone 703, but were only able to partially separate the isomers into two fractions
(Scheme 2.52).  Fraction A contained up to 3 diastereomers in an undetermined ratio.
This mixture was desilylated with TBAF and reduced to yield 9-epi-diplodialide C (709).
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We therefore concluded that two of the diastereomers present in fraction A were syn-cis-
704 and syn-trans-704.  However, these experiments do not confirm that only two
diastereomers are present in fraction A; the yield for desilylation is significantly lower
than expected and suggests that a third diastereomer, anti-trans-704, is present but
unstable to the reaction conditions for desilylation.  Further experiments were needed to
test this theory.  Fraction B, which was diastereomerically pure, contained only the
compound previously assigned as anti-cis-704.  This was again verified by desilylation
and olefin hydrogenation, furnishing diplodialide C (640).
Scheme 2.52. Partial determination of the diastereomeric mixture resulting from ring-closing
metathesis of silyl ether 703.
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In order to determine whether fraction A contained two or three diastereomers, we
changed the order of operations for the desilylation and hydrogenation sequence shown in
Scheme 2.52.  If fraction A contained a third diastereomer, namely anti-trans-704
diastereomer, hydrogenation might reveal its presence.  Furthermore, subsequent
desilylation would then lead to a mixture of 9-epi-diplodialide C (709) and diplodialide C
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(640).  To our delight, hydrogenation of fraction A led to isolation of a mixture of two
compounds, indicating that this fraction indeed contains three diastereomers (Scheme
2.53)  We were further pleased to find that desilylation produced a 5:1 mixture of 9-epi-
diplodialide C (709) and diplodialide C (640).  This confirms that all four potential
diastereomers, anti-cis-704, anti-trans-704, syn-cis-704, and syn-trans-704, are formed
during ring-closing metathesis of silyl ether 703 with Grubbs–Hoveyda 3rd generation
catalyst (707).  However, because of potential differences in reactivity under desilylation
and hydrogenation conditions, we were unable to determine the ratio of diastereomers
formed directly by the ring-closing metathesis.  At best, we have concluded that
following hydrogenation and desilylation, in that particular order, the ratio of anti-cis-
704 : syn-cis-704 : syn-trans-704 : anti-trans-704 is 3.5 : 1.6 : 1.0 : trace.
Scheme 2.53. Determination of all diastereomeric mixture components resulting from ring-closing
metathesis of silyl ether 703.
Fraction A
O
O
TBSO
TBAF
THF
(89% yield)syn-710
O
O
TBSO
H2, Pd/C
EtOH
O
HO
O
9-epi-Diplodialide C
(709)
anti-710
O
O
TBSO
O
HO
O
Diplodialide C
(640)5:1 ratio
Fraction A
O
O
TBSO
O
O
TBSO
syn-cis-704 syn-trans-704anti-trans-704
O
O
TBSO
Fraction B
O
O
TBSO
anti-cis-704
Although the sequence of ring-closing metathesis followed by desilylation,
hydrogenation, and Dess–Martin oxidation was an efficient means of generating !-
ketolactone 218, we sought to streamline the overall process in two separate ways.  The
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first was to develop a one-pot silylation–ring-closing metathesis–desilylation procedure
beginning from allylic alcohol 702 (Scheme 2.54).  This would have the net effect of
cutting two synthetic steps from our overall route.  Gratifyingly, silylation with
hexamethyldisilazide (HMDS) followed by ring-closing metathesis with
Grubbs–Hoveyda 3rd generation catalyst (707) and acidic hydrolysis of the trimethylsilyl
group generated !-hydroxylactone 705 as the expected mixture of diastereomers and
olefin isomers in 57% yield.  This mixture was then readily converted to !-ketolactone
218 by hydrogenation and Dess–Martin oxidation (Scheme 2.51).
Scheme 2.54. Development of a one-pot silylation–ring-closing metathesis–desilylation procedure.
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A second improvement we attempted to make to the synthesis of !-ketolacone
218 was to combine the hydrogenation and Dess–Martin oxidation operations into one
step.  As these two synthetic steps result in no net change in the overall oxidation state of
the molecule, we sought to bypass these redox manipulations by carrying out an olefin
isomerization reaction (Scheme 2.55).  Unfortunately, examination of a significant
number of catalysts known for their isomerization activity never led to any formation of
!-ketolactone 218.84  In many cases, the high temperatures required for olefin
isomerization led to decomposition of !-hydroxylactone 705.
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Scheme 2.55. Attempted isomerization reactions of !-hydroxylactone 705.
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In the culmination of these studies, we were able to access !-ketolactone 218 in
just four synthetic steps from known acetate 676 (Scheme 2.56).  The overall yield for
this process is 40% and allowed us to generate multigram quantities of !-ketolactone 218
for upcoming acyl-alkylation studies.  However, we had yet to devise a method for the
asymmetric synthesis of !-ketolactone 218.
Scheme 2.56. Synthesis of !-ketolactone 219 from acetate 676.
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2.4.6 Enantioselective !-Ketolactone Synthesis
In devising an asymmetric route to !-ketolactone 218, we recognized that chiral
secondary alcohol 678 would be our main target for synthesis.  All reactions that follow
secondary alcohol 678 in the synthetic sequence leading to !-ketolactone 218 would not
affect the absolute configuration of the single stereocenter; thus, this stereocenter could
be set early in the synthesis.  In the racemic sense, secondary alcohol 678 was prepared
by a Grignard addition of butenylmagnesium bromide 711 to acetaldehyde (712)
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(Scheme 2.57).  However, asymmetric versions of this transformation were not a viable
route to secondary alcohol 678.  An alternative disconnection of secondary alcohol would
involve nucleophilic ring-opening of a chiral epoxide.  Since (S)-propylene oxide ((S)-
713) is a readily available chiral building block, enantioenriched secondary alcohol (S)-
678 was targeted by this method.
Scheme 2.57. Retrosynthetic analysis of chiral secondary alcohol (S)-713.
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Although (S)-propylene oxide ((S)-713) is commercially available,85 it was
prepared from racemic propylene oxide (713) on large scale by hydrolytic kinetic
resolution according to the method described by Jacobsen and co-workers (Scheme
2.58).86  Hydrolysis of racemic propylene oxide (713) in the presence of (S,S)-
Co(salen)OTs (716) with water resulted in the isolation of unreacted (S)-propylene oxide
((S)-713) in greater than 99% ee, which could be distilled from the enantioenriched diol
product ((R)-715).  This procedure enabled the preparation of quantities of (S)-propylene
oxide ((S)-713) in excess of 20 grams at one time.
Scheme 2.58. Jacobsen hydrolytic kinetic resolution to produce (S)-propylene oxide (713).
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With (S)-propylene oxide in hand, we turned our attention to the key epoxide
opening reaction with the butenylmagnesium bromide reagent prepared in situ from
commercially available 4-bromo-1-butene (717) (Scheme 2.59).  At low temperature,
using Li2CuCl4 as a catalyst, (S)-propylene oxide ((S)-713) was selectively opened at the
less substituted position to yield chiral secondary alcohol 678.87  Because alcohol 678 is
volatile, it was immediately acetylated to furnish acetate 676 in 76% yield over the two-
step sequence.  Aldol reaction of chiral acetate 676 with acrolein then produced allylic
alcohol 702 as a 1:1 mixture of enantioenriched syn and anti diastereomers.  The
diastereomeric mixture of allylic alcohols (702) was then advanced through the one-pot
silylation-ring-closing metathesis-desilylation sequence to yield !-hydroxylactone 705 as
a mixture of diastereomers and olefin isomers.  Finally, hydrogenation and Dess–Martin
oxidation of !-hydroxylactone 705 generated enantioenriched !-ketolactone 218 for acyl-
alkylation studies in >99% ee.
Scheme 2.59. Asymmetric synthesis of !-ketolactone 218.
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2.4.7 Acyl-Alkylation Studies and Completion of (–)-Curvularin
Having developed an efficient means to produce multigram quantities of !-
ketolactone 218, we sought to employ this intermediate in an acyl-alkylation reaction
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with a suitably protected resorcinylic aryne to construct the benzannulated macrocyclic
framework of curvularin (Scheme 2.60).  To accomplish this, several different silyl aryl
triflates (e.g., 217 and 232) were investigated in acyl-alkylation reactions with !-
ketolactone 218.
Scheme 2.60. Acyl-alkylation reactions toward curvularin (221).
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We initially examined acyl-alkylation of !-ketolactone 218 with the unsubstituted
silyl aryl triflate (209) to determine if these types of substrates were suitable for the
transformation.  Prior to these studies, only cyclic !-ketoesters bearing exocyclic ester
groups had been investigated as substrates for acyl-alkylation.  A range of conditions was
examined for this reaction beginning with KF/18-crown-6 in THF at 60 °C (Table 2.5).
To our delight, benzannulated macrolactone 718 was isolated in 52% yield along with
17% recovered !-ketolactone 218 (entry 1).  Replacement of the KF/18-crown-6 fluoride
source with TBAT led to a decreased yield of 37% (entry 2).  Further optimization of
reactions in THF with either TBAT or KF/18-crown-6 proved difficult.  Alternatively, the
use of CsF in acetonitrile at 80 °C provided low yields of benzannulated macrolactone
718 in addition to several side products (entry 3).  Slow addition of the aryne precursor
(209) over 1.5 hours led to a significant increase in the yield to 57%, while slightly
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decreasing the number of side products (entry 4).  Finally, lowering the temperature to 40
°C in combination with the slow addition of silyl aryl triflate 209 led to 61% isolated
yield of benzannulated macrolactone 718 (entry 5).
Table 2.5. Acyl-alkylation reactions of silyl aryl triflate 209 with !-ketolactone 218.
(S)-218
O
O
O
TMS
OTf
209
conditions
718
O
O
O
entry F– source solvent temperature yield
1
2
3
4a
5a
KF/18-crown-6
TBAT
CsF
CsF
CsF
THF
THF
MeCN
MeCN
MeCN
60 °C
60 °C
80 °C
80 °C
40 °C
52%
37%
<10%
57%
61%
a Reaction performed with slow addition of silyl aryl triflate 209 over 1.5 hours.
Next, unsubstituted silyl aryl triflate 209 was replaced with dimethoxy aryne
precursor 232 in acyl-alkylation reactions with !-ketolactone 218 (Table 2.6).  In this
case, both KF/18-crown-6 and TBAT in THF were ineffective fluoride sources for the
insertion reaction (entries 1 and 2).  Upon use of CsF in acetonitrile, dimethylcurvularin
(510) was isolated along with significant quantities of the corresponding "-arylation
product (719).  In all cases, the "-arylation product was formed as a single isomer
resulting from regioselective addition of !-ketolactone 218 to the putative dimethoxy
aryne (606); furthermore, "-arylation product 719 was always isolated as a single
(unassigned) diastereomer at the C(2) and C(9) positions.  Under the standard acyl-
alkylation conditions, insertion product 510 and "-arylation product 719 were formed in
almost a 1:1 ratio, with insertion product 510 isolated in 32% yield (entry 3).  Decreasing
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the ratio of silyl aryl triflate 232 to !-ketolactone 218 from 1.2:1 to 1:1 somewhat
improved the ratio of insertion to " -arylation, leading to an increased yield of
macrolactone 510 (entry 4).  Further decreasing the ratio of silyl aryl triflate 232 to !-
ketolactone 218 to 1:1.2 slightly decreased the yield of insertion product 510 to 36%
while increasing the yield of "-arylation product 719 (entry 5).  We next investigated the
impact of fluoride equivalents on the reaction.  Decreasing the equivalents of CsF to 1.0
led to a high ratio of insertion (510) to "-arylation products (719), but resulted in
incomplete conversion of 232 and recovery of !-ketolactone 218 (entry 6).  On the other
hand, increasing the amount of CsF to 15 equivalents resulted in a 10:1 ratio of insertion
to "-arylation products and a 36% isolated yield of macrolactone 510 (entry 7).  Finally,
maintaining 15 equivalents of CsF while increasing the silyl aryl triflate (232) amount to
2 equivalents decreased the ratio of insertion to "-arylation to 1.23:1, leaving the yield of
insertion product 510 unaffected (entry 8).
Table 2.6. Acyl-alkylation reactions of dimethoxy silyl aryl triflate 232 with !-ketolactone 218.
(S)-218
O
O
O
TMS
OTf
232
conditions
510
O
O
O
719
O
O
O
MeO
MeO MeO
MeO MeO
OMe
entry F– source (equiv) solvent temperature equiv 232equiv 218 yield 510 ratio 510:719
1
2
3
4
5
6
7
8
KF/18-crown-6 (3.0)
TBAT (3.0)
CsF (3.0)
CsF (3.0)
CsF (3.0)
CsF (15.0)
CsF (1.0)
CsF (15.0)
THF
THF
MeCN
MeCN
MeCN
MeCN
MeCN
MeCN
60 °C
60 °C
80°C
80°C
80°C
80°C
80°C
80°C
1.2
1.2
1.2
1.0
1.0
1.0
1.0
2.0
1.0
1.0 1.0
1.0
1.2
1.0
1.0
1.0
– –
– –
32% 1.0:1.03
38% 1.4:1.0
36% 1.1:1.0
27% 4.6:1.0
36% 10.0:1.0
37% 1.23:1.0
2 9
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Although the yields of dimethylcurvularin (510) were modest, we were able to
investigate demethylation reactions to convert 510 to curvularin (221).  As anticipated
from previous studies, attempts to accomplish this transformation in our laboratory with
several reagents, including BCl3,88 AlCl3,89 cyclohexyl iodide,90 LiCl,91 and NaSEt,92 all
failed, resulting in either recovered starting material or decomposition (Scheme 2.61).
Scheme 2.61.  Attempted demethylation reactions of dimethylcurvularin (510).
510
O
O
O
MeO
MeO
221
O
O
O
HO
HO
BCl3, AlCl3, cyclohexyl iodide
LiCl, NaSEt
not observed
Given the difficulty observed for demethylation of dimethylcurvularin (510),
focus was shifted to use of a dibenzyl silyl aryl triflate (217) alternative.  Prior to acyl-
alkylation reactions of silyl aryl triflate 217 with !-ketolatone 218, we sought to verify
that the benzyl groups could be easily cleaved under reported conditions.  Acyl-alkylation
of silyl aryl triflate 217 with ethyl acetoacetate (222) yielded ketoester 223 in 58% yield
as a single isomer (Scheme 2.62). In order to verify the regioselectivity of insertion, the
ketoester was advanced through hydrogenolysis over palladium on carbon to provide
curvulin (224), an isolate of several species of Curvularia, in 93% yield.5  The synthesis
of curvulin (224) also constitutes a formal synthesis of curvulinic acid (474), which has
been obtained from curvulin by saponification with pig liver esterase.93
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Scheme 2.62. Synthesis of curvulin (224) and formal synthesis of curvulinic acid (474).
BnO
BnO
217
TMS
OTf
OEt
O O 222
KF, 18-crown-6
THF
(58% yield)
BnO
BnO
223
O
O OEt
H2, Pd/C
EtOAc, MeOH
(93% yield)
HO
HO
Curvulin (224)
O
O OEt
pig liver 
esterase
HO
HO
Curvulinic Acid (474)
O
O OH
Bracher
and Krauss
Encouraged by these preliminary findings, we turned our attention to the acyl-
alkylation of silyl aryl triflate 217 with !-ketolactone 218 and completion of (–)-
curvularin (221) (Scheme 2.63).  As in the case of dimethoxy silyl aryl triflate 232, both
TBAT and KF/18-crown-6 fluoride sources failed to produce any acyl-alkylation
products.  In general, yields were moderate across a wide range of conditions similar to
those listed in Table 6.  Under optimized conditions, reaction of 1.5 equivalents of silyl
aryl triflate 217 with 1.0 equivalent of !-ketolactone 218 and 3.0 equivalents CsF in
acetonitrile at 40 °C provided dibenzylcurvularin (220) in 30% yield.  Finally,
hydrogenolysis of the benzyl ethers28 produced (–)-curvularin (221) in 60% yield (8%
overall yield in only 6 linear steps from acetate 676).  Spectral data of the synthetic
curvularin matched that collected for the natural sample in all respects.
2.63. Completion of (–)-curvularin (221) by acyl-alkylation of silyl aryl triflate 217  with ! -
ketolactone 218.
(S)-218
O
O
O
BnO
BnO
217
TMS
OTf
CsF (3 equiv)
MeCN (0.1 M), 40 °C
(30% yield)
220
O
O
O
BnO
BnO
H2, Pd/C
MeOH, THF
(60% yield)
(–)-Curvularin (221)
O
O
O
HO
HO
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2.5 CONCLUDING REMARKS
In conclusion, we have successfully completed the total syntheses of the natural
products (–)-curvularin (221), (–)-diplodialide C (640), and curvulin (224).  A unique
resolution of diastereomers by ring-closing metathesis allowed for the preparation of
diplodialide C from a mixture of diastereomeric dienes.  Application of the aryne acyl-
alkylation en route to curvularin resulted in a general synthesis that we anticipate will be
applicable to a number of related natural and non-natural analogs.  Importantly, we have
devised an innovative and convergent route to these structures that generates two new
carbon–carbon bonds in a single operation, avoiding the need to perform tedious
macrolactonization reactions to build the 12-membered lactone of curvularin.
Furthermore, the aryne insertion technology has provided a synthetic bridge between two
biosynthetically distinct classes of compounds, the diplodialides and curvularin.  The
utilization of these methods in additional complex settings is currently underway in our
laboratories.
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2.6 EXPERIMENTAL SECTION
2.6.1 Materials and Methods
Unless stated otherwise, reactions were performed in flame-dried glassware under
an argon or nitrogen atmosphere using dry, deoxygenated solvents (distilled or passed
over a column of activated alumina).  Commercially obtained reagents were used as
received with the exception of acrolein, which was distilled over hydroquinone under an
argon atmosphere prior to use.  Syringe-pump additions were performed using a
kdScientific single syringe pump.  Reaction temperatures were controlled by an IKAmag
temperature modulator.  Thin-layer chromatography (TLC) was performed using E.
Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by UV fluorescence
quenching, potassium permanganate, or CAM staining.  SiliaFlash P60 Academic Silica
gel (particle size 0.040–0.063 mm) was used for flash chromatography.  1H and 13C NMR
spectra were recorded on a Varian 500 (at 500 MHz and 125 MHz, respectively) and are
reported relative to Me4Si ($ 0.0).  Data for 1H NMR spectra are reported as follows:
chemical shift ($ ppm) (multiplicity, coupling constant (Hz), integration).  Data for 13C
spectra are reported in terms of chemical shift relative to Me4Si ($ 0.0).  IR spectra were
recorded on a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of
absorption (cm–1). HRMS were acquired using an Agilent 6200 Series TOF with an
Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric
pressure chemical ionization (APCI), or mixed (MM) ionization mode. Optical rotations
were measured on a Jasco P-1010 polarimeter using a 50 mm path-length cell.
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2.6.2 Preprative Procedures and Spectroscopic Data
Br
MeO
MeO OH
613
NBS
CH2Cl2, –78 °C
(67% yield)
MeO
MeO OH
614
Bromophenol 614
A solution of phenol 613 (100 mg, 0.649 mmol) in CH2Cl2 (6.4 mL) was prepared
and cooled to –78 °C.  N-Bromosuccinimide (NBS, 115 mg, 0.649 mmol) was added and
the reaction was maintained at –78 °C until phenol 613 was consumed by TLC analysis.
The reaction was quenched at –78 °C with 10% aqueous K2CO3 solution (2 mL) and
warmed to room temperature.  The reaction was diluted with H2O (10 mL) and extracted
with CH2Cl2 (2 x 20 mL).  The combined organic extracts were dried with MgSO4,
concentrated under vacuum, and purified by flash chromatography (10:1 hexanes:ethyl
acetate eluent) to yield bromophenol 614 (101.9 mg, 67% yield): Rf = 0.28 (3:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.27 (d, J = 2.7 Hz, 1H), 6.12 (d, J
= 2.7 Hz, 1H), 5.67 (s, 1H), 3.86 (s, 3H), 3.78 (s, 3H); 13C NMR (125 MHz, CDCl3) $
160.69, 156.79, 153.84, 93.21, 92.50, 91.04, 56.27, 55.54; IR (NaCl/film) 3482, 2942,
1592, 1466, 1350, 1312, 1212, 1155, 1099, 1025, 813 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C8H9O379Br [M]+: 231.9735, found 231.9744.
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Br
MeO
MeO OH
614
HMDS, THF, 70 °C;
n-BuLi, then Tf2O
THF, –100 °C
(63% yield)
TMS
MeO
MeO OTf
232
Silyl aryl triflate 232
Bromophenol 614 (515 mg, 2.21 mmol) and hexamethyldisilazide (922 µL, 4.42
mmol) were combined in THF (5 mL).  The solution was heated to 70 °C and maintained
for 5 h.  The reaction was cooled to room temperature and concentrated under vacuum.
The resulting oil was immediately taken on to the next step.
The crude residue was taken up in THF (15 mL) and cooled to –100 °C.  n-
Butyllithium (2.17 M in hexanes, 1.12 mL, 2.43 mmol) was added slowly and the
reaction was allowed to warm to –82 °C.  The reaction was cooled again to –100 °C and
maintained between –100 °C and –82 °C for 30 minutes.  After this period, triflic
anhydride (446 µL, 2.65 mmol) was added at –100 °C.  The reaction was warmed to –80
°C, quenched by the addition of saturated aqueous sodium bicarbonate solution (5 mL),
and subsequently warmed to room temperature.  The reaction was diluted with diethyl
ether (25 mL) and washed with water (15 mL) and brine (15 mL).  The organic layer was
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(25:1 petroleum ether:diethyl ether eluent) to yield silyl aryl triflate 232 (493 mg, 63%
yield): Rf = 0.34 (10:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.48 (d, J =
2.0 Hz, 1H), 6.38 (d, J = 2.0 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 0.32 (s, 9H); 13C NMR
(125 MHz, CDCl3) $ 166.36, 162.69, 155.52, 118.82 (q, J = 320.9 Hz), 112.29, 98.32,
98.31, 98.29, 98.28, 97.56, 55.77, 55.69, 1.08; 19F NMR (282 MHz, CDCl3) $ –73.07; IR
(NaCl/film) 2960, 1609, 1565, 1460, 1407, 1311, 1245, 1213, 1141, 1094, 1053, 961, 846
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cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C12H17O5F3SSi [M+H]+: 358.0518, found
358.0511.
TIPSCl
imidazole
DMF
(41% yield)
OH
OHHO
615
OTIPS
OHHO
720
Silylphenol 720
Phloroglucinol (615, 500 mg, 3.96 mmol) and imidazole (90 mg, 1.32 mmol)
were combined in DMF (16 mL).  Chlorotriisopropylsilane (TIPSCl, 283 µL, 1.32 mmol)
was added and the resulting solution was maintained at room temperature for 36 hours.
After this period, the reaction was diluted with diethyl ether (25 mL).  The organic layer
was washed with water (25 mL) and brine (25 mL), dried with MgSO4, concentrated
under vacuum, and purified by flash chromatography (10:1 hexanes:ethyl acetate eluent)
to yield 720 (154.1 mg, 41% yield) as a clear oil: Rf = 0.20 (3:1 hexanes:ethyl acetate); 1H
NMR (500 MHz, CDCl3) $ 6.01 (d, J = 2.2 Hz, 2H), 5.97 (t, J = 2.1 Hz, 1H), 5.07 (s,
2H), 1.30–1.18 (m, 3H), 1.09 (d, J = 7.3 Hz, 18H); 13C NMR (125 MHz, CDCl3) $
158.08, 157.02, 100.38, 96.18, 17.89, 12.60; IR (NaCl/film) 3391, 2945, 2868, 1624,
1602, 1493, 1145, 1018, 881, 837, 818, 783, 689, 662 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C15H27O3Si [M+H]+: 283.1724, found 283.1723.
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OTIPS
OHHO
720
  1. BnBr, Cs2CO3
      MeCN
  2. TBAF, THF
(42% yield, 2 steps)
OH
OBnBnO
616
Phenol 616
Silylphenol 720 (135 mg, 0.478 mmol) and Cs2CO3 (343 mg, 1.05 mmol) were
combined in acetonitrile (5 mL).  Benzyl bromide (119 µL, 1.00 mmol) was added and
the resulting suspension was maintained at room temperature with stirring until
silylphenol 720 was fully consumed by TLC analysis.  Upon completion, the reaction
was diluted with diethyl ether (25 mL) and washed with water (10 mL) and brine (10
mL).  The organic layer was dried with MgSO4, concentrated under vacuum, and
immediately carried on to the next step.
The crude residue was taken up in THF (5 mL).  Tetra-n-butylammonium fluoride
solution (1 M in THF, 717 µL) was added and the solution was maintained at room
temperature until the starting material had been fully consumed by TLC analysis.  Upon
completion, the reaction was diluted with diethyl ether (25 mL) and washed with water
(10 mL) and brine (10 mL).  The organic layer was dried with MgSO4, concentrated
under vacuum, and purified by flash chromatography (5:1 hexanes:ethyl acetate eluent) to
yield phenol 616 (62 mg, 42% yield over two steps): Rf = 0.26 (3:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) $ 7.48–7.32 (m, 10H), 6.29 (t, J = 2.1 Hz, 1H),
6.13 (d, J = 2.1 Hz, 2H), 5.17 (s, 1H), 5.00 (s, 4H); 13C NMR (125 MHz, CDCl3) $
160.79, 157.27, 136.74, 128.62, 128.06, 127.57, 95.48, 95.03, 70.14; IR (NaCl/film)
3391, 3032, 2931, 1600, 1498, 1453, 1377, 1214, 1152, 1053, 820, 735, 697 cm–1; HRMS
(MM: ESI-APCI) m/z calc’d for C20H19O3 [M+H]+: 307.1329, found 307.1327.
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Br
OH
OBnBnO
616
NBS
CH2Cl2, –78 °C
(90% yield)
OH
OBnBnO
617
Bromophenol 617
A solution of phenol 616 (20 mg, 0.065 mmol) in CH2Cl2 (1.3 mL) was prepared
and cooled to –78 °C.  N-Bromosuccinimide (NBS, 11.6 mg, 0.0653 mmol) was added
and the reaction was maintained at –78 °C until phenol 616 was consumed by TLC
analysis.  The reaction was quenched at –78 °C by the addition of 10% aqueous K2CO3
solution (500 µL) and warmed to room temperature.  The reaction was diluted with H2O
(10 mL) and extracted with CH2Cl2 (2 x 20 mL).  The combined organic extracts were
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(10:1 hexanes:ethyl acetate eluent) to yield bromophenol 617 (22.6 mg, 90% yield): Rf
0.33 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 7.51–7.46 (m, 2H),
7.46–7.39 (m, 6H), 7.39–7.33 (m, 2H), 6.39 (d, J = 2.7 Hz, 1H), 6.28 (d, J = 2.7 Hz, 1H),
5.71 (s, 1H), 5.11 (s, 2H), 5.02 (s, 2H); 13C NMR (125 MHz, CDCl3) $ 159.74, 155.94,
153.91, 136.44, 136.33, 128.67, 128.61, 128.17, 128.01, 127.57, 127.04, 94.75, 94.63,
92.06, 70.80, 70.35; IR (NaCl/film) 3491, 1594, 1453, 1189, 1160, 1093, 1023, 810, 736,
696 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C20H16O379Br [M–H]–: 383.0288, found
383.0300; m/z calc’d for C20H16O381Br [M–H]–: 385.0270, found 385.0281.
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Br
OH
OBnBnO
617
HMDS, THF, 70 °C;
n-BuLi, then Tf2O
THF, –100 °C
(74% yield)
TMS
OTf
OBnBnO
217
Silyl aryl triflate 217
Bromophenol 617 (310 mg, 0.805 mmol) and hexamethyldisilazide (361 µL, 1.77
mmol) were combined in THF (3.2 mL).  The solution was heated to 70 °C and
maintained for 5 h.  The reaction was cooled to room temperature and concentrated under
vacuum.  The resulting oil was immediately taken on to the next step.
The crude residue was taken up in THF (11 mL) and cooled to –100 °C.  n-
Butyllithium (2.5 M in hexanes, 381 µL, 0.952 mmol) was added slowly and the reaction
was allowed to warm to –82 °C.  The reaction was cooled again to –100 °C and
maintained between –100 °C and –82 °C for 30 minutes.  After this period, triflic
anhydride (175 µL, 1.04 mmol) was added at –100 °C.  The reaction was warmed to –80
°C, quenched by the addition of saturated aqueous sodium bicarbonate solution (5 mL),
and subsequently warmed to room temperature.  The reaction was diluted with diethyl
ether (25 mL) and washed with water (15 mL) and brine (15 mL).  The organic layer was
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(50:1 petroleum ether:diethyl ether eluent) to yield silyl aryl triflate 217 (328 mg, 74%
yield): Rf = 0.55 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 7.45–7.33 (m,
10H), 6.59 (d, J = 2.0 Hz, 1H), 6.53 (d, J = 2.0 Hz, 1H), 5.03 (s, 2H), 5.02 (s, 2H), 0.30
(s, 9H); 13C NMR (125 MHz, CDCl3) $ 165.40, 161.69, 155.47, 136.10, 136.07, 128.93,
128.85, 128.57, 128.46, 128.00, 127.80, 118.8 (q, J = 320.9 Hz), 112.76, 99.48, 99.30,
71.05, 70.67, 1.19; 19F NMR (282 MHz, CDCl3) $ –73.04; IR (NaCl/film) 2954, 1604,
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1562, 1417, 1214, 1140, 1089, 1026, 952, 844, 736, 697 cm–1; HRMS (MM: ESI-APCI)
m/z calc’d for C24H24F3O5SSi [M–H]–: 509.1071, found 509.1062.
O
O
Br
OMe
OMe
O
DIBAL
CH2Cl2, –78 °C
(96% yield)
O
O
Br
OMe
OH
618 721
Benzyl alcohol 721
A solution of methyl ester 618 (3.0 g, 10.4 mmol) in CH2Cl2 (100 mL) was
prepared and cooled to –78 °C.  Diisobutylaluminum hydride (DIBAL, 4.1 mL, 22.8
mmol) was added dropwise and the reaction was maintained at –78 °C until methyl ester
618 was consumed by TLC analysis.  The reaction was quenched at –78 °C by the
addition of saturated aqueous sodium potassium tartrate solution (25 mL) and then
warmed to room temperature.  The reaction was diluted with H2O (25 mL) and extracted
with CH2Cl2 (3 x 25 mL).  The combined organic extracts were dried with MgSO4,
concentrated under vacuum, and purified by flash chromatography (3:1 hexanes:ethyl
acetate eluent) to yield benzylic alcohol 721 (2.6 g, 96% yield): Rf = 0.33 (3:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.70 (s, 1H), 6.05 (s, 2H), 4.66 (d,
J = 5.8 Hz, 2H), 3.90 (s, 3H), 1.99 (t, J = 6.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) $
147.00, 142.90, 135.00, 133.49, 108.42, 101.94, 93.34, 64.47, 56.75; IR (NaCl/film)
3187, 2904, 1628, 1486, 1465, 1446, 1343, 1165, 1106, 1038, 968, 931, 824, 701 cm–1;
HRMS (MM: ESI-APCI) m/z calc’d for C9H8O379Br [M–OH]+: 242.9651, found
242.9648; m/z calc’d for C9H8O381Br [M–OH]+: 244.9632, found 244.9629.
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O
O
O
Br
OMe
OH
721
DMP
CH2Cl2
(83% yield)
O
O
Br
OMe
H
619
Aldehyde 619
A solution of Dess–Martin periodinane (2.94 g, 6.92 mmol) in CH2Cl2 (28 mL)
was prepared under nitrogen.  Alcohol 721 (1.63 g, 6.24 mmol) in CH2Cl2 (72 mL) was
added and the reaction was maintained under nitrogen until alcohol 721 was fully
consumed by TLC analysis.  The reaction was quenched by the addition of a 1:1 v/v
solution of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 (60 mL total
volume). The reaction was extracted with CH2Cl2 (3 x 50 mL).  The combined organic
extracts were washed with water (50 mL) and brine (50 mL) and subsequently dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography (hexanes &
7:3 hexanes:ethyl acetate eluent) to yield aldehyde 619 (1.34 g, 83% yield): Rf = 0.37 (3:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 10.14 (s, 1H), 7.24 (s, 1H), 6.16 (s,
2H), 3.92 (s, 3H); 13C NMR (125 MHz, CDCl3) $ 189.5, 147.4, 143.5, 140.9, 127.6,
109.5, 103.0, 98.8, 56.8; IR (NaCl/film) 1683, 1619, 1485, 1446, 1351, 1315, 1169, 1112,
1048, 993, 928, 654 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C9H8O479Br [M+H]+:
258.96, found 258.9597; m/z calc’d for C9H8O481Br [M+H]+: 260.9581, found 260.9578.
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O
O
O
Br
OMe
H
619
m-CPBA, KHCO3
CH2Cl2
then K2CO3, MeOH
(65% yield)
O
O
Br
OMe
OH
620
Bromophenol 620
A flask was charged with aldehyde 619 (100 mg, 0.386 mmol) and KHCO3 (4 mg,
0.04 mmol) under a nitrogen atmosphere.  To this was added m-CPBA (20 mg, 0.116
mmol) as a solution in CH2Cl2 (4 mL).  Four additional portions of m-CPBA (20 mg,
0.116 mmol, each) were added as CH2Cl2 solutions (0.25 mL, each) at three-hour
intervals.  Nine hours following the final m-CPBA addition, the reaction was quenched
by the addition of saturated NaHCO3 aqueous solution (1 mL) and diluted with CH2Cl2
(25 mL).  The layers were separated and the aqueous layer was further washed with
CH2Cl2 (10 mL).  The combined organic layers were sequentially washed with water (10
mL), saturated aqueous NaHCO3 (2 x 10 mL), and brine (10 mL).  The resulting organic
layer was dried with MgSO4 and concentrated under vacuum to yield a crystalline solid.
The crude solid (103 mg) was taken up in a 10% solution of K2CO3 in methanol
(7.5 mL).  The resultant suspension was maintained with stirring at room temperature
until the starting material had been completely consumed by TLC analysis.  Following
this period, the reaction was concentrated under vacuum, diluted with water (10 mL), and
acidified to pH 1.5 with 6 N HCl.  Warning: vigorous gas evolution.  The aqueous
solution was extracted with ethyl acetate (2 x 25 mL).  The combined organic layers were
washed with brine (10 mL), dried with MgSO4, and concentrated under vacuum.  The
crude residue was purified by flash chromatography (5:1 hexanes:ethyl acetate eluent) to
yield bromophenol 620 (62 mg, 65% yield) as a white solid: Rf = 0.20 (3:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) $ 6.26 (s, 1H), 5.99 (s, 2H), 5.18 (s, 1H), 3.86 (s,
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3H); 13C NMR (125 MHz, CDCl3) $  148.42, 147.02, 143.93, 130.01, 102.37, 95.12,
83.45, 57.12, 57.10.; IR (NaCl/film) 3093, 2899, 1642, 1454, 1350, 1167, 1109, 1051,
971, 935, 874, 797, 700 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C8H7O479Br [M]+:
245.9522, found 245.9525; m/z calc’d for C8H7O481Br [M]+: 247.9502, found 247.9506.
O
O
Br
OMe
OH
620
HMDS, THF, 70 °C;
n-BuLi, then Tf2O
THF, –100 °C
(64% yield)
O
O
TMS
OMe
OTf
604
Silyl aryl triflate 604
Bromophenol 620 (149.6 mg, 0.606 mmol) and hexamethyldisilazide (253 µL,
1.21 mmol) were combined in THF (1.2 mL).  The solution was heated to 70 °C and
maintained for 8 h.  The reaction was cooled to room temperature and concentrated under
vacuum.  The resulting oil was immediately taken on to the next step.
The crude residue was taken up in THF (8 mL) and cooled to –100 °C.  n-
Butyllithium (2.5 M in hexanes, 266 µL, 0.666 mmol) was added slowly and the reaction
was allowed to warm to –82 °C.  The reaction was cooled again to –100 °C and
maintained between –100 °C and –82 °C for 30 minutes.  After this period, triflic
anhydride (122 µL, 0.727 mmol) was added at –100 °C.  The reaction was warmed to –80
°C, quenched by the addition of saturated aqueous sodium bicarbonate solution (4 mL),
and subsequently warmed to room temperature.  The reaction was diluted with diethyl
ether (25 mL) and washed with water (15 mL) and brine (15 mL).  The organic layer was
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(50:1 petroleum ether:diethyl ether eluent) to yield silyl aryl triflate 604 (144.6 mg, 64%
yield): Rf = 0.36 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.52 (s, 1H),
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5.99 (s, 2H), 3.89 (s, 3H), 0.36 (s, 9H); 13C NMR (125 MHz, CDCl3) $ 153.99, 148.40,
144.10, 133.88, 118.76 (q, J = 300.56 Hz), 107.02, 101.78, 101.32, 57.02, 0.23; 19F NMR
(282 MHz, CDCl3) $ –73.07; IR (NaCl/film) 2058, 2901, 1645, 1487, 1419, 1388, 1294,
1244, 1211, 1140, 1111, 1046, 984, 893, 845, 802 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C12H15O6SiSF3 [M+H]+: 372.0311, found 372.0321.
MeO
HO
O
H
Br2
AcOH
(99% yield)
MeO
HO
O
H
Br
621 722
3-Bromovanillin (722)
The following procedure was adopted from a literature report by Rao and
Stuber.52  A single-neck, 2 L round-bottom flask was charged with vanillin (621, 50 g,
328.6 mmol).  Glacial acetic acid was added (1.1 L, 3.0 M).  Following this, a mechanical
stirrer was affixed to the flask through the neck and, with vigorous but even stirring, the
vanillin dissolved to form a pale yellow solution.  At this point, neat bromine (16.84 mL,
361.5 mmol) was added in a rapid dropwise fashion to the stirring solution through the
flask neck to produce a deep red-orange solution.  Following addition, the reaction was
maintained with vigorous stirring for 90 minutes, after which time TLC analysis
indicated formation of the product (Rf = 0.32, 15% ethyl acetate in hexanes).  The
reaction also resulted in the formation of a bright orange-yellow precipitate when nearing
completion. Upon completion of the reaction, the mechanical stirrer was disengaged and
the contents of the reaction flask were poured onto chilled deionized water (0 °C, 600
mL), resulting in further precipitation of a pale yellow solid from the bright orange
aqueous layer.  The reaction flask was washed into this flask with more chilled water.
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While still cooled, the contents of the 1 L Erlenmeyer flask were filtered over a glass frit
to separate the desired solid product.  The isolated solid product (722, 75.25 g, 99%
yield) was transferred to a flask and dried under vacuum for a period of 8 hours.
MeO
HO
O
H Me2SO4, 
K2CO3
acetone
(96% yield)
MeO
MeO
O
H
Br
722 622
Br
3-bromo-4,5-dimethoxy benzaldehyde (622)
To a 1 L round-bottom flask was added anhydrous K2CO3 (113.56 g, 821.6
mmol), followed by a solution of bromobenzaldehyde 722 (75.25 g, 325.66 mmol) in
reagent grade acetone (700 mL).  A mechanical stirrer was affixed to the reaction flask,
and vigorous stirring was required to generate an evenly distributed, maroon suspension.
To this stirring mixture was added Me2SO4 (77.74 mL, 821.69 mmol) over 1 minute via
funnel.  The reaction was left to stir vigorously at 25 °C for 8 hours, at which point TLC
analysis confirmed the conversion of phenol 722 to a less polar product.  The reaction
contents were then vacuum filtered over a glass frit to separate residual solid K2CO3.  The
filtered solid was washed with acetone (2 x 100 mL) and methanol (100 mL).  The
organic filtrate was concentrated to an orange oil and purified by flash chromatography
(5% & 50% ethyl acetate in hexanes eluent) to yield bromobenzaldehyde 622 (76.6 g,
96% yield), which was isolated as a white powder: Rf = 0.56 (30% ethyl acetate in
hexanes); 1H NMR (500 MHz, CDCl3) $ 9.86 (s, 1H), 7.67 (d, J = 1.80 Hz, 1H), 7.40 (d,
J = 1.85 Hz, 1H), 3.96 (s, 3H), 3.95 (s, 3H); 13C NMR (125 MHz, CDCl3) $ 189.83,
154.17, 151.81, 133.03, 128.77, 117.92, 110.09, 60.83, 56.25; IR (NaCl/film) 2945, 2860,
1692, 1588, 1566, 1486, 1469, 1452, 1420, 1393, 1380, 1312, 1281, 1240, 1212, 1144,
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1133, 1048, 993, 855, 840 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C9H9BrO3 [M]+:
243.9735, found 243.9731.
623
MeO
MeO
O
H
Br
PdCl2(PPh3)2 (2.5 mol%)
SnMe4, LiCl 
DMF, 100 °C
(99% yield)
MeO
MeO
O
H
622
3,4-dimethoxy-5-methylbenzaldehyde (623)
A 250 mL round-bottom flask was charged with lithium chloride (4.32 g, 102.00
mmol) and then flame dried.  To this flask was added a solution of benzaldehyde 622 (5.0
g, 20.40 mmol) in N,N-dimethylformamide (200 mL) that had been rigorously sparged
with argon.  Next, PdCl2(PPh3)2 (0.358 g, 0.51 mmol) was added to the stirring mixture,
producing a bright yellow-orange solution that was stirred vigorously.  A reflux
condenser was affixed to the top of the reaction flask before adding, dropwise, neat
tetramethyltin (7.06 mL, 51.0 mmol).  The reaction vessel was sealed under an argon
atmosphere and heated to reflux in 100 °C oil bath.  The reaction was maintained at
reflux for 3 hours; during this period the color of the solution changed to dark red-
orange.94  TLC analysis of the reaction after this period showed full consumption of the
starting material.  The reaction was cooled to room temperature and then quenched by the
addition of H2O (200 mL).  The aqueous layer was thoroughly extracted with ethyl
acetate (5 x 200 mL), and the combined organic layers were washed with brine (150 mL).
The organic extract was dried over MgSO4, concentrated under vacuum, and purified by
flash chromatography (5% ethyl acetate in hexanes eluent) to furnish benzaldehyde 623
as a colorless oil (3.63 g, 99% yield): Rf = 0.42  (10% ethyl acetate in hexanes); 1H NMR
(500 MHz, CDCl3) $ 9.85 (s, 1H), 7.17 (d, J = 1.71 Hz, 1H), 7.16 (d, J = 0.60 Hz, 1H),
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3.78 (s, 3H), 3.77 (s, 3H), 2.19 (s, 3H); 13C NMR (125 MHz, CDCl3) $ 191.14, 153.02,
152.70, 126.95, 108.79, 60.05, 55.65, 15.75; IR (NaCl/film) 2939, 2833, 1693, 1586,
1491, 1465, 1422, 1387, 1329, 1299, 1233, 1140, 1096, 1003, 856 cm–1; HRMS (MM:
ESI-APCI) m/z calc’d for C10H12O3 [M]+: 180.0786, found 180.0779.
OHMeO
MeO
624623
MeO
MeO
O
H m-CPBA
NaHCO3 (10 mol%)
CH2Cl2
then
K2CO3, MeOH
(88% yield)
3,4-dimethoxy-5-methylphenol (624)
A 250 mL round-bottom flask was charged with anhydrous NaHCO3 (0.467 g,
0.56 mmol).  To this, was added a solution of benzaldehyde 623 (1.00 g, 5.55 mmol) in
CH2Cl2 (11 mL).  This mixture was vigorously stirred until the NaHCO3 fully dissolved.
At this point, m-CPBA (1.92 g, 11.10 mmol) was added as a solid in a single portion to
the pale yellow solution.  Immediately, the solution turned bright yellow, and was
maintained with stirring at 25 °C under an atmosphere of N2.  Notable accumulation of
precipitate resulted in increasing turbidity of the solution, and after 6 hours, TLC analysis
indicated formation of a new product (R f = 0.22, hexanes) and consumption of
benzaldehyde 623.  At this time, methanol (110 mL) and anhydrous K2CO3 (2.30 g, 16.65
mmol) were added, and the solution turned maroon in color.  The reaction was
maintained at 25 °C for 12 hours, resulting in formation of a new polar product.  The
reaction was stopped by concentration under vacuum to yield a dark maroon solid.  This
solid was dissolved in H2O (100 mL), and then neutralized with concentrated aqueous
HCl (6 mL).  Warning: vigorous gas evolution.  The resulting suspension was extracted
with CH2Cl2 (5 x 100 mL), and the combined organic extracts were washed with
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saturated aqueous NaHCO3 (2 x 200 mL) to remove benzoate byproducts.  The organic
layers were dried with Na2SO4, concentrated under vacuum, and purified by flash
chromatography (30% ethyl acetate in hexanes eluent) to provide phenol 624 (0.822 g,
4.89 mmol, 88% yield) as a white solid: Rf = 0.30 (30% ethyl acetate in hexanes); 1H
NMR (500 MHz, CDCl3) $ 6.29 (d, J = 2.80 Hz, 1H), 6.20 (d, J = 2.80 Hz, 1H), 4.53 (s,
1H), 3.81 (s, 3H), 3.73 (s, 3H), 2.21 (s, 3H); 13C NMR (125 MHz, CDCl3) $ 153.36,
151.78, 141.12, 132.41, 108.36, 98.17, 60.35, 55.69, 15.85; IR (NaCl/film) 3272, 2957,
1614, 1483, 1463, 1440, 1430, 1348, 1268, 1226, 1219, 1196, 1181, 1154, 1096, 1001,
854, 772, 737 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C9H12O3 [M]+: 168.0786,
found 168.0753.
NHi-PrOHMeO
MeO
624
i-PrNCO 
Et3N (20 mol%)
CH2Cl2
(94% yield)
OMeO
MeO
625
O
Isopropyl carbamate 625
This procedure was adopted from the literature procedure reported by Bronner, et
al.54  A 100 mL round-bottom flask was charged with a solution of phenol 624 (1.696 g,
10.08 mmol) in CH2Cl2 (35 mL).  The solution was stirred at 25 °C under an atmosphere
of N2 before neat isopropyl isocyanate (1.483 mL, 15.12 mmol) was added via syringe.
The solution turned orange, and after 5 minutes of stirring, freshly distilled Et3N (0.281
mL, 2.02 mmol) was added via syringe to effect the formation of a dark purple solution.
The reaction was maintained with stirring for 18 hours at 25 °C.  Following this period,
TLC analysis showed conversion of phenol 624 to a single product.  The reaction was
concentrated to an orange-brown residue and purified by flash chromatography (5% ethyl
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 167
acetate in hexanes eluent) to provide isopropyl carbamate 625 as a clear, pale yellow oil
(2.404 g, 94% yield): Rf = 0.48 (30% ethyl acetate in hexanes); 1H NMR (500 MHz,
CDCl3) $ 6.55 (d, J = 2.65 Hz, 1H), 6.54 (d, J = 2.65 Hz, 1H), 2.79 (s, 1H), 3.87 (m, 1H),
3.82 (s, 3H), 3.76 (s, 3H), 2.24 (s, 3H), 1.23 (d, J = 7.25 Hz, 6H); 13C NMR (125 MHz,
CDCl3) $ 153.92, 152.87, 146.66, 144.62, 115.29, 104.21, 60.15, 55.78, 43.44, 22.93,
15.91; IR (NaCl/film) 3326, 2972, 2936, 1715, 1604, 1529, 1490, 1466, 1422, 1332,
1220, 1190, 1175, 1142, 1095, 1050, 1009, 936, 854, 773 cm–1; HRMS (MM: ESI-APCI)
m/z calc’d for C13H19NO4 [M]+: 253.1314, found 253.1319.
NHi-PrOMeO
MeO
625
O
NHi-PrOMeO
MeO
626
O
TMS
TBSOTf, TMEDA
Et2O, 0 °C ! 25 °C;
n-BuLi, TMEDA, –78 °C;
then TMSCl
(86% yield)
TMS carbamate 626
This procedure was adopted from the literature procedure reported by Bronner, et
al.54  To a 25 mL round-bottom flask was added a solution of isopropyl carbamate 625
(2.404 g, 9.49 mmol) in diethyl ether (94 mL), followed by freshly distilled TMEDA
(1.56 mL, 10.44 mmol) via syringe.  The solution was cooled to 0 °C in an ice water bath.
Upon temperature equilibration (15 minutes), neat distilled TBSOTf (2.398 mL, 10.44
mmol) was added.  The resulting solution was maintained for 10 minutes at 0 °C and then
the flask was allowed to warm to 23 °C over 30 minutes.  At this point, TLC analysis
showed formation of a less polar product (Rf = 0.81, 15% ethyl acetate in hexanes)
corresponding to the N-silylated intermediate.  Additional TMEDA was added to the
mixture via syringe (5.688 mL, 37.964 mmol).  The reaction was then cooled to –78 °C
in a dry ice and acetone bath with vigorous stirring to avoid aggregation of triflate salts.
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Next, n-BuLi solution (2.32 M in hexanes, 16.36 mL, 37.96 mmol) was added dropwise
down the side of the flask of the cold solution.  The solution was maintained with stirring
at –78 °C for 4 hours, after which time freshly distilled TMSCl (8.432 mL, 66.437 mmol)
was added dropwise to the flask.  The reaction vessel, in the cold bath, was allowed to
warm to 23 °C over the course of two hours.  At this point, TLC analysis indicated the
presence of a single, new product.  Saturated aqueous NaHSO4 solution (50 mL) was
added and stirred with the reaction mixture for 1 hour.  The layers were separated and the
organic layer was washed with an additional 50 mL of the NaHSO4 solution.  The
combined aqueous layers were then extracted with diethyl ether (3 x 50mL).  The
combined organic extracts were washed with brine (50 mL), dried with MgSO4, and then
concentrated under vacuum to a colorless crystalline solid.  Purification via flash
chromatography (5% &  20% ethyl acetate in hexanes eluent) provided pure TMS
carbamate 626 (2.63 g, 86% yield): Rf = 0.63 (15% ethyl acetate in hexanes); 1H NMR
(500 MHz, CDCl3) $ 6.62 (s, 1H),  4.69 (d, J = 7.08 Hz, 1H), 3.89 (m, 1H), 3.83 (s, 3H),
3.76 (s, 3H), 2.23 (s, 3H), 1.23 (d, J = 6.75, 6H), 0.29 (s, 9H); 13C NMR (125 MHz,
CDCl3) $ 156.69, 153.00, 149.33, 147.28, 133.33, 121.79, 118.88, 59.19, 58.54, 42.27,
21.88, 14.83, 0.13; IR (NaCl/film) 3326, 2971, 2937, 1710, 1601, 1530, 1464, 1384,
1370, 1324, 1247, 1220, 1193, 1179, 1080, 1026, 987, 844, 810, 759 cm–1; HRMS (MM:
ESI-APCI) m/z calc’d for C16H27NO4Si [M+H]+: 326.1734, found 326.1725.
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NHi-PrOMeO
MeO
626
O
TMS
OTfMeO
MeO
605
TMS
Et2NH, DBU
MeCN, 40 °C
then PhNTf2
MeCN, 25 °C
(52% yield)
Silyl aryl triflate 605
This procedure was adopted from the literature procedure reported by Bronner, et
al.54  A 250 mL round-bottom flask was charged with a solution of TMS carbamate 626
(2.63 g, 8.10 mmol) in acetonitrile (80 mL).  To this was added diethylamine (1.01 mL,
9.71 mmol), followed by DBU (1.82 mL, 12.14 mmol).  The reaction was carefully
monitored by TLC as it was heated to 40 °C in an oil bath.  After 10 minutes, TLC
anaylsis indicated complete consumption of the starting material and conversion to two
spots (Rf1 = 0.78 and Rf2 = 0.60).95  The reaction was immediately removed from the oil
bath and a solution of PhNTf2 (4.34 g, 12.14 mmol) in acetonitrile (24 mL) was added via
syringe.  The reaction was maintained with stirring for 12 hours at 23 °C, at which point
the reaction solution was washed with saturated aqueous NaHSO4 (2 x 50 mL) and brine
(100 mL).  The organic extract was dried over MgSO4, concentrated under vacuum to an
orange oil, and purified via flash chromatography (5% ethyl acetate in hexanes eluent) to
yield silyl aryl triflate 605 (1.57 g, 52% yield) as a pale yellow oil: Rf = 0.68 (15% ethyl
acetate in hexanes); 1H NMR (500 MHz, CDCl3) $ 6.87 (s, 1H), 3.86 (s, 3H), 3.77 (s,
3H), 2.27 (s, 3H), 0.36 (s, 9H); 13C NMR (125 MHz, CDCl3) $ 158.72, 150.74, 149.21,
135.84, 117.49 (q, J = 320 Hz), 124.53, 117.96, 60.79, 60.03, 16.43, 1.41; 19F NMR (282
MHz, CDCl3) $ –73.10; IR (NaCl/film) 2956, 2858, 1600, 1464, 1420, 1383, 1368, 1292,
1248, 1213, 1179, 1142, 1068, 1023, 982, 930, 873, 846, 764 cm–1; HRMS (MM: ESI-
APCI) m/z calc’d for C13H19F3O5SSi [M]+: 372.0675, found 372.0674.
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TMS
MeO
MeO OTf
232
OEt
O O
+
KF, 18-crown-6
THF
(53% yield)222
MeO
MeO
627
O
CO2Et
Ketoester 627
Silyl aryl trilfate 232 (52 mg, 0.144 mmol) and ethyl acetoacetate (222, 15 mg,
0.115 mmol) were combined in THF (1.2 mL).  To this was sequentially added 18-
crown-6 (91 mg, 0.346 mmol) and KF (20 mg, 0.346 mmol).  The resulting suspension
was maintained at room temperature with vigorous stirring until silyl aryl triflate 232 had
been completely consumed by TLC analysis.  Following this period the reaction was
diluted with diethyl ether (10 mL) and washed with water (2 x 10 mL) and brine (10 mL).
The organic layer was dried with MgSO4, concentrated under vacuum, and purified by
flash chromatography (5:1 hexanes:ethyl acetate eluent) to yield ketoester 627 (16.2 mg,
53% yield): Rf = 0.23 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.42 (d,
J = 2.3 Hz, 1H), 6.37 (d, J = 2.2 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 3.83 (s,
3H), 3.70 (s, 2H), 2.52 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) $
203.83, 171.31, 161.51, 159.31, 134.98, 123.82, 108.12, 97.48, 60.84, 55.60, 55.39,
39.21, 32.26, 14.19; IR (NaCl/film) 2979, 2941, 1732, 1682, 1602, 1461, 1425, 1318,
1263, 1203, 1159, 1093, 1029, 947, 836 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C14H19O5 [M+H]+: 267.1232, found 267.1231.
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BnO
BnO
TMS
OTf
+
MeO
OMe
O O
217 225
KF, 18-crown-6
THF
(60% yield)
BnO
BnO
226
O
CO2Me
OMe
Ketoester 226
To a solution of silyl aryl triflate 217 (65.5 mg, 0.128 mmol) and !-ketoester 225
(15 mg, 0.103 mmol) in THF (1.0 mL) was sequentially added 18-crown-6 (81.3 mg,
0.308 mmol) and KF (17.9 mg, 0.308 mmol).  The resulting suspension was maintained
with vigorous stirring until !-ketoester 225 had been completely consumed by TLC
analysis.  Following this period, the reaction was diluted with diethyl ether (25 mL) and
washed with water (15 mL x 2) and brine (15 mL).  The organic layer was dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography (5:1
hexanes:ethyl acetate eluent) to yield ketoester 226 (26.8 mg, 60% yield): Rf = 0.13 (3:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 7.49–7.30 (m, 10H), 6.57 (d, J =
2.2 Hz, 1H), 6.51 (d, J = 2.2 Hz, 1H), 5.06 (s, 2H), 5.05 (s, 2H), 4.50 (s, 2H), 3.73 (s,
2H), 3.69 (s, 3H), 3.32 (s, 3H); 13C NMR (125 MHz, CDCl3) $ 202.33, 171.56, 161.19,
158.90, 136.17, 136.12, 135.72, 128.71, 128.70, 128.40, 128.28, 127.72, 127.57, 120.95,
109.95, 99.36, 78.78, 70.99, 70.24, 59.08, 52.04, 39.07; IR (NaCl/film) 2947, 1734, 1700,
1601, 1436, 1375, 1319, 1160, 1124, 1073, 739 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C26H26O6 [M+H]+: 434.1729, found 434.1720.
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O
O
TMS
OMe
OTf
604
OEt
O O
+
KF, 18-crown-6
MTBE, 40 °C
(45% yield)
O
O
OMe
628
O
CO2Et
222
Ketoester 628
To a solution of silyl aryl triflate 604 (23.8 mg, 0.0639 mmol) and ethyl
acetoacetate (222, 4.1 mL, 0.0320 mmol) in tert-butyl methyl ether (MTBE, 0.32 mL)
was added 18-crown-6 (25.3 mg, 0.0959 mmol) and KF (5.6 mg, 0.0959 mmol).  The
resulting suspension was heated in an oil bath to 40 °C and maintained for a period of 1
hour.  Following this time, the reaction was cooled to room temperature, diluted in
diethyl ether (25 mL), and washed with water (2 x 10 mL) and brine (10 mL).  The
organic layer was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (15:1 hexanes:ethyl acetate eluent) to yield ketoester 628 (4 mg, 45%
yield): Rf = 0.49 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.38 (s, 1H),
6.07 (s, 2H), 4.16 (q, J = 7.1 Hz, 2H), 3.94 (s, 3H), 3.81 (s, 2H), 2.55 (s, 3H), 1.28 (t, J =
7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) $ 189.5, 147.4, 143.5, 140.9, 127.6, 109.5,
103.0, 98.8, 56.8; IR (NaCl/film) 2985, 2904, 1731, 1674, 1632, 1427, 1312, 1281, 1162,
1100, 940, 854 cm–1; HRMS (MM:ESI-APCI) m/z calc’d for C14H16O6 [M+H]+:
281.1020, found 281.1020.
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OTf
OMe
MeO
605
TMS O O
OMe
229
OMe
MeO
629
O
CO2Me
CsF
MeCN
80 °C
(92% yield)
Ketoester 629
To a round-bottom flask was added oven-dried CsF (0.053 g, 0.348 mmol),
followed by a solution of methyl acetoacetate (229 , 0.025 mL, 0.232 mmol) in
acetonitrile (1 mL).  Next, aryne precursor 605 was added via syringe (0.108 g, 0.290
mmol), and the reaction was maintained with stirring in an oil bath at 80 °C for 2 hours.
The reaction was cooled to 25 °C, concentrated under vacuum, and the crude reaction
mixture was adsorbed onto Celite (1 g).  Ketoester 629  was purified by flash
chromatography (10% ethyl acetate in hexanes eluent) and isolated as a colorless oil (57
mg, 92 % yield): Rf = 0.56 (30% ethyl acetate in hexanes); 1H NMR (500 MHz, CDCl3) $
6.79 (s, 1H), 3.88 (s, 3H), 3.83, (s, 3H), 3.68 (s, 3H), 3.62 (s, 2H), 2.55 (s, 3H), 2.25 (s,
3H); 13C NMR (125 MHz, CDCl3) $ 204.42, 171.97, 150.74, 150.32, 134.33, 134.06,
128.55, 126.63, 61.14, 60.05, 51.95, 37.73, 32.23, 15.85; IR (NaCl/film) 2951, 2849,
1740, 1692, 1604, 1568, 1484, 1451, 1437, 1400, 1351, 1306, 1269, 1200, 1167, 1147,
1078, 1040, 1012 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C14H18O5 [M]+: 266.1154,
found 266.1152.
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BnO
BnO
O
O
OMe
OH
227
BnO
BnO
226
O
CO2Me
OMe NaOMe
MeOH
(51% yield)
Hydroxynaphthoquinone 227
To NaH (60 wt. % dispersion in mineral oil, 12.3 mg, 0.308 mmol) in a vial was
added MeOH (1.0 mL), and the resulting suspension was stirred for 10 minutes.
Warning: vigorous gas evolution.  A separate solution of ketoester 226 (26.8 mg, 0.0617
mmol) in MeOH (1.0 mL) was prepared.  Slowly the solution of NaOMe was added to
the solution of ketoester 226 and maintained with stirring at room temperature for 20
minutes.  Following this period, the vial was opened to the atmosphere and heated at 60
°C until ketoester 226 has been fully consumed by TLC analysis.  Upon completion, the
reaction was cooled to room temperature and diluted with ethyl acetate (10 mL).  The
resulting solution was washed with 1 N K2CO3 solution (5 x 15 mL), the combined
aqueous extracts were acidified with 6 N HCl to pH 1.5, and the acidic solution was
extracted with ethyl acetate (15 mL x 3).  The combined organic extracts were dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography to yield
hydroxynaphthoquinone 227 (13 mg, 51% yield): Rf = 0.43 (1:1 hexanes:ethyl acetate);
1H NMR (500 MHz, CDCl3) $ 7.61 (d, J = 7.1 Hz, 2H), 7.48–7.29 (m, 9H), 6.86 (d, J =
2.5 Hz, 1H), 6.55 (s, 1H), 5.21 (s, 2H), 5.18 (s, 2H), 4.21 (s, 3H); 13C NMR (125 MHz,
CDCl3) $ 182.23, 179.01, 163.28, 160.84, 140.79, 140.13, 135.84, 135.40, 133.06,
128.80, 128.65, 128.55, 127.87, 127.65, 126.58, 113.08, 106.98, 104.88, 70.92, 70.71,
60.69; IR (NaCl/film) 3367, 2944, 1653, 1592, 1440, 1318, 1207, 1169, 1052, 1010, 736
cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C25H20O6 [M+H]+: 416.1260, found
416.1251.
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BnO
BnO
O
O
OMe
OH
227
H2, Pd/C
MeOH, THF
(80% yield)
HO
HO
O
O
OMe
OH
228
3-Methoxy-2,5,7-trihydroxy-1,4-naphthaquinone (228)
To a solution of hydroxynaphthoquinone 227  (9.7 mg, 0.0233 mmol) in
MeOH/THF (1:1 (v/v) mixture, 2 mL total volume) was added 10 wt. % Pd/C (12.4 mg,
0.0116 mmol).  A hydrogen balloon was attached to the system and the suspension was
maintained under the H2 atmosphere with vigorous stirring at room temperature until
hydroxynaphthoquinone 227 had been fully consumed by TLC analysis.  The suspension
was filtered through Celite, concentrated under vacuum, and purified by flash
chromatography (1:1 dichloromethane:ethyl acetate eluent) to yield 3-methoxy-2,5,7-
trihydroxy-1,4-naphthaquinone (2 2 8 , 4.4 mg, 80% yield): R f = 0.17 (1:1
dichloromethane:ethyl acetate); 1H NMR (500 MHz, acetone-d6) $ 6.92 (d, J = 1.8 Hz,
1H), 6.45 (d, J = 2.2 Hz, 1H), 3.86 (s, 3H); 13C NMR (125 MHz, acetone-d6) $ 185.46,
181.62, 163.54, 163.48, 147.64, 140.50, 132.08, 107.91, 107.76, 106.93, 59.89; IR
(NaCl/film) 3305, 1611, 1467, 1284, 1170, 1096 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C11H8O6 [M]+: 236.0321, found 236.0357.
OTf
OMe
MeO
605
TMS CO2Me
H
N
O
BnO
630
N
OMe
MeO
CO2Me
OBn
631
TBAT
THF
25 °C
(81% yield)
Isoquinoline 631
A 100 mL round-bottom flask was charged with TBAT (0.225 g, 0.416 mmol).
To this flask was added a solution of N-acyl enamide 630 (0.049 g, 0.208 mmol) in THF
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(21 mL).  Finally, aryne precursor 605 was added (0.116 g, 0.312 mmol) via syringe.
The pale yellow solution turned bright yellow while stirring at 25 °C for 8 hours.  The
reaction was stopped by adsorbing the contents onto celite (1 g) and purifying the
reaction mixture via flash chromatography (5% ! 30% ethyl acetate in hexanes eluent),
providing the desired isoquinoline 631 (64 mg, 81% yield) as a pale yellow solid: Rf =
0.22 (30% ethyl acetate in hexanes); 1H NMR (500 MHz, CDCl3)
$ 8.37 (s, 1 H), 7.53 (s, 1H) 7.43 (d, J = 6.9 Hz, 2H) 7.32 (t, J = 7.28 Hz, 3H) 5.32 (s, 2H)
4.73 (s, 2H) 4.05 (s, 2H) 3.96 (s, 6H) 2.47 (s, 3H); 13C NMR (125 MHz, CDCl3)
$ 166.54, 155.93, 152.57, 149.20, 139.38, 138.46, 138.37, 134.31, 128.24, 128.20,
128.16, 127.47, 125.06, 123.56, 74.74, 73.00, 61.00, 60.06, 52.71, 16.92; IR (NaCl/film)
2948, 2856, 1738, 1716, 1667, 1616, 1558, 1486, 1453, 1402, 1354, 1333, 1310, 1263,
1130, 1089, 1055, 1008, 950, 909, 784, 742 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C22H23NO5 [M]+: 381.1576, found 381.1571.
O O
Ot-BuO
O
EtO Cl
O LDA
THF, –78 °C
then AcOH Cl
O
t-BuO
O Ac2O, H2SO4
acetone
0 ! 23 °C
(75% yield,
2 steps)
Cl
Et3N
THF
(84% yield)
O O
O
660 661 662 663 658
Vinyl dioxolenone 658
A solution of i-Pr2NH (6.27 mL, 44.7 mmol) in THF (100 mL) was cooled to –78
°C.  To this solution was slowly added n-BuLi (2.50 M solution in hexanes, 18.0 mL,
44.7 mmol).  The resulting solution was maintained with stirring at –78 °C for 30
minutes, after which time t-butyl acetate (660, 6.0 mL, 44.7 mmol) was slowly added.
The solution was maintained for 15 minutes with stirring at –78 °C.  Meanwhile, a
solution of ethyl 3-chloro propionate (661, 3.05 mL, 22.4 mmol) in THF (50 mL) was
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cooled to –78 °C.  This solution was transferred slowly by cannula to the stirring –78 °C
solution of t-butyl acetate enolate.  Following addition, the reaction was quenched by the
slow addition of acetic acid (20 mL).  The reaction was then warmed to room temperature
and diluted with Et2O (50 mL).  The resulting solution was washed sequentially with
water (50 mL), aqueous 20% K2CO3 solution (2 x 30 mL), and brine (50 mL).  The
organic layer was dried with Na2SO4 and concentrated under vacuum to yield !-ketoester
662 .  The crude pale yellow oil (4.63 g) was immediately used without further
purification.
Crude !-ketoester 662 (4.63 g, 22.4 mmol), acetic anhydride (6.34 mL, 67.2
mmol), and acetone (3.30 mL, 44.8 mmol) were combined in a round-bottom flask and
cooled to 0 °C with an ice bath.  Sulfuric acid (1.24 mL, 22.4 mmol) was added dropwise
by syringe.  The ice bath was removed, the reaction was warmed to room temperature,
where it was maintained with stirring for 16 hours.  Following this period, the reaction
was diluted with water (50 mL) and extracted with CH2Cl2 (70 mL, 2 x 50 mL).  The
combined organic extraxts were dried with MgSO4, concentrated under vacuum, and
purified by flash chromatography (10:1 &  7:1 &  5:1 &  4:1 &  3:1 &  2:1 &  1:1
hexanes:ethyl acetate eluent) to yield dioxolenone 663 (3.21 g, 75% yield, 2 steps).
Dioxolenone 663 (3.21 g, 16.8 mmol) was taken up in THF (42 mL) at room
temperature.  Et3N (4.70 mL, 33.7 mmol) was added and the reaction was maintained
with stirring at room temperature for 20 hours or until complete by TLC analysis.  Upon
completion, the reaction was diluted with Et2O (50 mL) and washed sequentially with
water (40 mL) and brine (40 mL).  The organics were dried with MgSO4, concentrated
under vacuum, and purified by flash chromatography (5:1 pentane:ethyl ether eluent) to
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yield vinyl dioxolenone 658  (2.17 g, 84% yield) as a clear oil.  Data for vinyl
dioxolenone 658 matched the reported literature values.72
665
OH
TBSCl, imidazole
DMF, 23 °C
(80% yield)
OTBS
664
Silyl ether 665
5-Hexen-1-ol (664, 1.2 mL, 9.98 mmol) and imidazole (1.02 g, 15.0 mmol) were
combined in a round-bottom flask in DMF (20 mL).  TBSCl (1.66 g, 10.98 mmol) was
added and the reaction was maintained with stirring at room temperature until complete
by TLC analysis.  Upon completion, the reaction was diluted with Et2O (50 mL) and
washed with water (25 mL) and brine (25 mL).  The organic layer was dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography (95:5
hexanes:ethyl ether eluent) to yield silyl ether 665 (1.72 g, 80% yield) as a clear oil.  Data
for silyl ether 665 matched the reported literature values.96
OTBS
665
O O
O
658
+ Grubbs 2 (5 mol%)
CH2Cl2 (0.4 M), 40 °C
24 h
(81% yield)
O O
O OTBS
667
Silyl ether 667
To a solution of Grubbs 2nd generation catalyst (146, 117 mg, 0.138 mmol) in
dichloromethane (10 mL) was added a solution of vinyl dioxolenone 658 (1.28 g, 8.30
mmol) and silyl ether 665 (593 mg, 2.80 mmol) in dichloromethane (10 mL).  The
reaction was heated at 40 °C for 12 hours.  Upon completion, the reaction mixture was
cooled to ambient temperature, concentrated under vacuum, and purified by flash
chromatography (20:1 hexanes:ethyl acetate eluent) to yield silyl ether 667 (772 mg, 81%
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 179
yield): Rf 0.34 (5:1 hexanes:ethyl acetate).  Silyl ether 667 was immediately used in the
next step.
O O
O OTBS
667
TBAF, AcOH
THF, 25 °C, 4 h
(93% yield)
O O
O OH
666
Primary alcohol 666
To a solution of silyl ether 667 (845 mg, 2.48 mmol) in THF (12.5 mL) was
added TBAF (1 M in THF, 4.96 mL) and acetic acid (284 µL, 4.95 mmol).  Upon
completion by TLC, the reaction solution was diluted with Et2O (50 mL) and washed
with water (25 mL) and brine (25 mL).  The combined organics were dried over Na2SO4,
concentrated under vacuum, and purified by flash chromatography (1:1 hexanes:ethyl
acetate eluent) to yield primary alcohol 666 (561 mg, 93% yield): Rf = 0.16 (1:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.55 (dt, J = 15.5, 7.0 Hz, 1H),
5.91 (dt, J = 15.5, 1.5 Hz, 1H), 5.24 (s, 1H), 3.67 (t, J = 6.2 Hz, 2H), 2.25 (qd, J = 7.2,
1.4 Hz, 2H), 1.70 (s, 6H), 1.66–1.52 (m, 4H), 1.47 (s, 1H); 13C NMR (125 MHz, CDCl3)
$ 163.7, 162.5, 142.5, 122.9, 106.5, 93.4, 62.5, 53.7, 32.5, 32.1, 25.1, 24.8; IR
(NaCl/film) 3423, 2939, 2864, 1723, 1652, 1591, 1391, 1276, 1205, 1061, 1019 cm-1;
HRMS (EI) m/z calc’d for C12H19O4 [M+H]+: 227.13, found 227.13.
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Br
Mg0, THF
sonication
then acetaldehyde
(70% yield)
OH
677 678
Secondary alcohol 678
A round-bottom flask was charged with Mg turnings (500 mg, 20.2 mmol) and
THF (5 mL).  1,2-Dibromoethane (80 µL) was added to activate the Mg turnings and the
suspension was sonicated for 1 hour at room temperature.  Following this period, 5-
bromo-1-pentene (677, 1.0 mL, 8.4 mmol) was added to the Mg turning suspension over
10 minutes as a solution in THF (20 mL).  The suspension was further sonicated for 3
hours, at which time acetaldehyde (2 mL, 35.6 mmol) was added slowly with sonication
as a solution in THF (2 mL).  Following addition of acetaldehyde, the reaction was
quenched by the addition of saturated aqueous NH4Cl (20 mL).  The reaction was
extracted with Et2O (100 mL) and the organic layer was then washed with brine (20 mL).
Finally, the organic layer was dried with MgSO4, concentrated under vacuum, and
purified by flash chromatography (5:1 hexanes:ethyl acetate eluent) to yield secondary
alcohol 678 (632 mg, 70% yield) as a clear oil.  All spectroscopic data for secondary
alcohol 678 matched that in the literature.79
O
OH
678
AcCl, Et3N
DMAP (10 mol%)
Et2O
(94% yield)
O
676
Acetate 676
To a solution of secondary alcohol 678 (632 mg, 5.5 mmol) in Et2O (50 mL) was
added DMAP (68 mg, 0.55 mmol), Et3N (2.31 mL, 16.6 mmol), and acetyl chloride (472
µL, 6.64 mmol).  The resulting suspension was maintained at room temperature with
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stirring until complete by TLC analysis.  After this period, the reaction was quenched by
the addition of 10% citric acid aqueous solution (25 mL).  The biphasic solution was then
extracted with additional ether (50 mL).  The organic layer was washed with brine (25
mL), dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (10:1 pentane:ethyl ether eluent) to yield acetate 676 (1.30 g, 94% yield)
as a clear oil.  All spectroscopic data for acetate 676 matched that in the literature.79
O OMe
O O
680
O
O
676
Grubbs 2 (5 mol%)
methyl acrylate
PhH, 40 °C
(74% yield)
Methyl ester 680
Acetate 676 (100 mg, 0.640 mmol) and methyl acrylate (288 µL, 3.20 mmol)
were combined in benzene (7 mL).  Grubbs 2nd generation catalyst (146, 27 mg, 0.0320
mmol) was added and the reaction was heated under a nitrogen atmosphere at 40 °C until
complete by TLC.  Upon completion, the reaction solution was cooled to ambient
temperature, concentrated under vacuum, and purified by flash chromatography (5:1
pentane:ethyl ether eluent) to yield 680 (137 mg, 74% yield): Rf = 0.19 (5:1 pentane:ethyl
ether); 1H NMR (300 MHz, CDCl3) $ 6.90 (dt, J = 15.7, 7 Hz, 1H), 5.78 (dt, J = 15.7, 1.5
Hz, 1H), 4.85 (m, 1H), 3.68 (s, 3H), 2.17 (m, 2H), 1.99 (s, 3H), 1.50 (m, 4H), 1.43 (d, J =
11.3 Hz, 3H) ; 13C NMR (125 MHz, CDCl3) $ 171.0, 167.3, 148.8, 121.7, 70.7, 51.8,
35.7, 32.1, 24.0, 21.5, 20.0; IR (NaCl/film) 2948, 1727, 1656, 1437, 1373, 1246, 1206,
1173, 1020 cm-1; HRMS (EI) m/z calc’d for C11H19O4 [M+H]+: 215.13, found 215.13.
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O OMe
O O
680
H2, Pd/C
EtOH
(97% yield)
O OMe
O O
681
Diester 681
To a solution of enoate 680 (81 mg, 0.378 mmol) in ethanol (4 mL) was added
10% palladium on carbon (10% w/w, 8.1 mg).  The reaction vessel was purged, flushed
with hydrogen, and maintained under 1 atm of hydrogen for 8 hours.  Upon completion,
the reaction mixture was filtered through a celite plug and concentrated under vacuum to
yield 681 (81.7 mg, 97% yield): Rf = 0.39 (3:1 hexanes:ethyl acetate); 1H NMR (300
MHz, CDCl3) $ 4.83 (m, 1H), 3.62 (s, 3H), 2.57 (t, J = 7.41 Hz, 2H), 1.98 (s, 3H), 1.41
(m, 8H), 1.15 (d, J = 6.18 Hz, 3H); 13C NMR (75 MHz, CDCl3) $ 174.3, 170.9, 71.0,
51.6, 35.8, 34.1, 29.1, 25.2, 24.9, 21.5, 20.1; IR (NaCl/film) 2939, 2862, 1736, 1437,
1372, 1246, 1170, 1022 cm-1; HRMS (EI) m/z calc’d for C11H21O4 [M+H]+: 217.14, found
217.14.
OH
Cl OMe
O O
683
664
Et3N, DMAP, Et2O
(87 % yield)
O
684
OMe
O O
Mixed malonate 684
To a solution of alcohol 664 (500 mg, 5.00 mmol) in ether (10 mL) at 0 °C was
sequentially added triethylamine (835 µL, 6.00 mmol), DMAP (6 mg, 0.005 mmol), and
methyl malonyl chloride (683, 642 µL, 6.00 mmol).  The reaction was allowed to warm
to ambient temperature.  Upon completion by TLC, the reaction was washed with 10%
aqueous citric acid (3 x 15 mL) and brine (15 mL).  The organics were dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography (5:1
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hexanes:ethyl acetate eluent) to yield mixed malonate 684 (1.00 g, 87% yield).  Mixed
malonate 684 was immediately carried on to the next step.
O
684
OMe
O O Grubbs 2 (5 mol%)
methyl acrylate
PhH, 40 °C
(94% yield)
O
685
OMe
O O
MeO
O
Enoate 685
Malonate 684 (866 mg, 4.32 mmol) and methyl acrylate (1.95 mL, 21.6 mmol)
were combined in benzene (21 mL).  Grubbs 2nd generation catalyst (146, 184 mg, 0.216
mmol) was added and the reaction was heated under a nitrogen atmosphere at 40 °C until
complete by TLC.  Upon completion, the reaction solution was cooled to ambient
temperature, concentrated under vacuum, and purified by flash chromatography (5:1
hexanes:ethyl acetate eluent) to yield 685  (1.05 g, 94% yield): R f = 0.23 (3:1
hexanes:ethyl acetate); 1H NMR (300 MHz, CDCl3) $ 6.94 (dt, J = 15.7, 7 Hz, 1H), 5.83
(dt, J = 15.7, 1.7 Hz, 1H), 4.15 (t, J = 6.3 Hz, 2H), 3.74 (s, 3H), 3.73 (s, 3H), 3.38 (s,
2H), 2.23 (m, 2H), 1.68 (m, 2H), 1.56 (m, 2H); 13C NMR (75 MHz, CDCl3) $ 167.2,
166.7, 148.8, 121.7, 120.1, 65.4, 52.8, 51.7, 41.6, 31.8, 28.1, 24.5; IR (NaCl/film) 2954,
1755, 1737, 1438, 1336, 1275, 1200, 1151, 1024 cm-1.
O
685
OMe
O O
MeO
O H2, Pd/C
O
686
OMe
O O
MeO
O
EtOH
(87% yield)
Mixed malonate 686
To a solution of enoate 685 (1.05 g, 4.07 mmol) in ethanol (8 mL) was added
10% palladium on carbon (5% w/w, 52.5 mg).  The reaction vessel was purged, flushed
with hydrogen, and maintained under 1 atm of hydrogen for 8 hours.  Upon completion,
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the reaction mixture was filtered through a celite plug and concentrated under vacuum to
yield 686 (1.06 g, 87% yield): Rf = 0.30 (3:1 hexanes:ethyl acetate); 1H NMR (300 MHz,
CDCl3) $ 4.13 (t, J = 6.59 Hz, 2H), 3.74 (s, 3H), 3.66 (s, 3H), 3.37 (s, 2H), 2.30 (t, J =
7.41 Hz, 2H), 1.63 (m, 4H), 1.35 (m, 4H); 13C NMR (125 MHz, CDCl3) $ 174.09, 167.02,
166.55, 65.50, 52.49, 51.49, 41.37, 33.91, 28.65, 28.23, 25.44, 24.75; IR (NaCl/film)
2952, 2861, 1736, 1437, 1337, 1271, 1200, 1154, 1021 cm-1; HRMS (MM: ESI-APCI)
m/z calc’d for C12H21O6 [M+H]+: 261.1333, found 261.1339.
OH
664
O O
O
658
+
heptane (0.2 M)
100 °C, 24 h
(97% yield)
O
O
O
689
Vinyl !-ketoester 689
Dioxolenone 658 (200 mg, 1.30 mmol) and alcohol 664 (156 µL, 1.30 mmol)
were combined in heptane (6 mL) and heated to reflux.  After 10 hours, the reaction
solution was concentrated under vacuum to yield 689 (237.5 mg, 97% yield) as a mixture
of keto and enol tautomers: Rf = 0.61 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz,
CDCl3) $ 11.80 (s, 1H), 6.42 (dd, J = 17.6, 10.6 Hz, 1H), 6.27 (d, J = 17.6 Hz, 1H), 6.10
(dd, J = 5.4, 2.8 Hz, 1H), 5.97 (d, J = 10.6 Hz, 1H), 5.86–5.73 (m, 1H), 5.55 (dd, J = 7.5,
4.5 Hz, 1H), 5.08 (s, 1H), 5.06–4.92 (m, 2H), 4.16 (dd, J = 13.8, 7.0 Hz, 2H), 3.63 (s,
1H), 2.13–2.04 (m, 2H), 1.67 (qd, J = 13.2, 6.7 Hz, 2H), 1.46 (tt, J = 17.6, 7.6 Hz, 2H);
13C NMR (75 MHz, CDCl3) $ 192.5, 172.8, 168.7, 138.3, 135.8, 131.2, 130.2, 122.6,
114.9, 100.0, 91.8, 65.4, 64.2, 46.5, 46.1, 33.2, 33.1, 28.1, 27.1, 25.1, 25.0 ; IR
(NaCl/film) 2938, 1741, 1703, 1688, 1659, 1641, 1422, 1236, 1149,  cm-1; HRMS (EI)
m/z calc’d for C11H17O3 [M+H]+: 196.11, found 196.11.
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O
O
O
689
TBSCl, Et3N
THF, 0 °C to 23 °C
(78% yield)
O
TBSO
O
695
Silyl enol ether 695
To a solution of 689 (100 mg, 0.510 mmol) and triethylamine (107 µL, 0.765
mmol) at 0 °C in THF (3 mL) was added TBSCl (115 mg, 0.765 mmol).  After 4 hours,
the reaction was warmed to ambient temperature, diluted with 25 mL ether, and filtered
through a celite plug.  The filtrate was concentrated under vacuum and purified by flash
chromatography on silica gel (50:1 to 20:1 pentane:ether eluent) to yield 695 (123 mg,
78% yield): Rf = 0.57 (10:1 pentane:ether); 1H NMR (500 MHz, CDCl3) $ 7.61 (dd, J =
17.3, 10.7 Hz, 1H), 5.92 (dd, J = 17.3, 2.2 Hz, 1H), 5.80 (m, 1H), 5.46 (m, 1H), 5.17 (d, J
= 1.38 Hz, 1H), 4.98 (comp m, 2H), 4.09 (t, J = 6.88 Hz, 2H), 2.09 (m, 2H), 1.67 (m,
2H), 1.46 (m, 2H), 0.98 (s, 9H), 0.24 (s, 6H); 13C NMR (125 MHz, CDCl3) $ 171.7,
168.9, 143.0, 135.4, 126.1, 119.3, 105.6, 68.3, 37.9, 32.8, 30.2, 29.9, 22.9, –4.3; IR
(NaCl/film) 2932, 2860, 1711, 1636, 1574, 1472, 1414, 1336, 1303, 1257, 1138, 1068,
1003 cm-1; HRMS (EI) m/z calc’d for C17H31O3Si [M+H]+: 311.20, found 311.20.
O
O
O
689
MsN3, Et3N
MeCN, 0 °C to 23 °C
(77% yield)
O
O
O
693
N2
"-Diazo-!-ketoester 693
To a solution of 689 (200 mg, 1.02 mmol) in acetonitrile (8 mL) at 0 °C was
added mesyl azide (617 mg, 5.10 mmol) as a solution in acetonitrile (2 mL).
Triethylamine (852 µL, 6.11 mmol) was then added dropwise to the reaction at 0 °C.
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After 10 minutes, the reaction was warmed to room temperature, concentrated under
vacuum, and purified by flash chromatography on silica gel (20:1 pentane:ether eluent) to
yield 693 (169.1 mg, 77% yield) as a yellow oil: Rf = 0.50 (5:1 pentane:ether); 1H NMR
(300 MHz, CDCl3) $ 7.37 (dd, J = 17.1, 10.2 Hz, 1H), 6.38 (dd, J = 17.1, 1.9 Hz, 1H),
5.68 (comp m, 2H), 4.95 (m, 2H), 4.21 (t, J = 6.87 Hz, 2H), 2.05 (m, 2H), 1.67 (m, 2H),
1.43 (m, 2H); 13C NMR (75 MHz, CDCl3) $ 182.0, 161.3, 138.2, 131.7, 128.7, 115.3,
65.6, 33.4, 28.2, 25.2; IR (NaCl/film) 3078, 2938, 2133, 1720, 1650, 1606, 1404, 1317,
1289, 1222, 1138, 1022 cm-1; HRMS (EI) m/z calc’d for C11H15O3N2 [M+H]+: 223.11,
found 223.11.
689
O
O
O
NaBH4
CeCl3•H2O
MeOH, 0 °C
(50% yield)
697
O
O
HO
!-Hydroxyester 697
To a solution of vinyl !-ketoester 689 (100 mg, 0.510 mmol) in MeOH (1.3 mL)
was added CeCl3•7H2O (190 g, 0.510 mmol).  The suspension was cooled to 0 °C and
NaBH4 (19.3 mg, 0.510 mmol) was added slowly.  The reaction was then allowed to
warm to room temperature, where it was maintained with stirring until vinyl !-ketoester
689 was consumed by TLC analysis.  The reaction was quenched by the addition of water
(5 mL) and subsequently extracted with ethyl acetate (3 x 20 mL).  The combined organic
layers were died with MgSO4, concentrated under vacuum, and purified by flash
chromatography (5:1 hexanes:ethyl acetate eluent) to yield !-hydroxyester 697 (50.2 mg,
50% yield), which was immediately carried on to the next step.
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697
O
O
HO
TBSCl
imidazole
DMF
(93% yield)
698
O
O
TBSO
Silyl ether 698
To a solution of !-hydroxyester 697 (50 mg, 0.255 mmol) in DMF (1 mL) was
added sequentially imidazole (41.7 mg, 0.612 mmol) and TBSCl (76.9 mg, 0.510 mmol).
The resulting solution was maintained at room temperature with stirring until !-
hydroxyester 697 was consumed by TLC analysis.  At this time, the reaction was diluted
with diethyl ether (25 mL) and washed with water (2 x 25 mL) and brine (25 mL).  The
organic phase was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (15:1 hexanes:ethyl acetate eluent) to yield silyl ether 698 (58.2 mg,
93% yield), which was immediately carried on to the next step.
698
O
O
TBSO
Grubbs 2 (30 mol%)
PhMe (3 mM), 80 °C
20 h
(54% yield) cis-699
O
O
TBSO
Lactone cis-699
Silyl ether 698 (50 mg, 0.160 mmol) and Grubbs 2nd generation catalyst (146, 40.8
mg, 0.048 mmol) were each taken up individually in toluene (20 mL each).  A 3-neck
reaction flask equipped with a condenser was charged with toluene (20 mL) and
subsequently heated to 80 °C.  The toluene solutions of silyl ether 698 and Grubbs 2nd
generation catalyst (146) were each added simultaneously to the reaction flask containing
the toluene solvent by syringe pump over 24 hours.  Following this period, the solution
was maintained with stirring at 80 °C for an additional 12 hours.  The solution was then
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cooled to room temperature, concentrated under vacuum, and purified by flash
chromatography (20:1 pentane:ethyl ether eluent) to yield lactone cis-699 (24.4 mg, 54%
yield), which was immediately carried on to the next step.
cis-700
O
O
HO
Dess–Martin
periodinane
CH2Cl2
(57% yield,
2 steps) cis-701
O
O
O
cis-699
O
O
TBSO
TBAF
THF
!-Ketolactone 701
To a solution of lactone cis-699 (24.4 mg, 0.086 mmol) in THF (1 mL) was added
TBAF (1 M solution in THF, 94.4 µL, 0.094 mmol).  The resulting solution was
maintained with stirring at room temperature until lactone cis-699 had been consumed by
TLC analysis.  The reaction was diluted with ethyl ether (30 mL) and washed with water
(10 mL) and brine (10 mL).  The organic layer was dried with MgSO4 and concentrated
under vacuum.  The crude allylic alcohol (cis-700) was used without further purification
for the next step.
The crude allylic alcohol (cis-700) (14.5 mg, 0.086 mmol) was taken up in
CH2Cl2 (1 mL).  Dess–Martin periodinane (72.8 mg, 0.172 mmol) was added as a solid
and the resulting suspension was maintained with stirring at room temperature until
allylic alcohol cis-700 was fully consumed by TLC analysis.  The reaction was then
quenched by the addition of a 1:1 v/v mixture of saturated Na2S2O3 and NaHCO3 aqueous
solutions (5 mL total volume).  The biphasic solution was vigorously stirred for 30
minutes, after which time the reaction was diluted with ethyl ether (20 mL).  The organic
phase was washed with brine (10 mL), dried with MgSO4, concentrated under vacuum,
and purified by flash chromatography (3:1 hexanes:ethyl acetate eluent) to yield !-
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 189
ketolactone cis-701 (8.2 mg, 57% yield): Rf = 0.32 (3:1 hexanes:ethyl acetate); 1H NMR
(500 MHz, CDCl3) $ 6.12 (dt, J = 12.1, 1.4 Hz, 1H), 5.70 (dt, J = 12.1, 8.2 Hz, 1H),
4.35–4.19 (m, 2H), 3.42 (s, 2H), 2.40 (dtd, J = 8.0, 6.4, 1.4 Hz, 2H), 1.80–1.54 (m, 4H);
13C NMR (125 MHz, CDCl3) $ 197.27, 166.15, 137.98, 130.01, 66.89, 50.58, 28.42,
26.71, 24.95; IR (NaCl/film) 2957, 2919, 2858, 1747, 1703, 1698, 1451, 1440, 1395,
1290, 1256, 1166, 1095, 1036, 943, 796 cm–1; HRMS (EI+) m/z calc’d for C9H12O3 [M]+•:
168.0786, found 168.0786.
O
O
676
LDA, then acrolein 
THF, –78 °C
(74% yield)
O
O
702
HO
!-Hydroxyester 702
To a solution of diisopropyl amine (987 µL, 7.04 mmol) in THF (28 mL) at –78
°C was added n-butyllithium (2.5 M solution in hexanes, 2.82 mL) dropwise.  After 30
minutes, acetate 676 (1.00 g, 6.40 mmol) was added at –78 °C as a solution in THF (2
mL).  After 20 minutes, acrolein (856 µL, 12.8 mmol) was added as a solution in THF
(2.5 mL) and the reaction was maintained for 20 minutes at –78 °C.  The reaction
solution was quenched with 10 mL saturated amminium chloride solution and warmed to
ambient temperature.  The reaction was diluted with brine (20 mL) and subsequently
extracted with diethyl ether (2 x 50 mL).  The combined organic extracts were dried over
magnesium sulfate, concentrated under vacuum, and purified by flash chromatography
(10:1 hexanes:ethyl acetate eluent) to yield 702 (1.04 g, 74% yield) as a 1:1 mixture of
diastereomers: Rf = 0.42 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 5.89
(ddd, J = 17.2, 10.5, 5.5 Hz, 1H), 5.85–5.72 (m, 1H), 5.33 (dt, J = 17.2, 1.4 Hz, 1H), 5.17
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(dt, J = 10.5, 1.4 Hz, 1H), 5.06–4.92 (m, 3H), 4.54 (d, J = 4.0 Hz, 1H), 3.00 (dd, J = 10.3,
4.6 Hz, 1H), 2.58 (dd, J = 16.2, 4.0 Hz, 1H), 2.55–2.46 (m, 1H), 2.07 (q, J = 6.9 Hz, 2H),
1.68–1.57 (m, 1H), 1.57–1.32 (m, 4H), 1.24 (d, J = 1.4 Hz, 1.5H), 1.23 (d, J = 1.4 Hz,
1.5H); 13C NMR (125 MHz, CDCl3) $ 172.16, 172.14, 139.02, 138.54, 115.60, 115.59,
115.07, 71.79, 71.76, 69.23, 69.16, 41.57, 41.56, 35.50, 35.49, 33.65, 33.64, 24.86, 24.84,
20.20; IR (NaCl/film) 3448, 2978, 2936, 1730, 1422, 1378, 1272, 1178, 1125, 1039 cm–1;
HRMS (MM: ESI-APCI) m/z calc’d for C12H21O3 [M+H]+: 213.1485, found 213.1478;
["]22D +7.51° (c 0.96, CH2Cl2).
O
O
702
HO TBSCl, imidazole
DMF
(93% yield)
O
O
703
TBSO
Silyl ether 703
To a solution of !-hydroxyester 702 (1.01 g, 4.76 mmol) in DMF (10 mL) was
added imidazole (485 mg, 7.14 mmol) and tert-butyl(chloro)dimethyl silane (TBSCl, 860
mg, 5.71 mmol).  The reaction was maintained at room temperature until !-hydroxyester
702 was fully consumed by TLC analysis.  Upon completion, the reaction was diluted
with ethyl ether (50 mL) and washed with water (25 mL) and brine (25 mL).  The organic
extracts were dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (25:1 hexanes:ethyl acetate eluent) to yield silyl ether 703 (1.43 g, 93%
yield) as a 1:1 mixture of diastereomers:  Rf = 0.43 (10:1 petroleum ether:ethyl ether); 1H
NMR (500 MHz, CDCl3) $ 5.90–5.71 (m, 2H), 5.22 (dt, J = 17.2, 1.4 Hz, 1H), 5.06 (d, J
= 10.4 Hz, 1H), 5.03–4.97 (m, 1H), 4.95 (ddd, J = 10.2, 2.0, 1.0 Hz, 1H), 4.93–4.84 (m,
1H), 4.57 (dd, J = 13.3, 6.1 Hz, 1H), 2.52 (ddd, J = 14.7, 7.6, 1.9 Hz, 1H), 2.41 (ddd, J =
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14.8, 5.6, 0.6 Hz, 1H), 2.05 (q, J = 6.7 Hz, 2H), 1.67–1.31 (m, 5H), 1.21 (d, J = 3.0 Hz,
1.5H), 1.20 (d, J = 3.0 Hz, 1.5H), 0.87 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (125
MHz, CDCl3) $ 175.73, 175.69, 145.34, 145.31, 143.44, 143.43, 119.76, 119.74, 119.64,
119.61, 76.04, 75.96, 75.87, 75.81, 48.90, 40.34, 38.53, 38.49, 30.81, 30.80, 29.67, 29.64,
25.01, 24.94, 23.13, 0.63, 0.03, 0.00; IR (NaCl/film) 2931, 1734, 1463, 1374, 1253, 1180,
1126, 1086, 956, 924, 836, 778 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C18H35O3Si
[M+H]+: 327.2350, found 327.2345; ["]25D +2.77° (c 0.55, CHCl3).
O
O
703
TBSO 146 (10 mol%)
PhH (0.002 M), reflux
(44% yield) Z-anti-704
O
O
TBSO
!-Silyloxy lactone Z-anti-704
A solution of silyl ether 703 (25 mg, 0.0766 mmol) in benzene (40 mL) in a 3-
neck flask equipped with a condenser was heated to reflux under a nitrogen atmosphere.
Meanwhile, a solution of Grubbs 2nd generation catalyst (146, 6.5 mg, 0.00766 mmol) in
benzene (10 mL) was prepared in a conical flask. A syringe filled with argon gas was
loaded into a syringe pump and connected to the flask containing catalyst 146.  A cannula
was inserted into the catalyst solution and connected to the refluxing substrate flask.
With the aid of the syringe pump, the catalyst solution was added by cannula to the
refluxing substrate solution over a period of 10 hours.  Following the addition, the
reaction was further maintained at reflux for 10 hours.  Upon completion, the reaction
was cooled to room temperature, quenched with ethyl vinyl ether (500 µL), concentrated
under vacuum, and purified by flash chromatography (50:1 petroleum ether:ethyl ether
eluent) to yield Z-anti-704 (10 mg, 44% yield): Rf = 0.32 (10:1 petroleum ether:ethyl
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ether); 1H NMR (500 MHz, CDCl3) $ 5.39 (ddd, J = 11.1, 9.0, 2.0 Hz, 1H), 5.35–5.25 (m,
1H), 5.15–5.03 (m, 1H), 5.00–4.88 (m, 1H), 2.79 (dd, J = 14.3, 5.8 Hz, 1H), 2.59 (m,
1H), 2.31 (dd, J = 14.2, 10.8 Hz, 1H), 2.13–1.96 (m, 2H), 1.90 (m, 2H), 1.50–1.30 (m,
3H), 1.26 (d, J = 6.7 Hz, 4H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (125
MHz, CDCl3) $ 174.51, 137.66, 135.14, 75.67, 70.21, 48.94, 34.27, 31.59, 30.69, 27.08,
23.04, 22.04, 0.38, 0.00; IR (NaCl/film) 2944, 1736, 1444, 1248, 1067 cm–1; HRMS
(MM: ESI-APCI) m/z calc’d for C16H30O3Si [M+H]+: 299.2037, found 299.2037; ["]25D
–12.1° (c 0.56, CHCl3).
Z-anti-704
O
O
TBSO
1. TBAF, THF
2. H2, Pd/C, EtOH
(88% yield, 2 steps)
O
HO
O
(–)-Diplodialide C (640)
(–)-Diplodialide C (640)
Tetra-n-butylammonium fluoride solution (1 M in THF, 131 µL, 0.131 mmol)
was added to a solution of Z-anti-704 (32.6 mg, 0.109 mmol) in THF (1.0 mL).  The
solution was maintained at room temperature until the starting material was consumed by
TLC analysis.  Upon completion, the reaction was diluted with ethyl ether (25 mL) and
washed with water (3 x 10 mL) and brine (10 mL).  The organic extracts were dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography (3:1
hexanes:ethyl acetate eluent).
The purified residue (19.1 mg, 0.104 mmol) was taken up in anhydrous ethanol
(1.0 mL).  To this solution was added 10 wt. % Pd/C (11 mg, 0.0104 mmol) and a
hydrogen balloon.  The reaction was maintained at room temperature with vigorous
stirring until the starting material had been consumed by TLC analysis.  Upon
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completion, the reaction was filtered through a silica plug, concentrated under vacuum,
and purified by flash chromatography (3:1 hexanes:ethyl acetate eluent) to yield (–)-
diplodialide C (640, 17.1 mg, 88% yield, 2 steps): Rf = 0.17 (3:1 hexanes:ethyl acetate);
1H NMR (500 MHz, CDCl3) $ 5.11–4.92 (m, 1H), 4.45–4.30 (m, 1H), 2.84 (dd, J = 15.4,
3.8 Hz, 1H), 2.36 (dd, J = 15.5, 10.0 Hz, 1H), 2.05–1.87 (m, 1H), 1.83–1.34 (m, 8H),
1.25 (comp m, 4H), 1.17–0.99 (m, 1H); 13C NMR (125 MHz, CDCl3) $ 170.64, 73.15,
66.42, 43.54, 36.95, 31.56, 25.46, 23.43, 22.86, 19.37; IR (NaCl/film) 3400, 2935, 1726,
1705, 1452, 1356, 1251, 1145, 1032, 963, 867 cm–1; HRMS (MM: ESI-APCI) m/z calc’d
for C10H19O3 [M+H]+: 187.1329, found 187.1323; ["]26D +34.6° (c 0.50, CHCl3).
O
O
703
TBSO
707 (10 mol%)
PhH (0.002 M), reflux
(77% yield)
O
TBSO
O
E-syn-704
O
TBSO
O
E-anti-704Z-anti-704
O
O
TBSO
Z-syn-704
O
O
TBSO
+ + +
!-Silyloxy lactone 704
A solution of silyl ether 703 (300 mg, 0.918 mmol) in benzene (450 mL) in a 3-
neck flask equipped with a condenser was heated to reflux under a nitrogen atmosphere.
Meanwhile, a solution of Grubbs–Hoveyda third generation catalyst (707, 52.5 mg,
0.0918 mmol) in benzene (10 mL) was prepared in a conical flask.  The catalyst solution
was added to the refluxing substrate solution over a period of 10 hours by syringe pump
using the method described for preparation of silyl ether Z-anti-704.  Following the
addition, the reaction was further maintained at reflux for 10 hours.  Upon completion,
the reaction was cooled to room temperature, quenched with ethyl vinyl ether (1 mL),
concentrated under vacuum, and purified by flash chromatography (25:1 petroleum
ether:ethyl ether eluent) to yield 704 (210.8 mg, 77% yield) as a complex mixture of
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diastereomers and olefin isomers: Rf = 0.32 (10:1 petroleum ether:ethyl ether); For 1H and
13C NMR data, see Figures A2.37.1 and A2.37.3; IR (NaCl/film) 3429, 2953, 2929, 2857,
1739, 1655, 1472, 1360, 1278, 1245, 1077, 966, 861, 837, 777, 735 cm–1; HRMS (MM:
ESI-APCI) m/z calc’d for C16H30O3Si [M+H]+: 299.2037, found 299.2032; ["]23D –13.5°
(c 0.69, CHCl3).
TBAF
THF
(91% yield)704
O
O
TBSO
705
O
O
HO
Allylic alcohol 705
To a solution of lactone 704 (476 mg, 1.60 mmol) in THF (16 mL) was added
TBAF (1 M solution in THF, 1.76 mL, 1.76 mmol).  The resulting solution was
maintained with stirring at room temperature until lactone 704 had been consumed by
TLC analysis.  Following this time, the reaction was diluted with diethyl ether (25 mL)
and washed sequentially with water (2 x 15 mL) and brine (15 mL).  The organic phase
was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (2:1 hexanes:ethyl acetate eluent) to yield allylic alcohol 705 (270 mg,
91% yield).  Allylic alcohol 705 was used in the next step immediately.
O
HO
O
705
O
O
HO
H2, Pd/C
EtOH
(98% yield) 708
!-Hydroxylactone 708
To a solution of allylic alcohol 705 (270 mg, 1.47 mmol) in ethanol (7.5 mL) was
added 10 wt.% Pd/C (46.8 mg, 0.044 mmol).  The reaction flask was then equipped with
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an H2 balloon.  The resulting suspension was maintained under an atmosphere of
hydrogen (1 atm) with vigorous stirring at room temperature until allylic alcohol 705 had
been consumed by TLC analysis.  Following this time, the reaction was filtered through
Celite, rinsing with CH2Cl2.  The filtrate was concentrated under vacuum to yield !-
hydroxylactone 708 (268 mg, 98% yield).  The crude product was used in the next step
without further purification.
(±)-Diplodialide C (640)
O
HO
O
Dess–Martin
periodinane
CH2Cl2
(99% yield) 218
O
O
O
!-Ketolactone 218
To a solution of (±)-diplodialide C (640, 268 mg, 1.44 mmol) in CH2Cl2 (8 mL)
was added Dess–Martin periodinane (916 mg, 2.16 mmol).  The resulting solution was
maintained with stirring at room temperature until diplodialide C (640) had been fully
consumed by TLC analysis.  Following this time, the reaction was quenched by the
addition of a 1:1 v/v mixture of saturated Na2S2O3 and NaHCO3 aqueous solutions (10
mL total volume) and then stirred vigorously for 30 minutes.  The biphasic solution was
then diluted with CH2Cl2 (10 mL).  The organic phase was washed with water (10 mL)
and brine (10 mL), dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (5:1 hexanes:ethyl acetate eluent) to yield !-ketolactone 218 (262 mg,
99% yield).  See experimental details for ! -ketolactone (S)-218 for complete
spectroscopic information.
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703
O
O
TBSO
Grubbs–Hoveyda 3 
(10 mol%)
PhH (2 mM), 18 h
(77% yield)
O
O
TBSO
TBAF
THF
(69% yield)
O
O
HO
H2, Pd/C
EtOH
(89% yield)
O
HO
O
9-epi-Diplodialide C
(709)
9-epi-Diplodialide C (709)
For detailed synthetic procedures, please refer to !-silyloxy lactone 704, allylic
alcohol 705, and !-hydroxylactone 708 (vide supra).  Rf = 0.17 (3:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) $ 5.00–4.81 (m, 1H), 4.08–3.91 (m, 1H), 2.59 (ddd,
J = 11.8, 4.2, 0.8 Hz, 1H), 2.41 (dd, J = 11.8, 9.7 Hz, 1H), 1.81–1.45 (m, 6H), 1.45–1.26
(m, 3H), 1.20 (d, J = 6.5 Hz, 3H), 1.03 (ddd, J = 11.7, 8.2, 5.6 Hz, 1H); 13C NMR (125
MHz, CDCl3) $ 171.17, 72.43, 69.79, 44.09, 35.40, 31.21, 26.64, 21.61, 20.86, 20.32; IR
(NaCl/film) 3434, 2938, 1727, 1470, 1288, 1184, 1137, 1045, 970 cm–1; HRMS (EI+) m/z
calc’d for C10H19O3 [M+H]+: 187.1334, found 187.1341.
717 (S)-678
Br
Mg, THF, 23 °C;
Li2CuCl4 (10 mol%)
THF, –30 °C
O
MeS
(S)-713
HO S
AcCl, pyridine
Et2O, 35 °C
(76% yield, 2 steps)
O S
O
(S)-676
(S)-Acetate 676
A flame-dried reaction flask was charged with Mg turnings (837 mg, 34.4 mmol).
To this was added THF (30 mL) and 1,2-dibromoethane (20 µL), and the resulting
suspension was maintained for 5 minutes with stirring at room temperature.  Following
this time, 4-bromo-1-butene (717, 2.09 mL, 20.7 mmol) was added, and the reaction was
maintained at room temperature with stirring for 1 hour.  In the meantime, a solution of
(S)-propylene oxide ((S)-713, 1.20 mL, 17.2 mmol) and Li2CuCl4 (0.5 M in THF, 3.44
mL, 1.72 mmol) in THF (30 mL) was cooled to –30 °C.  The Grignard reagent solution
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was added by cannula to the cold solution of (S)-propylene oxide and Li2CuCl4, being
careful to maintain the temperature of the reaction flask at –30 °C.  Following addition,
the reaction was maintained at –30 °C for 30 minutes and then quenched by the addition
of saturated NH4Cl aqueous solution (6 mL) and water (6 mL).  The biphasic solution
was then warmed to room temperature for work-up.  Diethyl ether (100 mL) and water
(25 mL) were added and the layers were separated.  The organic layer was washed with
brine (25 mL), dried with MgSO4, and concentrated under vacuum.  The crude secondary
alcohol ((S)-678) was carried on to the next step without further purification.
To a solution of crude secondary alcohol ((S)-678) and acetyl chloride (2.44 mL,
34.3 mmol) in diethyl ether (25 mL) was slowly added pyridine (2.78 mL, 34.3 mmol).
Following addition, additional diethyl ether (10 mL) was added to aid stirring.  The
reaction was then heated to reflux and maintained with stirring at reflux until secondary
alcohol (S)-678 had been consumed by TLC analysis.  Upon completion, the reaction was
diluted with diethyl ether (25 mL) and washed with 1 N HCl (3 x 20 mL) and brine (20
mL).  The organic layer was dried with MgSO4, concentrated under vacuum, and purified
by flash chromatography (10:1 pentane:diethyl ether eluent) to yield acetate (S)-676 (2.04
g, 76% yield, 2 steps).  All spectroscopic data was consistent with that published in the
literature.97
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O
O
702
HO
HMDS, TMSCl, THF
then 707 (10 mol%)
PhH (0.002 M), reflux
then 1 N HCl, THF
(57% yield)
O
HO
O
705
  1. H2, Pd/C
      EtOH
  2. DMP, CH2Cl2
(93% yield, 2 steps)
O
O
O
218
!-Ketolactone 218
!-Hydroxyketone 7 0 2  (50 mg, 0.236 mmol) was combined with
hexamethyldisilazane (HMDS, 49.2 µL, 0.236 mmol) and chlorotrimethyl silane
(TMSCl, 10 µL, 0.079 mmol) in THF (2.5 mL) and heated to 70 °C for a period of 5 h.
After this period, the reaction was filtered and concentrated under vacuum.  The residue
was then taken up in benzene (110 mL) in a flame-dried 3-neck flask equipped with a
condenser and heated to reflux under a nitrogen atmosphere.  Meanwhile, a solution of
Grubbs–Hoveyda 3rd generation catalyst (707, 13.4 mg, 0.0236 mmol) in benzene (10
mL) was prepared in a conical flask.  The catalyst solution was added to the refluxing
substrate solution over a period of 10 hours by syringe pump using the method described
for the preparation of Z-anti-704.  Following the addition, the reaction was further
maintained at reflux for 10 hours.  Upon completion, the reaction was cooled to room
temperature, quenched with ethyl vinyl ether (500 µL), and concentrated under vacuum.
The resulting residue was taken up in THF (2 mL) and 1 N hydrochloric acid solution (2
mL) and maintained at room temperature for 2 h.  Following this period, the reaction was
diluted with Et2O (25 mL) and washed with water (15 mL) and brine (15 mL).  The
organic layer was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (3:1 hexanes:ethyl acetate eluent) to yield !-hydroxylactone 705 (25 mg,
57% yield) as a mixture of diastereomers and olefin isomers.
!-Hydroxylactone 705 (29.8 mg, 0.162 mmol) was taken up in anhydrous ethanol
(2 mL).  To this solution was added 10 wt.% Pd/C (17.2 mg, 0.0162 mmol).  A hydrogen
balloon was added and the reaction was maintained with vigorous stirring until !-
hydroxylactone 705 was consumed by TLC analysis.  Upon completion, the reaction was
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filtered through silica and the filtrate was concentrated under vacuum.  The crude residue
was used without further purification.
The crude residue was taken up in CH2Cl2 (2 mL).  To this solution was added
Dess–Martin periodinane (DMP, 103 mg, 0.243 mmol) and the reaction was maintained
with stirring until all starting material had been consumed by TLC analysis.  Following
this period, the reaction was quenched by addition of a 1:1 v/v mixture of saturated
sodium bicarbonate and saturated sodium thiosulfate solutions (1 mL total volume) and
stirred for a period of 30 minutes.  The biphasic solution was then diluted with CH2Cl2
(25 mL) and washed with water (10 mL) and brine (10 mL).  The organic extracts were
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(10:1 hexanes:ethyl acetate eluent) to yield !-ketolactone 218 (27 mg, 93% yield, 2
steps): Rf = 0.38 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 5.22–4.95 (m,
1H), 3.41 (d, J = 15.1 Hz, 1H), 3.36 (d, J = 15.1 Hz, 1H), 2.74 (ddd, J = 14.3, 10.1, 4.4
Hz, 1H), 2.28 (ddd, J = 14.2, 6.8, 5.0 Hz, 1H), 2.02–1.90 (m, 1H), 1.83 (dddd, J = 14.4,
8.6, 3.4, 2.1 Hz, 1H), 1.74–1.63 (m, 1H), 1.62–1.52 (m, 1H), 1.50–1.38 (m, 2H),
1.35–1.28 (m, 1H), 1.27 (d, J = 6.4 Hz, 3H), 1.22–1.11 (m, 1H); 13C NMR (125 MHz,
CDCl3) $ 203.90, 167.39, 74.77, 51.96, 39.54, 33.76, 26.78, 23.62, 22.39, 20.52; IR
(NaCl/film) 2935, 1742, 1711, 1265, 1175, 1126, 1071, 961 cm–1; HRMS (MM: ESI-
APCI) m/z calc’d for C10H17O3 [M+H]+: 185.1172, found 185.1173; ["]25D +130.6° (c
1.53, MeOH).
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O
O
O
218
TMS
OTf
209
+ CsF
MeCN, 40 °C
(61% yield)
O
O
O
718
Lactone 718
!-Ketolactone 218 (10 mg, 0.0543 mmol) and CsF (24.7 mg, 0.163 mmol) were
combined in MeCN (0.5 mL) and heated in a sealed vial to 40 °C.  Silyl aryl triflate 209
(19 µL, 0.0651 mmol) was added to the !-ketolactone suspension over a period of 1.5
hours.  The suspension was maintained at 40 °C with stirring after the addition of aryne
precursor 209 until !-ketolactone 218 has been consumed by TLC analysis.  Upon
completion, the reaction was cooled to room temperature, concentrated under vacuum,
and purified by flash chromatography to yield lactone 718 (8.6 mg, 61% yield) as a
mixture of ester and enol tautomers in a 1.0:0.06 ratio (as determined by 1H NMR): Rf =
0.26 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 7.78 (dd, J = 5.6, 3.6 Hz,
0.06H), 7.68 (dd, J = 7.7, 1.3 Hz, 1H), 7.44 (td, J = 7.5, 1.4 Hz, 1H), 7.41–7.34 (m, 1H),
7.34–7.31 (m, 0.21H), 7.31–7.28 (m, 1H), 6.94–6.90 (m, 0.07H), 6.05 (s, 0.06H),
5.13–5.02 (m, 0.06H), 5.02–4.88 (m, 1H), 4.25 (d, J = 16.0 Hz, 1H), 3.87 (d, J = 16.0 Hz,
1H), 3.42 (ddd, J = 14.3, 9.1, 2.5 Hz, 0.06H), 3.11 (ddd, J = 14.4, 8.1, 3.7 Hz, 1H), 2.73
(ddd, J = 14.4, 8.5, 3.8 Hz, 1H), 2.56 (ddd, J = 14.3, 9.7, 2.7 Hz, 0.07H), 1.90 (d, J = 6.7
Hz, 0.08H), 1.82–1.68 (m, 2H), 1.57–1.25 (m, 6H), 1.13 (d, J = 6.4 Hz, 0.30H), 1.11 (d, J
= 6.4 Hz, 3H); 13C NMR (125 MHz, CDCl3) $ 205.71, 170.42, 138.15, 134.23, 132.61,
131.40, 130.40, 129.80, 128.75, 128.40, 127.27, 127.11, 126.55, 71.99, 54.06, 40.66,
40.57, 40.27, 31.39, 31.13, 26.13, 25.95, 23.02, 22.44, 22.22, 20.02, 19.77; IR (NaCl/
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film) 2929, 1724, 1447, 1244, 756 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C16H21O5 [M+H]+: 261.1485, found 261.1489; ["]26D +10.2° (c 0.87, CHCl3).
(S)-218
O
O
O
TMS
OTf
232
CsF
MeCN, 80 °C
(64% yield)
510
O
O
O
719
O
O
O
MeO
MeO MeO
MeO MeO
OMe
1:1 ratio
Di-O,O’-methyl curvularin (510) and "-arylation product 719
To a solution of !-ketolactone 218 (10 mg, 0.0543 mmol) and silyl aryl triflate
232 (23.3 mg, 0.0651 mmol) in MeCN (300 µL) was added CsF (24.7 mg).  The resulting
suspension was heated to 80 °C in a sealed vial and maintained at that temperature with
stirring until !-ketolactone 218 was fully consumed by TLC analysis.  Upon completion,
the contents of the reaction were adsorbed directly onto SiO2 and purified by flash
chromatography (20:1 hexanes:ethyl acetate eluent) to yield Di-O,O’-methyl curvularin
(510, 5.5 mg, 32% yield) and "-arylation product 719 (5.7 mg, 32% yield).  Data for di-
O,O’-methyl curvularin (510) matched the reported literature values.20,21,22  " -Arylation
product 719: Rf  = 0.33 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) $ 6.30 (t,
J = 2.2 Hz, 1H), 6.15 (d, J = 2.2 Hz, 2H), 5.13 (m, 1H), 4.92 (s, 1H), 3.76 (s, 6H), 3.35
(m, 1H), 2.23 (m, 1H), 1.91–1.48 (m, 8H), 1.29 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz,
CDCl3) $ 175.56, 167.46, 161.74, 155.26, 100.12, 98.87, 97.99, 70.53, 55.65, 33.19,
30.83, 27.16, 26.84, 20.53, 20.38; IR (NaCl/film) 2934, 1698, 1615, 1455, 1366, 1352,
1268, 1205, 1151, 1050, 840 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C18H25O5
[M+H]+: 321.1697, found 321.1697.
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OEt
O
222
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OTf
217
+ KF, 18-crown-6
THF
(75% yield)
OEt
O
O
223
O
BnO
BnO
BnO
BnO
Di-O,O’-benzyl curvulin (223)
Silyl aryl triflate 217 (65 mg, 0.127 mmol) and ethyl acetoacetate (222, 10.8 µL,
0.0849 mmol) were combined in THF (1 mL).  18-Crown-6 (67.3 mg, 0.255 mmol) and
KF (14.8 mg, 0.255 mmol) were added sequentially.  The suspension was maintained
with vigorous stirring at room temperature for a period of 18 hours.  Following this time,
the reaction was diluted with ethyl ether (10 mL) and washed with water (2 x 5 mL) and
brine (10 mL).  The organic extracts were dried with MgSO4, concentrated under
vacuum, and purified by flash chromatography (10:1 hexanes:ethyl acetate eluent) to
yield di-O,O’-benzyl curvulin (223, 26.7 mg, 75% yield): Rf = 0.30 (3:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) $ 7.51–7.31 (m, 10H), 6.56 (d, J = 2.2 Hz, 1H),
6.49 (d, J = 2.2 Hz, 1H), 5.07 (s, 2H), 5.06 (s, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.71 (s, 2H),
2.52 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) $ 203.87, 171.28,
160.58, 158.32, 136.29, 136.08, 135.01, 128.67, 128.66, 128.21, 128.18, 127.56, 127.43,
124.43, 109.39, 99.43, 70.72, 70.19, 60.88, 39.17, 32.45, 14.20; IR (NaCl/film) 2980,
1731, 1680, 1601, 1453, 1434, 1369, 1317, 1262, 1161, 1085, 1027, 834, 738, 697 cm–1;
HRMS (MM: ESI-APCI) m/z calc’d for C26H27O5 [M+H]+: 419.1853, found 419.1838.
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OEt
O
O
223
BnO
BnO
H2, Pd/C
EtOAc, MeOH
(93% yield) OEt
O
O
Curvulin (224)
HO
HO
Curvulin (224)
Di-O,O’-benzyl curvulin (223, 12.6 mg, 0.030 mmol) was dissolved in a 1:1 v/v
mixture of ethyl acetate (1 mL) and methanol (1 mL).  To this solution was added 10 wt.
% Pd/C (3.2 mg, 0.0030 mmol) and a hydrogen balloon.  The reaction was maintained
with vigorous stirring at room temperature until the starting material had been consumed
by TLC analysis.  Upon completion, the reaction was filtered, concentrated under
vacuum, and purified by flash chromatography (2:1 hexanes:ethyl acetate eluent) to yield
curvulin (224, 6.6 mg, 93% yield): Rf = 0.28 (1:1 hexanes:ethyl acetate); 1H NMR (500
MHz, acetone-d6) $ 6.37 (d, J = 2.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 4.11 (q, J = 7.1 Hz,
2H), 3.80 (s, 2H), 2.53 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, acetone-d6)
$ 202.57, 170.69, 160.97, 160.64, 137.09, 118.57, 111.46, 101.84, 60.19, 39.80, 31.28,
13.61; IR (NaCl/film) 3412, 1706, 1636, 1264, 1166, 1024 cm–1; HRMS (MM: ESI-
APCI) m/z calc’d for C12H15O5 [M+H]+: 239.0914, found 239.0917.
O
O
O
218
TMS
BnO
OTfBnO
217
+ CsF
MeCN, 80 °C
O
OBnO
BnO
O
220
H2, Pd/C
THF, MeOH
(18% yield,
2 steps) O
OHO
HO
O
(–)-Curvularin (221)
(–)-Curvularin (221)
!-Ketolactone 218 (15 mg, 0.0814 mmol) and CsF (37.1 mg, 0.244 mmol) were
combined in MeCN (800 µL) and heated in a sealed vial to 80 °C.  Silyl aryl triflate 217
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(62.3 mg, 0.122 mmol) was added to the !-ketolactone suspension as a 500 µL MeCN
solution over a period of 1.5 hours.  The suspension was maintained at 40 °C with stirring
following the addition of aryne precursor 217 until !-ketolactone 218 has been consumed
by TLC analysis.  The reaction was cooled to room temperature and purified by flash
chromatography (10:1 hexanes:ethyl acetate eluent) to yield lactone 220 (11.3 mg, 30%
yield), which was immediately carried on to the next step.
Lactone 220 (11.3 mg, 0.0239 mmol) was taken up in a 1:1 v/v mixture of THF
and MeOH (2 mL each).  To this solution was added 10 wt. % Pd/C (14 mg, 0.0131
mmol) and a hydrogen balloon.  The reaction was maintained at room temperature with
vigorous stirring until lactone 220 had been consumed by TLC analysis.  The suspension
was filtered and the filtrate concentrated under vacuum.  The resulting crude residue was
purified by flash chromatography (7:3 hexanes:ethyl acetate eluent) to yield (–)-
curvularin (221, 4.0 mg, 60% yield): Rf = 0.24 (1:1 hexanes:ethyl acetate); 1H NMR (500
MHz, acetone-d6) $ 6.39 (d, J = 2.3 Hz, 1H), 6.34 (d, J = 2.3 Hz, 1H), 4.91 (m, 1H), 3.78
(d, J = 15.7 Hz, 1H), 3.70 (d, J = 15.7 Hz, 1H), 3.11 (ddd, J = 15.5, 8.5, 3.0 Hz, 1H), 2.77
(ddd, J = 15.5, 9.7, 3.0 Hz, 2H), 1.81–1.68 (m, 1H), 1.66–1.18 (m, 7H), 1.12 (d, J = 6.3
Hz, 3H); 13C NMR (125 MHz, acetone-d6) $ 205.77, 170.10, 159.24, 157.34, 136.04,
120.46, 111.32, 101.64, 71.66, 43.07, 38.80, 32.00, 26.63, 23.68, 22.59, 19.68; IR
(NaCl/film) 3428, 1644, 1461, 1266, 1162, 845 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C16H21O5 [M+H]+: 293.1384, found 293.1385; ["]27D –31.2° (c 0.12, EtOH).
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 205
2.7 NOTES AND REFERENCES
(1) Musgrave, O. C. J. Chem. Soc. 1956, 4301–4305.
(2) a) Musgrave, O. C.  J. Chem. Soc. 1957, 1104–1108.  b) Birch, A. J.; Musgrave,
O. C.; Rickards, R. W.; Smith, H.  J. Chem. Soc. 1959, 3146–3152.  c) Musgrave,
O. C.; Templeton, R.; Munro, H. D.  J. Chem. Soc. C 1968, 250–255.  d) Munro,
H. D.; Musgrave, O. C.; Templeton, R.  J. Chem. Soc. C 1971, 95–98.  e) Birch,
A. J.; Moore, B.; Rickards, R. W.  J. Chem. Soc. 1962, 220–222.
(3) Munro, H. D.; Musgrave, O. C.; Templeton, R.  J. Chem. Soc. 1967, 947–948.
(4) Raistrick, H.; Rice, F. A. H.  J. Chem. Soc. 1971, 3069–3070.
(5) a) Kamal, A.; Ahmad, N.; Ali Khan, M.; Qureshi, I. H.  Tetrahedron 1962, 18,
433–436.  b) Kamal, A.; Ali Khan, M.; Ali Qureshi, A.  Tetrahedron 1963, 19,
111–115.
(6) a) Lai, S.; Shizuri, Y.; Yamamura, S.; Kawai, K.; Furukawa, H.  Bull. Chem. Soc.
Jpn. 1991, 64, 1048–1050.  b) Ghisalberti, E. L.; Rowland, C. Y.  J. Nat. Prod.
1993, 56, 2175–2177.  c) Kusano, M; Nakagami, K.; Fujioka, S.; Kawano, T.;
Shimada, A.; Kimura, Y.  Biosci. Biotechnol. Biochem. 2003, 67, 1413–1416.  d)
Greve, H.; Schupp, P. J.; Eguereva, E.; Kehraus, S.; Kelter, G.; Maier, A.; Fiebig,
H.-H.; König, G. M.  Eur. J. Org. Chem. 2008, 5085–5092.  e) Hyeon, S.-B.;
Ozaki, A.; Suzuki, A.; Tamura, S.  Agr. Biol. Chem. 1976, 40, 1663–1664.  f) Dai,
J.; Krohn, K.; Flörke, U.; Pescitelli, G.; Kerti G.; Papp, T.; Kövér, K. E.; Bényei,
A. C.; Draeger, S.; Schulz, B.; Kurtán, T.  Eur. J. Org. Chem. 2010, 6928–6937.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 206
(7) Lai, S.; Shizuri, Y.; Yamamura, S.; Kawai, K.; Terada, Y.; Furukawa, H.
Tetrahedron Lett. 1989, 30, 2241–2244.
(8) For structure and isolation, see: a) Aldridge, D. C.; Galt, S.; Giles, D.; Turner, W.
B.  J. Chem. Soc. C 1971, 1623–1627.  b) Lee, K.-H.; Hayashi, N.; Okano, M.;
Hall, I. H.; Wu, R.-Y.; McPhail, A. T.  Phytochemistry 1982, 21, 1119–1121.
(9) For structure and isolation, see: a) Delmotte, P.; Delmotte-Plaquee, J.  Nature
1953, 171, 344.  b) Ayer, W. A.; Lee, S. P.; Tsunda, A.; Hiratsuka, Y.  Can. J.
Microbiol. 1980, 26, 766–773.
(10) For structure and isolation, see: a) Stob, M.; Baldwin, R. S.; Tuite, J.; Andrews, F.
N.; Gillette, K. G.  Nature 1962, 196, 1318.  b) Urry, W. H.; Wehrmeister, H. L.;
Hodge, E. B.; Hidy, P. H.  Tetrahedron Lett. 1966, 3109–3114.
(11) For structure and isolation, see: Edrada, R. A.; Heubes, M.; Brauers, G.; Wray,
V.; Berg, A.; Gräfe, U.; Wohlfarth, M.; Mühlbacher, J.; Schaumann, K.;
Sudarsono; Bringmann, G.; Proksch, P.  J. Nat. Prod. 2002, 65, 1598–1604.
(12) For structure and isolation, see: a) Kinoshita, K.; Sasaki, T.; Awata, M.; Takada,
M.; Yaginuma, S.  J. Antibiot. 1997, 50, 961–964.  b) Murakami, Y.; Ishii, A.;
Mizuno, S.; Yaginuma, S.; Uehara, Y.  Anticancer Res. 1999, 19, 4145–4149.
(13) a) Arai, K.; Rawlings, B. J.; Yoshizawa, Y.; Vederas, J. C.  J. Am. Chem. Soc.
1989, 111, 3391–3399.  b) Liu, Y.; Li, Z.; Vederas, J. C.  Tetrahedron 1998, 54,
15937–15958.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 207
(14) a) Ghisalberti, E. L.; Hockless, D. C. R.; Rowland, C. Y.; White, A. H.  Aust. J.
Chem. 1993, 46, 571–575.  b) Almassi, F.; Ghisalberti, E. L.; Skelton, B. W.;
White, A. H.  Aust. J. Chem. 1994, 47, 1193–1197.
(15) Kobayashi, A.; Hino, T.; Yata, S.; Itoh, T. J.; Sato, H.; Kawazu, K.  Agric. Biol.
Chem. 1988, 52, 3119.
(16) Robeson, D. J.; Strobel, G. A.  J. Nat. Prod. 1985, 48, 139–141.
(17) De Souza, A. O.; Galetti, F. C. S.; Silva, C. L.; Bicalho, B.; Parma, M. M.;
Fonseca, S. F.; Marsaioli, A. J.; Trindade, A. C. L. B.; Gil, R. P. F.; Bezerra, F.
S.; Andrade-Neto, M.; de Oliveira, M. C. F.  Quim. Nova 2007, 30, 1563–1566.
(18) Xie, L. W.; Ouyang, Y. C.; Zou, K.; Wang, G. H.; Chen, M. J.; Sun, H. M.; Dai,
S. K.; Li, X.  Appl. Biochem. Biotechnol. 2009, 159, 284–293.
(19) a) Yao, Y.; Hausding, M.; Erkel, G.; Anke, T.; Förstermann, U.; Kleinert, H.
Mol. Pharm. 2003, 63, 383–391.  b) Schmidt, N.; Pautz, A.; Art, J.; Rauschkolb,
P.; Jung, M.; Erkel, G.; Goldring, M. B.; Kleinert, H.  Biochem. Pharm. 2010, 79,
722–732.
(20) a) Bycroft, B. W.; Roberts, J. C.; Baker, P. M.  J. Chem. Soc. 1964, 2289–2292.
b) Baker, P. M.; Bycroft, B. W.; Roberts, J. C.  J. Chem. Soc. 1967, 1913–1915.
(21) Takahashi, T.; Ikeda, H.; Tsuji, J.  Tetrahedron Lett. 1980, 21, 3885–3888.
(22) a) Wasserman, H. H.; Gambale, R. J.; Pulwer, M. J.  Tetrahedron 1981, 37,
4059–4067.  b) Wasserman, H. H.; Gambale, R. J.  Tetrahedron Lett. 1981, 22,
4849–4852.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 208
(23) Birch, A. J.; Mani, N. S.; Subba Rao, G. S. R.  J. Chem. Soc. Perkin Trans. I
1990, 1423–1427.
(24) Kasar, R. A.; Khan, R. A.; Deshpande, V. H.; Ayyangar, N. R.  Tetrahedron Lett.
1991, 32, 1599–1600.
(25) Liang, Q.; Sun, Y.; Yu, B.; She, X.; Pan, X.  J. Org. Chem. 2007, 72, 9846–9849.
(26) Yadav, J. S.; Raju, A.; Ravindar, K.; Reddy, B. V.  Synthesis 2010, 797–802.
(27) Miyagi, T.; Kuwahara, S.  Biosci. Biotechnol. Biochem. 2007, 71, 1592–1594.
(28) Gerlach, H.  Helv. Chim. Acta 1977, 60, 3039–3044.
(29) a) Bracher, F.; Schulte, B.  Liebigs Ann./Recueil 1997, 1979.  b) Bracher, F.;
Schulte, B.  Nat. Prod. Lett. 1995, 7, 65–68.
(30) Elzner, S.; Schmidt, D.; Schollmeyer, D.; Erkel, G.; Anke, T.; Kleinert, H.;
Förstermann, U.; Kunz, H.  ChemMedChem 2008, 3, 924–939.
(31) Mohapatra, D. K.; Rahaman, H.; Pal, R.; Gurjar, M. K.  Synlett 2008, 1801–1804.
(32) For reviews on the history of arynes and their use in synthesis, see: a) Bunnett, J.
F.  J. Chem. Educ. 1961, 38, 278–285.  b) Heaney, H.  Chem. Rev. 1962, 62,
81–97.  c) Hoffmann, R. W.  Dehydrobenzene and Cycloalkynes; Blomquist, A.
T., Ed.; Academic Press: New York, 1967.  d) Kessar, S. V.  Acc. Chem. Res.
1978, 11, 283–288.  e) Kessar, S.  In Comprehensive Organic Synthesis; Trost, B.
M., Fleming, I., Eds.; Pergamon Press: New York, 1991; Vol. 4, pp 483–515.  f)
Hart, H.  In The Chemistry of Triple-Bonded Functional Groups Supplement C2;
Patai, S., Ed.; Wiley: New York, 1994; pp 1017–1134.  g) Sander, W.  Acc.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 209
Chem. Res. 1999, 32, 669–676.  h) Pellissier, H.; Santelli, M.  Tetrahedron 2003,
59, 701–730.  i) Wenk, H. H.; Winkler, M.; Sander, W.  Angew. Chem., Int. Ed.
2003, 42, 502–528.
(33) The history and reactivity of arynes has also been extensively reviewed by Dr.
Kevin M. Allan, a former graduate student in the Stoltz research group.  See:
Allan, K. M.  Thesis, California Institute of Technology, Pasadena, CA, 2010.
(34) a) Bunett, J. F.; Happer, D. A. R.; Patsch, M.; Pyun, C.; Takayama, H.  J. Am.
Chem. Soc. 1966, 88, 5250–5254.  b) Biehl, E. R.; Nieh, E.; Li, H.-M.; Hong, C.-
I.  J. Org. Chem. 1969, 34, 500–505.  c) Johnson, W. T. G.; Cramer, C. J.  J. Am.
Chem. Soc. 2001, 123, 923.  d) Biehl, E. R.; Nieh, E.; Hsu, K. C.  J. Org. Chem.
1969, 34, 3595–3599.  e) Johnson, W. T. G.; Cramer, C. J.  J. Phys. Org. Chem.
2001, 14, 597–603.  f) Cheong, P. H.-Y.; Paton, R. S.; Bronner, S. M.; Im, G.-Y.
J.; Garg, N. K.; Houk, K. N.  J. Am. Chem. Soc. 2010, 132, 1267–1269.  g) Im,
G.-Y. J.; Bronner, S. M.; Goetz, A. E.; Paton, R. S.; Cheong, P. H.-Y.; Houk, K.
N.; Garg, N. K.  J. Am. Chem. Soc. 2010, 132, 17933–17944.  h) Bronner, S. M.;
Goetz, A. E.; Garg, N. K.  J. Am. Chem. Soc. 2011, 133, 3832–3835.
(35) Tadross, P. M.; Gilmore, C. D.; Bugga, P.; Virgil, S. C.; Stoltz, B. M.  Org. Lett.
2010, 12, 1224–1227.
(36) a) Tambar, U. K.; Stoltz, B. M.  J. Am. Chem. Soc. 2005, 127, 5340–5341.  b)
Ebner, D. C.; Tambar, U. K.; Stoltz, B. M.  Org. Synth. 2009, 86, 161–171.
(37) Tambar, U. K.  Thesis, California Institute of Technology, Pasadena, CA, 2005.
(38) a) Streuff, J.; White, D. E.; Virgil, S. C.; Stoltz, B. M.  Nature Chem. 2010, 2,
192–196.  b) Ma, S.; Han, X.; Krishnan, S.; Virgil, S. C.; Stoltz, B. M.  Angew.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 210
Chem., Int. Ed. 2009, 48, 8037–8041.  c) Seto, M.; Roizen, J. L.; Stoltz, B. M.
Angew. Chem., Int. Ed. 2008, 47, 6873–6876.  d) Enquist, J. A., Jr.; Stoltz, B. M.
Nature 2008, 453, 1228–1231.  e) Mohr, J. T.; Behenna, D. C.; Harned, A. M.;
Stoltz, B. M.  Angew. Chem., Int. Ed. 2005, 44, 6924–6927.  f) Behenna, D. C.;
Stoltz, B. M.  J. Am. Chem. Soc. 2004, 126, 15044–15045.  g) Ferreira, E. M.;
Stoltz, B. M.  J. Am. Chem. Soc. 2003, 125, 9578–9579.
(39) Himeshima, Y.; Sonoda, T.; Kobayashi, H.  Chem. Lett. 1983, 1211–1214.
(40) To the best of our knowledge, this type of transformation has not been previously
described for !-ketoesters.  Moreover, direct coupling of carbon nucleophiles of
the type Nuc–H with aryne precursors has not been reported.  For examples of
lithium and potassium enolate additions to benzyne to give cyclobutoxides
followed by fragmentation, see: a) Caubere, P.; Loubinoux, B.  Bull. Soc. Chim.
Fr. 1968, 3008–3012.  b) Guyot, M.; Molho, D.  Tetrahedron Lett. 1973, 14,
3433–3436.  c) Geoffroy, P.; Mouaddib, A.; Carre, M. C.; Caubere, P.
Tetrahedron Lett. 1988, 29, 1385–1388.  d) Jamart-Gregoire, B.; Leger, C.;
Caubere, P. Tetrahedron Lett. 1990 , 31 , 7599–7602.  e) Danheiser, R. L.;
Helgason, A. L.  J. Am. Chem. Soc. 1994, 116, 9471–9479.  f) Shair, M. D.;
Yoon, T. Y.; Mosny, K. K.; Chou, T. C.; Danishefsky, S. J.  J. Am. Chem. Soc.
1996, 118, 9509–9525.  g) Wang, A.; Tandel, S.; Zhang, H.; Huang, Y.;
Holdeman, T. C.; Biehl, E. R.  Tetrahedron 1998, 54, 3391–3400.
(41)  Formal aryne insertions into metal–metal, heteroatom–metal,
heteroatom–heteroatom, carbon–metal, and carbon–heteroatom '-bonds have
been reported previously.  See: a) Yoshida, H.; Tanino, K.; Ohshita, J.; Kunai, A.
Angew. Chem., Int. Ed. 2004, 43, 5052–5055.  b) Yoshida, H.; Terayama, T.;
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 211
Ohshita, J.; Kunai, A.  Chem. Commun. 2004 , 1980–1981.  c) Lin, W.;
Sapountzis, I.; Knochel, P.  Angew. Chem., Int. Ed. 2005, 44, 4258–4261.  d)
Petragnani, N.; Toscano, V. G.  Chem. Ber. 1970, 103, 1652–1653.  e) Nakayama,
J.; Tajiri, T.; Hoshino, M.  Bull. Chem. Soc. Jpn. 1986, 59, 2907–2908.  f)
Yoshida, H.; Ikadai, J.; Shudo, M.; Ohshita, J.; Kunai, A.  J. Am. Chem. Soc.
2003, 125, 6638–6639.  g) Yoshida, H.; Ikadai, J.; Shudo, M.; Ohshita, J.; Kunai,
A.  Organometallics 2005, 24, 156–162.  h) Yoshida, H.; Minabe, T.; Ohshita, J.;
Kunai, A.  Chem. Commun. 2005, 3454–3456.  i) Liu, Z.; Larock, R. C.  Org.
Lett. 2003, 5, 4673–4675.  j) Liu, Z.; Larock, R. C.  Org. Lett. 2004, 6, 99–102.
k) Yoshida, H.; Honda, Y.; Shirakawa, E.; Hiyama, T.  Chem. Commun. 2001,
1880–1881.  l) Sato, Y.; Kobayashi, Y.; Sugiura, M.; Shirai, H.  J. Org. Chem.
1978, 43, 199–202.  m) Yoshida, H.; Shirakawa, E.; Honda, Y.; Hiyama, T.
Angew. Chem., Int. Ed. 2002, 41, 3247–3249.  n) Liu, Z.; Larock, R. C.  J. Am.
Chem. Soc. 2005, 127, 13112–13113.
(42) Yet, L.  Chem. Rev. 2000, 100, 2963–3008.
(43) Gilmore, C. D.; Allan, K. M.; Stoltz, B. M.  J. Am. Chem. Soc. 2008, 130,
1558–1559.
(44) Allan, K. M.; Hong, B. D.; Stoltz, B. M.  Org. Biomol. Chem. 2009 , 7 ,
4960–4964.
(45) For examples of regioselective reactions of aryne 603, see: a) Yoshida, H.;
Morishita, T.; Ohshita, J.  Org. Lett. 2008, 10, 3845–3849.  b) Ni, C.; Zhang, L.;
Hu, J.  J. Org. Chem. 2008, 73, 5699–5713.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 212
(46) Trisubstituted arynes derived from precursors other than silyl aryl triflates are
known.
(47) Allan, K. M.; Stoltz, B. M.  J. Am. Chem. Soc. 2008, 130, 17270–17271.
(48) Peña, D.; Cobas, A.; Pérez, D.; Guitián, E.  Synthesis 2002, 1454–1458.
(49) Macrolide Antibiotics: Chemistry, Biology, and Practice, 2nd ed.; Omura, S., Ed.;
Academic Press: San Diego, CA, 2002.
(50) Greene, T. W.; Wuts, P. G. M.  Protective Groups in Organic Synthesis, 4th ed.;
Wiley-Interscience: New York, 2006.
(51) Alam, A.; Takaguchi, Y.; Ito, H.; Yoshida, T.; Tsuboi, S.  Tetrahedron 2005, 61,
1909–1918.
(52) Rao, D. V.; Stuber, F. A.  Synthesis 1983, 308.
(53) Corey, E. J.; Gin, D. Y.; Kania, R. S.  J. Am. Chem. Soc. 1996, 118, 9202–9203.
(54) Bronner, S. M.; Garg, N. K.  J. Org. Chem. 2009, 74, 8842–8843.
(55) No alternative substrate- or aryne-derived products were isolated or observed in
each of the aryne reactions reported herein.
(56) Assante, G.; Locci, R.; Camarda, L.; Merlini, L.; Nasini, G.  Phytochemistry
1977, 16, 243–247.
(57) Bentley, H. R.; Dawson, W.; Spring, F. S.  J. Chem. Soc. 1952, 1763–1768.
(58) Tambar, U. K.; Ebner, D. C.; Stoltz, B. M.  J. Am. Chem. Soc. 2006, 128,
11752–11753.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 213
(59) Ebner, D. C.  Thesis, California Institute of Technology, Pasadena, CA, 2008.
(60) For isolation, see: a) Boit, H. G.; Flentje, H.  Naturwiss. 1960, 47, 180.  b) Gözler,
B.; Lantz, M. S.; Shamma, M.  J. Nat. Prod. 1983, 46, 293–309.  For selected
syntheses of isopavine alkaloids, see: c) Gözler, B.  Pavine and Isopavine
Alkaloids.  In The Alkaloids; Brossi, A., Ed.; Academic Press: New York, 1987;
Vol. 31, pp 343–356.  d) Shinohara, T.; Takeda, A.; Toda, J.; Sano, T.
Heterocycles 1998, 48, 981–992.  e) Gottlieb, L.; Meyers, A. I.  J. Org. Chem.
1990, 55, 5659–5662.  f) Hanessian, S.; Mauduit, M.  Angew. Chem., Int. Ed.
2001, 40, 3810–3813.  g) Dragoli, D. R.; Burdett, M. T.; Ellman, J. A.  J. Am.
Chem. Soc. 2001, 123, 10127–10128.
(61) a) Ferreira, E. M.; Stoltz, B. M.  J. Am. Chem. Soc. 2001, 123, 7725–7726.  b)
Bagdanoff, J. T.; Ferreira, E. M.; Stoltz, B. M.  Org. Lett. 2003, 5, 835–837.  c)
Bagdanoff, J. T.; Stoltz, B. M.  Angew. Chem. Int. Ed. 2004, 43, 353–357.  d)
Trend, R. M.; Stoltz, B. M.  J. Am. Chem. Soc. 2004, 126, 4482–4483.  e) Trend,
R. M.; Stoltz, B. M.  J. Am. Chem. Soc. 2008, 130, 15957–15966.  f) Krishnan, S.;
Bagdanoff, J. T.; Ebner, D. C.; Ramtohul, Y. K.; Tambar, U. K.; Stoltz, B. M.  J.
Am. Chem. Soc. 2008, 130, 13745–13754.  g) Ebner, D. C.; Trend, R. M.; Genet,
C.; McGrath, M. J.; O’Brien, P.; Stoltz, B. M.  Angew. Chem. Int. Ed. 2008, 47,
6367–6370.  h) Ebner, D. C.; Bagdanoff, J. T.; Ferreira, E. M.; McFadden, R. M.;
Caspi, D. D.; Trend, R. M.; Stoltz, B. M.  Chem. Eur. J. 2009, 15, 12978–12992.
(62) For structure and isolation, see: a) Ishida, T.; Wada, K.  J. Chem. Soc. Chem.
Commun. 1975, 209–210.  b) Wada, K.; Ishida, T.  J. Chem. Soc. Perkin Trans. 1
1979, 1154–1158.
(63) Galli, C.; Mandolini, L.  Eur. J. Org. Chem. 2000, 3117–3125.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 214
(64) a) Ishida, T.; Wada, K.  J. Chem. Soc. Chem. Commun. 1977, 337–338.  b) Ishida,
T.; Wada, K.  J. Chem. Soc. Perkin Trans. I 1979, 323–327.
(65) Shenvi, A. B.; Gerlach, H.  Helv. Chim. Acta 1980, 63, 2426–2433.
(66) Boeckman, R. K., Jr.; Pruitt, J. R.  J. Am. Chem. Soc. 1989, 111, 8286–8288.
(67) Anand, R. V.; Baktharaman, S.; Singh, V. K.  J. Org. Chem. 2003 , 68 ,
3356–3359.
(68) Sharma, G. V. M.; Laxmi Reddy, K.  Tetrahedron: Asymm. 2006, 17, 3197–3202.
(69) Tsuji, J.; Mandai, T.  Tetrahedron Lett. 1978, 21, 1817–1820.
(70) a) Wakamatsu, T.; Akasaka, K.; Ban, Y.  Tetrahedron Lett. 1977, 32, 2755–2758.
b) Wakamatsu, T.; Akasaka, K.; Ban, Y.  J. Org. Chem. 1979, 44, 2008–2012.
(71) Ireland, R. E.; Brown, F. R., Jr.  J. Org. Chem. 1980, 45, 1868–1880.
(72) Ohta, S.; Shimabayashi, A.; Hatano, S.; Okamoto, M.  Synthesis 1983, 715–716.
(73) Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H.  J. Am. Chem. Soc.
2003, 125, 11360–11370.
(74) a) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H.  Org. Lett. 1999, 1, 953–956.
b) Sanford, M. S.; Love, J. A.; Grubbs, R. H.  J. Am. Chem. Soc. 2001, 123,
6543–6544.
(75) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H.  J. Am. Chem. Soc.
2000, 122, 8168–8179.
(76) Simpson, T. J.; Soulas, F.; Willis, C. L.  Synlett 2008, 2196–2198.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 215
(77) Booth, P. M.; Broughton, H. B.; Ford, M. J.; Fox, C. M. J.; Ley, S. V.; Slawin, A.
M. Z.; Williams, D. J.; Woodward, P. R.  Tetrahedron 1989, 45, 7565–7580.
(78) Leonard, N. J.; Schimelpfenig, C. W., Jr.  J. Org. Chem. 1958, 23, 1708–1710.
(79) Ashby, E. C.; Oswald, J.  J. Org. Chem. 1988, 53, 6068–6076.
(80) Bordwell, F. G.  Acc. Chem. Res. 1988, 21, 456–563.
(81) Broggini, G.; Molteni, G.; Pilati, T.  Tetrahedron: Asymm. 2000, 11, 1975–1986.
(82) To our knowledge, only two other examples of a resolution of diastereomers by
RCM using an achiral catalyst are known: a) Bajwa, N.; Jennings, M. P.
Tetrahedron Lett. 2008, 49, 390–393.  b) Magauer, T.; Martin, H. J.; Mulzer, J.
Angew. Chem., Int. Ed. 2009, 48, 6032–6036.
(83) a) Stewart, I. C.; Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.; Schrodi, Y.
Org. Lett. 2007, 9, 1589–1592.  b) Stewart, I. C.; Douglas, C. J.; Grubbs, R. H.
Org. Lett. 2008, 10, 441–444.
(84) a) Otsuka, S.; Tani, K.  In Transition Metals for Organic Synthesis, 2nd ed.; Beller,
M., Bolm, C., Eds.; Wiley-VCH Verlag GmbH & Co. KgaA: Weinheim,
Germany, 2004; Vol. 1, pp 199–209.  b) Herrmann, W. A.; Prinz, M.  In Applied
Homogeneous Catalysis with Organometallic Compounds, 2nd ed.; Cornils, B.,
Herrmann, W. A., Eds.; Wiley-VCH Verlag GmbH & Co. KgaA: Weinheim,
Germany, 2002; Vol. 3, pp 1119–1130.  c) Negishi, E.-I.  In Handbook of
Organopalladium Chemistry for Organic Synthesis; Negishi, E.-I., de Meijere, A.,
Eds.; John Wiley & Sons, Inc.: Hoboken, N.J., 2002; Vol. 2, pp 2783–2788.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 216
(85) (S)-Propylene oxide is currently available for purchase from Sigma–Aldrich for
$135.50 for 5 grams.
(86) a) Tokunaga, M; Larrow, J. F.; Kakiuchi, F.; Jacobsen, E. N.  Science 1997, 277,
936–938.  b) Schaus, S. E.; Brandes, B. D.; Larrow, J. F.; Tokunaga, M.; Hansen,
K. B.; Gould, A. E.; Furrow, M. E.; Jacobsen, E. N.  J. Am. Chem. Soc. 2002, 124,
1307–1315.  c) Nielsen, L. P. C.; Stevenson, C. P.; Blackmond, D. G.; Jacobsen,
E. N.  J. Am. Chem. Soc. 2004, 126, 1360–1362.
(87) a) Dixon, D. J.; Lev, S. V.; Tate, E. W.  J. Chem. Soc. Perkin Trans 1 2000,
2385–2394.  b) Tamura, M.; Kochi, J.  Synthesis 1971, 303–305.
(88) Nagaoka, H.; Schmid, G.; Iio, H.; Kishi, Y.  Tetrahedron Lett. 1981, 22, 899–902.
(89) a) Li, T.-T.; Wu, Y. L.  J. Am. Chem. Soc. 1981, 103, 7007–7009.  b) Parker, K.
A.; Petraitis, J. J.  Tetrahedron Lett. 1981, 22, 397–400.
(90) Zuo, L.; Yao, S.; Wang, W.; Duan, W.  Tetrahedron Lett. 2008, 49, 4054–4056.
(91) Bernard, A. M.; Ghiani, M. R.; Piras, P. P.; Rivoldini, A.  Synthesis 1989,
287–289.
(92) Dodge, J. A.; Stocksdale, M. G.; Fahey, K. J.; Jones, C. D.  J. Org. Chem. 1995,
60, 739–741.
(93) Bracher, F.; Krauss, J.  Nat. Prod. Lett. 1998, 12, 31–34.
(94) Cessation of the reaction occurs when exposed to air, and large amounts of Pd(0)
black deposits result in a grey solution and reduced yields.
Chapter 2 – The Enantioselective Total Synthesis of (–)-Curvularin 217
(95) Rf1 corresponds to the 2-TMS phenol, the desired cleavage product.  R f2
corresponds to undesired des-TMS phenol 624.
(96) Li, P.; Li, J.; Arikan, F.; Ahlbrecht, W.; Dieckmann, M.; Menche, D.  J. Org.
Chem. 2010, 75, 2429–2444.
(97) Lin, W.; Zercher, C. K.  J. Org. Chem. 2007, 72, 4390–4395.
Appendix 1 – Synthetic Summary for (–)-Curvularin 218
APPENDIX 1
Synthetic Summary for (–)-Curvularin
Appendix 1 – Synthetic Summary for (–)-Curvularin 219
Scheme A1.1.  Synthesis of silyl aryl triflate 217.
(90% yield)
OH
HO OH
1. TIPSCl, imidazole
    DMF
2. BnBr, Cs2CO3
    MeCN
3. TBAF, THF
(22% yield, 3 steps)
BnO
BnO OH
NBS
CH2Cl2, –78 °C
BnO
BnO OH
Br HMDS, THF, 70 °C;
n-BuLi, then Tf2O
THF, –100 °C
(74% yield)
BnO
BnO OTf
TMS
615 616 617 217
Scheme A1.2.  Synthesis of !-ketolactone 218.
717 (S)-678
Br
Mg, THF, 23 °C;
Li2CuCl4 (10 mol%)
THF, –30 °C
O
MeS
(S)-713
HO S
AcCl, pyridine
Et2O, 35 °C
(76% yield, 2 steps)
O S
O LDA, then
acrolein
THF, –78 °C
(76% yield)
(S)-702
O
O
HO
HMDS, THF, 70 °C;
Grubbs–Hoveyda 3 (10 mol%)
PhH, reflux;
1 N HCl, THF
(57% yield)
(S)-705
O
O
HO
1. H2, Pd/C
    EtOH
2. Dess–Martin periodinane
    CH2Cl2
      (92% yield, 2 steps) (S)-218
O
O
O
(S)-676
S S S
Scheme A1.3.  Synthesis of (–)-curvularin (221).
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217
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CsF (3 equiv)
MeCN (0.1 M), 40 °C
(30% yield)
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(60% yield)
(–)-Curvularin (221)
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APPENDIX 2
Spectra Relevant to Chapter 2:
The Total Synthesis of (–)-Curvularin
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Figure A2.1.3  13C NMR (125 MHz, CDCl3) of compound 614.
Figure A2.1.2  Infrared spectrum (thin film/NaCl) of compound 614.
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Figure A2.2.3  13C NMR (125 MHz, CDCl3) of compound 232.
Figure A2.2.2  Infrared spectrum (thin film/NaCl) of compound 232.
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Figure A2.3.3  13C NMR (125 MHz, CDCl3) of compound 720.
Figure A2.3.2  Infrared spectrum (thin film/NaCl) of compound 720.
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Figure A2.4.3  13C NMR (125 MHz, CDCl3) of compound 616.
Figure A2.4.2  Infrared spectrum (thin film/NaCl) of compound 616.
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Figure A2.5.3  13C NMR (125 MHz, CDCl3) of compound 617.
Figure A2.5.2  Infrared spectrum (thin film/NaCl) of compound 617.
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Figure A2.6.3  13C NMR (125 MHz, CDCl3) of compound 217.
Figure A2.6.2  Infrared spectrum (thin film/NaCl) of compound 217.
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Figure A2.7.3  13C NMR (125 MHz, CDCl3) of compound 721.
Figure A2.7.2  Infrared spectrum (thin film/NaCl) of compound 721.
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Figure A2.8.3  13C NMR (125 MHz, CDCl3) of compound 619.
Figure A2.8.2  Infrared spectrum (thin film/NaCl) of compound 619.
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Figure A2.9.3  13C NMR (125 MHz, CDCl3) of compound 620.
Figure A2.9.2  Infrared spectrum (thin film/NaCl) of compound 620.
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Figure A2.10.3  13C NMR (500 MHz, CDCl3) of compound 604.
Figure A2.10.2  Infrared spectrum (thin film/NaCl) of compound 604.
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Figure A2.11.3  13C NMR (125 MHz, CDCl3) of compound 622.
Figure A2.11.2  Infrared spectrum (thin film/NaCl) of compound 622.
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Figure A2.12.3  13C NMR (125 MHz, CDCl3) of compound 623.
Figure A2.12.2  Infrared spectrum (thin film/NaCl) of compound 623.
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Figure A2.13.3  13C NMR (125 MHz, CDCl3) of compound 624.
Figure A2.13.2  Infrared spectrum (thin film/NaCl) of compound 624.
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Figure A2.14.3  13C NMR (125 MHz, CDCl3) of compound 625.
Figure A2.14.2  Infrared spectrum (thin film/NaCl) of compound 625.
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Figure A2.15.3  13C NMR (125 MHz, CDCl3) of compound 626.
Figure A2.15.2  Infrared spectrum (thin film/NaCl) of compound 626.
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Figure A2.16.3  13C NMR (125 MHz, CDCl3) of compound 605.
Figure A2.16.2  Infrared spectrum (thin film/NaCl) of compound 605.
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Figure A2.17.3  13C NMR (125 MHz, CDCl3) of compound 627.
Figure A2.17.2  Infrared spectrum (thin film/NaCl) of compound 627.
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Figure A2.18.3  13C NMR (125 MHz, CDCl3) of compound 226.
Figure A2.18.2  Infrared spectrum (thin film/NaCl) of compound 226.
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Figure A2.19.3  13C NMR (125 MHz, CDCl3) of compound 628.
Figure A2.19.2  Infrared spectrum (thin film/NaCl) of compound 628.
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Figure A2.20.3  13C NMR (125 MHz, CDCl3) of compound 629.
Figure A2.20.2  Infrared spectrum (thin film/NaCl) of compound 629.
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Figure A2.21.3  13C NMR (125 MHz, CDCl3) of compound 227.
Figure A2.21.2  Infrared spectrum (thin film/NaCl) of compound 227.
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Figure A2.22.3  13C NMR (125 MHz, acetone-d6) of compound 228.
Figure A2.22.2  Infrared spectrum (thin film/NaCl) of compound 228.
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Figure A2.23.3  13C NMR (125 MHz, CDCl3) of compound 631.
Figure A2.23.2  Infrared spectrum (thin film/NaCl) of compound 631.
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Figure A2.24.3  13C NMR (500 MHz, CDCl3) of compound 666.
Figure A2.24.2  Infrared spectrum (thin film/NaCl) of compound 666.
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Figure A2.25.3  13C NMR (125 MHz, CDCl3) of compound 681.
Figure A2.25.2  Infrared spectrum (thin film/NaCl) of compound 681.
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Figure A2.26.3  13C NMR (125 MHz, CDCl3) of compound 682.
Figure A2.26.2  Infrared spectrum (thin film/NaCl) of compound 682.
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Figure A2.27.3  13C NMR (125 MHz, CDCl3) of compound 685.
Figure A2.27.2  Infrared spectrum (thin film/NaCl) of compound 685.
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Figure A2.28.3  13C NMR (125 MHz, CDCl3) of compound 686.
Figure A2.28.2  Infrared spectrum (thin film/NaCl) of compound 686.
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Figure A2.29.3  13C NMR (125 MHz, CDCl3) of compound 689.
Figure A2.29.2  Infrared spectrum (thin film/NaCl) of compound 689.
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Figure A2.30.3  13C NMR (125 MHz, CDCl3) of compound 695.
Figure A2.30.2  Infrared spectrum (thin film/NaCl) of compound 695.
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Figure A2.31.3  13C NMR (125 MHz, CDCl3) of compound 693.
Figure A2.31.2  Infrared spectrum (thin film/NaCl) of compound 693.
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Figure A2.32.3  13C NMR (125 MHz, CDCl3) of compound cis-701.
Figure A2.32.2  Infrared spectrum (thin film/NaCl) of compound cis-701.
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Figure A2.33.3  13C NMR (125 MHz, CDCl3) of compound 702.
Figure A2.33.2  Infrared spectrum (thin film/NaCl) of compound 702.
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Figure A2.34.3  13C NMR (125 MHz, CDCl3) of compound 703.
Figure A2.34.2  Infrared spectrum (thin film/NaCl) of compound 703.
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Figure A2.35.3  13C NMR (125 MHz, CDCl3) of compound Z-anti-704.
Figure A2.35.2  Infrared spectrum (thin film/NaCl) of compound Z-anti-704.
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Figure A2.36.3  13C NMR (125 MHz, CDCl3) of compound 640.
Figure A2.36.2  Infrared spectrum (thin film/NaCl) of compound 640.
Appendix 2 – Spectra Relevant to Chapter 2 293
Fi
gu
re
 A
2.
37
.1
  
H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
70
4.
Appendix 2 – Spectra Relevant to Chapter 2 294
Figure A2.37.3  13C NMR (125 MHz, CDCl3) of compound 704.
Figure A2.37.2  Infrared spectrum (thin film/NaCl) of compound 704.
Appendix 2 – Spectra Relevant to Chapter 2 295
Fi
gu
re
 A
2.
38
.1
  
H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
21
8.
Appendix 2 – Spectra Relevant to Chapter 2 296
Figure A2.38.3  13C NMR (125 MHz, CDCl3) of compound 218.
Figure A2.38.2  Infrared spectrum (thin film/NaCl) of compound 218.
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Figure A2.39.3  13C NMR (125 MHz, CDCl3) of compound 709.
Figure A2.39.2  Infrared spectrum (thin film/NaCl) of compound 709.
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Figure A2.40.3  13C NMR (125 MHz, CDCl3) of compound 718.
Figure A2.40.2  Infrared spectrum (thin film/NaCl) of compound 718.
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Figure A2.41.3  13C NMR (125 MHz, CDCl3) of compound 719.
Figure A2.41.2  Infrared spectrum (thin film/NaCl) of compound 719.
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Figure A2.42.3  13C NMR (125 MHz, CDCl3) of compound 223.
Figure A2.42.2  Infrared spectrum (thin film/NaCl) of compound 223.
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Figure A2.43.3  13C NMR (125 MHz, acetone-d6) of compound 224.
Figure A2.43.2  Infrared spectrum (thin film/NaCl) of compound 224.
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Figure A2.44.2  Infrared spectrum (thin film/NaCl) of compound 221.
Figure A2.44.3  13C NMR (125 MHz, acetone-d6) of compound 221.
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Chapter 3
Efforts Toward the Total Synthesis of Integrastatins A and B†
3.1 INTRODUCTION
Since its discovery in 1981, the United Nations and World Health Organization
have estimated that HIV/AIDS has claimed more than 25 million lives, placing it among
the most destructive pandemics in history.1  With approximately 39 million people
currently living with HIV/AIDS worldwide, the unabated spread of the virus is one of the
most pressing issues confronting the scientific community in modern times.  In 2006
alone, roughly 4.3 million people were newly infected with HIV and another 2.9 million
died of the virus.  The urgency of the matter is emphasized by the explosion of research
over the past 25 years geared toward the development of new therapies aimed at disabling
viral replicative processes.  Despite this growth, novel drugs are needed to supplant the
use of HIV protease and reverse transcriptase inhibitors known for numerous side effects,
while minimizing the potential for the emergence of drug-resistant viral strains.
                                                 
† The work described in this chapter was completed in collaboration with Pradeep Bugga, a former
undergraduate researcher in the Stoltz group.
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Toward this end, the synthesis and implementation of small molecule inhibitors
has become central to the development of new chemotherapeuties.  One biological target
that holds particular promise for inhibiting viral replication is the enzyme HIV integrase.
Because of the potential that integrase inhibitors hold for the advancement of HIV
therapy, we sought to synthesize the naturally occurring integrase inhibitors integrastatin
A and B, as well as related structural analogs for biological screening.
3.1.1 HIV-1 Integrase Inhibition
Current FDA-approved treatments for HIV target either the viral reverse
transcriptase or protease enzymes.2,3  Though effective, these therapies are prohibitively
expensive and often lead to multidrug resistance.  Additionally, the presence of
equivalents of these viral enzymes within the host cell renders the leading drug regimens
toxic because of their interference with normal cellular processes.  For example, HAART
(Highly Active Antiretroviral Therapy), the leading combination therapy for HIV
treatment, is known to cause nausea, anemia, lipodystrophy and diabetes-like problems,
forcing many patients to switch medications or cease use entirely.2,3  For these reasons,
there has been an ongoing search for more attractive targets for HIV chemotherapies.!
Over the past decade, the principle target emerging from this search has been the enzyme
HIV integrase.4
Importantly, unlike HIV reverse transcriptase and HIV protease, HIV integrase
has no host-cell equivalent, diminishing the potential for drug interference with normal
cellular processes.  An additional benefit of targeting integrase is emerging evidence that
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mutated forms of integrase possess reduced viral replicative fitness.5  Thus, HIV
integrase exhibits a decreased likelihood of evolving drug-resistant viral strains.
HIV integrase is responsible for transporting viral cDNA from the cytoplasm into
the nucleus of the host cell, and subsequently inserting it into the host genome.6,7  This
complex and highly specialized integration process is essential for retroviral replication
because transcription of viral proteins is only possible if the cDNA is fully integrated into
a host chromosome.  More specifically, integrase has two primary tasks: 3’-processing of
viral cDNA and strand transfer of the processed cDNA into the host genome.8  It has been
shown that small-molecule inhibitors can interrupt the 3’-processing and strand-transfer
steps, shutting down the HIV replication process.4e  As a consequence, there have been
increasing efforts to develop new inhibitors of integrase for biological assays and in vivo
testing.
 Studies have produced a general hypothesis concerning the mechanism of
integrase inhibition that has aided researchers in discovering new inhibitors (Figure
3.1).6,9,10  In the absence of an inhibitor, binding and 3’-processing of viral cDNA at the
integrase donor (blue) site promotes a conformational change in the acceptor (red) site,
which, in turn, allows binding of host DNA.10  Upon host DNA binding, the strand
transfer reaction occurs, inserting the viral cDNA into the host genome (path a).  It is
believed that some integrase inhibitors intercept the integrase-cDNA complex following
the 3’-processing step and subsequent conformational shift (path b).  Apparent
stabilization of the pre-integration complex prevents the strand transfer reaction from
occurring, effectively shutting down the integration pathway.  Structural and mechanistic
data have indicated that binding of the inhibitor to the pre-integration complex occurs
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through chelation of divalent metal cofactors in integrase.9  Since the mechanism of
integrase inhibition is relatively well understood, the integrase enzyme represents an
excellent target for development of HIV chemotherapy.
Figure 3.1.  Proposed mechanism of action of integrase inhibitors.6
3'
Viral DNA
(donor)
Donor
site
Acceptor 
site
3'-processing
acceptor site
conformational 
change
Host DNA
(acceptor)
Stra
nd T
rans
fer
(pat
h a)
Inhibition(path b)
Inhibitor
While there are a number of HIV reverse transcriptase inhibitors and protease
inhibitors available as treatments, therapies that target HIV integrase are relatively rare.2,3
At this time, raltegravir (Isentress, 724), which was approved by the FDA in 2007, is the
only HIV integrase inhibitor on the market (Figure 3.2).11  Three other integrase
inhibitors are currently in Phase 3 clinical trials: dolutegravir (GSK-572, 725),12
elvitegravir (GS-9137, 726),13 and MK-2048 (727).14
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Figure 3.2.  HIV integrase inhibitors approved by the FDA and in Phase III clinical trials.    
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3.1.2 Integrastatins A and B: Naturally Occurring HIV Integrase Inhibitors
Natural products have historically served as excellent sources for the discovery of
biologically active agents that act as the basis for lead candidates in drug development.15
In particular, the naturally occurring compounds integrastatin A and B display inhibitory
activity against HIV-1 integrase at micromolar concentrations and are thus attractive
targets for new therapeutic development.16  Synthetic access to these naturally occurring
inhibitors would allow for more thorough biological testing as well as structure-activity
relationship (SAR) studies to optimize potency and antiviral activity.
Integrastatins A (728) and B (729) were isolated as racemic compounds in 2002
from an unidentified fungus found in herbivore dung in New Mexico (Figure 3.3).16  Both
compounds display potent inhibition of the strand transfer reaction of recombinant HIV-1
integrase at micromolar concentrations.  IC50 values for integrastatin A and B are 1.1 µM
and 2.5 µM, respectively.
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Figure 3.3. Integrastatins A (728) and B (729).
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Biosynthetically, the integrastatins are believed to arise from a polyketide
pathway by condensation of nine acetate units (Scheme 3.1).16  Subsequent
decarboxylation, methylation at C(10), and oxidation of the putative intermediate (732)
result in formation of the integrastatins.
Scheme 3.1. Proposed biosynthesis of the integrastatins.
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Their isolation as racemic compounds invites the question of whether the
integrastatins are biosynthetically produced racemically or whether this racemization
occurs in vivo after enantioselective biosynthesis.  A third possibility is that racemization
occurrs in vitro upon isolation.  One potential racemization pathway would involve the
achiral intermediate 734 (Scheme 3.2).  We believe that total syntheses of these
compounds will shed more light on this peculiarity.
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Scheme 3.2. Potential racemization pathway for integrastatins A and B (only integrastatin A shown).
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3.1.3 Previous Synthetic Efforts Toward Integrastatins A and B
To date, there are no reported synthetic routes to the integrastatins.  However, the
integrastatin tetracyclic core has been accessed by Taylor and co-workers17 through a
Ramberg-Bäcklund olefination paired with a Lewis acid-promoted cyclization (Scheme
3.3).  Taylor’s first sulfone olefination substrate (739) was prepared by coupling of
benzyl bromide 736 and benzyl thiol 738 under basic conditions followed by m-CPBA
oxidation of the sulfide to the sulfone.  Unfortunately, this substrate performed poorly
under Ramberg-Bäcklund olefination conditions.  However, following acetal cleavage
and ketone reduction, cis-stilbene 743 was formed in high yield and with excellent
selectivity for the Z-olefin.  At this point, benzylic oxidation of activated secondary
alcohol 743 with MnO2 gave acetophenone 744, which, upon exposure to SnCl2•2H2O,
cyclized to provide tetracycle 745, lacking oxidation at C(9).  Installation of the benzylic
ketone was accomplished by oxidation with tert-butyl hydroperoxide (TBHP) and
pyridinium dichromate (PDC) supported on Celite to give the integrastatin core (746).  In
summary, the integrastatin core (746 ) was constructed beginning with 2-
hydroxyacetophenone (737) in 11 linear steps (13 total operations).
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Scheme 3.3. Taylor and co-workers’ synthesis of the integrastatin core (746).
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Following the efforts of Taylor and co-workers, the Ramana group reported a
one-step synthesis of tetracycle 749 that relies upon a pinacol coupling to unite two
aromatic fragments (747  and 748) (Scheme 3.4a).18  In the event, treatment of o-
phthalaldehyde (748) and o-hydroxybenzaldehyde (747) with Mg(Hg) and TiCl4 in THF
at 0 °C produced tetracycle 749 in 42% isolated yield.  The authors note that the reaction
generally results in a complex mixture of compounds, including homocoupled products.
While this process permits some variation of substitution around the core structure, use of
2-formylacetophenone (756) in the pinacol coupling, which would install the methyl
group corresponding to C(18) of integrastatin, failed to provide tetracycle 757 (Scheme
3.4b).
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Scheme 3.4. a) Ramana and co-workers’ synthesis of tetracycle 749 and analogs, and b) failed
pinacol coupling of 2-formylacetophenone (756).
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3.2 AN ARYNE ACYL-ALKYLATION APPROACH TO INTEGRASTATINS A AND B
3.2.1 Strategy and Retrosynthesis
Our initial efforts toward a synthesis of integrastatins A and B (728 and 729)
focused on application of an acyl-alkylation reaction to convergently unify two highly
functionalized aromatic fragments.  This strategy would allow for a concise synthesis that
is amenable to analog synthesis.
Retrosynthetically, disconnection of the natural products along the acetal of the
central [3.3.1]-dioxabicycle leads back to !-hydroxyketone 758 containing appropriately
protected catechol and ketone groups (Scheme 3.5).  We anticipated that the
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!-hydroxyketone functionality could be derived from stilbene 759, which would, in turn,
be available from benzyl ketone 760.  In one of the key transformations, benzyl ketone
760 would be the result of an anionic ortho-Fries-type rearrangement of acyl-alkylation
product 761.  Finally, ketoester 761 could arise from acyl-alkylation of silyl aryl triflate
604 with "-ketoester 762.
Scheme 3.5.  Retrosynthetic analysis of integrastatins A (728) and B (729).
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 The proposed route tackles a number of the synthetic challenges presented by the
integrastatins, such as the acid-sensitive acetal that forms the central [3.3.1]-dioxabicycle.
The potential for racemization and the lability of this group will mandate its late
installation.  Additionally, the phenol moieties on both rings will require appropriate
protection throughout the synthesis to avoid unwanted oxidation to ortho-quinones.
Finally, the unsymmetrical pattern of oxygenation on the aryl rings is a significant
difficulty, but will be well addressed by our unique approach.
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3.2.2 Aryne Acyl-Alkylation Approach
Our synthesis commenced with preparation of "-ketoester 762 beginning with
commercially available methyl gallate (763) (Scheme 3.6).  Mono-methylation using
borax with dimethyl sulfate provided the methyl gallate methyl ether (764) in 86%
yield.19  Selective bromination of the 6-position of the arene was accomplished in
quantitative yield using the mild electrophilic bromine source N ,N’-
dibromodimethylhydantoin (DBDMH) to generate bromoarene 765.20  At this point, the
catechol moiety was protected with diiodomethane using KF as a base, producing
methylenedioxy arene 618 in 64% yield.  In the final two steps of the sequence, the
methyl ester was fully reduced with diisobutyl aluminum hydride (DIBAL) to the
primary alcohol, which was subsequently acylated with diketene to give the desired "-
ketoester (762).  Using this optimized procedure, we have been able to carry out this
process on 25-gram scale to generate large quantities of "-ketoester 762 for acyl-
alkylation studies.
Scheme 3.6. Synthesis of "-ketoester 762 from methyl gallate (763).
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In order to test the viability of "-ketoester 762 in the aryne insertion reaction, we
examined a model acyl-alkylation reaction using an unfunctionalized benzyne precursor
(209) (Scheme 3.7).  To our delight, reaction of "-ketoester 762 with aryne precursor 209
in the presence of KF and 18-crown-6 led to formation of aryne insertion product 766 in
56% yield (unoptimized).  It is worth noting that the use of KF and 18-crown-6 as the
fluoride source significantly suppressed the formation of the !-arylation side product
(767) in this reaction.  Additionally, we found that lower temperatures were required
since rapid decomposition of "-ketoester 762 was observed at elevated and room
temperatures under the reaction conditions.
Scheme 3.7. Acyl-alkylation of "-ketoester 762 with silyl aryl triflate 209.
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With "-ketoester 762 in hand, we turned our attention to preparation of silyl aryl
triflate 604 by a route divergent from the synthesis of "-ketoester 762 (Scheme 3.8).  In
this way, we can exploit the similar substitution patterns on the aromatic rings of the
integrastatins to derive both silyl aryl triflate 604 and "-ketoester 762 from benzyl
alcohol 721. Beginning with benzyl alcohol 721, oxidation with Dess–Martin periodinane
resulted in aldehyde 619.  Subsequent Baeyer–Villiger oxidation of the aldehyde
followed by basic methanolysis generated bromophenol 620, which was then converted
to silyl aryl triflate 604 by a known procedure.21
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Scheme 3.8. Preparation of silyl aryl triflate 604 from benzyl alcohol 721.
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Prior to investigating the acyl-alkylation of silyl aryl triflate 604 with "-ketoester
762, simpler "-ketoester substrates were examined.  We first attempted to demonstrate its
ability to participate in a model acyl-alkylation with ethyl acetoacetate (222) under
standard conditions using CsF in MeCN at 80 °C (Table 3.1, entry 1).  As has been
shown previously in related systems, the acyl-alkylation proceeded regioselectively to
give a single isomer (628).2  However, the low isolated yield of 628 prompted us to
examine alternative fluoride sources and solvents for this transformation.  When using
KF/18-crown-6 in THF at room temperature, the only observed product was THF ring-
opened enol ether 768 (R1,R2 = H, entry 2).  Attempts to circumvent this pathway by
using 2-Me-THF were also complicated by ring-opened products 768 (R1 = H, R2 = Me
and R1=Me, R2 = H, entry 3).  In general, arynes derived from silyl aryl triflates
possessing high degrees of oxygenation appear to have a higher propensity for reaction
with THF and its substituted variants.  In an effort to circumvent this difficulty, we turned
our attention to acyclic ethereal solvents that might be less likely to add to the reactive
aryne bond (entries 4–7).  After much optimization, we found that KF/18-crown-6 in tert-
butyl methyl ether (TBME) produced the corresponding acyl-alkylation product (628) in
the best yield and without any ether addition side products (entry 6).
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Table 3.1. Acyl-alkylation reactions of silyl aryl triflate 604 and ethyl acetoacetate (222).
OTfMeO
TMSO
O
604
OEt
O O
conditions
MeO
O
O
628
O
CO2Et
+
OMeO
O
O
768 (tentative assignment)
O
OEtO
Fluoride Sourcea Solventb Temperature Yield 628 Yield 768c
R1
R2
KF/18-crown-6
CsF
KF/18-crown-6
KF/18-crown-6
KF/18-crown-6
KF/18-crown-6
KF/18-crown-6
MeCN
THF
2-Me-THF
DME
TBME
TBME
TBME
80 °C
23 °C
23 °C
23 °C
23 °C
23 °C
40 °C
18%
–
–
–
36%
45%d
45%e
–
>60%
(R1, R2 = H)
28%
(R1 = H, R2 = Me)
2%
(R1=Me, R2 = H)
–
–
–
–
222 (1 equiv)
a All reactions run with 3.0 equiv of indicated fluoride source and 1.25 equiv 604. b All reactions run 0.1 M 604 in
indicated solvent.  c Isolated as a single unassigned enol ether isomer. d Reaction run with 2.0 equiv 604. e Reaction 
run with 3.0 equiv 604.
Entry
1
2
3
4
5
6
7
Despite the success of these model reactions, acyl-alkylations of silyl aryl triflate
604 with "-ketoester 762 proved to be a significant challenge (Table 3.2).  We were faced
initially with the prospect of reconciling the high temperatures required for efficient
reaction of silyl aryl triflate 604 with the low reaction temperatures required to prevent
decomposition of "-ketoester 762 under the reaction conditions.  In all cases, KF and 18-
crown-6 served as the fluoride source while the solvent and reaction temperature were
varied.  In THF at 0 °C (entry 1), decomposition of "-ketoester 762 was not an issue;
however, ring-opening of the solvent was problematic.  Control experiments showed that
"-ketoester 762 was stable to the fluoride source in TBME over a range of temperatures
up to 50 °C.  However, reactions with silyl aryl triflate 604 in TBME at 0 °C, 23 °C, and
40 °C showed no consumption of "-ketoester 762 (entries 2–4).  Similar results were seen
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with Et2O as solvent (entry 5).  Ultimately, only traces of the desired acyl-alkylation
product (761) of silyl aryl triflate 604 and "-ketoester 762 were ever observed.
Table 3.2.  Attempted acyl-alkylations of silyl aryl triflate 604 with "-ketoester 762.
OTf
OMe
TMS
O
O
604
Solventb Temperature
THF
TBME
TBME
TBME
0 °C
23 °C
0 °C
23 °C
40 °C
a All reactions run with 3.0 equiv each of KF and 18-
crown-6 and 1.25 equiv 604. b All reactions run 0.1 M 
604 in indicated solvent.
Entrya
1
5
2
3
4
KF, 18-crown-6
solvent
temperature
MeO
BrO
O
O
O O
762
O
MeO
BrO
O
761
O
O
Et2O
O
O
OMe
Although ketoester 761 was not available by direct acyl-alkylation of silyl aryl
triflate 604 with "-ketoester 762, we did have an alternative route by which to access this
key intermediate.  Saponification of ketoester 628, resulting from reaction of silyl aryl
triflate 604 with ethylacetoacetate (222), followed by coupling to benzyl alcohol 721
would generate acyl-alkylation product 761 (Scheme 3.9).
Scheme 3.9. Alternative synthesis of acyl-alkylation product 761.
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Saponification and coupling were initially investigated on ketoester 572 in order
to conserve material.  The saponification of acyl-alkylation products, such as ketoester
572, was somewhat problematic initially due to the propensity of these substrates to
undergo Dieckmann cyclizations under basic conditions.  Most standard bases for this
transformation, including carbonates and many hydroxides, failed to produce carboxylic
acid 770.  Following an extensive screen of mild conditions for saponification, we found
that Ba(OH)2•8H2O in methanol produced the corresponding carboxylic acid (770) in
almost quantitative yield (Scheme 3.10).
Scheme 3.10. Mild saponification of acyl-alkylation product 572.
572
O
CO2Me
770
O
CO2HBa(OH)2•8H2O
MeOH
(96% yield)
A number of conditions were examined for coupling of carboxylic acid 770 with
benzyl alcohol 721 including acid chloride couplings, Mitsunobu reactions, and standard
peptide coupling conditions (Table 3.3).  Ultimately, the best results were obtained by
treatment of benzylic alcohol 721 with DIAD and PPh3 followed by addition of the
carboxylic acid nucleophile (770) to provide ester 771 in a modest 30% yield (entry 4).
Unfortunately this success did not translate to preparation of acyl-alkylation product 761
containing the fully elaborated aromatic rings.  In fact, even saponification of ketoester
628 was unsuccessful with our optimized conditions.
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Table 3.3. Attempted couplings of carboxylic acid 770 and benzyl alcohol 721.
770
O
CO2H
721
MeO
BrO
O
OH
O
MeO
BrO
O
771
O
O
conditions
conditions resultentry
1
2
3
4
5
6
acid 770 + SOCl2 in CH2Cl2
then alcohol 721, 40 °C
—
acid 770 + SOCl2 and DMF in CH2Cl2
then alcohol 721
< 5%
acid 770 + (COCl)2 and DMF in CH2Cl2
then alcohol 721, 40 °C
< 5%
alcohol 721 + DIAD and PPh3 in THF
then acid 770, 65 °C
30%
EDC and DMAP in DMF < 5%
acid 770 + isobutyl chloroformate and
N-methyl morpholine in CH2Cl2
then alcohol 721
< 5%
Concurrent with our efforts to construct ketoester 761, we investigated the
proposed anionic ortho-Fries-type rearrangement in the context of a simpler model
system lacking the extensive aromatic functionalization (Scheme 3.11).  Beginning with
2-bromobenzaldehyde (772), reduction with sodium borohydride followed by acylation
with the diketene acetone adduct (774) provided model "-ketoester 775 in excellent yield.
Compared to "-ketoester 762, this model compound (775) exhibits excellent stability
over a wide temperature range in the presence of various fluoride sources.  Upon
treatment of the model "-ketoester (775) with the parent silyl aryl triflate (209) in the
presence of KF and 18-crown-6, acyl-alkylation product 776 was formed in 67% yield.
Acetalization of acyl-alkylation product 776 with ethylene glycol was inconsistent and
often resulted in variable yield of acetal 777.  While acetal 777 could be rapidly accessed
in good quantities, all attempts to effect the anionic ortho-Fries-type rearrangement under
lithium-halogen exchange conditions failed to produce the desired product (778).  In most
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cases, reactions either returned starting material or butylated side products (when n-BuLi
was used).
Scheme 3.11. Attempted model anionic ortho-Fries-type rearrangement.
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Given the complex difficulties encountered during our investigations into this
strategy toward integrastatins A and B, at this juncture we elected to pursue an alternative
route toward the natural products.  Importantly, this new strategy would make use of
many of the valuable intermediates that had already been prepared, some in significant
quantity.  Furthermore, in devising an alternative approach to the integrastatins, we
sought to shorten the synthesis as well.
3.3 AN OXIDATIVE CYCLIZATION APPROACH TO INTEGRASTATINS A AND B
3.3.1 Strategy and Retrosynthesis
In redesigning our approach to the integrastatins, we again focused our attention
on a key !-hydroxyketone intermediate bearing two fully functionalized aromatic rings
(758) (Scheme 3.12).  Given the difficulty experienced in accessing this structure by an
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anionic ortho-Fries-type rearrangement, we sought to access intermediates such as these
in a more direct manner.  Furthermore, in an effort to minimize protecting group
manipulation, we opted to mask the protected acetophenone moiety as an olefin.  With
this modification to !-hydroxyketone 758, the central [3.3.1]-dioxabicycle could be
installed in the late stages of the synthesis by a palladium(II)-catalyzed oxidative
cyclization of the !-hydroxyl group onto the olefin followed by ketalization with the
pendant phenol.  Cyclizations of this type to form bicyclic acetal structures are
precedented in the literature.22  In a final simplification of !-hydroxyketone 758, the
oxidation at C(9) was removed, leading to tertiary alcohol 779 as our key synthetic target.
Importantly, this approach would make use of several intermediates already prepared for
the acyl-alkylation studies.
Scheme 3.12.  Wacker cyclization approach to integrastatins A and B.
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3.3.2  Model System Wacker Cyclization Study23
Before exploring this strategy in the fully elaborated system, we turned to a model
system to test its feasibility.  Toward this end, we disconnected the tetracyclic core of the
integrastatins along the two C–O acetal bonds of the central [3.3.1]-dioxabicycle and
removed the oxidation at C(9), leading back to diol 782 (Scheme 3.13).  Diol 782 could
be prepared in turn from two aromatic fragments (783 and 784) of similar complexity by
a Grignard addition.
Scheme 3.13.  Retrosynthetic analysis of tetracycle 746.
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cyclization
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HO
Grignard
addition782
O
OTBS
Br
783 784
In the forward sense, we began with the synthesis of benzyl bromide 783 from
commercially available 2-carboxybenzaldehyde (785) (Scheme 3.14).  Wittig olefination
of benzaldehyde 785 produced styrene 786,24 which was subsequently reduced to the
primary benzyl alcohol (788) through an intermediate mixed anhydride (787).25,26
Moving forward, a number of conditions were examined for the conversion of primary
alcohol 788 to the benzyl bromide (784); ultimately we found that use of NBS with
triphenylphosphine accomplished the transformation in high yield.  With benzyl bromide
784 in hand, ketone 783 was prepared in one step from commercially available 2-
hydroxyacetophenone (737) by protection of the phenol as a silyl ether (Scheme 3.15).27
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Scheme 3.14.  Preparation of benzyl bromide 784.
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Scheme 3.15. Preparation of ketone 783.
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(94% yield)
We next turned our attention toward coupling of benzyl bromide 784 with ketone
783 and construction of an appropriate Wacker cyclization substrate.  To this end,
Grignard addition of the organomagnesium reagent derived from benzyl bromide 784
into ketone 783 furnished tertiary alcohol 789, which was subsequently desilylated under
standard conditions to yield diol 782 (Scheme 3.16).  Treatment of diol 782 with catalytic
quantities of PdCl2 and CuCl2 under an oxygen atmosphere resulted in cyclization of both
the phenol and tertiary alcohol of diol 782 onto the styrenyl olefin to generate the [3.3.1]-
dioxabicycle central to the integrastatin core (745).28  This key cyclization reaction likely
proceeds first through palladium-catalyzed formation of a 6-membered ring enol ether
(790).  At this point, the pendant phenol can cyclize onto the enol ether, furnishing the
ketal moiety.  Importantly, Taylor and co-workers have shown that tetracycle 745 can
undergo benzyl oxidation when treated with PDC, Celite, and t-BuOOH to produce
benzyl ketone 746 in good yield.17a
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Scheme 3.16.  Coupling of benzyl bromide 784 and ketone 783 and completion of the integrastatin
core.
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3.3.3  Attempted Synthesis of Tertiary Alcohol 779: Alkali and Transition Metal
Coupling Strategies
With this key proof of principle result, we focused our efforts on preparation of
appropriately functionalized ketone and benzyl bromide fragments (Scheme 3.17a).  In a
departure from the acyl-alkylation route, the two catechol units must be differentially
protected to allow for selective cleavage of the protecting group on the western catechol
(791, R " CH2) over that of the eastern catechol.  We anticipated that revealing both
catechols simultaneously prior to oxidative cyclization would result in preferential
benzofuran formation with the proximal hydroxyl group (795 !  797) instead of the
desired 6-membered ring formation and ketalization (795 !  796) (Scheme 3.17b).29
However, due to the ease of preparing large quantities of protected catechol 618 (i.e.,
793, R = CH2), the synthesis of a suitable ketone partner (i.e., 792, R = CH2) was
investigated on this compound.  As such, we first sought to convert intermediate
bromoarene 793 (R = CH2) into acetophenone 792 (R = CH2).
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Scheme 3.17.  Synthetic strategy for the Wacker cyclization route.
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 Initially, we targeted acetophenone 801 by a strategy involving reduction and
protection of the ester (618), Stille coupling of a vinyl stannane, and Wacker oxidation.
Benzoate 618 was readily reduced by DIBAL to the primary alcohol (721), which was
subsequently protected as the silyl ether (798) (Scheme 3.18).  To our surprise though we
were unable to install the vinyl group on this compound by a number of palladium-
catalyzed methods, including Stille and Suzuki couplings.  We postulated that the
extreme electron-rich nature of these compounds, in combination with the dual ortho
substitution to the bromide, prevent oxidative addition even under very forcing
conditions.  To circumvent this problem, cross-coupling of tributyl(vinyl)stannane was
performed on benzoate 618 to yield styrene 800, which was subsequently reduced and
protected as the silyl ether (799).  However, to our disappointment, we were unable to
convert this intermediate to the acetophenone under a variety of Wacker oxidation
conditions.28b Furthermore, attempts to install the benzylic oxidation by rhodium-
catalyzed hydroboration methods also failed.30
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Scheme 3.18.  Attempted synthesis of acetophenone 801 by oxidation of styrene 799.
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Given the success of the Stille coupling of tributyl(vinyl)stannane to benzoate
618, we investigated a sequence involving iso-propenylation and oxidative olefin
cleavage to generate acetophenone 804 (Scheme 3.19).  Under highly optimized
conditions, palladium-catalyzed Suzuki coupling of iso-propenyl boronic ester31 with
benzoate 618 yielded !-methylstyrene 802, which was then reduced and protected as the
silyl ether (803).  All attempts to produce the ketone by ozonolysis of !-methylstyrene
803 resulted only in complete decomposition of the electron rich substrate.  However,
oxidative olefin cleavage with catalytic OsO4, 2,6-lutidine, and NaIO4 yielded
acetophenone 804 in 42% yield.  Simply switching the base from 2,6-lutidine to DABCO
increased the yield of acetophenone 804 to 82%.
Scheme 3.19.  Preparation of acetophenone 804 by oxidative olefin cleavage.
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With acetophenone 804 in hand, we sought to test its viability in a Grignard
reaction with benzyl bromide 784 as a model system.  To our delight, smooth addition of
the organomagnesium reagent derived from bromide 784 to acetophenone 804 generated
tertiary alcohol 805 in 81% yield (Scheme 3.20).
Scheme 3.20.  Grignard coupling of benzylic bromide 784 with acetophenone 804.
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Encouraged by this promising result, we turned next to preparation of a
differentially protected ketone (811) and the fully functionalized benzyl bromide (813).
In place of the formaldehyde acetal protecting the catechol of acetophenone 804 we opted
to install a more acid labile orthoester functionality.  However, due to difficulty with the
Suzuki coupling in the presence of an orthoester,32 early intermediates en route to
acetophenone 811 required TBS protective groups (Scheme 3.21).  Treatment of catechol
765 with TBSCl generated protected catechol 806, which underwent facile Suzuki
coupling to yield !-methyl styrene 807.  Reduction of the ester and protection of the
resultant benzyl alcohol as the methoxymethyl ether (808) was followed by removal of
the TBS protective groups and reaction of the resulting catechol with triethylorthoformate
in the presence of an acidic resin to produce orthoester 810 in moderate yield.33  Finally,
oxidative olefin cleavage using the conditions developed on the model system furnished
the desired acetophenone (811).
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Scheme 3.21.  Synthesis of acetophenone 811 featuring an acid-labile orthoester.
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Synthesis of the fully functionalized benzyl bromide (813) was readily
accomplished by with reduction of Stille coupling product 800 and subsequent
bromination with NBS and PPh3 (Scheme 3.22).  Although benzyl bromide 813 could be
generated in moderate yield, it was somewhat unstable and underwent decomposition
within a period of one day at room temperature.  As an alternative, benzyl chloride 814
could be prepared by treatment of the corresponding alcohol (812) with mesyl chloride,
lithium chloride, and triethylamine in THF.  Both the benzyl bromide (813) and chloride
(814) were investigated as coupling partners for acetophenone 811.
Scheme 3.22.  Synthesis of benzyl bromide 813 and benzyl chloride 814.
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First attempts to couple the benzyl halides (813 and 814) with acetophenone 811
focused on standard Grignard reaction conditions.  Treatment of either benzyl bromide
813 or chloride 814 with Mg(0) in ethereal solvents led to rapid and exclusive formation
of dimer 815, with no traces of the desired addition product (816) (Scheme 3.23).
Furthermore, all attempts to preclude this side reactivity by slow addition or temperature
control failed to produce anything but dimer 815.  Efforts to effect a lithium-halogen
exchange on benzyl chloride 814 using inverse addition techniques at –100 °C with t-
BuLi resulted only in several unidentified t-butylated products.  We reasoned that the
highly electron rich nature of benzyl chloride 814 and bromide 813 is likely responsible
for the difficulties in effecting metal-halogen exchanges on these compounds.
Scheme 3.23.  Attempted Grignard addition reactions with benzyl halides 813 and 814 into
acetophenone 811.
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Throughout the course of our investigations into metallation of benzyl halides 813
and 814, only one method ever resulted in effective formation of a benzyl organometallic
reagent.  Treatment of benzyl chloride 814 with ZnCl2, LiCl, and Mg(0) under conditions
developed by Knochel34 led exclusively to formation of the organozinc reagent with no
noticeable dimer (Scheme 3.24).  However, attempts to add this species into
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acetophenone 811 failed to produce any product, presumably because the ketone is not
electrophilic enough for the less nucleophilic organozinc reagent.
Scheme 3.24.  Successful formation of the oganozinc reagent of benzyl chloride 814 according to
Knochel conditions.
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In an effort to take advantage of the success of organozinc reagent formation, we
prepared the corresponding aldehyde (822) instead of the less electrophilic ketone (811)
(Scheme 3.25).  Stille coupling of a vinyl stannane with orthoester 818, was followed by
reduction of the ester (819) and protection of the benzyl alcohol as a methoxymethyl
ether (821).  Finally, oxidative olefin cleavage furnished the desired aldehyde coupling
partner (822).  Unfortunately, all efforts to couple aldehyde 822 with the organozinc
reagent (814) failed to produce any tractable products.
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Scheme 3.25.  Synthesis of aldehyde 822 and attempted organozinc reagent coupling.
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In considering the difficulties experienced trying to functionalize benzyl halides
813 and 814, we recognized that these structures also possess the ability to directly
eliminate their respective halides to generate a para-quinonemethide structure (e.g., 824)
(Scheme 3.26).  While this elimination pathway was likely contributing to the instability
of halides 813 and 814 and hindering our efforts at coupling them to aldehydes and
ketones, we considered the potential to take advantage of the ease of this process in an
umpolung fashion in which aldehyde 822 serves as a nucleophile and adds into a para-
quinonemethide (824) derived from benzyl chloride 814.  To accomplish this, we turned
to thiazolium catalysts such as 827, which, upon deprotonation by an amine base, form
N-heterocyclic carbenes.  Upon reaction with aldehydes, these carbenes catalyze the
formation of an acyl anion (829), which have been previously utilized for additions to a
range of electrophiles, including enones (830).35
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Scheme 3.26.  Stetter reaction strategy for coupling of benzyl chloride 814 and aldehyde 822.
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In our initial attempt to couple aldehyde 822 and benzyl chloride 814 by a Stetter
reaction with thiazolium catalyst 827 with ethanol as solvent, only ethyl ether 833 was
isolated from the reaction (Scheme 3.27a).  No traces of coupled products were observed.
To avoid reaction with the ethanol, the solvent was changed to dioxane; however, under
these conditions, rapid decomposition of benzyl chloride 814 was not accompanied by
consumption of aldehyde 822.  As an alternative to thiazolium catalysts, acyl anion
generation from the cyanohydrin of aldehyde 822 was investigated (Scheme 3.27b).36
Unfortunately, this method too yielded none of the desired ketone product (835).
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Scheme 3.27.  Attempted acyl anion couplings of aldehyde 822 and benzyl chloride 814.
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At this juncture, we recognized the significant difficulties in forming the
C(8)–C(9) bond of the integrastatins due to a variety of steric and electronic difficulties.
As such, we considered disconnecting tertiary alcohol 816 in a somewhat different
fashion, instead targeting enone 836 by the coupling of !-bromostyrene (837) and
Weinreb amide (838) (Scheme 3.28).  Enone 836 appeared to be an intermediate that
could be converted readily to !-hydroxyketone 816 by a number of different methods,
including a hydrosilylation/Rubottom oxidation sequence.
Scheme 3.28.  Revised strategy to tertiary alcohol 816 via enone 836.
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Weinreb amide 838 was readily accessed in one synthetic step from styrene 800,
an intermediate en route to benzyl halides 813 and 814 (Scheme 3.29).37  The synthesis of
!-bromostyrene 837 was investigated on a model system bearing the formaldehyde acetal
on the catechol (800) (Scheme 3.30).  Beginning again with styrene 800, bromination
with Br2 yielded vicinal dibromide 839, which was subsequently treated with DBU to
effect the elimination of the "-bromide.  Among literature reports for this elimination, all
examples give exclusively the !-bromostyrene product (841).38  However, it was clear to
us that treatment of dibromide 839 with DBU produced exclusively the "-bromostyrene
(840).  We reasoned that the presence of ortho- and para-alkoxy groups significantly
increases the lability of the !-bromide, resulting in more facile elimination of this
bromide over the "-bromide.
Scheme 3.29.  Synthesis of Weinreb amide 838.
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Scheme 3.30.  Selectivity issues in the attempted synthesis of !-bromostyrene 841.
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To circumvent this selectivity issue, we reasoned that it might be easier to access
!-bromostyrene 841 from acetylene 843 by an acidic bromination (Scheme 3.31).  This
method would take advantage of the stability of a carbocation at the !-styrenyl position,
giving good selectivity for the desired !-bromostyrene.  On a model system to test this
concept, Sonogashira coupling of aryl bromide 618 with TIPS acetylene produced the
corresponding aryl alkyne (842) in moderate yield.  Interestingly, when using PPh3 as the
ligand, no reaction was ever observed even at elevated temperatures; product was only
obtained using the more electron-rich P(t-Bu)3 as the ligand for palladium.  Aryl alkyne
842 was next desilylated with TBAF, yielding the terminal alkyne (843) in preparation
for bromination.  To our delight, treatment of terminal alkyne 843 with anhydrous HBr in
acetic acid produced the desired !-bromostyrene (841) in excellent yield.39  Furthermore,
following reduction of the ester and protection of the resulting primary alcohol,
!-bromostyrene 844 could be effectively coupled to Weinreb amide 838 to furnish enone
845 in very good yield.  This marked the first time that both fully functionalized aromatic
rings of integrastatin had been incorporated into a synthetic intermediate.
Scheme 3.31.  Synthesis of !-bromostyrene 844 and successful coupling with Weinreb amide 838.
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Encouraged by this key result, we turned our attention to the synthesis of an
!-bromostyrene with a more labile protective group masking the catechol functionality,
such as an orthoester.  Beginning with orthoester 818, an intermediate used en route to
aldehyde 822, Sonogashira coupling to install the TIPS acetylene proceeded in low yield
to give aryl alkyne 846, which was subsequently desilylated to give terminal alkyne 847
(Scheme 3.32).  Unfortunately, though, under the acidic bromination conditions,
orthoester cleavage was rapid.  This forced us to investigate alternative protective groups
for the catechol that would remain intact when treated with acetic acid and HBr at room
temperature.
Scheme 3.32.  Attempted synthesis of !-bromostyrene 848, with an orthoester protective group.
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Eventually, we focused our efforts on a diphenyl acetal protective group for the
catechol.  The diphenyl acetal was installed by treatment of catechol 765 with
acetophenone dimethyl acetal and p-TsOH•H2O in refluxing toluene to provide diphenyl
acetal 849, albeit in quite low yields (Scheme 3.33).  A number of different conditions to
effect this transformation were investigated, with none offering any improvement over
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standard conditions.  Furthermore, the Sonogashira coupling of TIPS acetylene with
diphenyl acetal 849  was plagued by variable yields and poor conversion, often
accompanied by palladium black formation.  Fortuitously, we found that use of a Negishi
coupling with the zinc reagent of TIPS acetylene remedied this problem and led to very
good yields of aryl alkyne 850.40  Following desilylation of aryl alkyne 850, bromination
under our optimized conditions cleanly produced the desired !-bromostyrene (852) in
excellent yield.  The synthesis of the fully elaborated coupling partner (853) was then
achieved by simple DIBAL reduction of the ester and protection of the resultant alcohol
as a methoxymethyl ether.
Scheme 3.33.  Synthesis of !-bromostyrene 853, bearing a diphenyl acetal.
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With !-bromostyrene 853 in hand, we were eager to test the key coupling
reaction.  Upon inverse addition of !-bromostyrene 853 to a cooled THF solution of t-
BuLi, the color of the solution turned a deep red, indicating formation of the lithiated
species (Scheme 3.34).  Furthermore, TLC analysis showed complete consumption of !-
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bromostyrene 853.  This behavior was identical to that observed in the model system
coupling between !-bromostyrene 844 and this same Weinreb amide (838) (i.e., Scheme
3.31).  However, unlike in the model system, no consumption of Weinreb amide (838)
was ever observed upon its addition to the solution of lithiated !-bromostyrene 853 over
a range of temperatures.  We reasoned that the bulky phenyl substituents on the
neighboring acetal significantly hindered the addition of lithiated !-bromostyrene 853
into Weinreb amide 838, prohibiting coupling of these two components.
Scheme 3.34.  Attempted coupling of !-bromostyrene 853 and Weinreb amide 838.
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This result was consistent with a pattern throughout our studies toward the
integrastatins, in which we routinely found that modifying our substrates in any subtle
way usually significantly altered the reactivity of these species.  Often, steric and
electronic factors were to blame for these differences in reactivity.  As such, we were
never able to access an intermediate that could be selectively deprotected to allow
investigation of the proposed palladium-catalyzed Wacker cyclization.
While we never were able to test the key oxidative cyclization, enone
functionalization to install the tertiary alcohol of !-hydroxyketone 857 was briefly
examined on model system enone 845 (Scheme 3.35).  From attempts at hydrosilylation
as well as L-Selectride and Stryker’s reagent 1,4-reductions, it appears that enone 845
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does not exhibit typical enone reactivity.  In fact, 1,4-reduction of any type was never
observed in these reactions.  This is likely due to a conformational preference for enone
845 in which the olefin and ketone moieties are oriented perpendicularly to one another,
disrupting the conjugation required for 1,4-reduction of the system.  These results cast
further doubt on the feasibility of this strategy for accessing a suitable oxidative
cyclization precursor.
Scheme 3.35.  Attempted functionalization of enone 845.
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At this point, it appears that a new strategy aimed at the synthesis of ! -
hydroxyketone 858 is necessary to circumvent the difficulties encountered in preparing a
suitably protected enone (i.e., 845), as well as the challenges of converting such an enone
to the !-hydroxyketone (Scheme 3.36).  Upon synthesis of a suitably protected !-
hydroxyketone, we anticipate that integastatin A (728) will be completed in short order
by a sequence involving selective protective group cleavage, palladium-catalyzed
oxidative cyclization, and global deprotection.  Furthermore, integrastatin B (729) will
then be obtained by selective oxidation of integrastatin A (728).
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Scheme 3.36.  Proposed completion of integrastatins A and B (728 and 729) from !-hydroxyketone
858.
MeO O
RO
858
MOMO
O
OMe
O
OHO selective deprotection
oxidative cyclization
global deprotection O
O
O
MeO
OH
OMe
HO
OH
OH
Integrastatin A (728)
O
O
O
MeO
OH
OMe
O
OH
OH
Integrastatin B (729)
H
oxidation
3.4 CONCLUDING REMARKS
In designing our various approaches to the integrastatin natural products, we
always sought to limit the amount of late-stage aromatic functionalization required while
maintaining a high level of convergency.  In this way, even though we moved on from
the acyl-alkylation approach, we have drawn from the core strategic advantages of aryne-
based methods in the total synthesis of natural products.  While we were able to achieve
the synthesis of enone 845, a molecule containing all the carbon atoms comprising the
integrastatins, we were unable to recognize our goal of converting this intermediate to the
tetracyclic core of the natural products.  Given the success of the model system Wacker
oxidative cyclization to produce the [3.3.1]-dioxabicyclic core of the integrastatins, we
are confident that upon synthesis of an appropriately protected version of ! -
hydroxyketone 858, the natural products will be accessible by this route. 
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3.5  EXPERIMENTAL SECTION
3.5.1 Materials and Methods
Unless stated otherwise, reactions were performed in flame-dried glassware under
an argon or nitrogen atmosphere using dry, deoxygenated solvents (distilled or passed
over a column of activated alumina).  Commercially obtained reagents were used as
received.  Reaction temperatures were controlled by an IKAmag temperature modulator.
Thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 F254
precoated plates (0.25 mm) and visualized by UV fluorescence quenching, potassium
permanganate, or CAM staining.  SiliaFlash P60 Academic Silica gel (particle size
0.040-0.063 mm) was used for flash chromatography.  1H and 13C NMR spectra were
recorded on a Varian 500 (at 500 MHz and 125 MHz, respectively) and are reported
relative to Me4Si (# 0.0).  Data for 1H NMR spectra are reported as follows: chemical
shift (# ppm) (multiplicity, coupling constant (Hz), integration).  Data for 13C spectra are
reported in terms of chemical shift relative to Me4Si (# 0.0).  IR spectra were recorded on
a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption
(cm–1). HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A
Multimode source in electrospray ionization (ESI), atmospheric pressure chemical
ionization (APCI) or mixed (MM) ionization mode.
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 348
3.5.2 Preprative Procedures and Spectroscopic Data
O
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DIBAL
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(90% yield)
O
O
Br
OMe
OH
618 721
Benzyl alcohol 721
A solution of methyl ester 618 (3.0 g, 10.4 mmol) in CH2Cl2 (100 mL) was
prepared and cooled to –78 °C.  Diisobutylaluminum hydride (DIBAL, 4.1 mL, 22.8
mmol) was added dropwise and the reaction was maintained at –78 °C until methyl ester
618 was consumed by TLC analysis.  The reaction was quenched at –78 °C by the
addition of saturated aqueous sodium potassium tartrate solution (25 mL) and then
warmed to room temperature.  The reaction was diluted with H2O (25 mL) and extracted
with CH2Cl2 (3 x 25 mL).  The combined organic extracts were dried with MgSO4,
concentrated under vacuum, and purified by flash chromatography (3:1 hexanes:ethyl
acetate eluent) to yield benzylic alcohol 721 (2.6 g, 96% yield): R f = 0.33 (3:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.70 (s, 1H), 6.05 (s, 2H), 4.66 (d,
J = 5.8 Hz, 2H), 3.90 (s, 3H), 1.99 (t, J = 6.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) #
147.00, 142.90, 135.00, 133.49, 108.42, 101.94, 93.34, 64.47, 56.75; IR (NaCl/film)
3187, 2904, 1628, 1486, 1465, 1446, 1343, 1165, 1106, 1038, 968, 931, 824, 701 cm–1;
HRMS (MM: ESI-APCI) m/z calc’d for C9H8O379Br [M–OH]+: 242.9651, found
242.9648; m/z calc’d for C9H8O381Br [M–OH]+: 244.9632, found 244.9629.
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To a solution of benzylic alcohol 721 (33.3 mg, 0.128 mmol) in THF (0.65 mL)
were added DMAP (1.6 mg, 0.013 mmol) and diketene (20 µL, 0.255 mmol).  The
reaction was maintained with stirring at room temperature until benzylic alcohol 721 was
consumed by TLC analysis.  Following this time, the reaction was diluted with diethyl
ether (25 mL) and washed with water (10 mL) and brine (10 mL).  The organic phase was
dried with Na2SO4, concentrated under vacuum, and purified by flash chromatography
(2:1 hexanes:ethyl acetate eluent) to yield "-ketoester 762 (36.3 mg, 83% yield) as a
mixture of keto and enol tautomers (4.5:1 ratio by 1H NMR): Rf = 0.21 (3:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) # 11.96 (s, 0.22H), 6.68 (s, 1H), 6.65 (2, 0.22H),
6.05 (s, 2H), 6.05 (s, 0.44H), 5.16 (s, 2H), 5.15 (s, 0.44H), 5.04 (s, 0.22H), 3.90 (s, 3H),
3.89 (s, 0.66H), 3.51 (s, 2H), 2.26 (s, 3H), 1.96 (s, 0.66H); 13C NMR (125 MHz, CDCl3)
# 200.27, 176.15, 172.04, 166.70, 147.19, 142.76, 142.70, 135.75, 135.62, 128.64,
128.04, 110.37, 110.25, 102.11, 102.05, 94.83, 94.76, 89.44, 66.10, 64.67, 56.85, 49.93,
30.26, 21.27; IR (NaCl/film) 2936, 1745, 1714, 1628, 1488, 1435, 1351, 1319, 1254,
1167, 1149, 1108, 1036, 963, 934, 837 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C9H8O379Br [M]•+: 242.9651, found 242.9645.
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Aldehyde 619
A solution of Dess–Martin periodinane (2.94 g, 6.92 mmol) in CH2Cl2 (28 mL)
was prepared under nitrogen.  Alcohol 721 (1.63 g, 6.24 mmol) in CH2Cl2 (72 mL) was
added and the reaction was maintained under nitrogen until alcohol 721 was fully
consumed by TLC analysis.  The reaction was quenched by the addition of a 1:1 v/v
solution of saturated aqueous NaHCO3 and saturated aqueous Na2S2O3 (60 mL total
volume). The reaction was extracted with CH2Cl2 (3 x 50 mL).  The combined organic
extracts were washed with water (50 mL) and brine (50 mL) and subsequently dried with
MgSO4, concentrated under vacuum, and purified by flash chromatography (hexanes $
7:3 hexanes:ethyl acetate eluent) to yield aldehyde 619 (1.34 g, 83% yield): Rf = 0.37 (3:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 10.14 (s, 1H), 7.24 (s, 1H), 6.16 (s,
2H), 3.92 (s, 3H); 13C NMR (125 MHz, CDCl3) # 189.5, 147.4, 143.5, 140.9, 127.6,
109.5, 103.0, 98.8, 56.8; IR (NaCl/film) 1683, 1619, 1485, 1446, 1351, 1315, 1169, 1112,
1048, 993, 928, 654 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C9H8O479Br [M+H]+:
258.96, found 258.9597; m/z calc’d for C9H8O481Br [M+H]+: 260.9581, found 260.9578.
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A flask was charged with aldehyde 619 (100 mg, 0.386 mmol) and KHCO3 (4 mg,
0.04 mmol) under a nitrogen atmosphere.  To this was added m-CPBA (20 mg, 0.116
mmol) as a solution in CH2Cl2 (4 mL).  Four additional portions of m-CPBA (20 mg,
0.116 mmol, each) were added as CH2Cl2 solutions (0.25 mL, each) at three-hour
intervals.  Nine hours following the final m-CPBA addition, the reaction was quenched
by the addition of saturated NaHCO3 aqueous solution (1 mL) and diluted with CH2Cl2
(25 mL).  The layers were separated and the aqueous layer was further washed with
CH2Cl2 (10 mL).  The combined organic layers were sequentially washed with water (10
mL), saturated aqueous NaHCO3 (2 x 10 mL), and brine (10 mL).  The resulting organic
layer was dried with MgSO4 and concentrated under vacuum to yield a crystalline solid.
The crude solid (103 mg) was taken up in a 10% (w/v) solution of K2CO3 in
methanol (7.5 mL).  The resultant suspension was maintained with stirring at room
temperature until the starting material had been completely consumed by TLC analysis.
Following this period, the reaction was concentrated under vacuum, diluted with water
(10 mL), and acidified to pH 1.5 with 6 N HCl.  Warning: vigorous gas evolution.  The
aqueous solution was extracted with ethyl acetate (2 x 25 mL).  The combined organic
layers were washed with brine (10 mL), dried with MgSO4, and concentrated under
vacuum.  The crude residue was purified by flash chromatography (5:1 hexanes:ethyl
acetate eluent) to yield bromophenol 620 (62 mg, 65% yield) as a white solid: Rf = 0.20
(3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.26 (s, 1H), 5.99 (s, 2H), 5.18
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(s, 1H), 3.86 (s, 3H); 13C NMR (125 MHz, CDCl3) # 148.42, 147.02, 143.93, 130.01,
102.37, 95.12, 83.45, 57.12, 57.10.; IR (NaCl/film) 3093, 2899, 1642, 1454, 1350, 1167,
1109, 1051, 971, 935, 874, 797, 700 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C8H7O479Br [M]+: 245.9522, found 245.9525; m/z calc’d for C8H7O481Br [M]+: 247.9502,
found 247.9506.
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HMDS, THF, 70 °C;
n-BuLi, then Tf2O
THF, –100 °C
(64% yield)
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Silyl aryl triflate 604
Bromophenol 620 (149.6 mg, 0.606 mmol) and hexamethyldisilazide (253 µL,
1.21 mmol) were combined in THF (1.2 mL).  The solution was heated to 70 °C and
maintained for 8 h.  The reaction was cooled to room temperature and concentrated under
vacuum.  The resulting oil was immediately taken on to the next step.
The crude residue was taken up in THF (8 mL) and cooled to –100 °C.  n-
Butyllithium (2.5 M in hexanes, 266 µL, 0.666 mmol) was added slowly and the reaction
was allowed to warm to –82 °C.  The reaction was cooled again to –100 °C and
maintained between –100 °C and –82 °C for 30 minutes.  After this period, triflic
anhydride (122 µL, 0.727 mmol) was added at –100 °C.  The reaction was warmed to –80
°C, quenched by the addition of saturated aqueous sodium bicarbonate solution (4 mL),
and subsequently warmed to room temperature.  The reaction was diluted with diethyl
ether (25 mL) and washed with water (15 mL) and brine (15 mL).  The organic layer was
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(50:1 petroleum ether:diethyl ether eluent) to yield silyl aryl triflate 604 (144.6 mg, 64%
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yield): Rf = 0.36 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.52 (s, 1H),
5.99 (s, 2H), 3.89 (s, 3H), 0.36 (s, 9H); 13C NMR (125 MHz, CDCl3) # 153.99, 148.40,
144.10, 133.88, 118.76 (q, J = 300.56 Hz), 107.02, 101.78, 101.32, 57.02, 0.23; 19F NMR
(282 MHz, CDCl3) # –73.07; IR (NaCl/film) 2058, 2901, 1645, 1487, 1419, 1388, 1294,
1244, 1211, 1140, 1111, 1046, 984, 893, 845, 802 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C12H15O6SiSF3 [M+H]+: 372.0311, found 372.0321.
O
O
TMS
OMe
OTf
604
OEt
O O
+
KF, 18-crown-6
MTBE, 40 °C
(45% yield)
O
O
OMe
628
O
CO2Et
222
Ketoester 628
To a solution of silyl aryl triflate 604 (23.8 mg, 0.0639 mmol) and ethyl
acetoacetate (222, 4.1 mL, 0.0320 mmol) in tert-butyl methyl ether (MTBE, 0.32 mL)
was added 18-crown-6 (25.3 mg, 0.0959 mmol) and KF (5.6 mg, 0.0959 mmol).  The
resulting suspension was heated in an oil bath to 40 °C and maintained for a period of 1
hour.  Following this time, the reaction was cooled to room temperature, diluted in
diethyl ether (25 mL), and washed with water (2 x 10 mL) and brine (10 mL).  The
organic layer was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (15:1 hexanes:ethyl acetate eluent) to yield ketoester 628 (4 mg, 45%
yield): Rf = 0.49 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.38 (s, 1H),
6.07 (s, 2H), 4.16 (q, J = 7.1 Hz, 2H), 3.94 (s, 3H), 3.81 (s, 2H), 2.55 (s, 3H), 1.28 (t, J =
7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 189.5, 147.4, 143.5, 140.9, 127.6, 109.5,
103.0, 98.8, 56.8; IR (NaCl/film) 2985, 2904, 1731, 1674, 1632, 1427, 1312, 1281, 1162,
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1100, 940, 854 cm–1; HRMS (MM:ESI-APCI) m/z calc’d for C14H16O6 [M+H]+:
281.1020, found 281.1020.
572
O
CO2Me
770
O
CO2HBa(OH)2•8H2O
MeOH
(96% yield)
Acid 770
To a solution of ketoester 572 (200 mg, 1.04 mmol) in methanol (5 mL) was
added Ba(OH)2•8H2O (460 mg, 1.46 mmol).  The resulting solution was maintained with
stirring at room temperature until complete by TLC analysis (about 12 hours).  The
reaction was diluted with diethyl ether (25 mL) and sequentially washed with 1 N HCl
solution (2 x 10 mL) and brine (10 mL).  The combined organic extracts were dried with
MgSO4 and concentrated under vacuum to yield acid 770 (179 mg, 96% yield): Rf = 0.15
(1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.84 (dd, J = 7.8, 1.2 Hz, 1H),
7.51 (ddd, J = 7.5, 7.5, 1.4 Hz, 1H), 7.42 (ddd, J = 7.6, 7.6, 1.3 Hz, 1H), 7.35 (dd, J = 7.6,
0.7 Hz, 1H), 3.91 (s, 2H), 2.65 (s, 2H); 13C NMR (125 MHz, CDCl3) # 202.93, 174.67,
136.92, 133.78, 132.77, 132.67, 130.17, 127.75, 40.74, 28.79; IR (NaCl/film) 3033, 2916,
1705, 1673, 1424, 1360, 1256, 1232, 930, 766 cm–1; HRMS (MM: ESI-APCI) m/z calc’d
for C10H11O3 [M+H]+: 179.0703, found 179.0709.
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775773
Br
OH
O O
O
774
PhMe, reflux
(95% yield)
Br
O
O O
"-Ketoester 775
To a solution of benzylic alcohol 773 (968 mg, 5.18 mmol) in toluene (21 mL)
was added diketene acetone adduct (774, 684 µL, 5.18 mmol)) via syringe.  The reaction
was equipped with a reflux condenser an heated to reflux.  After six hours at reflux, the
reaction was cooled to room temperature and concentrated under vacuum.  The crude
residue was purified by flash chromatography (5:1 hexanes:ethyl acetate eluent) to yield
"-ketoester 775 (1.33 g, 95% yield) as a mixture of keto and enol tautomers (6.5:1 ratio
by 1H NMR): Rf = 0.23 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 11.97
(s, 0.15H), 7.58 (ddd, J = 8.0, 3.5, 1.2 Hz, 1H), 7.55 (dd, J = 8.0, 1.1 Hz, 0.15H),
7.51–7.47 (m, 0.15H), 7.45–7.38 (m, 1.15H), 7.36–7.29 (m, 1.15H), 7.23–7.14 (m,
1.15H), 5.27 (s, 2H), 5.26 (s, 0.30H), 5.10 (s, 0.15H), 3.54 (s, 2H), 2.28 (s, 3H), 1.98 (s,
0.45H); 13C NMR (125 MHz, CDCl3) # 200.25, 176.21, 166.71, 139.74, 135.25, 134.57,
132.89, 132.81, 132.57, 130.18, 130.00, 129.66, 129.61, 129.09, 128.87, 127.64, 127.60,
127.51, 123.54, 123.21, 122.54, 89.43, 66.68, 65.14, 65.06, 62.98, 49.93, 30.23, 21.30;
IR (NaCl/film) 2929, 1744, 1717, 1570, 1474, 1441, 1408, 1359, 1314, 1255, 1147, 1027,
752 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H11O379Br [M–H]–: 268.9819, found
268.9842.
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775
Br
O
O O
TMS
OTf
209
KF, 18-crown-6
THF
(67% yield)
Br
O
O
776
O Br
O
O
777
O
O
HOCH2CH2OH
p-TsOH•H2O
PhH, reflux
(25–78% yield)
Acetal 777
Silyl aryl triflate 209 (280 µL, 1.15 mmol) and "-ketoester 775 (240 mg, 0.885
mmol) were combined in THF (9 mL).  To this solution were sequentially added 18-
crown-6 (700 mg, 2.66 mmol) and KF (154 mg, 2.66 mmol).  The resulting suspension
was maintained at room temperature with stirring until "-ketoester 775 was fully
consumed by TLC analysis.  Following this time, the reaction was diluted with diethyl
ether (25 mL) and washed with water (2 x 10 mL) and brine (10 mL).  The organic phase
was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (10:1 hexanes:ethyl acetate eluent) to yield ketoester 776 (182.5 mg,
59% yield).
Ketoester 776 (182.5 mg, 0.526 mmol) was taken up in benzene (5 mL).  To this
were added ethylene glycol (176 µL, 3.15 mmol) and p-TsOH•H2O (1 mg, 0.0053
mmol).  The reaction flask was equipped with a Dean–Stark trap (filled with benzene)
and reflux condenser and heated to reflux, where it was maintained for 24 hours.
Following this time, the reaction was cooled to room temperature, concentrated under
vacuum, and purified by flash chromatography (10:1 hexanes:ethyl acetate eluent) to
yield acetal 777 (52.2 mg, 25% yield): Rf = 0.30 (5:1 hexanes:ethyl acetate); 1H NMR
(500 MHz, CDCl3) # 7.60–7.55 (m, 2H), 7.41–7.37 (m, 1H), 7.32–7.21 (m, 4H), 7.18 (m,
1H), 5.24 (s, 2H), 3.97 (s, 2H), 3.92 (dt, J = 6.2, 4.2 Hz, 2H), 3.64 (dt, J = 6.1, 4.2 Hz,
2H), 1.67 (s, 3H); 13C NMR (125 MHz, CDCl3) # 171.76, 141.31, 135.47, 132.73, 132.58,
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131.31, 129.66, 129.51, 128.18, 127.40, 127.31, 126.39, 123.19, 109.06, 65.79, 64.19,
39.24, 27.57; IR (NaCl/film) 2986, 2890, 1740, 1473, 1442, 1374, 1333, 1240, 1199,
1152, 1034, 950, 869, 754 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C19H19O479Br
[M+H] +: 391.0539, found 391.0555.
784
OH NBS, PPh3
CH2Cl2
0 °C
(85% yield)
Br
788
Benzyl bromide 784
A solution of benzyl alcohol 788 (736 mg, 5.49 mmol) in CH2Cl2 (27 mL) was
cooled to 0 °C in an ice bath.  Triphenylphospine (1.67 g, 6.36 mmol) was added as a
solid in one portion and the resulting solution was maintained at 0 °C for 10 minutes with
stirring.  Following this period, N-bromosuccinimide (1.13 g, 6.36 mmol) was added
portion-wise as a solid over 5 minutes.  The reaction was then maintained with stirring at
0 °C for 20 minutes or until benzyl alcohol 788 was consumed by TLC analysis.  The
reaction was concentrated under vacuum and purified by flash chromatography (10:1
hexanes:ethyl acetate eluent) to yield benzyl bromide 784 (932 mg, 85% yield): Rf 0.56
(10:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) #  7.56–7.51 (m, 1H),
7.35–7.29 (m, 2H), 7.28–7.23 (m, 1H), 7.11 (dd, J = 17.3, 11.0 Hz, 1H), 5.76 (dd, J =
17.3, 1.2 Hz, 1H), 5.45 (dd, J = 11.0, 1.2 Hz, 1H), 4.58 (s, 2H); 13C NMR (125 MHz,
CDCl3) # 137.25, 134.56, 133.36, 130.23, 129.13, 128.11, 126.43, 117.08, 31.63; IR
(NaCl/film) 3066, 1847, 1627, 1569, 1486, 1453, 1416, 1223, 1210, 1184, 987, 917, 772,
758 cm–1; HRMS (EI+) m/z calc’d for C9H979Br [M]+: 195.9888, found 195.9897.
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Mg0
Et2O
(65% yield)
Br
784
O
OTBS
783
OTBS
789
HO
Tertiary alcohol 789
A flame-dried reaction flask was charged with Mg turnings (141 mg, 5.79 mmol).
The flask was evacuated and backfilled with nitrogen.  Diethy ether (5 mL) was added,
followed by 1,2-dibromoethane (20 µL).  The suspension was stirred for 15 minutes and
then concentrated under vacuum.  Next, benzyl bromide 784 (457 mg, 2.32 mmol) was
added as a solution in diethyl ether (23 mL), and the resulting suspension was maintained
at room temperature with stirring for 2 hours.  Following this time, ketone 783 (870 mg,
3.47 mmol) was added to the reaction as a solution in diethyl ether (5 mL).  The reaction
was maintained for 1 hour with stirring at room temperature and then quenched by the
addition of saturated aqueous NH4Cl solution (5 mL).  Water (10 mL) was added and the
biphasic solution was extracted with diethyl ether (25 mL).  The organic phase was
washed sequentially with saturated aqueous NaHCO3 (25 mL) and brine (25 mL), dried
with MgSO4, and concentrated under vacuum.  The crude isolate was purified by flash
chromatography (30:1 petroleum ether:diethyl ether eluent) to yield tertiary alcohol 789
(556 mg, 65% yield): Rf 0.38 (10:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) #
7.45 (dd, J = 7.8, 1.1 Hz, 1H), 7.18–7.11 (m, 2H), 7.08–7.00 (m, 2H), 6.93 (dd, J = 17.3,
10.9 Hz, 1H), 6.88–6.81 (m, 2H), 6.78 (dd, J = 7.7, 1.1 Hz, 1H), 5.51 (dd, J = 17.3, 1.4
Hz, 1H), 5.13 (dd, J = 10.9, 1.4 Hz, 1H), 4.42 (s, 1H), 3.37 (d, J = 13.4 Hz, 1H), 3.31 (d,
J = 13.4 Hz, 1H), 1.56 (s, 3H), 1.08 (s, 9H), 0.42 (s, 3H), 0.39 (s, 3H); 13C NMR (125
MHz, CDCl3) # 153.22, 138.25, 135.68, 135.53, 135.46, 132.02, 128.16, 127.97, 127.22,
126.77, 125.89, 121.24, 118.46, 115.23, 76.45, 44.79, 27.07, 26.30, 18.70, –3.36, –3.64;
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IR (NaCl/film) 3532, 2931, 2859, 1598, 1577, 1485, 1445, 1255, 1234, 1052, 906, 838,
781, 753 cm–1; HRMS (FAB+) m/z calc’d for C23H33O2Si [M+H]+: 369.2250, found
369.2260.
OTBS
789
HO
TBAF
THF
(89% yield)
OH
782
HO
Diol 782
To a solution of silyl ether 789 (475 mg, 1.29 mmol) in THF (3 mL) was added
TBAF (1 M solution in THF, 1.41 mL, 1.42 mmol).  The resulting solution was then
maintained with stirring at room temperature until silyl ether 789 was consumed by TLC
analysis (about 1 hour).  The reaction was diluted with water (10 mL) and then extracted
with diethyl ether (25 mL).  The organic phase was washed with water (3 x 10 mL) and
brine (10 mL), dried with MgSO4, and concentrated under vacuum.  The crude product
was purified by flash chromatography (12:1 $ 10:1 hexanes:ethyl acetate eluent) to yield
diol 782 (291 mg, 89% yield): Rf 0.22 (10:1 hexanes:ethyl acetate); 1H NMR (500 MHz,
CDCl3) # 9.11 (s, 1H), 7.55 (dd, J = 7.7, 1.3 Hz, 1H), 7.33–7.25 (m, 1H), 7.25–7.14 (m,
2H), 7.12–6.96 (m, 3H), 6.89 (dd, J = 8.1, 1.3 Hz, 1H), 6.87–6.79 (m, 1H), 5.63 (dd, J =
17.3, 1.3 Hz, 1H), 5.29 (dd, J = 10.9, 1.3 Hz, 1H), 3.36 (d, J = 13.9 Hz, 1H), 3.20 (d, J =
13.9 Hz, 1H), 2.51 (s, 1H), 1.59 (s, 3H); 13C NMR (125 MHz, CDCl3) # 155.81, 138.43,
135.12, 133.51, 132.13, 129.72, 129.09, 127.53, 127.46, 126.37, 126.12, 119.54, 117.76,
116.21, 79.13, 44.54, 28.12; IR (NaCl/film) 3306, 1618, 1582, 1491, 1453, 1374, 1293,
1237, 1154, 1095, 1036, 989, 914, 865, 752 cm–1; HRMS (FAB+) m/z calc’d for C17H17O
[M+H]+–H2O: 237.1279, found 237.1268.
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OH
782
HO
PdCl2 (20 mol%)
CuCl2 (20 mol%)
O2 (1 atm), THF
(61% yield)
O
O
745
Tetracycle 745
A flame-dried reaction flask was charged with PdCl2 (6.9 mg, 0.0393 mmol) and
CuCl2 (5.3 mg, 0.0393 mmol).  THF (1.5 mL) was added followed by diol 782 (50 mg,
0.197 mmol) as a solution in THF (500 µL).  The reaction was placed under an oxygen
atmosphere (1 atm) and maintained at room temperature with vigorous stirring until diol
782 was consumed by TLC analysis (about 24 hours).  Upon completion, the reaction
solution was passed through a short column of MgSO4, concentrated under vacuum, and
purified by flash chromatography (50:1 $ 25:1 hexanes:ethyl acetate eluent) to yield
tetracycle 745 (30.4 mg, 61% yield): Rf 0.41 (10:1 hexanes:ethyl acetate); 1H NMR (500
MHz, CDCl3) # 7.45 (dd, J = 7.7, 1.3 Hz, 1H), 7.23–7.12 (m, 2H), 7.11–7.02 (m, 2H),
7.02–6.97 (m, 1H), 6.85 (td, J = 7.5, 1.2 Hz, 1H), 6.71 (dd, J = 8.2, 1.1 Hz, 1H), 3.29 (d,
J = 16.0 Hz, 1H), 2.95 (d, J = 16.1 Hz, 1H), 1.98 (s, 3H), 1.76 (s, 3H); 13C NMR (125
MHz, CDCl3) # 151.06, 135.87, 133.19, 128.20, 128.18, 128.06, 127.42, 126.75, 125.72,
124.58, 120.71, 116.81, 97.66, 73.08, 43.09, 27.62, 26.67; IR (NaCl/film) 2994, 2932,
1607, 1585, 1484, 1452, 1382, 1299, 1275, 1249, 1115, 1081, 978, 899, 879, 760 cm–1;
HRMS (MM: ESI-APCI) m/z calc’d for C17H17O2 [M+H]+: 253.1223, found 253.1211.
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Br
O
OMeO
HO
TBSCl, imidazole
DMF
(92% yield)
Br
O
OMeO
TBSO
721 798
Silyl ether 798
To a solution of benzyl alcohol 721 (1.0 g, 3.83 mmol) in DMF (10 mL) were
sequentially added imidazole (0.52 g, 7.66 mmol) and TBSCl (0.86 g, 5.75 mmol).  The
resulting solution was maintained with stirring at room temperature until benzyl alcohol
721 had been fully consumed by TLC analysis.  At this time, the reaction was diluted
with diethyl ether (25 mL) and washed with water (3 x 10 mL) and brine (10 mL).  The
organic phase was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (50:1 hexanes:ethyl acetate eluent) to yield silyl ether 798 (1.32 g, 92%
yield): Rf = 0.70 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.80 (s, 1H),
6.03 (s, 2H), 4.66 (d, J = 0.9 Hz, 2H), 3.89 (s, 3H), 0.96 (s, 9H), 0.13 (s, 6H); 13C NMR
(125 MHz, CDCl3) # 146.69, 143.03, 134.40, 134.19, 106.82, 101.92, 91.87, 64.16,
56.65, 26.04, 18.49, -5.17; IR (NaCl/film) 2928, 1628, 1431, 1345, 1253, 1162, 1110,
1045, 937, 836, 775 cm–1; HRMS (MM: ESI-APCI) m/z  calc’d for C9H8O379Br
[M–OTBS]•+: 242.9651, found 242.9653.
Br
O
OMeO
MeO O
618
PdCl2(PPh3)2 (5 mol%)
LiCl, DMF, 100 °C
(81% yield)
(n-Bu)3Sn
O
OMeO
MeO O
800
Styrene 800
Lithium chloride (367 mg, 8.65 mmol) was flame dried in the reaction flask under
vacuum.  PdCl2(PPh3)2 (61 mg, 0.087 mmol) was added, and the flask was evacuated and
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backfilled with nitrogen.  In a different flame-dried flask, a solution of aryl bromide 618
(500 mg, 1.73 mmol) and tri-n-butyl(vinyl)stannane (1.01 mL, 3.46 mmol) in DMF (17
mL) was sparged with argon for 10 minutes.  The DMF solution was transferred to the
reaction flask containing the LiCl and palladium catalyst and heated to 100 °C in an oil
bath.  The reaction was maintained at 100 °C with stirring under nitrogen atmosphere
until aryl bromide 618 was fully consumed by TLC analysis.  Following this time, the
reaction was diluted with diethyl ether (50 mL) and washed with water (4 x 25 mL) and
brine (25 mL).  The organic phase was dried with MgSO4, concentrated under vacuum,
and purified by flash chromatography (15:1 hexanes:ethyl acetate eluent) to yield styrene
800 (329 mg, 81% yield): Rf = 0.33 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz,
CDCl3) # 7.25–7.15 (m, 2H), 6.10 (s, 2H), 5.91 (dd, J = 17.8, 1.8 Hz, 1H), 5.49 (dd, J =
11.7, 1.8 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H); 13C NMR (125 MHz, CDCl3) # 167.17,
147.28, 141.89, 138.47, 129.67, 123.00, 118.95, 116.30, 110.85, 102.15, 56.52, 52.10; IR
(NaCl/film) 2976, 2904, 2841, 2797, 1710, 1636, 1589, 1497, 1432, 1323, 1248, 1194,
1167, 1083, 1041, 991, 958, 900, 851, 785, 759 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C12H13O5 [M+H] +: 237.0757, found 237.0758.
O
OMeO
MeO O
800
DIBAL
CH2Cl2, – 78 °C
(94% yield) O
OMeO
HO
812
Benzyl alcohol 812
A solution of styrene 800 (300 mg, 1.27 mmol) in CH2Cl2 (13 mL) was cooled to
–78 °C.  DIBAL (500 µL, 2.79 mmol) was added dropwise, and the reaction was
maintained for 15 minutes at –78 °C, until styrene 800 was consumed by TLC analysis.
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The reaction was quenched at –78 °C by the addition of a saturated solution of Rochelle’s
salt (5 mL) and subsequently warmed to room temperature over about one hour with
vigorous stirring.  The biphasic solution was diluted with CH2Cl2 (10 mL) and the layers
were separated.  The organic phase was washed with brine (10 mL), dried with MgSO4,
and concentrated under vacuum to yield benzyl alcohol 812 (247 mg, 94% yield): Rf =
0.16 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.77 (dd, J = 17.7, 11.7
Hz, 1H), 6.57 (s, 1H), 6.03 (s, 2H), 5.93 (dd, J = 17.7, 1.8 Hz, 1H), 5.45 (dd, J = 11.7, 1.8
Hz, 1H), 4.66 (s, 2H), 3.90 (s, 3H), 1.77 (s, 1H); 13C NMR (125 MHz, CDCl3) # 147.21,
142.43, 134.95, 132.47, 128.15, 118.34, 113.06, 108.10, 101.68, 63.49, 56.54; IR
(NaCl/film) 3270, 2910, 1639, 1489, 1432, 1343, 1317, 1289, 1147, 1095, 1038, 994,
942, 908, 830 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H11O3 [M–OH]•+:
191.0703, found 191.0705.
O
OMeO
HO
812
TBSCl, imidazole
DMF
(77% yield)
O
OMeO
TBSO
799
Silyl ether 799
To a solution of benzyl alcohol 812 (21 mg, 0.101 mmol) in DMF (1 mL) were
added imidazole (14 mg, 0.202 mmol) and TBSCl (23 mg, 0.151 mmol).  The resulting
solution was maintained at room temperature with stirring until benzyl alcohol 812 was
completely consumed by TLC analysis.  At this time, the reaction was diluted with
diethyl ether (25 mL) and washed with water (3 x 10 mL) and brine (10 mL).  The
organic phase was dried with MgSO4, concentrated under vacuum and purified by flash
chromatography (20:1 hexanes:ethyl acetate eluent) to yield silyl ether 799 (32.5 mg,
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77% yield): Rf = 0.39 (10:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) #
6.74–6.61 (m, 2H), 6.02 (s, 2H), 5.87 (dd, J = 17.7, 1.8 Hz, 1H), 5.40 (dd, J = 11.7, 1.8
Hz, 1H), 4.71 (d, J = 0.6 Hz, 2H), 3.90 (s, 3H), 0.94 (s, 9H), 0.10 (s, 6H); 13C NMR (125
MHz, CDCl3) # 147.11, 142.62, 134.41, 133.25, 128.37, 117.90, 112.36, 106.58, 101.75,
63.40, 56.59, 26.12, 18.58, -5.02; IR (NaCl/film) 2953, 2928, 2855, 1639, 1492, 1462,
1446, 1431, 1346, 1312, 1255, 1154, 1121, 1046, 1005, 947, 910, 836, 775 cm–1; HRMS
(MM: ESI-APCI) m/z calc’d for C11H11O3 [M–OTBS]•+: 191.0703, found 191.0702.
Br
O
OMeO
MeO O
618
O
OMeO
MeO O
802
PdCl2(PPh3)2 
(5 mol%)
Na2CO3
DME, H2O, 85 °C
(84% yield)
B
O
O
!-Methyl styrene 802
Aryl bromide 618 (100 mg, 0.346 mmol), PdCl2(PPh3)2 (12 mg, 0.0173 mmol),
and Na2CO3 (110 mg, 1.04 mmol) were combined in a flame-dried reaction flask.  To this
were added DME (3.5 mL) and water (0.85 mL) (each sparged with argon), followed by
the boronic ester (87 mg, 0.519 mmol).  The sealed reaction was heated to 85 °C in an oil
bath and maintained at 85 °C with stirring until aryl bromide 618 was consumed by TLC
analysis (about 5 hours).  At this time, the reaction was cooled to room temperature,
diluted with ethyl acetate (10 mL), and filtered over a pad of Celite (rinsing with ethyl
acetate).  The filtrate was washed with water (10 mL) and brine (10 mL), dried with
MgSO4, and concentrated under vacuum.  The crude residue was purified by flash
chromatography (15:1 hexanes:ethyl acetate eluent) to yield !-methyl styrene 802 (73
mg, 84% yield): Rf = 0.13 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.14
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(s, 1H), 6.04 (s, 2H), 5.28–5.15 (m, 1H), 4.86 (dd, J = 1.7, 0.9 Hz, 1H), 3.92 (s, 3H), 3.82
(s, 3H), 2.15–1.98 (m, 3H); 13C NMR (125 MHz, CDCl3) # 167.25, 146.16, 141.87,
140.11, 137.92, 123.53, 121.15, 115.12, 110.32, 102.11, 56.58, 51.96, 23.41; IR
(NaCl/film) 2913, 1711, 1635, 1499, 1427, 1325, 1244, 1194, 1174, 1112, 1049, 1038,
962, 899, 862, 789, 757 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C13H15O5 [M+H] +:
251.0914, found 251.0919.
O
OMeO
MeO O
802
DIBAL
CH2Cl2, – 78 °C
(99% yield) O
OMeO
HO
859
Benzyl alcohol 859
A solution of !-methyl styrene 802 (25 mg, 0.10 mmol) in CH2Cl2 (2 mL) was
cooled to –78 °C.  To this solution was added DIBAL dropwise.  The reaction was
maintained at –78 °C for 15 minutes, at which time TLC analysis indicated complete
consumption of !-methyl styrene 802.  The reaction was quenched at –78 °C by the
addition of a saturated solution of Rochelle’s salt (1 mL) and subsequently warmed to
room temperature over one hour with vigorous stirring.  The reaction was diluted with
CH2Cl2 (10 mL) and the layers were separated.  The organic phase was washed with brine
(10 mL), dried with MgSO4, and concentrated under vacuum to yield benzylic alcohol
859 (22 mg, 99% yield): Rf = 0.18 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz,
CDCl3) # 6.65 (s, 1H), 5.97 (s, 2H), 5.33 (dd, J = 2.0, 1.6 Hz, 1H), 4.97 (dd, J = 2.0, 1.0
Hz, 1H), 4.58 (d, J = 0.4 Hz, 2H), 3.90 (s, 3H), 2.05 (dd, J = 1.5, 1.0 Hz, 3H), 1.73 (s,
1H); 13C NMR (125 MHz, CDCl3) # 145.74, 142.46, 139.13, 134.20, 132.26, 118.49,
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117.21, 107.65, 101.52, 62.93, 56.55, 23.86; IR (NaCl/film) 3358, 2887, 1639, 1596,
1498, 1425, 1338, 1317, 1164, 1115, 1039, 943, 908, 834 cm–1; HRMS (MM: ESI-APCI)
m/z calc’d for C12H13O3 [M–OH]•+: 205.0859, found 205.0858.
O
OMeO
HO
859
TBSCl, imidazole
DMF
(98% yield)
O
OMeO
TBSO
803
Silyl ether 803
To a solution of benzyl alcohol 859 (22 mg, 0.1 mmol) in DMF (1 mL) were
added imidazole (13.6 mg, 0.2 mmol) and TBSCl (22.6 mg, 0.150 mmol).  The resulting
solution was maintained at room temperature with stirring until TLC analysis indicated
complete consumption of benzyl alcohol 859.  At this time, the reaction was diluted with
diethyl ether (25 mL) and washed with water (3 x 10 mL) and brine (10 mL).  The
organic phase was dried with MgSO4 and concentrated under vacuum to yield silyl ether
803 (33 mg, 98% yield): Rf = 0.59 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz,
CDCl3) # 6.75 (s, 1H), 5.96 (s, 2H), 5.29 (d, J = 1.9 Hz, 1H), 4.91 (dd, J = 2.0, 1.0 Hz,
1H), 4.63 (d, J = 0.6 Hz, 2H), 3.90 (s, 3H), 2.13–1.89 (m, 3H), 0.94 (s, 9H), 0.09 (s, 6H);
13C NMR; IR (NaCl/film) 2853, 2928, 2855, 1639, 1597, 1497, 1462, 1424, 1343, 1254,
1164, 1119, 1050, 948, 836, 775 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C12H13O3
[M–OTBS]•+: 205.0859, found 205.0859.
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O
OMeO
TBSO
803
OsO4 (10 mol%)
NaIO4, DABCO
dioxane:H2O (3:1)
(82% yield) O
OMeO
TBSO
804
O
Acetophenone 804
Silyl ether 803 (25 mg, 0.0743 mmol), DABCO (42 mg, 0.393 mmol), and NaIO4
(159 mg, 0.743 mmol) were combined in dioxane (0.75 mL) and water (0.75 mL).
Osmium tetroxide (1 mg, 0.00393 mmol) was added and the reaction was maintained
with vigorous stirring at room temperature until silyl ether 803 was consumed by TLC
analysis.  At this time, the reaction was filtered through a Celite plug (rinsing with ethyl
acetate).  The filtrate was washed with brine (10 mL), dried with MgSO4, and
concentrated under vacuum.  The crude residue was purified by flash chromatography
(7:1 hexanes:ethyl acetate eluent) to yield acetophenone 804 (21 mg, 82% yield): Rf =
0.26 (10:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.11 (t, J = 1.1 Hz, 1H),
6.07 (s, 2H), 4.96 (d, J = 1.1 Hz, 2H), 3.95 (s, 3H), 2.55 (s, 3H), 0.96 (s, 9H), 0.11 (s,
6H); 13C NMR (125 MHz, CDCl3) # 197.18, 150.18, 146.30, 139.41, 133.53, 112.64,
105.34, 102.02, 63.72, 56.39, 32.38, 26.12, 18.49, –5.18; IR (NaCl/film) 2923, 2853,
1657, 1626, 1462, 1423, 1360, 1284, 1259, 1155, 1093, 1049, 1004, 956, 867, 839, 774
cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C17H27O5Si [M+H]+: 339.1622, found
339.1628.
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O
OMeO
TBSO
804
O
Br
Mg(0), Et2O, 23 °C, then
(81% yield)
O
OMeO
TBSO
805784
OH
Tertiary alcohol 805
A flame-dried flask was charged with magnesium turnings (106 mg, 4.36 mmol),
evacuated, and backfilled with nitrogen.  Diethyl ether (1 mL) was added, followed by
1,2-dibromoethane (15 µL).  After 15 minutes, benzyl bromide 784 (344 mg, 1.75 mmol)
was added as a solution in diethyl ether (5 mL).  The suspension was maintained at room
temperature with stirring for 2.5 hours, at which time, acetophenone 804 (295 mg, 0.873
mmol) was added dropwise as a solution in diethyl ether (4 mL).  The reaction was
further maintained for 15 minutes at room temperature with stirring until acetophenone
804 was completely consumed by TLC analysis.  The reaction was quenched by the
addition of a saturated solution of NH4Cl (4 mL).  The biphasic suspension was then
diluted with diethyl ether (25 mL) and washed with saturated NaHCO3 solution (10 mL),
water (10 mL), and brine (10 mL).  The organic phase was dried with MgSO4,
concentrated under vacuum, and purified by flash chromatography (15:1 hexanes:ethyl
acetate eluent) to yield tertiary alcohol 805 (321 mg, 81% yield): Rf = 0.42 (5:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.46 (d, J = 7.6 Hz, 1H), 7.22–7.05
(m, 3H), 6.37 (s, 1H), 5.95 (s, 2H), 5.53 (dd, J = 17.4, 1.5 Hz, 1H), 5.17 (dd, J = 11.0, 1.5
Hz, 1H), 4.80 (s, 1H), 4.65 (dd, J = 40.5, 11.6 Hz, 2H), 3.88 (s, 3H), 3.30 (dd, J = 32.8,
13.9 Hz, 2H), 1.63 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz,
CDCl3) # 145.72, 141.43, 138.29, 136.10, 135.80, 134.84, 132.18, 131.85, 127.01,
126.51, 125.48, 123.04, 114.52, 110.73, 100.97, 76.73, 66.92, 56.69, 43.69, 29.30, 26.03,
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18.37, -4.80, -4.94; IR (NaCl/film) 3435, 2953, 2928, 2855, 1639, 1462, 1412, 1382,
1313, 1253, 1139, 1038, 999, 943, 837, 777 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C26H34O4Si [M–OH]•+: 439.2299, found 439.2295.
Br
MeO
MeO O
765
OH
OH
TBSCl
imidazole
DMF
(77% yield)
Br
MeO
MeO O
806
PdCl2(PPh3)2 
(5 mol%)
Na2CO3
DME, H2O, 85 °C
(62% yield)
B
O
O
MeO
MOMO
808
TBAF
THF
(80% yield)
MeO
MOMO
809
(EtO)3CH
Amberlyst 15
PhH, reflux
(38% yield)
MeO
MOMO
810
O
O
OEt
OsO4 (5 mol%)
DABCO, NaIO4
THF, H2O, 23 °C
(78% yield)
MeO
MOMO
811
O
O
OEt
O
OTBS
OTBS MeO
MeO O
807
OTBS
OTBS
1. DIBAL, CH2Cl2
2. MOMCl, i-Pr2NEt
    CH2Cl2
(84% yield, 2 steps)
OTBS
OTBS
OH
OH
Acetophenone 811
To a solution of catechol 765 (5.693 g, 20.5 mmol) in DMF (103 mL) were added
imidazole (4.20 g, 61.6 mmol), DMAP (251 mg, 2.05 mmol), and TBSCl (9.29 g, 61.6
mmol).  The resulting solution was maintained with stirring at room temperature until
catechol 765 was fully consumed by TLC.  At that time, the reaction was diluted with
diethyl ether (150 mL) and washed with water (3 x 50 mL) and brine (50 mL).  The
organic phase was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (25:1 hexanes:ethyl acetate eluent) to yield bis-silyl ether 806 (7.96 g,
77% yield).
Bis-silyl ether 806 (1.0 g, 1.98 mmol), PdCl2(PPh3)2 (76 mg, 0.109 mmol), and
Na2CO3 (629 mg, 5.93 mmol) were combined in a flame-dried reaction flask.  The flask
was evacuated and backfilled with nitrogen.  To the solids were added DME (20 mL) and
water (5 mL) (both sparged with argon), followed by the boronic ester (559 µL, 2.97
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mmol).  The sealed reaction flask was heated to 85 °C in an oil bath and maintained at 85
°C until bis-silyl ether 806 was fully consumed by TLC analysis.  At that time, the
reaction was cooled to room temperature and filtered through a Celite plug (washing with
ethyl acetate).  The filtrate was washed with water (25 mL) and brine (25 mL), dried over
MgSO4, and concentrated under vacuum.  The crude residue was purified by flash
chromatography (20:1 hexanes:ethyl acetate eluent) to yield !-methyl styrene 807 (576
mg, 62% yield).
A solution of !-methyl styrene 807 (2.01 g, 4.31 mmol) in CH2Cl2 (43 mL) was
cooled to –78 °C.  To this was added DIBAL (1.69 mL, 9.49 mmol) dropwise, and the
reaction was maintained at –78 °C until !-methyl styrene 807 was fully consumed by
TLC.  At this time, the reaction was quenched by the addition of a saturated solution of
Rochelle’s salt (15 mL) and subsequently warmed to room temperature over one hour
with vigorous stirring.  The reaction was diluted with CH2Cl2 (25 mL) and washed with
water (25 mL) and brine (25 mL).  The organic phase was dried with MgSO4 and
concentrated under vacuum to yield the benzyl alcohol (1.59 g, 84% yield), which was
immediately taken on to the next step.
A solution of the benzyl alcohol (1.59 g, 3.64 mmol) in CH2Cl2 (15 mL) was
cooled to 0 °C in an ice bath.  To this were added i-Pr2Net (1.65 mL, 9.46 mmol) and
MOMCl (0.581 mL, 7.64 mmol) sequentially.  The resulting solution was allowed to
warm to room temperature over several hours with stirring and subsequently maintained
at room temperature until the benzyl alcohol was consumed by TLC analysis.  At this
time, the reaction was diluted with CH2Cl2 (25 mL) and washed with 10% citric acid
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solution (2 x 10 mL) and brine (10 mL).  The organic phase was dried with MgSO4 and
concentrated under vacuum to yield methoxymethyl ether 808 (1.76 g, 99% yield).
To a solution of methoxymethyl ether 808 (1.76 g, 3.64 mmol) in THF (12 mL)
was added TBAF (8.01 mL, 8.01 mmol, 1.0 M solution in THF).  The resulting solution
was maintained with stirring at room temperature until methoxymethyl ether 808 was
fully consumed by TLC analysis.  At that time, the reaction was diluted with diethyl ether
(50 mL) and washed with water (2 x 25 mL) and brine (25 mL).  The organic phase was
dried with MgSO4, concentrated under vacuum, and purified by flash chromatography
(5:1 $  3:1 $  1:1 hexanes:ethyl acetate eluent) to yield catechol 809 (737 mg, 80%
yield).
To a solution of catechol 809 (437 mg, 1.72 mmol) in benzene (17 mL) were
added triethyl orthoformate (0.86 mL, 5.16 mmol) and Amberlyst 15 (9 mg, 5 mg/mmol).
The reaction flask was equipped with a Dean–Stark condenser (empty) and reflux
condenser.  The reaction was heated to reflux and maintained at reflux with distillation of
the ethanol/benzene azeotrope into the Dean–Stark condenser.  Benzene was replenished
into the reaction flask as needed.  After two days, the reaction was cooled to room
temperature, filtered through a Celite plug, and concentrated under vacuum.  The crude
residue was purified by flash chromatography (5:1 hexanes:ethyl acetate eluent) to yield
orthoester 810 (200 mg, 38% yield).
Orthoester 810 (200 mg, 0.644 mmol), DABCO (361 mg, 3.22 mmol), and NaIO4
(1.38 g, 6.44 mmol) were combined in THF (6.4 mL) and water (6.4 mL).  Osmium
tetroxide (8 mg, 0.032 mmol) was added and the resulting suspension was maintained
with vigorous stirring until orthoester 810 was consumed by TLC analysis.  At that time,
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the reaction was filtered through a Celite plug (washing with ethyl acetate).  The filtrate
was washed with water (20 mL) and brine (20 mL), dried with MgSO4, and concentrated
under vacuum.  The crude residue was purified by flash chromatography (6:1
hexanes:ethyl acetate eluent) to yield acetophenone 811 (140 mg, 70% yield): Rf = 0.17
(5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.98 (s, 1H), 6.90 (s, 1H), 4.84
(s, 2H), 4.73 (s, 2H), 3.98 (s, 3H), 3.83–3.69 (m, 2H), 3.41 (s, 3H), 2.59 (s, 3H), 1.28 (t, J
= 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 197.00, 147.87, 145.13, 134.57, 132.69,
119.74, 113.24, 107.11, 96.34, 67.82, 59.66, 56.56, 55.49, 32.10, 14.81; IR (NaCl/film)
2982, 2943, 1673, 1634, 1446, 1427, 1360, 1286, 1266, 1149, 1106, 1040, 958, 917, 842,
783 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C13H15O5 [M–OMOM]•+: 251.0914,
found 251.0920.
O
OMeO
HO
812
NBS, PPh3
CH2Cl2, 0 °C
(56% yield)
O
OMeO
Br
813
Benzyl bromide 813
A solution of benzyl alcohol 812 (245 mg, 1.18 mmol) in CH2Cl2 (6 mL) was
cooled to 0 °C in an ice bath.  Triphenylphosphine (358 mg, 13.7 mmol) was added,
followed by NBS (243 mg, 13.7 mmol), and the reaction was maintained at 0 °C until
benzyl alcohol 812 was consumed by TLC analysis.  Following this time, the reaction
was warmed to room temperature and concentrated under vacuum.  The crude residue
was purified by flash chromatography (15:1 hexanes:ethyl acetate eluent) to yield benzyl
bromide 813 (180.5 mg, 56% yield): Rf = 0.56 (3:1 hexanes:ethyl acetate); 1H NMR (500
MHz, CDCl3) # 6.81 (dd, J = 17.6, 11.7 Hz, 1H), 6.57 (s, 1H), 6.07 (s, 2H), 6.02 (dd, J =
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17.6, 1.7 Hz, 1H), 5.57 (dd, J = 11.7, 1.7 Hz, 1H), 4.57 (s, 2H), 3.93 (s, 3H); 13C NMR
(125 MHz, CDCl3) #  147.37, 142.50, 135.99, 129.08, 127.84, 119.06, 113.75, 109.76,
101.92, 56.60, 32.67; IR (NaCl/film) 2901, 1637, 1495, 1456, 1431, 1351, 1319, 1149,
1089, 1045, 947, 919, 834, 768 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H11O3
[M–Br]+: 191.0703, found 191.0700.
O
OMeO
HO
812
MsCl, LiCl, Et3N
THF
(80% yield) O
OMeO
Cl
814
Benzyl chloride 814
Lithium chloride (61 mg, 1.44 mmol) was flame dried in a reaction flask.  Benzyl
alcohol 812 (200 mg, 0.961 mmol) was added to the LiCl as a solution in THF (2 mL),
and the resulting solution was cooled to 0 °C in an ice bath.  Triethylamine (201 µL, 1.44
mmol) was added, followed by MsCl (82 µL, 1.05 mmol), dropwise.  The reaction was
then allowed to warm to room temperature over one hour, at which point it was
maintained at room temperature until benzylic alcohol was consumed by TLC analysis.
The reaction was quenched by the addition of a saturated solution of NH4Cl (3 mL) and
extracted with diethyl ether (25 mL).  The ether extracts were washed with brine (10
mL), dried with MgSO4, and concentrated under vacuum.  The crude residue was purified
by flash chromatography (15:1 hexanes:ethyl acetate eluent) to yield benzyl chloride 814
(139.6 mg, 64% yield): Rf = 0.10 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz,
CDCl3) # 6.80 (dd, J = 17.6, 11.7 Hz, 1H), 6.56 (s, 1H), 6.06 (s, 2H), 6.04–5.92 (m, 1H),
5.53 (dd, J = 11.7, 1.7 Hz, 1H), 4.63 (s, 2H), 3.92 (s, 3H), 1.60–1.48 (m, 3H); 13C NMR
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(125 MHz, CDCl3) #  147.33, 142.45, 135.88, 128.91, 127.79, 119.12, 113.80, 109.84,
101.88, 56.62, 44.94; IR (NaCl/film) 3435, 1639, 1496, 1459, 1431, 1355, 1317, 1262,
1149, 1090, 1046, 1018, 951, 919, 837, 772 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C11H11O3 [M–Cl]•+: 191.0708, found 191.0704.
Br
MeO
MeO O
818
O
O
OEt
Br
MeO
MeO O
765
(EtO)3CH
Amberlyst 15
PhH, reflux
(53% yield)OH
OH
Orthoester 818
To a solution of catechol 765 (1.94 g, 7.50 mmol) in benzene (70 mL) were added
triethyl orthoformate (3.5 mL, 21.0 mmol) and Amberlyst 15 (35 mg, 5 mg/mmol).  The
reaction flask was equipped with a Dean–Stark condenser (empty) and reflux condenser.
The reaction was heated to reflux and maintained at reflux with distillation of the
ethanol/benzene azeotrope into the Dean–Stark condenser.  Benzene was replenished into
the reaction flask as needed.  After two days, the reaction was cooled to room
temperature, filtered through a Celite plug, and concentrated under vacuum.  The crude
residue was purified by flash chromatography (7:1 hexanes:ethyl acetate eluent) to yield
orthoester 818 (1.25 g, 53% yield): Rf = 0.25 (5:1 hexanes:ethyl acetate); 1H NMR (500
MHz, CDCl3) # 7.26 (s, 1H), 7.01 (s, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.78 (dq, J = 7.1, 1.1
Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 165.55, 146.37, 141.62,
136.77, 124.22, 120.05, 111.89, 93.99, 59.99, 56.77, 52.35, 14.74; IR (NaCl/film) 2981,
2950, 1728, 1629, 1600, 1490, 1436, 1348, 1319, 1249, 1175, 1109, 1092, 1036, 939,
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852, 770 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C12H14O679Br [M+H]+: 332.9968,
found 332.9996.
Br
MeO
MeO O
818
O
O
OEt
PdCl2(PPh3)2  (5 mol%)
LiCl
DMF, 100 °C
(89% yield)
Bu3Sn
MeO
MeO O
819
O
O
OEt
Styrene 819
Lithium chloride (63.6 mg, 1.50 mmol) was flame dried in the reaction flask
under vacuum.  PdCl2(PPh3)2 (10.5 mg, 0.015 mmol) was added, and the flask was
evacuated and backfilled with nitrogen.  In a different flame-dried flask, a solution of aryl
bromide 818 (100 mg, 0.30 mmol) and tri-n-butyl(vinyl)stannane (175 µL, 0.60 mmol) in
DMF (3 mL) was sparged with argon for 10 minutes.  The DMF solution was transferred
to the reaction flask containing the LiCl and palladium catalyst by cannula and heated to
100 °C in an oil bath.  The reaction was maintained at 100 °C with stirring under nitrogen
atmosphere until aryl bromide 818 was fully consumed by TLC analysis.  Following this
time, the reaction was diluted with diethyl ether (25 mL) and washed with water (4 x 20
mL) and brine (20 mL).  The organic phase was dried with MgSO4, concentrated under
vacuum, and purified by flash chromatography (15:1 hexanes:ethyl acetate eluent) to
yield styrene 819 (70.5 mg, 84% yield): Rf = 0.33 (5:1 hexanes:ethyl acetate); 1H NMR
(500 MHz, CDCl3) # 7.25–7.17 (m, 2H), 7.00 (s, 1H), 5.95 (dd, J = 17.8, 1.7 Hz, 1H),
5.51 (dd, J = 11.7, 1.7 Hz, 1H), 3.93 (s, 3H), 3.87 (s, 3H), 3.74 (q, J = 7.1 Hz, 2H), 1.26
(t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 167.22, 145.52, 141.29, 136.99,
129.45, 122.89, 119.93, 119.27, 115.82, 110.41, 59.44, 56.51, 52.15, 14.79; IR
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(NaCl/film) 2981, 2951, 1716, 1637, 1590, 1496, 1434, 1346, 1318, 1245, 1192, 1167,
1133, 1089, 1038, 964, 917, 865, 787 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C14H17O6 [M+H]+: 281.1020, found 281.1032.
MeO
MeO O
819
O
O
OEt
LiAlH4
THF, 0 °C
(91% yield)
MeO
HO
820
O
O
OEt
Benzyl alcohol 820
A solution of styrene 819 (70.5 mg, 0.251 mmol) in THF (2.5 mL) was cooled to
0 °C in an ice bath.  Lithium aluminum hydride (9.5 mg, 0.251 mmol) was added and the
reaction was maintained at 0 °C for 5 minutes, at which time, TLC analysis showed full
consumption of styrene 819.  The reaction was quenched at 0 °C by the sequential
addition of 10 µL water, 10 µL of 20% NaOH solution, and 30 µL water and then
warmed to room temperature with vigorous stirring over one hour.  Following this time,
the suspension was filtered and the filtrate was concentrated under vacuum to yield
benzyl alcohol 820 (58.2 mg, 92% yield): Rf = 0.13 (3:1 hexanes:ethyl acetate); 1H NMR
(500 MHz, CDCl3) # 6.95 (s, 1H), 6.78 (dd, J = 17.7, 11.7 Hz, 1H), 6.59 (s, 1H), 5.97
(dd, J = 17.7, 1.7 Hz, 1H), 5.47 (dd, J = 11.7, 1.7 Hz, 1H), 4.67 (s, 2H), 3.91 (s, 3H), 3.74
(q, J = 7.1 Hz, 2H), 1.80 (s, 1H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) #
145.47, 141.79, 133.61, 132.29, 127.96, 119.59, 118.58, 112.55, 107.90, 63.49, 59.27,
56.54, 14.83; IR (NaCl/film) 3368, 2979, 1642, 1497, 1448, 1437, 1376, 1311, 1154,
1131, 1093, 1034, 1006, 927, 833, 771 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C13H15O4 [M–OH]•+: 235.0965, found 235.0962.
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MeO
HO
820
O
O
OEt
MOMCl, i-Pr2NEt
CH2Cl2, 0 °C ! 23 °C
(83% yield)
MeO
MOMO
821
O
O
OEt
Methoxymethyl ether 821
A solution of benzyl alcohol 820 (58.2 mg, 0.231 mmol) in CH2Cl2 (2.3 mL) was
cooled to 0 °C in an ice bath.  To this were added i-Pr2Net (104 µL, 0.60 mmol) and
MOMCl (36.8 µL, 0.484 mmol) sequentially.  The resulting solution was allowed to
warm to room temperature over several hours with stirring and subsequently maintained
at room temperature until benzyl alcohol 820 was consumed by TLC analysis.  At this
time, the reaction was diluted with diethyl ether (25 mL) and washed with 10% citric acid
solution (2 x 10 mL) and brine (10 mL).  The organic phase was dried with MgSO4 and
concentrated under vacuum to yield methoxymethyl ether 821 (57.1 mg, 83% yield): Rf =
0.38 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.96 (s, 1H), 6.77 (dd, J =
17.7, 11.7 Hz, 1H), 6.60 (s, 1H), 5.97 (dd, J = 17.7, 1.7 Hz, 1H), 5.46 (dd, J = 11.7, 1.6
Hz, 1H), 4.69 (s, 2H), 4.59 (s, 2H), 3.92 (s, 3H), 3.74 (q, J = 7.1 Hz, 2H), 3.42 (s, 3H),
1.26 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 145.45, 141.66, 133.82, 129.14,
128.21, 119.57, 118.39, 113.21, 109.05, 95.48, 67.35, 59.11, 56.56, 55.54, 14.83; IR
(NaCl/film) 2980, 2841, 1642, 1498, 1448, 1437, 1379, 1312, 1148, 1093, 1038, 916,
831, 770 cm–1; HRMS (MM: ESI-APCI) m/z  calc’d for C13H15O4 [M–OMOM]•+:
235.0965, found 235.0959.
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MeO
MOMO
821
O
O
OEt
OsO4 (5 mol%)
DABCO, NaIO4
THF, H2O, 23 °C
(81% yield)
MeO
MOMO
822
O
O
OEt
O
H
Benzaldehyde 822
Orthoester 821 (57.1 mg, 0.193 mmol), DABCO (108 mg, 0.963 mmol), and
NaIO4 (412 mg, 1.93 mmol) were combined in THF (2 mL) and water (2 mL).  Osmium
tetroxide (2.4 mg, 0.0096 mmol) was added and the resulting suspension was maintained
with vigorous stirring until orthoester 821 was consumed by TLC analysis.  Following
that time, the reaction was filtered through a Celite plug (washing with ethyl acetate).
The filtrate was washed with water (20 mL) and brine (20 mL), dried with MgSO4, and
concentrated under vacuum.  The crude residue was purified by flash chromatography
(4:1 hexanes:ethyl acetate eluent) to yield benzaldehyde 822 (46 mg, 81% yield): Rf =
0.29 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 10.28–10.19 (m, 1H),
7.01 (s, 1H), 6.83 (s, 1H), 5.02–4.82 (m, 2H), 4.75 (s, 2H), 4.00 (s, 3H), 3.78 (qd, J = 7.1,
1.2 Hz, 2H), 3.41 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 186.69,
151.11, 146.81, 135.09, 133.00, 120.72, 110.87, 107.18, 96.23, 67.11, 59.98, 56.75,
55.57, 14.75; IR (NaCl/film) 2942, 1684, 1635, 1502, 1448, 1387, 1291, 1130, 1037, 916,
774 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C14H19O7 [M+H]+: 299.1125, found
299.1115.
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OMe
O
O
O
838
N
O
OMe
O
O
O
800
MeO
(MeO)MeNH•HCl
i-PrMgCl
THF, –20 ! –10 °C
(91% yield)
Weinreb amide 838
A slurry of ester 800 (1.08 g, 4.57 mmol) and (MeO)MeNH•HCl (691 mg, 7.08
mmol) in THF (9 mL) was cooled to –20 °C.  The i-PrMgCl (8.36 mL, 13.7 mmol, 1.64
M solution in THF) was added very slowly over 5–10 minutes.  Following addition, the
reaction was maintained with stirring between –10 °C and –20 °C for 20 minutes, at
which point it was quenched by the addition of a saturated solution of NH4Cl (10 mL).
The reaction was then warmed to room temperature, diluted with diethyl ether (25 mL),
and washed with water (25 mL) and brine (25 mL).  The organic phase was dried with
Na2SO4, concentrated under vacuum, and purified by flash chromatography (1:1
hexanes:ethyl acetate eluent) to yield Weinreb amide 838 (1.10 g, 91% yield): Rf = 0.27
(1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 6.51 (m, 2H), 6.07 (s, 2H),
5.93 (dd, J = 17.7, 1.2 Hz, 1H), 5.39 (d, J = 11.6 Hz, 1H), 3.89 (s, 3H), 3.57 ( br s, 3H),
3.27 ( br s, 3H); 13C NMR (125 MHz, CDCl3) # 146.64, 142.60, 135.97, 128.70, 118.35,
112.20, 106.37, 101.95, 61.09, 56.62; IR (NaCl/film) 2935, 1648, 1633, 1493, 1461,
1430, 1379, 1303, 1156, 1074, 1040, 982, 938, 839, 800 cm–1; HRMS (MM: ESI-APCI)
m/z calc’d for C13H16O5N [M+H]+: 266. 1023, found 266.1027.
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MeO O
O
O
800
MeO
Br2
CH2Cl2, 0 °C
MeO O
O
O
839
MeO
Br
Br DBU
MeCN, 23 °C
(96% yield,
2 steps)
MeO O
O
O
840
MeO
Br! " !
"
"-Bromo styrene 840
A solution of styrene 800 (31 mg, 0.131 mmol) in CH2Cl2 (1.3 mL) was cooled to
0 °C.  Bromine (7.1 µL, 0.138 mmol) was added dropwise to the styrene solution, and the
resulting solution was maintained with stirring at 0 °C until styrene 800 was consumed
by TLC analysis.  At that time, the reaction was concentrated under vacuum at 0 °C.
Dichloromethane (2 x 1 mL) was added to the concentrated residue and evaporated under
vacuum at 0 °C to remove excess bromine.
The concentrated residue was warmed to room temperature and acetonitrile (1.6
mL) was added to the concentrated mixture, followed by DBU (39.2 µL, 0.262 mmol).
The resulting solution was maintained with stirring until dibromide 839 was fully
consumed by TLC analysis.  The reaction was then quenched by the addition of a 1 N
HCl solution (1.5 mL).  The reaction was diluted with ethyl acetate (25 mL) and washed
with water (10 mL) and brine (10 mL).  The organic phase was dried with MgSO4,
concentrated under vacuum, and purified by flash chromatography (10:1 hexanes:ethyl
acetate eluent) to yield "-bromo styrene 840 (39.6 mg, 96% yield): Rf = 0.29 (5:1
hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.82 (d, J = 14.0 Hz, 1H), 7.23 (s,
1H), 7.11 (d, J = 14.0 Hz, 1H), 6.11 (s, 2H), 3.94 (s, 3H), 3.90 (s, 3H); 13C NMR (125
MHz, CDCl3) # 166.69, 147.00, 142.18, 138.52, 129.70, 122.01, 113.99, 111.79, 111.28,
102.33, 56.57, 52.29; IR (NaCl/film) 2909, 1705, 1631, 1583, 1490, 1432, 1323, 1246,
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1189, 1164, 1060, 1038, 965, 937, 926, 888, 862, 760 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C12H12O579Br [M+H]+: 314.9863, found 314.9862.
Br
MeO O
O
O
618
MeO
PdCl2(PPh3)2 (5 mol%)
P(t-Bu)3 (10 mol%)
CuI (20 mol%)
Et2NH, 60 °C
(50% yield)
H TIPS
MeO O
O
O
842
MeO
TIPS
Aryl TIPS acetylene 842
Aryl bromide 618 (50 mg, 0.173 mmol), PdCl2(PPh3)2 (6.0 mg, 0.00865 mmol),
and CuI (6.6 mg, 0.0346 mmol) were combined in a flame-dried reaction tube.  The tube
was evacuated and transferred to a glove box, where P(t-Bu)3 (3.5 mg, 0.0173 mmol) was
added.  The flask was sealed and removed from the glove box and placed under an
atmosphere of nitrogen in the hood.  Diethylamine (1 mL, degassed) was added, followed
by TIPS acetylene (46.6 µL, 0.208 mmol).  The reaction tube was sealed and heated to 60
°C in an oil bath, where it was maintained for 12 hours with stirring.  Following this time,
the reaction was cooled to room temperature and concentrated under vacuum.  The crude
residue was purified by flash chromatography (15:1 hexanes:ethyl acetate eluent) to yield
aryl TIPS acetylene 842 (34 mg, 50% yield): Rf = 0.53 (3:1 hexanes:ethyl acetate); 1H
NMR (500 MHz, CDCl3) # 7.25 (s, 1H), 6.12 (s, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 1.15 (s,
21H); 13C NMR (125 MHz, CDCl3) # 166.34, 152.10, 142.79, 138.09, 126.10, 111.00,
102.75, 100.04, 99.33, 98.35, 56.61, 52.12, 18.66, 11.33; IR (NaCl/film) 2940, 2863,
2148, 1720, 1638, 1589, 1495, 1430, 1327, 1248, 1195, 1173, 11131, 1048, 993, 961,
882, 773 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C21H31O5Si [M+H]+: 391.1935,
found 391.1947.
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MeO O
O
O
842
MeO
TIPS
TBAF
THF
(88% yield)
MeO O
O
O
843
MeO
H
HBr (33% in AcOH)
AcOH
(99% yield)
MeO O
O
O
841
MeO
Br
!
!-Bromo styrene 841
To a solution of aryl TIPS acetylene 842 (34 mg, 0.0871 mmol) in THF (1 mL)
was added TBAF (104 µL, 0.104 mmol, 1.0 M solution in THF).  The resulting solution
was maintained at room temperature with stirring until aryl TIPS acetylene 842 was fully
consumed by TLC analysis.  At that time, the reaction was diluted with diethyl ether (25
mL) and washed with water (2 x 10 mL) and brine (10 mL).  The organic phase was dried
with MgSO4 and concentrated under vacuum to yield aryl acetylene 843 (18 mg, 88%
yield).
To a solution of aryl acetylene 843 (18 mg, 0.0769 mmol) in acetic acid (1 mL)
was added HBr in acetic acid (14 µL, 0.0769 mmol, 33% solution of HBr in acetic acid).
The resulting solution was maintained at room temperature until aryl acetylene 843 was
consumed by TLC analysis.  At that time, water (2 mL) and CH2Cl2 (3 mL) were added
and the biphasic solution was stirred vigorously for 5 minutes.  The layers were separated
and the organic phase was washed with saturated NaHCO3 solution (10 mL), dried with
MgSO4, and concentrated under vacuum to yield !-bromo styrene 841 (24.1 mg, 99%
yield): Rf = 0.36 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.19 (s, 1H),
6.10 (s, 2H), 5.92 (s, 1H), 5.80 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H); 13C NMR (125 MHz,
CDCl3) # 166.20, 146.75, 142.99, 138.10, 123.55, 121.94, 121.07, 117.29, 110.94,
102.73, 56.73, 52.33; IR (NaCl/film) 2948, 1718, 1641, 1591, 1496, 1430, 1358, 1320,
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1249, 1192, 1171, 1136, 1044, 959, 899, 870, 784, 757 cm–1; HRMS (MM: ESI-APCI)
m/z calc’d for C12H12O579Br [M+H]+: 314.9863, found 314.9868.
MeO O
O
O
841
MeO
Br
1. DIBAL
    CH2Cl2, – 78 °C
2. MOMCl, i-Pr2NEt
    CH2Cl2, 0 ! 23 °C
 (96% yield, 2 steps)
MeO O
O
844
MOMO
Br
"
Methoxymethyl ether 844
A solution of !-bromo styrene 841 (118.2 mg, 0.375 mmol) in CH2Cl2 (4 mL)
was cooled to –78 °C.  To this was added DIBAL (154 µL, 0.863 mmol) dropwise, and
the reaction was maintained at –78 °C until !-bromo styrene 841 was fully consumed by
TLC.  At this time, the reaction was quenched by the addition of a saturated solution of
Rochelle’s salt (15 mL) and subsequently warmed to room temperature over one hour
with vigorous stirring.  The reaction was diluted with CH2Cl2 (25 mL) and washed with
water (25 mL) and brine (25 mL).  The organic phase was dried with MgSO4 and
concentrated under vacuum.  The crude isolate was immediately taken on to the next step.
A solution of the crude product in CH2Cl2 (15 mL) was cooled to 0 °C in an ice
bath.  To this were added i-Pr2NEt (229 µL, 1.31 mmol) and MOMCl (85.5 µL, 1.12
mmol) sequentially.  The resulting solution was allowed to warm to room temperature
over several hours with stirring and subsequently maintained at room temperature until
the starting material was consumed by TLC analysis.  At this time, the reaction was
diluted with CH2Cl2 (25 mL) and washed with 10% citric acid solution (2 x 10 mL) and
brine (10 mL).  The organic phase was dried with MgSO4, concentrated under vacuum,
and purified by flash chromatography (5:1 hexanes:ethyl acetate eluent) to yield
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methoxymethyl ether 844 (118.9 mg, 95% yield, 2 steps): Rf = 0.27 (5:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) # 6.66 (s, 1H), 6.05 (s, 2H), 6.02 (d, J = 1.5 Hz,
1H), 5.89 (d, J = 1.5 Hz, 1H), 4.73 (s, 2H), 4.59 (s, 2H), 3.94 (s, 3H), 3.44 (s, 3H); 13C
NMR (125 MHz, CDCl3) # 146.31, 143.78, 134.48, 129.82, 124.14, 120.62, 115.81,
108.16, 102.14, 95.96, 66.43, 56.61, 55.54; IR (NaCl/film) 2941, 2885, 1644, 1628, 1498,
1432, 1381, 1315, 1210, 1147, 1101, 1041, 948, 916, 834, 748 cm–1; HRMS (MM: ESI-
APCI) m/z calc’d for C11H10O379Br [M–OMOM]•+: 268.9808, found 268.9810.
MeO O
O
844
MOMO Br
t-BuLi, THF, –78 °C
then
       (71% yield)
OMe
O
O
O
838
N
O
MeO O
O
845
MOMO
O
OMe
O
O
Enone 845
In a flame-dried reaction flask under nitrogen, THF (7 mL) was cooled to –78 °C.
To this was added t-BuLi (741 µL, 0.963 mmol, 1.3 M solution in pentane), followed by
!-bromo styrene 844 (151.9 mg, 0.459 mmol) dropwise as a solution in THF (1.5 mL).
The resulting solution was maintained at –78 °C for 10 minutes.  Following this time,
Weinreb amide 838 (146 mg, 0.550 mmol) was added dropwise as a solution in THF (1.5
mL).  The reaction was maintained at –78 °C for 10 minutes, after which time, it was
allowed to warm to room temperature, where it was maintained for three hours with
stirring.  Following that time, the reaction was quenched by the addition of a saturated
solution of NH4Cl (6 mL) and stirred vigorously for 10 minutes.  The reaction was then
diluted with ethyl acetate (25 mL) and washed with water (25 mL) and brine (25 mL).
The organic phase was dried with MgSO4, concentrated under vacuum, and purified by
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flash chromatography (3:1 hexanes:ethyl acetate eluent) to yield enone 845 (149.3 mg,
71% yield): Rf = 0.40 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) #
6.83–6.74 (m, 2H), 6.67 (s, 1H), 6.20 (d, J = 1.0 Hz, 1H), 6.19 (d, J = 1.0 Hz, 1H), 6.10
(s, 2H), 6.00–5.91 (m, 3H), 5.40 (dd, J = 11.7, 1.6 Hz, 1H), 4.62 (s, 2H), 4.46 (s, 2H),
3.92 (s, 3H), 3.87 (s, 3H), 3.36 (s, 3H); 13C NMR (125 MHz, CDCl3) # 196.12, 147.18,
146.95, 143.15, 142.89, 141.69, 137.22, 134.47, 132.97, 132.10, 130.02, 129.32, 118.52,
114.39, 113.20, 109.79, 109.31, 102.10, 101.66, 95.33, 67.03, 56.62, 56.60, 55.49; IR
(NaCl/film) 2942, 2888, 1653, 1632, 1590, 1491, 1430, 1317, 1156, 1123, 1037, 920, 837
cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C22H19O779Br [M–OMOM]•+: 395.1125,
found 395.1140.
Br
MeO O
O
O
765
MeO
OEt
PdCl2(PPh3)2 (5 mol%)
P(t-Bu)3 (10 mol%)
CuI (20 mol%)
Et2NH, 60 °C
(32% yield)
H TIPS
MeO O
O
O
818
MeO
TIPS
OEt
TBAF
THF
(68–84% yield)
MeO O
O
O
846
MeO
H
OEt
Aryl acetylene 846
Aryl bromide 765 (50 mg, 0.150 mmol), PdCl2(PPh3)2 (5.3 mg, 0.0075 mmol),
and CuI (5.7 mg, 0.030 mmol) were combined in a flame-dried reaction tube.  The tube
was evacuated and transferred to a glove box, where P(t-Bu)3 (3.0 mg, 0.015 mmol) was
added.  The flask was sealed and removed from the glove box and placed under an
atmosphere of nitrogen in the hood.  Triethylamine (250 µL, degassed) and DMF (500
µL, degassed) were added, followed by TIPS acetylene (40.3 µL, 0.180 mmol).  The
reaction tube was sealed and heated to 100 °C in an oil bath, where it was maintained for
12 hours with stirring.  Following this time, the reaction diluted with diethyl ether (25
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mL) and washed with 10% citric acid (15 mL), water (3 x 10 mL) and brine (10 mL).
The organic phase was dried with MgSO4 and concentrated under vacuum.  The crude
residue was purified by flash chromatography (15:1 hexanes:ethyl acetate eluent) to yield
aryl TIPS acetylene 818 (21.2 mg, 32% yield).
To a solution of aryl TIPS acetylene 818 (21.2 mg, 0.0488 mmol) in THF (500
µL) was added TBAF (53.6 µL, 0.054 mmol, 1.0 M solution in THF).  The resulting
solution was maintained at room temperature with stirring until aryl TIPS acetylene 818
was fully consumed by TLC analysis.  At that time, the reaction was diluted with diethyl
ether (25 mL) and washed with water (2 x 10 mL) and brine (10 mL).  The organic phase
was dried with MgSO4 and concentrated under vacuum to yield aryl acetylene 846 (18
mg, 88% yield): Rf = 0.22 (5:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) # 7.30
(s, 1H), 7.03 (s, 1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.78 (qd, J = 7.1, 2.7 Hz, 2H), 3.54 (s,
1H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) # 165.58, 150.30, 142.51,
136.75, 126.07, 120.54, 110.89, 98.36, 85.07, 75.72, 59.88, 56.68, 52.17, 14.73; IR
(NaCl/film) 3280, 2981, 2950, 1723, 1637, 1590, 1499, 1435, 1364, 1320, 1249, 1192,
1171, 1124, 1092, 1035, 966, 901, 860, 778, 753 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C14H15O6 [M+H]+: 279.0863, found 279.0872.
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O
849
MeO
Ph2C(OMe)2
p-TsOH•H2O
PhMe, reflux
(28% yield)
Ph Ph
Pd2(dba)3 (5 mol%)
PPh3 (17 mol%)
THF, 80 °C
(84% yield)
ClZn TIPS
MeO O
O
O
850
MeO
Ph Ph
TIPS
TBAF
THF
(75% yield)
MeO O
O
O
851
MeO
Ph Ph
H
HBr (33% in AcOH)
AcOH
(98% yield)
MeO O
O
O
852
MeO
Ph Ph
Br
!-Bromo styrene 852
Catechol 765 (100 mg, 0.361 mmol), Ph2C(OMe)2 (87 mg, 0.379 mmol), and p-
TsOH•H2O (1 mg, 0.00361 mmol) were combined in toluene (4 mL).  The reaction flask
was equipped with a Dean–Stark trap (filled with toluene) and reflux condenser.  The
reaction was heated to reflux and maintained for 16 hours.  After that time, the reaction
was cooled to room temperature and washed with saturated NaHCO3.  The toluene
solution was dried with MgSO4, concentrated under vacuum, and purified by flash
chromatography (10:1 hexanes:ethyl acetate eluent) to yield diphenyl acetal 849 (44.3
mg, 28%yield).
A solution of TIPS acetylene (500 mg, 2.74 mmol) in diethyl ether (3 mL) was
cooled to –78 °C.  To this was added n-BuLi (1.34 mL, 3.01 mmol, 2.25 M solution in
hexanes).  The resulting solution was maintained for one hour at –78 °C.  In the
meantime, ZnCl2 (523 mg, 3.84 mmol) was flame dried under vacuum and cooled to
room temperature under nitrogen.  The lithium acetylide solution was transferred to the
flask containing ZnCl2 by cannula, and the resulting suspension was stirred at room
temperature for one hour before use.  Immediately prior to use, stirring was stopped to
allow salts to settle.  Only the supernatant was used for subsequent transformations.
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 388
A flame-dried reaction tube was charged with Pd2(dba)3 (5.2 mg, 0.00567 mmol)
and PPh3 (5.1 mg, 0.0193 mmol), evacuated, and backfilled with nitrogen.  Diphenyl
acetal 849 (50 mg, 0.113 mmol) was added as a THF solution (0.6 mL), followed by the
zinc acetylene solution (231 mL, 0.136 mmol, 0.59 M solution in diethyl ether).  The
sealed reaction tube was then heated to 80 °C, where it was maintained with stirring until
complete by TLC analysis.  After that time, the reaction was cooled to room temperature,
diluted with diethyl ether (25 mL), and washed with saturated NH4Cl solution (2 x 10
mL) and brine (10 mL).  The organic phase was dried with MgSO4, concentrated under
vacuum, and purified by flash chromatography (10:1 hexanes:ethyl acetate eluent) to
yield aryl TIPS acetylene 850 (52.8 mg, 84% yield).
To a solution of aryl TIPS acetylene 850 (204.5 mg, 0.377 mmol) in THF (4 mL)
was added TBAF (414 µL, 0.414 mmol, 1.0 M solution in THF).  The resulting solution
was maintained at room temperature with stirring until aryl TIPS acetylene 850 was fully
consumed by TLC analysis.  At that time, the reaction was diluted with diethyl ether (25
mL) and washed with water (2 x 10 mL) and brine (10 mL).  The organic phase was dried
with MgSO4 and concentrated under vacuum to yield aryl acetylene 851 (110 mg, 75%
yield).
To a solution of aryl acetylene 851 (110 mg, 0.285 mmol) in acetic acid (3 mL)
was added HBr in acetic acid (77 µL, 0.427 mmol, 33% solution of HBr in acetic acid).
The resulting solution was maintained at room temperature until aryl acetylene 851 was
consumed by TLC analysis.  At that time, toluene (3 mL) was added and the reaction was
sparged with air for 5 minutes to remove any excess HBr.  The solution was then
concentrated from toluene three times.  The crude residue was purified by flash
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chromatography (10:1 hexanes:ethyl acetate eluent) to yield !-bromo styrene 852 (130.7
mg, 98% yield): Rf = 0.42 (3:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) #
7.67–7.54 (m, 4H), 7.43–7.31 (m, 6H), 7.18 (s, 1H), 5.95 (d, J = 1.7 Hz, 1H), 5.83 (d, J =
1.7 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H); 13C NMR (125 MHz, CDCl3) # 166.34, 146.44,
142.98, 139.32, 137.73, 129.42, 128.32, 126.38, 123.40, 121.90, 121.27, 119.07, 117.30,
110.78, 56.69, 52.22; IR (NaCl/film) 2948, 1724, 1641, 1582, 1494, 1449, 1431, 1360,
1323, 1202, 1133, 1044, 1019, 974, 948, 906, 778 cm–1; HRMS (MM: ESI-APCI) m/z
calc’d for C24H20O579Br [M+H]+: 467.0489, found 467.0486.
MeO O
O
O
852
MeO
Ph Ph
Br
1. DIBAL
    CH2Cl2, –78 °C
2. MOMCl, i-Pr2NEt
    CH2Cl2, 0 ! 23 °C
 (87% yield, 2 steps)
MeO O
O
853
MOMO
Ph Ph
Br
Methoxymethyl ether 853
A solution of !-bromo styrene 852 (130.7 mg, 0.280 mmol) in CH2Cl2 (3 mL)
was cooled to –78 °C.  To this was added DIBAL (115 µL, 0.643 mmol), dropwise, and
the reaction was maintained at –78 °C until !-bromo styrene 852 was fully consumed by
TLC.  At this time, the reaction was quenched by the addition of a saturated solution of
Rochelle’s salt (3 mL) and subsequently warmed to room temperature over one hour with
vigorous stirring.  The reaction was diluted with diethyl ether (25 mL) and washed with
water (25 mL) and brine (25 mL).  The organic phase was dried with MgSO4 and
concentrated under vacuum.  The crude isolate was immediately taken on to the next step.
A solution of the crude product in CH2Cl2 (3 mL) was cooled to 0 °C in an ice
bath.  To this were added i-Pr2Net (94.5 µL, 0.543 mmol) and MOMCl (30.9 µL, 0.407
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mmol) sequentially.  The resulting solution was allowed to warm to room temperature
over several hours with stirring and subsequently maintained at room temperature until
the starting material was consumed by TLC analysis.  At this time, the reaction was
diluted with diethyl ether (25 mL) and washed with 10% citric acid solution (2 x 10 mL)
and brine (10 mL).  The organic phase was dried with MgSO4, concentrated under
vacuum, and purified by flash chromatography (10:1 hexanes:ethyl acetate) to yield
methoxymethyl ether 853 (118.2 mg, 90% yield, 2 steps): Rf = 0.43 (3:1 hexanes:ethyl
acetate); 1H NMR (500 MHz, CDCl3) # 7.73–7.57 (m, 4H), 7.47–7.33 (m, 6H), 6.65 (s,
1H), 6.04 (d, J = 1.5 Hz, 1H), 5.91 (d, J = 1.5 Hz, 1H), 4.72 (s, 2H), 4.59 (s, 2H), 3.96 (s,
3H), 3.44 (s, 3H); 13C NMR (125 MHz, CDCl3) # 146.06, 143.69, 139.81, 134.24, 129.51,
129.18, 128.19, 126.51, 124.05, 120.85, 118.24, 115.87, 108.29, 95.96, 66.53, 56.67,
55.53; IR (NaCl/film) 2934, 1644, 1495, 1446, 1433, 1382, 1317, 1265, 1208, 1140,
1042, 1020, 947, 915, 833, 777 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for
C25H24O579Br [M+H]+: 483.0802, found 483.0807.
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 391
3.6  NOTES AND REFERENCES
(1) Joint United Nations Programme on HIV/AIDS; World Health Organization.
AIDS epidemic update: Special report on HIV/AIDS; December 2006; Geneva,
Switzerland, 2006.
(2) Cohen, J.  Science 2002, 296, 2320–2324.
(3) Richman, D. D.  Nature 2001, 410, 995–1001.
(4) a) Johnson, A. A.; Marchand, C.; Pommier, Y.  Curr. Top. Med. Chem. 2004, 4,
1059–1077.  b) Dayam, R.; Neamati, N.  Curr. Pharm. Des. 2003, 9, 1789–1802.
c) Witvrouw, M.; Van Maele, B.; Vercammen, J.; Hantson, A.; Engelborghs, Y.;
De Clercq, E.; Pannecouque, C.; Debyser, Z.  Curr. Drug. Metab. 2004, 5,
291–304.  d) Young, S. D.  Curr. Opin. Drug Discov. Devel. 2001, 4, 402–410.
e) Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.;
Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D.  Science 2000,
287, 646–650.
(5) Bonnenfant, S.; Thomas, C. M.; Vita, C.; Subra, F.; Deprez, E.; Zouhiri, F.;
Desmaële, D.; d’Angelo, J.; Mouscadet, J. F.; Leh, H.  J. Virol. 2004, 78,
5728–5736.
(6) Werber, Y.  Nature Rev. Drug Discov. 2003, 2, 513–514.
(7) Turlure, F; Devroe, E.; Silver, P. A.; Engelman, A.  Front. Biosci. 2004, 9,
3187–3208.
(8) Chiu, T. K.; Davies, D. R.  Curr. Top. Med. Chem. 2004, 4, 965–977.
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 392
(9) Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.;
Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.;
Vacca, J.; Hazuda, D. J.  Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661–6666.
(10) Marchand, C.; Zhang, X.; Pais, G. C. G.; Cowansage, K.; Neamati, N.; Burke, T.
R.; Pommier, Y.  J. Biol. Chem. 2002, 277, 12596–12603.
(11) Croxtall, J. D.; Keam, S. J.  Drugs 2009, 69, 1059–1075.
(12) Eron, J.; Kumar, P.; Lazzarin, A.; Richmond, G.; Soriano, V.; Guang, J.; Vavro,
C.; Ait-Khaled, M.; Min, S.; Yeo, J.  Presented at the 18th Conference on
Retroviruses and Opportunistic Infections, Boston, MA, 2011; Paper #151LB.
(13) Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki Y.; Watanabe, W.;
Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.;
Matsuoka, M.  J. Virol. 2008, 82, 764–774.
(14) Mascolini, M.  Presented at the 10th International Workshop on Clinical
Pharmacology of HIV Therapy, Amsterdam, The Netherlands, 2009.
(15) a) Newman, D. J.; Cragg, G. M.  J. Nat. Prod. 2007, 70, 461–477.  b) Cragg, G.
M.; Newman, D. J.; Snader, K. M.  J. Nat. Prod. 1997, 60, 52–60.  c) Newman,
D. J.; Cragg, G. M.; Snader, K. M.  J. Nat. Prod. 2003, 66, 1022–1037.
(16) Singh, S. B.; Zink, D. L.; Quamina, D. S.; Pelaez, F.; Teran, A.; Felock, P.;
Hazuda, D. J.  Tetrahedron Lett. 2002, 43, 2351–2354.
(17) a) Foot, J. S.; Giblin, G. M. P.; Taylor, R. J. K.  Org. Lett. 2003, 5, 4441–4444.
b) Foot, J. S.; Giblin, G. M. P.; Whitwood, A. C.; Taylor, R. J. K.  Org. Biomol.
Chem. 2005, 3, 756–763.
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 393
(18) Ramana, C. V.; Reddy, C. N.; Gonnade, R. G.  Chem. Commun. 2008 ,
3151–3153.
(19) Pettit, G. R.; Singh, S. B.  Can. J. Chem. 1987, 65, 2390–2396.
(20) Alam, A.; Takaguchi, Y.; Ito, H.; Yoshida, T.; Tsuboi, S.  Tetrahedron 2005, 61,
1909–1918.
(21) Peña,!D.; Cobas,!A.; Pérez,!D.; Guitián,!E.  Synthesis 2002, 1454–1458.
(22) One example of the use of a palladium-catalyzed oxidative cyclization to form
bicyclic acetals in total synthesis is the synthesis of endo-brevicomin.  See:
Byrom, N. T.; Grigg, R.; Kongkathip, B.; Reimer, G.; Wade, A. R.  J. Chem. Soc.
Perkin Trans. 1 1984, 1643–1653.
(23) Tadross, P. M.; Bugga, P.; Stoltz, B. M.  Org. Biomol. Chem. 2011, 9,
5354–5357.
(24) Seijas, J. A.; Vázquez-Tato, M. P.; Entenza, C.; Martínez, M. M.; Ónega, M. G.;
Veiga, S.  Tetrahedron Lett. 1998, 39, 5073–5076.
(25) Bonnaud, B.; Funes, P.; Jubault, N.; Vacher, B.  Eur. J. Org. Chem. 2005,
3360–3369.
(26) All attempts to reduce the acid directly (e.g., with LiAlH4) resulted in significant
quantities of the fully reduced product (859), lacking the key terminal olefin.
786
OH
O
LiAlH4
Et2O
(79% yield) 788
OH
859
OH
10:1 ratio by NMR
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 394
(27) Murata, T.; Sasaki, S.; Takashi, Y.; Ikegami, Y.; Masuda, T.; Shimada, M.;
Shintani, T.; Shimazaki, M.; Lowinger, T. B.; Ziegelbauer, K. B.; Fuchikami, K.;
Umeda, M.; Komura, H.; Yoshida, N.  U.S. Patent US2004/97563 A1, 2004.
(28) For selected examples of palladium(II)-catalyzed oxidations of olefins in alcohols
to produce ketals, see: a) Byrom, N. T.; Grigg, R.; Kongkathip, B.  J. Chem. Soc.
Chem. Commun. 1976, 216–217.  b) Tsuji, J. Synthesis 1984, 369–384.  c)
Perlmutter, P.; Selajerem, W.; Vounatsos, F.  Org. Biomol. Chem. 2004 , 2 ,
2220–2228.  d) Balija, A. M.; Stowers, K. J.; Schultz, M. J.; Sigman, M. S.  Org.
Lett. 2006, 8, 1121–1124.  e) Yadav, J. S.; Hossain, S. S.; Madhu, M.; Mohapatra,
D. K.  J. Org. Chem. 2009, 74, 8822–8825.
(29) For an example of this reactivity, see: Pedras, M. S. C.; Hossain, M.  Bioorg.
Med. Chem. 2007, 15, 5981–5996.
(30) a) Burgess, K.; Van der Donk, W. A.; Westcott, S. A.; Marder, T. B.; Baker, R.
T.; Calabrese, J. C.  J. Am. Chem. Soc. 1992, 114, 9350–9359.  b) Crudden, C.
M.; Hleba, Y. B.; Chen, A. C.  J. Am. Chem. Soc. 2004, 126, 9200–9201.
(31) Morrill, C.; Grubbs, R. H.  J. Org. Chem. 2003, 68, 6031–6034.
(32) Attempts to introduce the isopropenyl group by Suzuki coupling on aryl bromide
860 resulted only in reduction of the bromide:
MeO
MeO O
860
O
O
OEt
Br
MeO
MeO O
818
O
O
OEt
PdCl2(PPh3)2 
(5 mol%)
Na2CO3
DME, H2O, 85 °C
B
O
O
Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B 395
(33) Hu, B.-H.; Messersmith, P. B.  Tetrahedron Lett. 2000, 41, 5795–5798.
(34) Blümke, T. D.; Piller, F. M.; Knochel, P  Chem. Commun. 2010, 46, 4082–4084.
(35) a) Johnson, J. S.  Curr. Opin. Drug. Disc. Dev. 2007, 10, 691–703.  b) Johnson, J.
S.  Angew. Chem., Int. Ed. 2004, 43, 1326–1328.  c) Enders, D.; Balensiefer, T.
Acc. Chem. Res. 2004, 37, 534–541.
(36) Barton, J. P.; Clarke, D. S.; Davies, C. D.; Hargreaves, R. B.; Rankine, M. T.;
Pease, J. E.  Patent WO2004/11410 A1, 2004.
(37) Williams, J. M.; Jobson, R. B.; Yasuda, N.; Marchesini, G.; Dolling, U.-H.;
Grabowski, E. J. J.  Tetrahedron Lett. 1995, 36, 5461–5464.
(38) For selected examples of elimination of vicinal dibromides to generate !-
bromostyrenes, see: a) Gillis, E. P.; Burke, M. D.  J. Am. Chem. Soc. 2007, 129,
6716–6717.  b) Larock, R. C.; Varaprath, S.; Lau, H. H.; Fellows, C. A.  J. Am.
Chem. Soc. 1984, 106, 5274–5284.  c) Harris, P. W. R.; Rickard, C. E. F.;
Woodgate, P. D.  J. Organomet. Chem. 2000, 601, 172–190.
(39) Rosiak, A.; Frey, W.; Christoffers, J.  Eur. J. Org. Chem. 2006, 4044–4054.
(40) Elliott, E. L.; Ray, C. R.; Kraft, S.; Atkins, J. R.; Moore, J. S.  J. Org. Chem.
2006, 71, 5282–5290.
Appendix 3 – Spectra Relevant to Chapter 3 396
APPENDIX 3
Spectra Relevant to Chapter 3:
Efforts Toward the Total Synthesis of Integrastatins A and B
Appendix 3 – Spectra Relevant to Chapter 3 397
Fi
gu
re
 A
3.
1.
1 
 H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
72
1.
Appendix 3 – Spectra Relevant to Chapter 3 398
Figure A3.1.3  13C NMR (125 MHz, CDCl3) of compound 721.
Figure A3.1.2  Infrared spectrum (thin film/NaCl) of compound 721.
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Figure A3.2.3  13C NMR (125 MHz, CDCl3) of compound 762.
Figure A3.2.2  Infrared spectrum (thin film/NaCl) of compound 762.
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Figure A3.3.3  13C NMR (125 MHz, CDCl3) of compound 619.
Figure A3.3.2  Infrared spectrum (thin film/NaCl) of compound 619.
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Figure A3.4.3  13C NMR (125 MHz, CDCl3) of compound 620.
Figure A3.4.2  Infrared spectrum (thin film/NaCl) of compound 620.
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Figure A3.5.3  13C NMR (125 MHz, CDCl3) of compound 604.
Figure A3.5.2  Infrared spectrum (thin film/NaCl) of compound 604.
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Figure A3.6.3  13C NMR (125 MHz, CDCl3) of compound 628.
Figure A3.6.2  Infrared spectrum (thin film/NaCl) of compound 628.
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Figure A3.7.3  13C NMR (125 MHz, CDCl3) of compound 770.
Figure A3.7.2  Infrared spectrum (thin film/NaCl) of compound 770.
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Figure A3.8.3  13C NMR (125 MHz, CDCl3) of compound 775.
Figure A3.8.2  Infrared spectrum (thin film/NaCl) of compound 775.
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Figure A3.9.3  13C NMR (125 MHz, CDCl3) of compound 777.
Figure A3.9.2  Infrared spectrum (thin film/NaCl) of compound 777.
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Figure A3.10.3  13C NMR (125 MHz, CDCl3) of compound 784.
Figure A3.10.2  Infrared spectrum (thin film/NaCl) of compound 784.
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Figure A3.11.3  13C NMR (125 MHz, CDCl3) of compound 789.
Figure A3.11.2  Infrared spectrum (thin film/NaCl) of compound 789.
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Figure A3.12.3  13C NMR (125 MHz, CDCl3) of compound 782.
Figure A3.12.2  Infrared spectrum (thin film/NaCl) of compound 782.
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Figure A3.13.3  13C NMR (125 MHz, CDCl3) of compound 745.
Figure A3.13.2  Infrared spectrum (thin film/NaCl) of compound 745.
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Figure A3.14.3  13C NMR (125 MHz, CDCl3) of compound 798.
Figure A3.14.2  Infrared spectrum (thin film/NaCl) of compound 798.
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Figure A3.15.3  13C NMR (125 MHz, CDCl3) of compound 800.
Figure A3.15.2  Infrared spectrum (thin film/NaCl) of compound 800.
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Figure A3.16.3  13C NMR (125 MHz, CDCl3) of compound 812.
Figure A3.16.2  Infrared spectrum (thin film/NaCl) of compound 812.
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Figure A3.17.3  13C NMR (125 MHz, CDCl3) of compound 799.
Figure A3.17.2  Infrared spectrum (thin film/NaCl) of compound 799.
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Figure A3.18.3  13C NMR (125 MHz, CDCl3) of compound 802.
Figure A3.18.2  Infrared spectrum (thin film/NaCl) of compound 802.
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Figure A3.19.3  13C NMR (125 MHz, CDCl3) of compound 859.
Figure A3.19.2  Infrared spectrum (thin film/NaCl) of compound 859.
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Figure A3.20.3  13C NMR (500 MHz, CDCl3) of compound 803.
Figure A3.20.2  Infrared spectrum (thin film/NaCl) of compound 803.
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Figure A3.21.3  13C NMR (125 MHz, CDCl3) of compound 804.
Figure A3.21.2  Infrared spectrum (thin film/NaCl) of compound 804.
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Figure A3.22.3  13C NMR (125 MHz, CDCl3) of compound 805.
Figure A3.22.1  Infrared spectrum (thin film/NaCl) of compound 805.
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Figure A3.23.3  13C NMR (125 MHz, CDCl3) of compound 811.
Figure A3.23.2  Infrared spectrum (thin film/NaCl) of compound 811.
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Figure A3.24.3  13C NMR (125 MHz, CDCl3) of compound 813.
Figure A3.24.2  Infrared spectrum (thin film/NaCl) of compound 813.
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Figure A3.25.3  13C NMR (125 MHz, CDCl3) of compound 814.
Figure A3.25.2  Infrared spectrum (thin film/NaCl) of compound 814.
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Figure A3.26.3  13C NMR (125 MHz, CDCl3) of compound 818.
Figure A3.26.2  Infrared spectrum (thin film/NaCl) of compound 818.
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Figure A3.27.3  13C NMR (125 MHz, CDCl3) of compound 819.
Figure A3.27.2  Infrared spectrum (thin film/NaCl) of compound 819.
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Figure A3.28.3  13C NMR (125 MHz, CDCl3) of compound 820.
Figure A3.28.2  Infrared spectrum (thin film/NaCl) of compound 820.
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Figure A3.29.3  13C NMR (125 MHz, CDCl3) of compound 821.
Figure A3.29.2 Infrared spectrum (thin film/NaCl) of compound 821.
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Figure A3.30.3  13C NMR (125 MHz, CDCl3) of compound 822.
Figure A3.30.2  Infrared spectrum (thin film/NaCl) of compound 822.
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Figure A3.31.3  13C NMR (125 MHz, CDCl3) of compound 838.
Figure A3.31.2  Infrared spectrum (thin film/NaCl) of compound 838.
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Figure A3.32.3  13C NMR (125 MHz, CDCl3) of compound 840.
Figure A3.32.2  Infrared spectrum (thin film/NaCl) of compound 840.
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Figure A3.33.3  13C NMR (125 MHz, CDCl3) of compound 842.
Figure A3.33.2  Infrared spectrum (thin film/NaCl) of compound 842.
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Figure A3.34.3  13C NMR (125 MHz, CDCl3) of compound 841.
Figure A3.34.2  Infrared spectrum (thin film/NaCl) of compound 841.
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Figure A3.35.3  13C NMR (125 MHz, CDCl3) of compound 844.
Figure A3.35.2  Infrared spectrum (thin film/NaCl) of compound 844.
Appendix 3 – Spectra Relevant to Chapter 3 467
Fi
gu
re
 A
3.
36
.1
  
H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
84
5.
Appendix 3 – Spectra Relevant to Chapter 3 468
Figure A3.36.3  13C NMR (125 MHz, CDCl3) of compound 845.
Figure A3.36.2  Infrared spectrum (thin film/NaCl) of compound 845.
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Figure A3.37.3  13C NMR (125 MHz, CDCl3) of compound 846.
Figure A3.37.2  Infrared spectrum (thin film/NaCl) of compound 846.
Appendix 3 – Spectra Relevant to Chapter 3 471
Fi
gu
re
 A
3.
38
.1
  
H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
85
2.
Appendix 3 – Spectra Relevant to Chapter 3 472
Figure A3.38.3  13C NMR (125 MHz, CDCl3) of compound 852.
Figure A3.38.2  Infrared spectrum (thin film/NaCl) of compound 852.
Appendix 3 – Spectra Relevant to Chapter 3 473
Fi
gu
re
 A
3.
39
.1
  
H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
85
3.
Appendix 3 – Spectra Relevant to Chapter 3 474
Figure A3.39.3  13C NMR (125 MHz, CDCl3) of compound 853.
Figure A3.39.2  Infrared spectrum (thin film/NaCl) of compound 853.
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NOTEBOOK CROSS-REFERENCE FOR NEW COMPOUNDS
The following notebook cross-reference has been included to facilitate access to the
original spectroscopic data obtained for the compounds presented in this thesis.  For each
compound, both hard copy and electronic characterization folders containing the original
1H NMR, 13C NMR, 19F NMR, and IR spectra have been created.  All notebooks and
spectroscopic data are stored in the Stoltz research group archive.
Table A5.1. Compounds in Chapter 2 – The Total Synthesis of (–)-Curvularin
Compound 1H NMR 13C NMR IR
614 PMT-IX-77-1H PMT-IX-77-13C PMT-IX-81
232 PMT-VII-33-1H PMT-VII-33-13C PMT-VII-33
720 PMT-VIII-107-1H PMT-VIII-107-13C PMT-VIII-107
616 PMT-VIII-121-1H PMT-VIII-121-13C PMT-VIII-121
617 PMT-VIII-103-1H PMT-VIII-103-13C PMT-VIII-103
217 PMT-VII-273-1H PMT-VII-273-13C PMT-VII-273
721 PB-I-179.pur1 PB-I-179.pur1 PB-I-179
619 PB-II-119.2ndpur01 PB-II-119.2ndpurC PB-I-225 bc
620 PB-II-97.purchar PB-II-97.purcharC PB-II-97
604 PMT-IX-85-1H PMT-VII-189 PMT-IX-85
622 CDG-XII-247 CDG-XII-247 CDG-XII-247
623 CDG-XIV-289C-2 CDG-XIV-289C-2 CDG-XIV-289
624 CDG-XIV-117C CDG-XIV-117C CDG-XIV-117
625 CDG-XV-123C-C13 CDG-XV-123C-C13 CDG-XV-123
626 CDG-XV-163C-C13 CDG-XIV-273B-201 CDG-XIV-273
605 CDG-XIV-267B CDG-XIV-293D-C13 CDG-XIV-293
627 PMT-IX-99-1H PMT-IX-99-13C PMT-IX-99
226 PMT-IX-83-1H PMT-IX-83.13C PMT-IX-83
628 PB-II-105.3rdpur3 PB-II-105.3rdpur3 PB-II-105.3rdpur3
629 CDG-XIV-299C CDG-XIV-299C-C13 CDG-XIV-299
227 PMT-IX-91-1H PMT-IX-91-13C PMT-IX-91
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228 PMT-IX-109 PMT-IX-109 PMT-IX-109
631 CDG-XIV-301C CDG-XIV-301C-C13 CDG-XIV-301
666 PMT-II-159 PMT-II-159 PMT-II-159
680 PMT-III-209 PMT-III-209-13C PMT-III-209
681 PMT-III-217 PMT-III-217-13C PMT-III-217
685 PMT-III-273 PMT-III-273-13C PMT-III-273
686 PMT-III-275 PMT-III-275 PMT-III-275
689 PMT-II-211 PMT-II-211 PMT-II-211
695 PMT-II-225-1H PMT-II-225-13C PMT-II-225
693 PMT-II-205-1H PMT-II-205-13C PMT-II-205
cis-701 PMT-III-29 PMT-III-29 PMT-III-29
702 PMT-VIII-135-1H PMT-VIII-135-13C PMT-VIII-135
703 PMT-VI-121-1H PMT-VI-121-13C PMT-VI-121
Z-anti-704 PMT-IX-33-1H PMT-IX-33-13C PMT-IX-33
640 PMT-V-57-1H PMT-V-57-13C PMT-V-57
704 PMT-VII-29-1H PMT-VII-29-13C PMT-VII-29
709 PMT-IV-301 PMT-IV-301 PMT-IV-301
218 PMT-VII-73-1H PMT-VII-73-13C PMT-VII-73
718 PMT-VI-187 PMT-VI-187-13C PMT-VI-187
719 PMT-VII-55 PMT-VII-55 PMT-VII-55
223 PMT-VIII-285-1H PMT-VIII-285-13C PMT-VIII-285
224 PMT-VIII-289-1H PMT-VIII-289-13C PMT-VIII-289
221 PMT-IX-31-1H PMT-IX-31-13C PMT-IX-31
Table A5.2. Compounds in Chapter 3 – Efforts Toward the Total Synthesis of Integrastatins A and B
Compound 1H NMR 13C NMR IR
721 PB-I-179.pur1 PB-I-179.pur1 PB-I-179
762 PB-II-133 PB-II-133 PB-II-133
619 PB-II-119.2ndpur01 PB-II-119.2ndpurC PB-I-225 bc
620 PB-II-97.purchar PB-II-97.purcharC PB-II-97
604 PMT-IX-85-1H PMT-VII-189 PMT-IX-85
628 PB-II-105.3rdpur3 PB-II-105.3rdpur3 PB-II-105.3rdpur3
770 PB-I-171 PB-I-171 PB-I-171
Appendix 5 – Notebook Cross-Reference 573
775 PB-II-89 PB-II-89 PB-II-89
777 PB-II-99 PB-II-99 PB-II-99
784 PMT-XI-245 PMT-XI-245 PMT-XI-245
789 PMT-XI-247 PMT-XI-247 PMT-XI-247
782 PMT-XI-251 PMT-XI-251 PMT-XI-251
745 PMT-XI-255.1 PMT-XI-255.1 PMT-XI-255
798 PMT-XII-113 PMT-XII-113 PMT-XII-113
800 PB-III-165.char1H PB-III-165.char13C PB-III-165char
812 PMT-X-273 PMT-X-273 PMT-X-273
799 PMT-XII-143 PMT-XII-143 PMT-XII-143
802 PB-II-229 PB-II-229 PB-II-229
859 PMT-XII-115 PMT-XII-115 PMT-XII-115
803 PMT-XII-117 PMT-XII-117 PMT-XII-117
804 PB-II-273 PB-II-273 PB-II-273
805 PB-III-45 PB-III-45 PB-III-45
811 PMT-X-279 PMT-X-279 PMT-X-279
813 PMT-X-217 PMT-X-217 PMT-X-217
814 PMT-X-275 PMT-X-275 PMT-X-275
818 PB-III-117 PB-III-117 PB-III-117
819 PMT-XII-119 PMT-XII-119 PMT-XII-119
820 PMT-XII-125 PMT-XII-125 PMT-XII-125
821 PMT-XII-127 PMT-XII-127 PMT-XII-127
822 PMT-XII-137 PMT-XII-137 PMT-XII-137
838 PMT-XI-51 PMT-XI-51 PMT-XI-51
840 PMT-XII-165 PMT-XII-165 PMT-XII-165
842 PMT-XI-125 PMT-XI-125 PMT-XI-125
841 PMT-XI-151 PMT-XI-151 PMT-XI-151
844 PMT-XII-263 PMT-XII-263 PMT-XII-263
845 PMT-XII-267 PMT-XII-267 PMT-XII-267
846 PMT-XII-171 PMT-XII-171 PMT-XII-171
852 PMT-XI-205 PMT-XI-205 PMT-XI-205
853 PMT-XII-155 PMT-XII-155 PMT-XII-155
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Table A5.3. Compounds in Chapter 4 – Progress Toward the Total Synthesis of Jorumycin
Compound 1H NMR 13C NMR IR
933 PMT-XII-227 PMT-XII-227 PMT-XII-227
932 PMT-XII-241 PMT-XII-241 PMT-XII-241
935 PMT-XII-245 PMT-XII-245 PMT-XII-245
939 PMT-XII-225 PMT-XII-225 PMT-XII-225
622 CDGXII-247 CDGXII-247 CDGXII-247
623 CDGXIV-289C-2 CDGXIV-289C-2 CDGXIV-289
624 CDGXIV-117C CDGXIV-117C CDGXIV-117
625 CDGXV-123C-C13 CDGXV-123C-C13 CDGXV-123
626 CDGXV-163C-C13 CDGXIV-273B-201 CDGXIV-273
605 CDGXIV-267B CDGXIV-293D-C13 CDGXIV-293
629 CDGXIV-299C CDGXIV-299C-C13 CDGXIV-299
956 CDGXXI-131B-1-C13 CDGXXI-131B-1-C13 CDGXXI-131C
957 CDGXXI-147B-C13 CDGXXI-147B-C13 CDGXXI-135C
924 CDGXII-075-SM-C13 CDG-PMT-12-079 PMT-12-079
923 CDGXXI-107B-2 CDGXXI-107B-2-C13 CDGXXI-107B-2
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